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ABSTRACT 
Christine Marie Hebling: 
Investigation of Membrane Protein Dynamics of Gamma-Glutamyl Carboxylase using 
Liquid Chromatography and Mass Spectrometry 
(Under the direction of Dr. James W. Jorgenson and Dr. Darrel W. Stafford) 
 
 Membrane proteins are involved in numerous biological processes, including 
transport, signal transduction, and a variety of metabolic pathways.  Despite their abundance, 
however, membrane proteins largely remain resistant to biophysical characterization due to 
complexities in sample preparation and limited knowledge regarding structural elucidation.  
The overlying objective of the work reported in this dissertation is focused upon developing 
proteomics based approaches for the structural investigation of integral membrane proteins 
involved in the vitamin K cycle.   
Vitamin K is an essential micronutrient that functions as a coenzyme in the 
carboxylation of vitamin K-dependent (VKD) proteins by the integral membrane protein 
Gamma-Glutamyl Carboxylase (GGCX).  Concomitant with VKD modification, vitamin K is 
regenerated by a mechanism involving the enzyme Vitamin K Epoxide Reductase (VKOR) 
and the cycle continues.  Structural analysis of GGCX and VKOR is of particular interest in 
understanding their functional involvement in blood coagulation, calcification, and cell 
growth control.  Although the mechanisms for carboxylation and epoxidation have been 
investigated for over thirty years, biological recognition involving structural conformations 
and protein associations are not yet completely understood.   
iv 
As an alternative approach to classical biochemical experimentation, methods were 
developed to investigate GGCX protein dynamics by ultra-performance liquid 
chromatography (UPLC) coupled to mass spectrometry.  Following a brief overview of the 
vitamin K cycle (Chapter 1), Chapters 2-4 aim to develop analytical approaches for 
identifying the catalytic active site in GGCX using covalent cross-linking mass spectrometry.  
A comprehensive bottom-up proteomics methodology (Chapter 2) was applied to identify 
site-specific covalent attachment of synthetically modified VKD cross-linker substrates in 
Chapters 3 and 4.  In Chapter 5, a new class of model membrane, Nanodiscs, are introduced 
providing a controlled, native phospholipid structure in which membrane proteins can be 
isolated in a water-soluble environment.  Incorporation of GGCX embedded Nanodiscs are 
further investigated by hydrogen exchange mass spectrometry (HX MS) in Chapter 6.  This 
novel system demonstrates the first reported application for investigation of membrane 
protein dynamics in a near-native environment by HX MS.  The work outlined in this 
dissertation not only offers significant advancements in the structural investigation of GGCX, 
but provides unique platforms in which to investigate other complex membrane protein 
systems.   
 
 
 
 
 
 
 
v 
 
 
 
 
To My Parents 
For instilling in me the willingness  
to succeed and the love of life. 
vi 
ACKNOWLEDGMENTS 
I would not be where I am today without the guidance and support of many 
influential people throughout my life.  I am profoundly grateful to those who have believed 
in my potential to succeed and appreciative of the life lessons I have learned along the way.  
First and foremost, I would like to thank my family and friends who have stood by me 
through both the challenges and triumphs life has had to offer.  Their unconditional love and 
support continually motivates me to live up to a greater potential.   
The work presented in this dissertation is truly a collaborative effort by a number of 
individuals whom need to be recognized.  I would especially like to thank my advisors Dr. 
James Jorgenson and Dr. Darrel Stafford for providing an environment in which I can 
develop analytical intellect while allowing the freedom to explore my own scientific 
intuitions.  In addition I would like to thank both the Jorgenson and Stafford groups both past 
and present for thoughtful discussions, advice, and guidance.  A special thank you goes to my 
committee members: Dr. Jorgenson, Dr. Stafford, Dr. Wightman, Dr. Schoenfisch, and Dr. 
Gagné for taking the time to review my dissertation and to participate in my final defense. 
I would also like to extend my thanks to Dr. James Morrisey at the University of 
Illinois and Dr. John Engen, Dr. Kasper Rand, and Christopher Morgan at Northeastern 
University for their collaboration with the Nanodisc and Hydrogen-Exchange projects.  
Having the opportunity to work with both of these groups has been a truly valuable 
vii 
experience.  It has been a very exciting process to be involved in such a dynamic and 
collaboration and I value their willingness to welcome me into their research groups. 
As a scientist, I would not be where I am today without the guidance of Dr. Timothy 
Strein at Bucknell University.  Through his guidance, expertise, and unconditional support, I 
have matured as an individual and grown as a scientist.  Dr. Strein’s dedication to academics 
is truly inspiring.  His mentorship throughout the past seven years has taught me to persevere 
through the challenging times, but to live off of the successes.   
As I begin the next stage of my life, I am very excited for what the future holds in 
store.  In the past five years, I have grown as a scientist, but much more I have grown as 
person.  I have learned what really matters is not what you accomplish, but the lives you 
touch along the way.  For this, I owe a very special recognition to my best friend and fellow 
colleague Joseph Parker.  The words “thank you” do not give justice to the unwavering 
support provided by Joe over the past five years, but I will forever be grateful for having him 
as a part of my life.  For those individuals mentioned in this acknowledgement and for those I 
may have forgotten to name, I thank you for your support and for your friendship along this 
journey. 
viii 
TABLE OF CONTENTS 
LIST OF TABLES……………………………………………………………………..….xviii 
LIST OF FIGURES………………………………………………………………………....xix 
LIST OF ABBREVIATIONS ……………………………………………………………xxviii 
CHAPTER 1: The Vitamin K Cycle…………………………………………………..............1 
1.1 Vitamin K………………………………………………………………………….1 
1.2 The Vitamin K Cycle…………………………………………………………..….4 
1.3 Gamma-Glutamyl Carboxylase (GGCX)…………………………………………5 
1.3.1 GGCX Substrate Recognition…………………………………………6 
1.3.2 The Carboxylation Mechanism………………………………..............7 
1.3.3 A Processive Carboxylation Mechanism…………………………….11 
1.4 Vitamin K Epoxide Reductase (VKOR)…………………………………………12 
1.4.1 Structural Representation of VKOR…………………………………13 
1.4.2 Catalytic Responsibilities of VKOR…………………………………15 
1.4.3 Functional Relations of VKOR………………………………………16 
1.4.4 Warfarin Inhibition of VKOR………………………………………..17 
1.5 Thesis Scope……………………………………………………………………..19 
1.6 References………………………………………………………………………..21 
1.7 Figures……………………………………………………………………………29 
CHAPTER 2: Improved Digestion Conditions for Integral Membrane Protein Gamma-
Glutamyl Carboxylase……………………………………………………………………….35 
ix 
 
2.1  Introduction………………………………………………………………...…...35 
2.1.1 Evolution of Mass Spectrometry…………………………………….35 
2.1.2 Mass Spectrometry for Protein Investigation……………………......36 
2.1.3 Tandem Mass Spectrometry of Peptides………………………..…...38 
2.1.4 Separation Technology for Proteomics………………………...……40 
2.1.5 Proteomic Study of Membrane Proteins……………………………..41 
2.1.6 Recent Advances in In-Gel Digestion of Membrane Proteins……….44 
2.2 Chapter Scope……………………………………………………………………46 
2.3 Experimental……………………………………………………………………..47 
2.3.1 Materials………………………………………………………..........47 
2.3.2 Purification of Recombinant Wild-Type Gamma-Glutamyl 
Carboxylase…………………………………………………...……..48 
 
2.3.3 In-Gel Digestion Protocol for Gamma-Glutamyl Carboxlyase...........48 
2.3.4 Modification to In-Gel Digestion Protocol for Gamma-Glutamyl 
Carboxylase…………………………………………………....……..51 
 
2.3.5 Bottom-Up Peptide Separation Using UHPLC/UPLC-MS………….52 
2.3.5.1 Instrumentation and Run Conditions: UHPLC………............52 
2.3.5.1.1 Reverse Phase Capillary Column  
Preparation……………………………………….52 
2.3.5.1.2 UHPLC Instrumentation…………………………53 
2.3.5.2 NanoACQUITYTM UPLC Instrumentation………………….55 
2.3.5.3 MS Instrumentation: DDA…………………………...……...56 
2.3.5.4 MS Instrumentation: MSE…………………………...............59 
2.3.6 Data Processing……………………………………………...............60 
x 
2.3.6.1 Protein-Lynx Global Server – DDA………………….……...60 
2.3.6.2 Protein-Lynx Global Server – MSE………………………….63 
2.3.6.3 Peptide Identification…………………………………...........64 
2.4 Results and Discussion……………………………………………………..........66 
2.4.1 Sample Acquisition: Data Independent LC-MS versus Data  
Dependent LC-MSMS…..…………………………………...…....…66 
 
2.4.2 Peptide Detection: Data Independent LC-MS versus Data     
Dependent LC-MSMS…………………..…………………...............69 
 
2.4.3 Optimization of In-Gel Digestions for Gamma-Glutamyl 
Carboxylase.........................................................................................73 
 
2.4.4 Modeling of In-Gel Digestions for GGCX...…………………...........77 
2.4.5 In-Gel Chymotrypsin Digestions…………………………………….79 
2.4.5.1 Specificity of Chymotrypsin Digestions……………………..79 
2.4.5.2 Evaluation of Chymotyrpsin In-Gel Method  
Variations….............................................................................82 
2.4.6 In-Gel Trypsin Digestions……………………………………………86 
2.4.7 Sample Preparation Reproducibility…………………………………88 
2.4.8 Conclusions…………………………………………………………..90 
2.5 References……………………………………………………………………......91 
2.6 Tables.……………………………………………………………………………95 
2.7 Figures……………………………………………………………………………99 
CHAPTER 3: Identifying the Catalytic Active Site of GGCX – Biological Development      
of Cross-linker Substrates…………………………………………………..………………132 
 
3.1 Introduction…………………………………………………………….….........132 
3.1.1 Catalytic Carboxylation Domain…………………………………...132 
3.1.2 Chemical Cross-linkers……………………………………….…….135 
xi 
3.1.2.1 Reactivity…………………………………………………...135 
3.1.2.2 Cross-linker Design………………………………………...138 
3.1.3 Benzoylphenylalanine………………………………………………139 
3.1.4 Additional Cross-linking Strategies………………………….……..141 
3.2 Chapter Scope…………………………………………………………………..141 
3.3 Experimental……………………………………………………………..……..142 
3.3.1 Materials……………………………………………………………142 
3.3.2 Gamma-Glutuamyl Carboxylase – Recombinant, Mutant, and 
Construct Modifications……………………………………………143 
 
3.3.3 Synthetic Vitamin K-Dependent Peptides…………………..……...144 
3.3.4 Photochemical Cross-linking Experimentation………………….....145 
3.3.5 Conformation of Fluorescent Covalent Cross-linking by SDS-
PAGE…………………………..…………………………………...145 
 
3.3.6 In Vitro Carboxylation Assay……..………………………………..146 
3.3.6.1 FLEEL Inhibition…….………..…………………………....147 
3.3.6.2 Determination of Km………………..………………………148 
3.3.6.3 Consensus Propeptide Inhibition………..……………….....148 
3.3.7 Circular Dichroism…………………………………..……………..148 
3.3.8 Fluorescence Anisotropy………………………………..……….....149 
3.4 Results and Discussion…………………………………………………..……..150 
3.4.1 Development of Synthetic Vitamin K-Dependent Cross-linker 
Substrates………………………………………………………..….150 
 
3.4.2 Confirmation of Structure and Catalytic Activity………………......154 
3.4.3 Optimization of Covalent Attachment……………………………...157 
3.4.3.1 33mer Cross-linker Substrate……………………..………...157 
xii 
3.4.3.2 27mer Cross-linker Substrate……………...………………..159 
3.4.4 Specificity of Covalent Attachment…………………...……………161 
3.4.4.1 Cross-linking to Inactive GGCX…………………..…….…161 
3.4.4.2 Cross-linking Investigated by Fluorescence Anisotropy…...162 
 
3.4.4.3 Competitive Inhibition of Photochemical 
Cross-linking…......................................................................164 
3.4.4.4 Cross-linking to Mutant GGCX…………………...………..165 
3.4.4.5 Cross-linking to Two-Chain GGCX……………..................166 
3.4.5 Conclusions…………………………………………………………166 
3.5 References…………………………………………………………...………….169 
3.6 Tables……………………………………………………………………...……173 
3.7 Figures……………………………………………………………………..........175 
CHAPTER 4: Identifying the Catalytic Active Site of GGCX – Cross-linker Substrate 
Identification by LC-MS…………………………………………………………………....191 
 
4.1 Introduction………………………………………………………………..…....191 
4.1.1 Mass Spectrometric Determination of Protein Cross-linking……....191 
4.1.2 Benzoylphenylalanine Photphore Cross-linking……...…………….195 
4.2 Chapter Scope………………………………………………………...………...198 
4.3 Experimental……………………………………………………………...…….199 
4.3.1 Materials………………………………………………....................199 
4.3.2 Purification of Recombinant Wild-Type Gamma-Glutamyl 
Carboxylase…………………………………………........................201 
 
4.3.3 Synthetic Vitamin K-Dependent Peptides……………………..…...201 
4.3.4 Photochemical Cross-linking Experimentation……………….........202 
4.3.5 Proteolytic Digestions………………………………..……………..203 
xiii 
4.3.5.1 In-Gel Digestion Protocol for Gamma-Glutamyl 
Carboxylase………………………………………………....203 
 
4.3.5.2 In-Gel Digestion Protocol for Bovine Serum Albumin.........204 
4.3.5.3 In-Solution digestion of 27mer and 33mer Cross-linker 
Substrates…………………………………………………...204 
 
4.3.6 Bottom-Up Peptide Separation and Mass Spectrometric 
Detection............................................................................................205 
 
4.3.6.1 Reverse Phase Capillary Column Preparation………..…….205 
4.3.6.2 UHPLC Instrumentation…………………………………....205 
4.3.6.3 Capillary LC Instrumentation………………..……………..206 
4.3.6.4 NanoACQUITYTM UPLC Instrumentation……..………….207 
4.3.6.5 MS Instrumentation: DDA and MSE………………..……...208 
4.3.7 Data Processing………………………………………………….....209 
4.3.7.1 Protein-Lynx Global Server – DDA…..……………………209 
4.3.7.2 Protein-Lynx Global Server – MSE………..……………….211 
4.3.8 Photoaffinity Cross-linker Identification……………..…………….211 
4.4 Results and Discussion………………………………………………..………..214 
4.4.1 Identification of Characteristic 33mer Cross-linker Peptides……....215 
4.4.2 Validation of In-Gel Digestion Methodology for Fluorescein     
Labeled Substrates………………………………..………………...217 
 
4.4.3 Identification of Photochemically Cross-linked 33mer-GGCX 
Complex…………………………………………..………………...219 
 
4.4.4 Characterization of 1:1 (w/w) 27mer (d0/d3) Cross-linker by LC-
MS……………………………………………………...……...……224 
 
4.4.5 Identification of Photochemically Cross-linked 27mer GGCX 
Complex……………………………………………………….........227 
 
4.4.6 Conclusions…………………………………………………………230 
xiv 
4.5 References………………………………………………………………………233 
4.6 Figures………………………………………………………………………….236 
CHAPTER 5: Nanodisc Formation – Biological Applications to the Vitamin K Cycle…...257 
5.1 Introduction…………………………………………………………………….257 
5.1.1 Development of Model Membranes………………………………..257 
5.1.2 Overview of Nanodisc Technology………………………………...259 
5.1.3 Nanodisc Formation………………………………………………...261 
5.1.4 Nanodisc Applications……………………………………………...263 
5.1.4.1 Bacteriorhodopsin……………….………………………….263 
5.1.4.2 Cytochrome P450……………….…………………………..264 
5.1.4.3 Tissue Factor…………………….………………………….266 
5.1.4.4 Future of Nanodiscs……………….………………………..267 
5.2 Chapter Scope…………………………………………………………………..268 
5.3 Experimental……………………………………………………………………269 
5.3.1 Materials……………………………………………………………269 
5.3.2 Purification of Recombinant Wild-Type Gamma-Glutamyl 
Carboxylase………………………………..………………………..270 
 
5.3.3 Purification of Recombinant Wild-Type Vitamin K Epoxide 
Reductase………………………………….………………………..271 
 
5.3.4 Membrane Scaffold Protein (MSP1D1) Expression and 
Purification.........................................................................................272 
 
5.3.5 Nanodisc Formation and Purification………………………………272 
5.3.5.1 Phosphate Analysis…………………………………………273 
5.3.5.2 SDS-PAGE…………………………………………………274 
5.3.6 In Vitro Carboxylation Assay...…………………………………….274 
xv 
5.3.7 Fluorescence Anisotropy of GGCX Nanodiscs…………...………..276 
5.3.8 In Vitro VKOR Activity Assay……………………………………..277 
5.3.9 Atomic Force Microscopy………………………………………….277 
5.4 Results and Discussion…………………………………………………………279 
5.4.1 Optimized Empty Nanodisc Assembly……………………………..280 
5.4.2 Incorporation of Purified GGCX in Nanodiscs…………………….282 
5.4.2.1 Optimization of GGCX Reconstitution Mixture……………285 
5.4.2.2 Modifications to in vitro GGCX Activity Assay…………...289 
5.4.3 Incorporation of Purified VKOR in Nanodiscs…………………….297 
5.4.4 Future Applications of Nanodiscs in the Vitamin K Cycle………...303 
5.4.5 Conclusions…………………………………………………………305 
5.5 References………………………………………………………………………307 
5.6 Tables…………………………………………………………………………...311 
5.7 Figures…………………………………………………………………………..312 
CHAPTER 6: Nanodisc Applications to Hydrogen Deuterium Exchange Mass 
Spectrometry………………………………………………………………………………..333 
 
6.1 Introduction……………………………………………………………………..333 
6.1.1 Hydrogen Exchange Fundamentals………………………………...334 
6.1.2 Hydrogen Exchange Mass Spectrometry…………………………...337 
6.1.3 Hydrogen Exchange of Membrane Proteins………………………..339 
6.2 Chapter Scope…...……………………………………………………………...340 
6.3 Experimental……………………………………………………………………341 
6.3.1 Materials……………………………………………………………341 
xvi 
6.3.2 Purification of Recombinant Wild-Type Gamma-Glutamyl 
Carboxylase…………………………………………………………342 
 
6.3.3 Membrane Scaffold Protein (MSP1D1) Expression and 
Purification……………………………………………………….…343 
 
6.3.4 Self-Assembly of Nanodiscs…………………………………….….343 
6.3.5 Conventional HPLC – Hydrogen Exchange Reaction and Analysis    
by Mass Spectrometry……………………………...…………….…344 
 
6.3.6 UPLC – Hydrogen Exchange Reaction and Analysis by Mass 
Spectrometry………………………………………………………..346 
 
6.4 Results and Discussion…………………………………………………………348 
6.4.1 HX MS of Empty and GGCX Embedded Nanodiscs –       
Conventional HPLC…..…………………………….........................348 
 
6.4.1.1 Structural Evaluation of GGCX…………………………….351 
6.4.1.2 Protein Dynamics of MSP1D1……………………………..353 
6.4.2 Improvements in Sample Preparation for Nanodsic HX MS……....355 
6.4.3 HX MS of GGCX Nanodiscs – UPLC……………………………..357 
6.4.4 Biological Validation – HX MS of Propeptide Embedded GGCX 
Nanodiscs…………………………………………………………...360 
 
6.4.5 Improvements to Nanodisc HX MS Methodology – Future 
Experimentation………………………………………………….....368 
 
6.4.6 Conclusions………………………………………………………....370 
6.5 References……………………………………………………………………....372 
6.6 Figures…………………………………………………………………………..377 
APPENDIX A1: Purification of Recombinant Wild-Type Gamma-Glutamyl 
Carboxylase…………………………………………………………………………………400 
 
A1.1 Materials……………………………………………………...…………….…400 
A1.2 GGCX Microsome Preparation and Solubilization..........................................402 
xvii 
A1.3 GGCX Affinity Purification………………………...…………..……….…...404 
A1.4 GGCX SP Sepharose Concetration………………………………..………....407 
A1.5 References………………………………………………..…………..………409 
A1.6 Figures………………………………………………………..………..……..410 
APPENDIX A2: Purification of Recombinant Wild-Type Vitamin K Epoxide 
Reductase…………………………………………………………………………..……….411 
 
A2.1 Materials……………………………………………………….……………...411 
A2.2 VKOR Microsome Preparation and Solubilization..........................................413 
A2.3VKOR Reconstitution and Affinity Purification……….……….………….....414 
A2.4 VKOR Recovery of Activity…….………………………………..……..……417 
A2.5 References…………………………………………………………..…..…….420 
A2.6 Figures………………………………………………………………....……...421 
APPENDIX A3: Expression and Purification of Membrane Scaffold Protein 
MSP1D1…............................................................................................................................422 
 
A3.1 Materials…………………………………………………….………..………422 
A3.2 MSP1D1 Expression – E. coli BL21 Codon Plus (DE3).................................423 
A3.3 MSP1D1 Cell Lysis…………………………………….………………...…..426 
A3.4 MSP1D1 Purification – Ni-NTA Agarose Affinity Purification……...……...427 
A3.5 References…………………………………………………………….………429 
A3.6 Figures…………………………………………………………….………….430 
APPENDIX A4: Nanodisc Hydrogen Deuterium Exchange Uptake Curves………………432 
A4.1 Tables………………………………………………………….…………...…433 
A4.2 Figures…………………………………………………..................................434 
xviii 
LIST OF TABLES 
Table 2.1 Collision energy profile for data directed analysis (DDA) MSMS 
acquisition……………………………………………………………..…………95 
 
Table 2.2 Data preparation and workflow template ProteinLynx Global Server (PLGS) 
processing parameters for data directed analysis (DDA) MSMS files…..............96 
 
Table 2.3 Data preparation and workflow template ProteinLynx Global Server (PLGS) 
processing parameters for data independent analysis (MSE) files………………...97 
 
Table 2.4 Chymotrypsin in-gel digestion parameters for Gamma-Glutamyl Carboxylase 
(GGCX)……………………………………………………………………..……98 
 
Table 3.1 Relative Kd values and sequence alignment for human vitamin K-dependent 
propeptides………………………………………………………………………….173 
 
Table 3.2 N-terminal sequence alignment for human vitamin K-dependent Gla 
domains…………………………………………………………………...……..174 
 
Table 5.1 Phospholipids per leaflet and diameter for corresponding membrane scaffold 
protein (MSP) constructs in Nanodisc formation…………………………………..311 
 
Table A4.1 Topological prediction for Gamma-Glutamyl Carboxylase (GGCX)……..…..433 
xix 
LIST OF FIGURES 
Figure 1.1 Vitamin K analogs: Vitamin K1 phylloquinone, Vitamin K2 menaquinone, and 
Vitmain K3 menadione…………………………………….........................................29 
 
Figure 1.2 The Vitamin K Cycle………………………………………………………..……30 
 
Figure 1.3 Proposed membrane topology for Gamma-Glutamyl Carboxylase (GGCX)...….31 
 
Figure 1.4 The Dowd mechanism of carboxylation……………………………………..…...32 
 
Figure 1.5 Proposed membrane topology of Vitamin K Epoxide Reductase (VKOR)……...33 
 
Figure 1.6 Proposed mechanism of Vitamin K Epoxide Reductase (VKOR)...…………..…34 
 
Figure 2.1 Common fragmentation pattern for low energy collision induced dissociation 
(CID) during MSMS fragmentation………………………….....................................99 
 
Figure 2.2 Systematic diagram illustrating operation of UHPLC custom system………….100 
 
Figure 2.3 nanoACQUITYTM UPLC system module………………………………………101 
 
Figure 2.4 Schematic comparison of data directed analysis (DDA) and data independent 
analysis (MSE) fragmentation modes……………………………………………….102 
 
Figure 2.5 Experimental overview of DDA MSMS acquisition……………………………103 
 
Figure 2.6 Experimental overview of MSE acquisition…………………………………….104 
 
Figure 2.7 Comparison of MSE and DDA chromatograms for a GGCX protein digest 
sample……………………………………………………………………………....105 
 
Figure 2.8 Experimental peptide detection by DDA acquisition…………………………...106 
 
Figure 2.9 Experimental peptide detection by MSE acquisition……………………………107 
 
Figure 2.10 Evaluation of experimental reproducibility of triplicate MSE injections for a 
single peptide digest sample of GGCX……..………………………………………108 
 
Figure 2.11 Predicted planar topology for transmembrane protein GGCX…….………..…109 
 
Figure 2.12 SDS-PAGE gel illustrating purified GGCX migration after deglycosylation       
or limited trypsin digestion…………………………………………………………110 
 
Figure 2.13 Experimental flow diagram for in-gel digestion of GGCX followed by            
LC-MS analysis……………………………..……………………………………...111 
xx 
Figure 2.14 GRand AVerage of HydropathicitY (GRAVY) index profile for GGCX     
protein sequence…………………………………………………………………….112 
 
Figure 2.15 In silico digestion of GGCX by chymotrypsin or trypsin and corresponding 
hydropathy histogram for simulated digestion…………………………………......113 
 
Figure 2.16 In silico digestion of GGCX by chymotrypsin or trypsin and corresponding 
precursor ion frequency for simulated digestion…………………………………...114 
 
Figure 2.17 Experimental GGCX chromatograms for chymotrypsin and trypsin in-gel 
digestions…………………………………………………………………………...115 
 
Figure 2.18 Chromatographic comparison of in-gel GGCX chymotrypsin digestion with 
chymotrypsin digested gel control………………………………………………….116 
 
Figure 2.19 Peptide recovery topology for GGCX upon chymotrypsin in-gel digestion.  
Peptides identified by PLGS processing evaluating missed cleavage efficiency        
for chymotrypsin (C-terminal to F/Y/W not before proline) digestion………..…...117 
 
Figure 2.20 Peptide recovery topology for GGCX upon chymotrypsin in-gel digestion.  
Peptides identified by PLGS processing evaluating extended chymotrypsin     
digestion (C-terminal to F/Y/W/M/L not before proline)……………….……….....118 
 
Figure 2.21 Peptide recovery topology for GGCX upon chymotrypsin in-gel digestion.  
Peptide identification by PLGS processing evaluating nonspecific digestion 
conditions…………………………………………………………………………...119 
 
Figure 2.22 Amino acid preferential C-terminal cleavages upon chymotrypsin in-gel 
digestion of GGCX…………………………………………………………………120 
 
Figure 2.23 Peptide recovery topology for GGCX upon chymotrypsin in-gel digestion 
comparing MSE and DDA data acquisition methods……………………………….121 
 
Figure 2.24 Peptide percent recovery for GGCX upon varying chymotrypsin in-gel   
digestion conditions.  Parameters considered include concentration of proteolytic 
enzyme and digestion duration……………………………………………………..122 
 
 Figure 2.25 Peptide percent recovery for GGCX upon varying chymotrypsin in-gel  
digestion conditions.  Parameters considered include gel extraction temperature      
and column temperature…………..……………………...………………………....123 
 
Figure 2.26 Chromatographic comparison of in-gel GGCX chymotrypsin digestions 
evaluated at varying column temperatures…………………………………………124 
 
xxi 
Figure 2.27 Experimental peptide recovery compared to in silico digestion of GGCX by 
chymotrypsin.  Evaluation of peptide precursor frequency and hydropathy 
index………………………………………………………………………………...125 
 
Figure 2.28 Peptide recovery topology for GGCX upon trypsin in-gel digestion………….126 
 
Figure 2.29 Peptide percent recovery for GGCX upon in-gel digestion with varying 
concentration of trypsin proteolytic enzyme………………………………………..127 
 
Figure 2.30 Experimental peptide recovery compared to in silico digestion of GGCX           
by trypsin.  Evaluation of peptide precursor frequency and hydropathy index….....128 
 
Figure 2.31 Comparison of peptide recovery topology for GGCX upon chymotrypsin           
or trypsin in-gel digestions………………………………………………………….129 
 
Figure 2.32 Evaluation of sample preparation reproducibility of triplicate MSE          
injections for duplicate chymotrypsin peptide digest samples of GGCX………..…130 
 
Figure 2.33 Evaluation of sample contaminant reproducibility for duplicate        
chymotrypsin peptide digest samples of GGCX…………………………………....131 
 
Figure 3.1 Schematic diagram of processive mechanism of carboxylation………………...175 
 
Figure 3.2 Photoaffinity cross-linker vitamin K-dependent substrates: 33mer and 
27mer……………………………………………………………………………….176 
 
Figure 3.3 Circular dichroism overlaid spectra comparing the synthetic vitamin K-  
dependent substrates: 33mer cross-linker, 27mer AH3 (d0) cross-linker, 27mer       
AD3 (d3), and FIXQ/S……………………………….……………………………...177 
 
Figure 3.4 Reaction velocity curve at increasing concentrations of FIXQ/S with       
calculated Vmax and Km values…………………...………………………………....178 
 
Figure 3.5 Reaction velocity curve at increasing concentrations of 33mer cross-linker 
substrate with calculated Vmax and Km values………………………………………179 
 
Figure 3.6 Reaction velocity curve at increasing concentrations of 27mer cross-linker 
substrates with calculated Vmax and Km values……………………………………..180 
 
Figure 3.7 SDS-PAGE gel confirming 33mer photoactive cross-linking efficiency……….181 
 
Figure 3.8 Schematic cartoon representing GGCX carboxylation mechanism for FLEEL 
compared to cross-linker substrates………………………………………………...182 
 
Figure 3.9 SDS-PAGE gel confirming photoactive cross-linking efficiency at varying 
concentrations of the 33mer substrate………………………………………………183 
xxii 
Figure 3.10 SDS-PAGE gel confirming photoactive cross-linking efficiency at varying 
irradiation times for the 33mer substrate…………………………………………...184 
 
Figure 3.11 Percent FLEEL inhibition for 27mer and 33mer photoactive cross-linker 
substrates under varying conditions of cross-linker concentration and irradiation 
time…………………………………………………………………………………185 
 
Figure 3.12 SDS-PAGE gel confirming 33mer cross-linking specificity requires   
catalytically active GGCX……………………………………………………...…..186 
 
Figure 3.13 Fluorescent anisotropy binding curves confirming site-directed specificity        
for 33mer cross-linking………………………………...…………………………...187 
 
Figure 3.14 SDS-PAGE gel confirming 33mer cross-linking competitive inhibition           
with excess consensus propeptide……………….………………………………….188 
 
Figure 3.15 SDS-PAGE gel confirming inhibition of the 33mer cross-linker to the        
Y395A single-point GGCX mutant…………...……………………………………189 
 
Figure 3.16 SDS-PAGE gel confirming 33mer cross-linking site-specific covalent  
attachment to the 60 kDa C-terminal domain of GGCX………….…......................190 
 
Figure 4.1 Photochemistry of p-benzoylphenylalanine (Bpa) and radical recombination 
mechanism………………………………………………………………………….236 
 
Figure 4.2 Photochemistry of p-benzoylphenylalanine (Bpa) and modified radical 
recombination mechanism where proton abstraction occurs at the electron rich   
teriary Cγ-H center of leucine………………………………………………………237 
 
Figure 4.3 Photochemistry of p-benzoylphenylalanine (Bpa) and inhibited radical 
recombination……...……………………………………………………………….238 
 
Figure 4.4 Fluorescein ionization equilibrium and correlation of pH variations in visible 
absorbance spectra………………………………………………………………….239 
 
Figure 4.5 In-solution trypsin digestion of the 33mer cross-linker substrate and        
evaluation of mobile phase modifiers…………..…………………………………..240 
 
Figure 4.6 In-solution chymotrypsin digestion of the 33mer cross-linker substrate and 
evaluation of mobile phase modifiers………………………………………………241 
 
Figure 4.7 In-solution chymotrypsin and trypsin digestion of the 33mer cross-linker  
substrate in 10 mM ammonium acetate.  Cross-linker peptide fragments         
validated by MSMS sequencing……………………………………………..……..242 
 
xxiii 
Figure 4.8 In-gel chymotrypsin digestion of BSA-FITC and BSA.  Peptide separations 
completed on a capillary LC system in mobile phase supplemented with 10 mM 
ammonium acetate.  Detection by absorbance at 492 nm prior to mass analysis         
on a Waters® QTof MicroTM………………………...…………………………..…243 
 
Figure 4.9 Experimental flow diagram for in-gel digestion of 33mer photo cross-linked 
GGCX………………………………………………………………………………244 
 
Figure 4.10 In-gel chymotrypsin digestion of 33mer-GGCX and GGCX.  Peptide    
separations completed on a capillary LC system in mobile phase supplemented     
with 10 mM ammonium acetate.  Detection by absorbance at 492 nm prior to       
mass analysis on a Waters® QTof MicroTM…….………...………………………..245 
 
Figure 4.11 33mer-GGCX screened chymotrypsin digestion identifying uncross-linked 
33mer peptide fragments and sequence validation by MSMS fragmentation……...246 
 
Figure 4.12 Evaluation of 33mer-GGCX sample digest and identification of cross-         
linked peptide complex…………….……………………………………………….247 
 
Figure 4.13 Identification of 33mer cross-linker peptides by fragment ion selection 
patterns……………………………………………………………………………...248 
 
Figure 4.14 In-solution chymotrypsin and trypsin digestion of the 1:1(w/w) 27mer d0/d3 
cross-linker substrate……………………………………………………………….249 
 
Figure 4.15 In-solution chymotrypsin and trypsin digestion of the 1:1(w/w) 27mer d0/d3 
cross-linker substrate.  Cross-linker peptide fragments validated by MSE 
sequencing…………………………………………………………………………..250 
 
Figure 4.16 Total ion and mass slice chromatospectra for 1:1 (w/w) 27mer d0/d3             
cross-linker chymotrypsin digestion.……………………………………….............251 
 
Figure 4.17 27mer cross-linker identification by selected ion chromatospecta analysis.  
Precursor ions matching in retention time and intensity and varying in mass by      
three Daltons are amplified after treatment with an inverse log intensity function...252 
 
Figure 4.18 Experimental flow diagram for in-gel digestion of 1:1 (w/w) 27mer d0/d3     
photo cross-linked GGCX..…………………………………………………………253 
 
Figure 4.19 In-gel chymotrypsin digestion of 1:1 (w/w) 27mer d0/d3-GGCX and GGCX.  
Peptide separations and mass analysis completed on a nanoACQUITYTM UPLC 
system coupled to a Waters® QTof PremierTM operated in MSE  mode…………...254 
 
Figure 4.20 Total ion and mass slice chromatospecta for 1:1 (w/w) 27mer d0/d3-GGCX 
chymotrypsin digestion……………………………………………………………..255 
xxiv 
Figure 4.21 Selected ion chromatospectra for 1:1 (w/w) 27mer d0/d3-GGCX       
chymotrypsin digestion and identification of candidate GGCX cross-linked 
peptides……………………………………………………………………………..256 
 
Figure 4.22 Validation of a potential 27mer-GGCX cross-linked peptide complex      
observed in the selected ion chromatospectra plots in Figure 4.21...........................257 
 
Figure 5.1 Illustration of Nanodisc structure for an empty Nanodisc and protein       
embedded Nanodisc…………………………...……………………........................312 
 
Figure 5.2 Flow diagram of Nanodisc formation for empty Nandodiscs and protein   
embedded Nanodiscs………………...……………………………………………..313 
 
Figure 5.3 Size exclusion chromatograms of self-assembled empty Nanodiscs…………...314 
 
Figure 5.4 Size exclusion chromatograms overlaying self-assembled empty Nanodiscs       
and free MSP1D1 protein……….………………………………………………….315 
 
Figure 5.5 Size exclusion chromatograms overlaying self-assembled empty Nanodiscs       
and GGCX Nanodiscs…….………………………………………………………...316 
 
Figure 5.6 GGCX stability at 25oC for purified or Nanodisc embedded protein monitored    
by percent activity with and without consensus propeptide incorporation.....……...317 
 
Figure 5.7 Size exclusion chromatograms overlaying self-assembled GGCX Nanodiscs     
and Nanodiscs in which GGCX is catalytically inactive……………….……..........318 
 
Figure 5.8 Size exclusion chromatograms overlaying self-assembled GGCX Nanodiscs 
prepared with MSP1D1 to GGCX ratios of 20:1 and 10:1…………………………319 
 
Figure 5.9 Size exclusion chromatograms overlaying varied conditions for GGCX     
Nanodisc self-assembly.  Variables include: DOPC concentration or         
deoxycholate supplementation during reconstitution…………………….………...320 
 
Figure 5.10 Titration of GGCX embedded Nanodiscs against a constant concentration        
(14 nM) of a fluorescein-labeled consensus propeptide (FpCon) in standard        
buffer at 4oC in determination of stoichometric coefficients…………………….....321 
 
Figure 5.11 Size exclusion chromatograms of GGCX Nanodisc self-assembly with 
incorporated fluorescein labeled consensus propeptide (FpCon)…………………..322 
 
Figure 5.12 GGCX activity assay results for purified and GGCX embedded 
Nanodiscs……………………………………………………………………….…..323 
 
Figure 5.13 Characterization of fractionated GGCX Nanodiscs by SDS-PAGE and      
catalytic activity….…………………………………………………………………324 
xxv 
Figure 5.14 Characterization of fractionated FIXQ/S embedded GGCX Nanodiscs by     
SDS-PAGE and catalytic activity………………...………………………………...325 
 
Figure 5.15 Evaluation of VKOR Nanodisc preparation by SEC chromatography and  
activity assay measurements for VKOR purified with or without DOPC…...……..326 
 
Figure 5.16 Chromatographic representation of purified VKOR activity assay designed        
to measure the production of vitamin K1(20) from vitamin K epoxide (KO) by 
VKOR………………………………………………………………………………327 
 
Figure 5.17 Size exclusion chromatograms overlaying self-assembled empty Nanodiscs     
and attempted VKOR Nanodisc preparation…………………….…………………328 
 
Figure 5.18 Size exclusion chromatograms overlaying self-assembled VKOR Nanodisc 
preparations prepared with MSP1D1 to VKOR ratios of 20:1 and 10:1…………...329 
 
Figure 5.19 Characterization of fractionated VKOR Nanodisc preparation by SEC and 
catalytic activity…………………………………………………………………….330 
 
Figure 5.20 Comparison of percent catalytic activity for GGCX and VKOR when       
purified target membrane protein is spiked with low concentrations of purified 
membrane scaffold protein (MSP1D1) or empty Nanodiscs………..……………...331 
 
Figure 5.21 Atomic force microscopy (AFM) as a nanotool in membrane protein        
biology.  Evaluation of experimental force-distance curve of membrane protein 
unfolding experimentation with GGCX Nanodiscs………………………………...332 
 
Figure 6.1 Schematic diagram illustrating hydrogen deuterium exchange of proteins…….377 
 
Figure 6.2 Conventional HPLC Nanodisc HX MS workflow……………………….……..378 
 
Figure 6.3 Conventional HPLC chromatographic separation of empty Nanodisc pepsin 
digestion without lipid trapping…………………………………………………….379 
 
Figure 6.4 Conventional HPLC chromatographic separation of Nanodisc pepsin       
digestions comparing empty Nanodiscs and GGCX embedded Nanodiscs with      
lipid trapping……………………………………………………………………......380 
 
Figure 6.5 Evaluation of Nanodisc HX MS data quality and generation of deuterium     
uptake curves….……………………………………………………………………381 
 
Figure 6.6 Deuterium incorporation of GGCX from embedded Nanodisc pepsin       
digestions and analysis by conventional HPLC HX MS……………………….......382 
 
Figure 6.7 PONDR® plots predicting naturally distorted regions in GGCX and 
MSP1D1…………………………………………………………………………….383 
xxvi 
Figure 6.8 Deuterium incorporation of lipid-free MSP1D1 pepsin digestion and           
analysis by conventional HPLC HX MS..………...………………………………..384 
 
Figure 6.9 Deuterium incorporation of MSP1D1 from embedded Nanodisc pepsin      
digestion and analysis by conventional HPLC HX MS.  Overlaying uptake         
curves are indicative of changes in deuterium uptake for selected peptides when  
incorporated into GGCX occupied Nanodiscs, empty Nanodiscs, or lipid-free 
MSP1D1…………………………………………………………………………….385 
 
Figure 6.10 Evaluation of deuterium uptake for undigested MSP1D1 in conventional     
HPLC HX MS analysis………………….………………………………………….386 
 
Figure 6.11 Size exclusion chromatograms overlaying self-assembled empty Nanodiscs     
and empty Nanodiscs prepared under quench conditions (pH 2.5)……….…..........387 
 
Figure 6.12 Evaluation of empty Nanodisc cholate disassembly by conventional HPLC      
HX MS………….…………………………………………………………………..388 
 
Figure 6.13 Evaluation of zirconium oxide selected phospholipid removal in empty 
Nanodiscs…………………………………………………………………………...389 
 
Figure 6.14 UPLC Nanodisc HX MS workflow…………………………………………....390 
 
Figure 6.15 Chromatographic separations of empty Nanodisc pepsin digestions       
comparing conventional HPLC and UPLC HX systems.  Peptide elution profiles  
were compared over the acetonitrile concentration range of 12.5-28.5%.................391 
 
Figure 6.16 Evaluation of empty Nanodisc cholate disassembly by UPLC HX MS………392 
 
Figure 6.17  UPLC HX MS chromatographic time course exchange reaction of GGCX 
Nanodisc peptic digests and corresponding empty Nanodisc and GGCX         
Nanodisc undeuterated controls…………………………………………………….393 
 
Figure 6.18 Evaluation of experimental reproducibility of duplicate UPLC HX MS        
empty Nanodisc peptide digestion preparations…………….……………………...394 
 
Figure 6.19 Deuterium incorporation of GGCX from embedded Nanodisc pepsin      
digestion and analysis by UPLC HX MS…………………………………………..395 
 
Figure 6.20 UPLC chromatographic separations of GGCX Nanodisc pepsin digestions     
with and without incorporated consensus propeptide………………………………396 
 
Figure 6.21 UPLC HX MS chromatographic time course exchange reactions after         
pepsin digestion for consensus propeptide (pCon) with and without          
incorporation into GGCX Nanodiscs……………...………………………………..397 
 
xxvii 
Figure 6.22 UPLC HX MS deuterium incorporation of GGCX from embedded Nanodisc 
pepsin digestions with and without the presence of incorporated consensus   
propeptide (pCon)…………………..…………………………………...………….398 
 
Figure 6.23 Summary of peptide normalized percent deuterium change for GGCX    
Nanodisc samples prepared with and without the incorporation of consensus 
propeptide (pCon)………………..…………………………………………………399 
 
Figure A1.1 Gamma-Glutamyl Carboxylase (GGCX) HPC4 affinity purification.            
SDS-PAGE gel confirming GGCX purity with overlay of active GGCX       
concentration for each fraction.…..………………………………………………...410 
 
Figure A2.1 Vitamin K Epoxide Reductase (VKOR) HPC4 affinity purification.              
SDS-PAGE gel confirming GGCX purity with overlay of calibrated VKOR 
concentration for each fraction……………………………………...……………...421 
 
Figure A3.1 Membrane Scaffold Protein (MSP1D1) expression vector and        
corresponding protein and DNA sequence. ...……………………………………...430 
 
Figure A3.2 Membrane Scaffold Protein (MSP1D1) expression in E.coli BL-21 Codon     
Plus (DE3) cells and purification by Ni-NTA Agarose…………………………….431 
 
Figure A4.1 Relative deuterium incorporation curves for MSP1D1 in GGCX embedded 
Nanodiscs for analysis by conventional HPLC HX MS.  ………………………….434 
 
Figure A4.2 Relative deuterium incorporation curves for MSP1D1 in GGCX embedded 
Nanodiscs, empty Nanodiscs, or lipid-free samples for analysis by conventional 
HPLC HX MS……………………………………………….……………………...437 
 
Figure A4.3 Relative deuterium incorporation curves for GGCX in embedded          
Nanodiscs for analysis by UPLC HX MS…………………..………………………439 
 
Figure A4.4 Comparison of relative deuterium incorporation curves for GGCX in    
embedded Nanodiscs for analysis by conventional HPLC or UPLC HX MS 
methods……………………………………………………………………………..442 
 
Figure A4.5 Relative deuterium incorporation curves for GGCX in embedded         
Nanodiscs with and without incorporated consensus propeptide for analysis by   
UPLC HX MS……………………………………………………………………....446 
 
 
 
 
 
xxviii 
LIST OF ABBREVIATIONS AND SYMBOLS 
1D   one-dimensional 
2D   two-dimensional 
2D-PAGE  two-dimensional polyacrylamide gel electrophoresis 
Å   Angstroms 
ACN   acetonitrile 
Aβ   β-amyloid 
Ad3   deuteroalanine 
ALS   acid-labile surfactant 
AFM   atomic force microscopy 
ASAP   Automated Spectrum Assignment Program 
BEH   bridged ethyl hybrid 
BID   N-benzyliminodiacetoyloxysuccinimide 
BLAST  Basic Local Alignment Search Tool 
Bpa   p-benzoyl-L-phenylalanine 
BP   benzophenone 
BPI   base peak intensity 
bR   bacteriorhodopsin 
BSA   bovine serum albumin 
BSA-FITC  BSA-isothiocyanate 
BSM   binary solvent manager 
oC   degrees Celsius 
CapLC   Waters® capillary LC system 
xxix 
CHAPS 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate hydrate 
CI   chemical ionization 
CD   circular dichroism 
CID   collision-induced dissociation 
CMC   critical micelle concentration 
cpm   counts per minute 
CYPs   Cytochrome P450s 
Da   Dalton 
DDA   data directed analysis 
DHPC   1,2-diheptanoyl-sn-glycero-3-phosphocholine 
DNFB   2,4-dinitrofluorobenzene-d0/d3 
DOPC   1,2-dioleoyl-sn-glycero-3-phosphocholine 
dp   particle diameter 
DTSSP  3,3’-dithio-bis(succinimidylpropionate) 
DTT   dithiothreitol 
DXC   dynamic external calibration 
EDC   1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
EDTA   ethylenediamine-tetraacetic acid 
EI   electron ionization 
EMRT   exact mass retention time 
ER   endoplasmic reticulum 
ESI   electrospray ionization 
eV   electronvolts 
xxx 
FAB   fast atom bombardment 
FLEEL  Phe-Leu-Glu-Glu-Leu 
fmol   femtomole 
FpCon   fluorescein-labeled consensus propeptide 
FT-ICR  fourier-transform ion cyclotron resonance 
FWHM  full width at half maximum 
g   gram (milligram-mg; microgram-g; nanogram-ng) 
GGCX   Gamma-Glutamyl Carboxylase 
Gla   gamma-carboxy glutamic acid 
Glu   glutamic acid 
GPMAW  General Protein/Mass Analysis for Windows 
GRAVY  Grand Average Hydropathy 
HDL   high-density lipoprotein 
HDX   hydrogen deuterium exchange 
HPC4   calcium dependent epitope tage (EDQVDPRLIDGK) 
HPLC   high performance liquid chromatography 
hr   hour 
HSP70   heat shock protein 70 
HX MS  hydrogen deuterium exchange mass spectrometry 
ID   inner diameter 
IEF   isoelectric focusing 
IgG   immunoglobulin 
IR   infrared 
xxxi 
Kd   dissociation rate constant 
kDa   kiloDalton 
KH2   vitamin K hydroquinone 
keV   kiloelectron volts 
Kfl   5(6)-carboxyfluorescein 
Km   Michaelis constant 
KO   vitamin K 2,3 epoxide 
LC   liquid chromatography 
LD   laser desorption 
L   liter (milliliter-mL; microliter-L; nanoliter-nL) 
LSPR   localized surface plasmon resonance 
LUV   large unilamellar vesicles 
M   molar (milimolar-mM; micromolar-M; nanomolar-nM) 
m   meter (milimeter-mm; micrometer-m;- nanometer-nm) 
MALDI  matrix-assisted laser desorption ionization 
MAXEnt1  maximum entropy processing 
MC   missed cleavages 
MES   2-(N-morpholino)ethanesulfonic acid 
MIX   mixed isotope cross-linking 
MK-n   menaquinone-n 
MK0   menadione 
MLH   medium-low-high scanning 
min   minute 
xxxii 
MLV   multilamellar vesicales 
MOPS   3-(N-morpholino)-propanesulfonic acid 
MP   mobile phase 
MPG   matrix Gla protein 
MS   mass spectrometry 
MSE   Waters® high-low energy collision energy fragmentation acquisition 
MSMS   tandem mass spectrometry 
MSP   membrane scaffold protein 
NHS   N-hydroxysuccinimide  
NMR   nuclear magnetic resonance 
OBG   octyl-β-glucopyranoside 
OD   outer diameter 
OTC   open tube capitally 
PAGE   polyacrylamide gel electrophoresis 
pCon   consensus propeptide 
PD   plasma desorption 
PDI   protein disulfide isomerase 
pFIX   propeptide factor IX 
PGLS   Waters® Protein Lynx Global Server 
PICUP   photo-induced cross-linking of unmodified proteins 
PMF   peptide-mass fingerprinting 
PMFS   phenylmethyl sulfonyl fluoride 
pmol   picomole 
xxxiii 
ppm   parts per million 
psi   pounds per square inch 
PTM   posttranslational modification 
QTof   quadrupole time of flight 
r   fluorescence anisotropy 
RPLC   reverse phase liquid chromatography 
RT   retention time 
S   substrate 
sec   second 
SAM   self-assembled monolayer 
SAXS   small angle X-ray studies 
SEC   size exclusion chromatography 
Sf9   Spodoptera frugiperda 
siRNA   small interfering RNA  
SDS   sodium dodecyl sulfate 
SDS-PAGE  sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SIC   selected ion chromatogram 
SNPs   single nucleotide polymorphisms 
SPR   surface plasmon resonance 
SUV   small lamellar vesicles 
TF   tissue factor 
TFA   trifluoroacetic acid 
THP   tris(hydroxypropyl)phosphine 
xxxiv 
TIC   total ion current 
TOF   time-of-flight 
Tris-HCl  tris(hydroxymethyl)aminomethane hydrochloride 
UHPLC  ultra high pressure liquid chromatography 
UPLC   ultra performance liquid chromatography 
UV   ultraviolet 
Vis   visible 
VKD   vitamin K-dependent 
VKOR   Vitamin K Epoxide Reductase 
VKORC1  Vitamin K Epoxide Reductase complex subunit 1 
v   reaction velocity 
v/v   volume to volume ratio 
Vmax   maximum reaction velocity 
w/w   weight to weight ratio 
Warfarin  3-(α-acetonylbenzyl)-4-hydroxycoumarin 
 
 
 
 
 
 
CHAPTER 1: The Vitamin K Cycle 
________________________________________________________ 
1.1 Vitamin K 
Vitamin K was first discovered in 1929 when Henrik Dam was studying the synthesis of 
cholesterol in chickens.1  Dam noted that chickens being fed a lipid-free diet developed a 
bleeding diathesis.  This observation later led to the discovery of the fat-soluble nutrient 
vitamin K, named after the Scandinavian spelling of the word koagulation for its crucial role 
in blood coagulation.2  After the initial discovery of vitamin K, Edward Doisy determined 
that the main source of vitamin K was through the diet, particular from green vegetables and 
fish meal.3   
Further characterization of the chemical structure classified vitamin K in a family of 
methylated napthoquinone ring structures occupying variable aliphatic side chains at position 
three (Figure 1.1).  Vitamin K1, also called phylloquinone, has a side chain consisting of four 
isoprenoid units, one of which is unsaturated.  Similarly, vitamin K2, or menaquinone, 
contains an unsaturated side chain of repeating isoprenoid groups that vary in length from 4 
to 13 units and is found in milk, cheese, and fermented soy products.  K2 analogues are 
typically called menaquinone-n or MK-n, where n is the number of isoprenoid groups.  The 
third synthetic form of vitamin K is vitamin K3 or menadione (MK0), which has a methyl 
group present at the second position on the napthoquinone ring.  Menadione’s primary use is 
in animal feed and is converted by the body to menaquinone for biological function.4 
2 
Shortly after the discovery of vitamin K, another important discovery in blood 
coagulation was made.  During the early 1940s, cows were bleeding to death after eating 
moldy sweet clover hay.5  Karl Link discovered that these deaths could be attributed to a 
fungal vitamin K antagonist, dicumarol.  Further studies led to the synthesis of a series of 
derivatives of dicumarol.  One of these derivatives, Warfarin named after the Wisconsin 
Alumni Research Foundation was initially used as a rat poison before being used as an 
anticoagulant.  Despite the potential harmful side effects, Warfarin has continued to be 
regarded as the preferred choice of anticlotting agent. 
The actual role of vitamin K in blood coagulation did not become apparent until 1974 
when Stenflo, Nelsestuen, and Magnusson independently discovered the novel amino acid 
gamma-carboxy glutamic acid (Gla).6-8  In this study, it was observed that Gla residues were 
absent from bovine prothromin following vitamin K deficient diets or treatment with the 
anticoagulant dicumarol, a vitamin K antagonist.  Thus, it was hypothesized that vitamin K 
serves as an obligatory cofactor for carboxylation of protein bound glutamic acid (Glu) in 
prothrombin and other vitamin K-dependent proteins.   
Further work investigating the role of vitamin K, allowed identification of a family of Gla 
proteins referred to as vitamin K-dependent (VKD) proteins.  Most of these proteins play a 
role in blood coagulation, including those with procoagulant functions (prothrombin, factor 
VII, factor IX, and factor X) and those with anticoagulant function (proteins C, X, and Z).  
Outside of the coagulation cascade, VKD proteins are also involved in calcification and cell 
growth.  One such example was demonstrated with the observation that a knockout of matrix 
Gla protein (MGP) leads to complete calcification of arteries within two months of age.9  
This condition may be reversed, however, if MGP is locally expressed in smooth muscle 
3 
cells, demonstrating the importance and specificity of this reaction.10  Transgenic expression 
of MGP with two or four of its Glu residues modified to aspartate prevents carboxylation and 
renders MGP incapable of rescuing the calcification of arteries in a knockout mouse.  Thus, 
the carboxylation of Glu residues is found necessary for the function of MGP in bone 
metabolism.  Other VKD proteins include osteocalcin, involved in calcification,11 the growth 
arrest protein Gas 6,12, 13 known to activate the Axl tyrosine kinase receptor, and four proline-
rich Gla proteins of unknown function: PRRG1, PRRG2, PRRG3, and PRRG4.14, 15 
Several factors influence the impact of vitamin K during the carboxylation process 
including source, location, and side chain additions.  The amount of vitamin K in the diet is 
often a limiting factor in the carboxylation reaction.  For example, osteocalcin or bone Gla 
protein is partially carboxylated in normal healthy volunteers, however, becomes fully 
carboxylated only when vitamin K is supplemented into the diet.16  Likewise, it has been 
commonly assumed that vitamin K produced by enteric bacteria can be absorbed.  If 
coprophagy is prevented, however, rats fed a vitamin K-free diet develop severe bleeding 
problems within weeks.17, 18  In addition to vitamin K source, the location and half-lives of 
vitamin K analogs also play an important role.  A recent observation concluded that K1 
appears to be taken up primarily in the liver whereas K2 appears to preferentially accumulate 
in arteries and extrahepatic locations.17, 19  Increasing the hydrophobicity of vitamin K2 
analogues MK7 and MK9 has also been shown to contribute to longer half-lives in plasma 
compared to short chain analogues such as MK4.20, 21 
Further investigation of vitamin analogues disproved the former assumption that vitamin 
K functions solely as a co-substrate for carboxylation of VKD proteins.  Although it was 
known that K2 promoted bone formation, it was assumed that its function was exclusively 
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through its action on the Gla proteins osteocalcin and MGP.22  Recently, however, it has been 
reported that K2 can directly stimulate mRNA production of osteoblast mRNA markers as 
well as function as a transcriptional regulator of bone-specific genes.23  Such findings not 
only expand current knowledge of the overall physiological importance of vitamin K, but 
provides additional information on vitamin K involvement in carboxylation. 
 
1.2 The Vitamin K Cycle 
The enzyme that modifies vitamin K-dependent proteins is Gamma-Glutamyl 
Carboxylase (GGCX).  Glutamic acid (Glu) residues in vitamin K-dependent (VKD) proteins 
are carboxylated to form gamma-carboxy glutamic acid (Gla) residues (Figure 1.2, I).  
Concomitant with Gla modification, reduced vitamin K hydroquinone (KH2) is converted to 
vitamin K 2,3 epoxide (KO).  Before KH2 can be reused in the carboxylation mechanism, it 
must be converted from KO to vitamin K by Vitamin K Epoxide Reductase (VKOR) (Figure 
1.2, II).  During this recycling, cysteine residues in VKOR at positions 132 and 135 are 
oxidized to a disulfide bond.  Despite the known functionality of this center, the identity of 
electron donation for VKOR remains unknown.  As KH2 is regenerated (Figure 1.2, III), the 
disulfide bond in VKOR is reduced back to its thiol form and the cycle continues.  Although 
VKOR itself can catalyze both the conversion of KO to vitamin K and vitamin K to KH2,24, 25 
patients poisoned with the anticoagulant Warfarin can be maintained with vitamin K 
treatment.  Thus it is hypothesized that enzymes, other than VKOR, may also be involved in 
the conversion of vitamin K to KH2.  For example, it has been shown that DT diaphorase can 
function to convert K to KH2.26, 27  Reports studying this quionone reductase, have concluded 
that DT diaphorase acts as the antidotal enzyme.  Future experimentation, however, is needed 
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to determine the precise mechanism and enzymatic participants necessary for the conversion 
of K to KH2.   
After carboxylation of vitamin K-dependent coagulation factors, the mature protein is 
secreted into the circulatory system where two or three of the Gla residues bind a single 
calcium ion stabilizing the final tertiary structure of the protein.28, 29  This process is 
associated with conformational change, exposing phospholipid membrane-binding sites.  In 
the event of an injury, the VKD coagulation is triggered by a protein complex consisting of 
tissue factor and factor VII promoting clot formation. 
 
1.3 Gamma-Glutamyl Carboxylase (GGCX) 
Vitamin K-dependent Gamma-Glutamyl Carboxylase, GGCX, was first discovered in 
1975, but was not purified and cloned until 1991.30-32  Human GGCX is a 758 amino acid 
integral membrane glyocoprotein33 with five transmembrane domains and one disulfide bond 
between residues 99 and 450 (Figure 1.3).34, 35  GGCX is found most commonly in the liver, 
where the VKD proteins are synthesized, but is also found in the lungs, skin, and kidney.36  
In addition to its prevalence in vertebrates, GGCX is also found to be highly conserved in 
two species of invertebrates Conus and Drosophilia.  Topological studies demonstrate that 
each transmembrane domain passes through the endoplasmic reticulum (ER) with the N-
terminal in the cytoplasm and the C-terminal in the lumen.37  The predicted topology of 
GGCX is shown in Figure 1.3. 
The vitamin K-dependent enzyme Gamma-Glutamyl Carboxylase is responsible for the 
post-translational modification of selected glutamic acids (Glu) to gamma-carboxy glutamic 
acid (Gla) on VKD proteins.  In addition to a vitamin K-dependent protein, carboxylation 
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requires three cosubstrates: vitamin K hydroquinone, oxygen, and carbon dioxide.  Since the 
amount of vitamin K available in the body is limited, the vitamin K cycle will act to recycle 
formation of vitamin K hydroquionone promoting continual carboxylation.  As a result of the 
interdependence of proteins in the vitamin K cycle, depletion of KH2 and reduced 
carboxylation is shown to result when Vitamin K Epoxide Reductase (VKOR) is inhibited by 
Warfarin treatment, a commonly used anti-coagulant.  Interruption of the vitamin K cycle by 
Warfarin, thus results in a dramatic decrease in blood coagulation.   
1.3.1 GGCX Substrate Recognition 
GGCX recognizes VKD protein substrates through an eighteen amino acid region, 
termed the propeptide.  This region, labeled as -18 to -1, contains three highly conserved 
amino acid residues; phenylalanine at -16, alanine at -10, and leucine at -6.38  When these 
conserved residues are mutated, carboxylation is reduced or completely eliminated.39  For 
vitamin K-dependent coagulation proteins, the N-terminal propeptide domain demonstrates 
high affinity binding to GGCX that serves to anchor the substrate on GGCX while multiple 
Glu residues in the VKD protein are modified.   
Contrastingly, the VKD bone proteins, have a slightly different recognition mechanism.  
Matrix Gla protein lacks a propeptide domain on the amino terminal of the protein, but 
instead contains a propeptide-like sequence in the middle of the mature protein.40  
Osteocalcin, on the other hand, contains a propeptide but it has very poor affinity for 
GGCX.41  Here the remaining protein sequence is shown to have a high affinity for GGCX 
thus promoting binding.   
The location of the propeptide binding site has been extensively studied and has been 
determined to bind the amino acid residues from 495 to 513 on GGCX.42, 43  Cross-linking 
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and site-specific mutations present in this region of GGCX result in a decrease in the 
enzyme’s affinity for the propeptide.  Several studies have been conducted evaluating the 
influence of the propeptide domain on carboxylation.  Although the propeptide domains have 
similar sequences, their affinities are seen to vary over 100-fold.41  The precise explanation 
for this variability is not yet known, however, it has been concluded that the binding of a 
vitamin K-dependent protein to GGCX is a cooperative event between both the propeptide 
and the Gla domain.    
In most VKD proteins, a highly conserved Gla domain follows the propeptide.  This 
approximately 45 amino acid residue region contains the Glu residues that are converted to 
Gla.44-46  In a typical VKD protein, approximately 9-12 Glu residues are carboxylated.  
Exceptions to this are osteocalcin and MGP, which do not have typical Gla domains, 
carboxylating only 3-5 Glu residues.  Once carboxylation converts the selected Glu residues 
in the clotting cascade proteins to Gla residues, the propeptide is proteolytically cleaved and 
the mature protein is secreted from the cell.47  When the VKD protein is in the presence of 
calcium, the Gla domain undergoes a conformational change, allowing association with 
phospholipids on the membrane surface near damaged vascular tissue. 
1.3.2 The Carboxylation Mechanism 
An elegant theory explaining a chemical model for carboxylation was proposed by 
Dowd and colleagues.48  According to this model, described as a base amplification, KH2 is 
transformed to KO through the formation of a reactive strong base napthoquinone 
intermediate.  This base is hypothesized to abstract a hydrogen ion from the gamma-
methylene group of glutamate (with a pKa ~ 25-28) to produce a reactive carbanion 
intermediate.  Subsequent CO2 addition to the glutamate carbanion promotes formation of the 
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product, gamma-carboxy glutamic acid.  The Dowd base amplification mechanism is 
illustrated in Figure 1.4. 
Recently, Davis et al. investigated quantum mechanical methods to evaluate Dowd’s 
hypothesis.49, 50  The geometries of the proposed model intermediates were energetically 
optimized to confirm the strong base to be an alkoxide of vitamin K (Figure 1.2, Ia).  Since 
formation of such a strong base does not occur naturally, it is hypothesized that a weak 
GGCX catalytic base acts to deprotonate KH2 promoting formation of the alkoxide.48  This is 
further confirmed by quantum calculations that indicate the initial, crucial step in the reaction 
is the removal of a proton from the hydroxyl group on position 1 of vitamin K 
hydroquinone.49, 50  After this initial event, the energetics of the reaction is favorable.  
Initially it was experimentally hypothesized that cysteine residues on the enzyme must 
be involved in the formation of Gla residues.51-53  Original experiments by Pudota et al. 
showed that when isotopically-modified N-ethyl maleimide, a thiol binding reagent, was 
incubated with purified GGCX in the absence of cofactors, two cysteine residues were 
modified, resulting in loss of epoxidation and carboxylation.54  The two residues were 
identified to be Cys-99 and Cys-450.  Later, Tie et al. proved this to be untrue by 
characterizing all ten cysteine residues in GGCX.55  Analysis of protease digested GGCX 
using matrix-assisted laser desorption ionization time-of-flight mass spectrometry revealed 
that Cys-99 and Cys-450 were involved in a disulfide linkage.35  Therefore, Cys-99 and Cys-
450 are unlikely to be part of the active site of the enzyme.  Mutations to either cysteine 
resulted in loss of activity but could be attributed to structural changes caused by the 
elimination of the disulfide linkage.  The remaining eight cysteine residues were found to be 
free sulfhydryls, and mutational analysis concluded that these residues are not responsible for 
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the catalytic activation of GGCX.  As a result of these finding, other residues in GGCX were 
investigated.56, 57  
Only a limited number of functional GGCX residues are known to affect enzymatic 
activity.  Recently, 2D crystals of GGCX were produced allowing structural investigation by 
electron crystallographic methods.58  A cryo-EM projection map at 12Å resolution revealed 
that GGCX crystallizes as a monomer.  Despite this significant advancement, further studies 
are currently underway aimed at constructing a high-resolution model of the enzyme to help 
identify functional residues of importance.  In the mean time, the identification of naturally 
occurring missense mutations has been particularly informative in guiding structure-function 
relationships for GGCX.  The human GGCX gene is autosomal59 and until recently, only five 
mutations were known, four of which have been tested in vitro60-62.  All of these mutations 
cause serious bleeding complications due to combined VKD factor deficiency.   
The first naturally occurring mutant identified as causing combined deficiency of 
hemostatic VKD proteins was L394R.63  L394 resides within a highly evolutionarily 
conserved region of GGCX between residues 394 to 404.61, 64  Substitutions in L394 and in 
neighboring residues Y395 and W399 result in significant inhibition of carboxylation 
implying this region is important for Glu domain binding.64  Two of the mutations L394R 
and W399A also showed decreased propeptide binding consistent with the interrelationship 
between the Gla domain and propeptide binding.  It is interesting to note that L394, Y395, 
and W399 are all hydrophobic residues, indicating that GGCX is not binding Glu residues 
through ionic interaction and may instead be binding either the peptide backbone or 
hydrophobic residues that are adjacent to selected glutamic acids. 
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W501S, is a second mutation which is shown to result in combined VKD protein 
deficiency.65  Kinetic and structural analysis of this mutant concluded that inhibition was 
primarily linked to the propeptide-binding site rather than an internal regulatory 
sequence.42,62  Naturally occurring mutations in residues W157 and T591, which are both 
evolutionarily conserved, have also been investigated in vitro.  The W157R and T591N 
mutations were identified in a patient who also contained a third GGCX missense mutation 
D31N, resulting in combined VKD protein deficiency.60  Unlike with the L394R or W501S 
mutant which showed partial restoration of VKD function when supplemented with vitamin 
K, a patient containing W157R and T591N mutants did not respond to vitamin K 
supplementation.63, 65  The lack of response in the patient with such mutations therefore 
suggests that W157 and T591 participate in roles other than VKD protein binding. 
Comparison of evolutionarily distinct vitamin K-dependent GGCX orthologs has also 
been informative in suggesting functional regions of GGCX.  The evolutionary divergence of 
the L. interrogans VKD ortholog was particularly useful in identifying the potential catalytic 
base that initiates the carboxylation reaction.66  Rishavy et al. concluded complete loss of 
GGCX catalytic activity upon mutation of residue K218A.67  The activity of this K218A 
mutant was restored by exogenously added amines where activity rescue was dependent on 
the basicity of the amine.  Thus, it was concluded that L218 is the catalytic base that 
deprotonates vitamin K hydroquinone to initiate carboxylation.  In order to function as the 
catalytic base, it was concluded that L218 must be in an unprotonated state.  One mechanism 
used by other enzymes is the presence of a second lysine, where close juxtapositioning of 
two positively charged residues decrease the affinity of one lysine for a proton and results in 
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deprotonation at physiological pH.  This mechanism adheres well with the structure of 
GGCX with two neighboring lysine residues at positions 217 and 218 respectively. 
1.3.3 A Processive Carboxylation Mechanism 
Our current theory on how carboxylation occurs is that the VKD substrate binds 
GGCX primarily through the high affinity propeptide domain.  As the VKD protein binds 
GGCX, conformational changes result in carboxylation regulation.  Propeptide binding is 
shown to increase GGCX affinity for the Glu substrate,68 whereas Glu binding modulates 
GGCX affinity for the propeptide.69  Likewise, binding of a substrate in which both domains 
are covalently attached increases the affinity of GGCX for vitamin K cofactors.70   
For covalently linked vitamin K-dependent proteins, carboxylation is shown to occur 
through a processive mechanism where the propeptide binding is relatively tight, and all 
substrate carboxylations that are to occur for a given substrate, occur during a single binding 
event.71, 72  In a processive carboxylation mechanism, the relative rates of catalysis and 
release of VKD proteins from GGCX can be explained.  In one study, a kinetic time course 
experiment characterizes the carboxylation of a vitamin K-dependent substrate to include a 
burst phase followed by a prolonged steady-state rate.73  In an enzyme-excess environment 
(burst phase), the carboxylation rate is linear up to ten Gla residues and then slows for the 
addition of the last two glutamic acids in a factor IX substrate.  The slower steady-state rate 
constant, on the other hand, corresponds to the release of the fully carboxylated K-dependent 
substrate from GGCX.  Based on these in vitro experiments, it was concluded that substrate 
release, not carboxylation, is the rate limiting step in the GGCX mechanism.  The extent of 
carboxylation is not only determined by the relative rate of carboxylation itself but is also 
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dependent on the level of vitamin K available, the dissociation rate of the substrate from 
GGCX, and the addition or modification of co-substrates. 
Efficient carboxylation is limited in mammalian cells.  Low-levels of VKD 
expression result in the secretion of fully carboxylated VKD proteins, however, high-level 
expression saturates the capacity for carboxylation resulting both fully and uncarboxylated 
VKD protein.  This limitation in carboxylation has been a major impediment for producing 
VKD proteins for therapeutic applications.74-76  Similarly, GGCX overexpression does not 
improve carboxylation.77, 78  Even though recombinant GGCX is functional, the supply of 
vitamin K hydroquinone is limiting.  Subsequent studies, however, showed that 
overexpression of VKOR and consequently an increase in the reduced vitamin K cofactor 
results in an increased VKD protein carboxylation.79-81 
 
1.4 Vitamin K Epoxide Reductase (VKOR) 
The enzyme responsible for the regeneration of vitamin K from vitamin K epoxide is 
VKOR.  This activity was first reported in 1970,82 but it proved refractory to purification for 
more than 30 years until 2004, when the gene that codes for VKOR was independently 
identified by two laboratories.83, 84  In one study, Rost et al. investigated patients and rats 
with inherited defects in VKOR activity.84  They found that mutations in one particular gene 
occurred in two families with defective vitamin K-dependent clotting factors, in four families 
with hereditary Warfarin resistance, and in several rat strains with resistance to Warfarin-like 
poisons.  They also showed that this candidate VKOR gene encodes a small transmembrane 
protein that is found in the endoplasmic reticulum.  They named this protein, Vitamin K 
Epoxide Reductase complex subunit 1 (VKORC1), thus taking into consideration the 
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possibility that it might be only one component of a larger complex.  Meanwhile, Li et al. 
identified the VKORC1 gene using another approach.83  They constructed a candidate locus 
on chromosome 16.  Ruling out genes that encoded proteins with known functions, they then 
selected transmembrane predicted genes and conducted knockdown experiments using 
double-stranded small interfering RNA molecules (siRNAs) for each of the thirteen gene 
candidates.  Knockdown of only one of the thirteen genes resulted in significant reduction of 
VKOR activity.  The putative VKOR gene was cloned and overexpressed in insect cells to 
confirm VKOR function and Warfarin sensitivity. 
1.4.1 Structural Representation of VKOR 
Determination of the structure of the VKOR protein has been one of the primary 
research goals since cloning.  In vitro translation experiments as well as electronic structure 
predictions suggest a 163 amino acid protein topology comprising three transmembrane 
domains (Figure 1.5).85  The amino-terminus is located in the lumen of the endoplasmic 
reticulum, and the carboxy-terminus is exposed to the cytoplasm.  Another feature in the 
topology model of VKOR is the distribution of tryptophan residues in the interfacial regions 
of the membrane bilayers.  It is reported that tryptophan residues exhibit a strong tendency to 
remain within the interfacial region serving as anchor residues that fix the transmembrane 
helix within the lipid bilayer.86  Moreover, it has been suggested that tryptophan residues 
support transmembrane helix-helix interactions.87  The four interfacial tryptophan residues in 
VKOR are highlighted in the predicted topology diagram shown in Figure 1.5.   
Looking in more detail at the sequence homology of VKOR, four cysteine residues 
(aa 43, 51, 132, and 135) and one residue which is either a serine or threonine (aa 57) were 
found to be completely conserved in all species analyzed.  In several studies, the importance 
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of these residues on VKOR activity was investigated by in vitro mutagenesis and 
recombinant expression.25, 88-90  Concordantly, all studies revealed complete loss of VKOR 
enzymatic activity, when Cys132 and Cys135 located in the third transmembrane helix were 
mutated.  The hydrophobic location of cysteines 132 and 135 is consistent with the 
observation that the active site of VKOR is located in a hydrophobic environment.91  In 
addition, a lipid membrane environment is most likely required for these active site cysteines 
to maintain proper structure further explaining the loss of VKOR enzymatic activity when 
the microsomal membrane is solubilized by detergent.  Thus, the two vicinal cysteines 132 
and 135 have been proposed to form the VKOR redox center, where a CXXC motif 
characterizes the active center of redox enzymes similar to that identified in the thioredoxin 
family.88  Such redox containing CXXC proteins are shown to complex with other proteins to 
facilitate reduction by cysteine thiol-disulfide exchange.   
The importance of cysteine mutations was further explored by Jin et al. and Rost et 
al. in which VKOR mutants were evaluated.25, 88, 89  Although similar results were achieved 
in both experiments confirming that C132 and C135 of the CXXC motif participate as the 
redox active site in VKOR, there was also a persuasive argument for the importance of C43 
and C51.  Removing cysteines 43 and 51 together with the intervening amino acids, however, 
was found to persist without significant loss of activity.25  Thus, the role of these two 
residues has yet to conclude their functional importance.  One hypothesis is that C43 and C51 
function to regulate VKOR activity as a potential transmembrane electron transporter system 
that maintains redox conditions for the CXXC motif.25  This notion begins to question the 
possibility of a single-enzyme VKOR system rather than a multi-protein complex.  It is clear, 
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however, that the discussion of VKOR as a single or multi-enzyme complex will only be 
clarified with future in vivo studies designed to address this question. 
Since the discovery of the enzymatic activity of VKOR in 1970, numerous 
unsuccessful attempts to purify VKOR from hepatic microsomes were investigated.92-96  It 
was not until 2006, that the purification of active VKOR from Sf9 insect cells was reported 
by Chu et al.24 The most critical aspect of the purification was to find conditions that allowed 
reconstitution of the enzyme after purification.  Since VKOR must maintain membrane 
structure for activity, the addition of detergents to microsomes containing recombinant 
VKOR in insects cells results in a loss of activity.  Although VKOR has encountered 
problems with solubility during purification, understanding issues with solubility may begin 
to open the door towards understanding the complex nature of VKOR.   
1.4.2 Catalytic Responsibilities of VKOR 
The main role of VKOR is to catalyze the reduction of vitamin K epoxide and 
vitamin K to vitamin K hydroquinone, a cofactor required for the GGCX carboxylation 
reaction.  In vitro, the enzymatic activity of VKOR requires a dithiol compound to reduce the 
critical disulfide within the active site of VKOR.  Based on a chemical model study, a 
reaction mechanism for converting KO to vitamin K by VKOR was proposed by Silverman 
(Figure 1.6, steps 1-7).97  In this model, an active site disulfide bond of VKOR (1) is reduced 
by a thiol to activate the enzyme (2).  KO binds to the reduced form of VKOR and the 
epoxide oxygen is protonated by a nearby acid residue (3).  One of the sulfhydryls in the 
active site attacks the carbon at position 2 of KO forming a -hydroxy sulfide adduct (4).  
Protonation of the -hydroxyl group then generates an active leaving group for reductive 
elimination (5) which is promoted by another active site sulfhydryl group (6).  In this 
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reaction, KO is reduced to vitamin K and the active site cysteines in VKOR are oxidized to a 
disulfide (7).  A quantum chemical study of the reaction mechanism of KO reduction by 
VKOR supports and extends the Silverman mechanism.98, 99  This model demonstrates that 
once the disulfide bond of VKOR is broken, the reaction is energetically favorable.  The only 
difference, between these two models is that Davis et al. predicts the proton source that 
protonates the epoxide oxygen to be donated from an active site sulfhydryl group rather than 
from a nearby acidic residue.98 
The requirement for breaking an active site disulfide bond of VKOR to initiate its 
enzymatic activity stimulated the search for its physiological reductant.  Here a compelling 
argument was made that there must be at least a temporary complex that occurs when 
oxidized VKOR is reduced by an in vivo reductant, similar to the thioredoxin reductase.  
Investigating in vitro microsomal preparations potential target VKOR reductants include: 
lipoamide reductase,100 reduced thioredoxin,101 and protein disulfide isomerase.102  Wallin 
and co-authors reported that protein disulfide isomerase (PDI) is the reductant that reduces 
the disulfide bond in VKOR created during each K cycle.103  In this report, they 
demonstrated the ability to immunoprecipitate VKOR together with PDI when using an anti-
PDI antibody tag.  It was concluded from this study that treating the cells with RNAi against 
PDI decreased the activity of VKOR in microsomes.  Although there still remains some 
uncertainty in the identification of the antidotal VKOR reductant, the CXXC center of 
VKOR is shown to play a central mechanistic role in the vitamin K cycle.   
1.4.3 Functional Relations of VKOR 
Some authors claimed there to be an alternative multicomplex subunit with VKOR 
such as microsomal epoxide hydrolase, glutathione-S-transferase, or calumenin.84, 93, 94, 104  
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Despite these predictions, there is considerable evidence negating these speculations.  For 
example, creation of a knockout mouse for microsomal epoxide hydrolase was shown to 
exhibit no abnormal phenotype.105  Similarly, calumenin a member of the subfamily of 
calcium binding proteins, was shown to inhibit VKOR activity and confer Warfarin 
resistance to VKOR.  Moreover, there is no further evidence that glutathione S-transferase is 
a component of VKOR.  Despite evidence of complex formation, all known mutations that 
affect vitamin K-dependent carboxylation can be assigned to either VKOR or GGCX.84  
It was originally proposed that reduction of KO to vitamin K was carried out by the 
sulfhydryl-dependent VKOR and that the conversion of vitamin K to KH2 might be 
accomplished by a second enzyme.  Certainly, there are enzymes that can convert vitamin K 
to KH2 and can function as antidotal enzymes when vitamin K is given to patients with 
Warfarin poisoning.  Current understanding is that the reduction of vitamin K to KH2 can be 
accomplished by at least two reductases including NAD(P)H-dependent quinone 
oxidoreductase and sulfhydral dependent reductase (VKOR).  Although the exact answer to 
this mystery is not yet known, continued support of VKOR reduction either as a single or 
multi-enzyme complex is growing.  In order for the vitamin K cycle to function, both VKOR 
and GGCX must remain in close proximity in the ER membrane to provide efficient 
exchange of cofactors.  Despite the close proximity of these two transmembrane proteins, 
however, it does not appear that VKOR and GGCX participate in complex formation. 
1.4.4 Warfarin Inhibition of VKOR 
Warfarin (3-(-acetonylbenzyl)-4-hydroxycoumarin) is a widely prescribed oral 
anticoagulation drug that targets VKOR.  The mechanism of Warfarin action is now believed 
to limit the availability of KH2 regenerated from KO by VKOR.  Inadequate amounts of 
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KH2, the essential cofactor for carboxylation, results in the production of an under-
carboxylated form of coagulation factors that are biologically inactive.  Thus, Warfarin 
indirectly prevents the production of functional coagulation factors involved in the clotting 
cascade.  It is suggested that Warfarin binds tightly and irreversibly to the disulfide form of 
VKOR, preventing the formation of the free sulfhydryls requisite for activity.106, 107  
Mutational studies have proposed that the Thr-Tyr139-Ala sequence of VKOR forms part of 
the Warfarin binding site in VKOR.89, 108, 109  Substitution of tyrosine 139 by phenylalanine 
results in a VKOR molecule that is resistant to Warfarin and exhibits wild-type enzyme 
activity.89  Since the only difference between tyrosine and phenylalaine is the hydroxyl group 
of tyrosine, it is proposed that this hydroxyl group plays an essential role in Warfarin 
binding.  Similar to the CXXC catalytic domain, the Warfarin binding domain in VKOR is 
located in the third transmembrane domain.  This notion is compatible with the fact that both 
Warfarin and vitamin K are hydrophobic and preferably localized in a lipid environment.  
The physical adjacency of structural elements important for the VKOR Warfarin interaction 
and vitamin K epoxide reduction suggest possible mechanisms for Warfarin inhibition of 
VKOR activity.  The dose of Warfarin required for a therapeutic level of anticoagulation 
varies greatly among patients resulting in accompaniment by either a high risk of bleeding or 
a thrombotic event especially during the initial phase of treatment.  Therefore, tailoring 
therapy to reduce side effects is appealing especially since Warfarin remains the drug of 
choice for anticoagulation treatment.   
Studies of the pharmacodynamics and pharmacokinetics of Warfarin have revealed 
several environment and genetic factors which may determine the variability of dose.  
Among the genetic factors, studies have demonstrated a strong association between single 
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nucleotide polymorphisms (SNPs) in VKOR and the requirement of Warfarin dosage.  It was 
demonstrated that SNPs in VKOR could reduce VKOR activity, like R98W, or result in 
Warfarin resistance, like R58G, V29L, V45A, and L128R.110-114  The screening of VKOR 
polymorphisms that evidently effect Warfarin dosage could be helpful to tailor dosage at the 
onset of treatment.  The dietary intake of vitamin K will also affect a patient’s response to 
Warfarin.  Therefore, many patients receive supplements of vitamin K when undergoing 
anticoagulation treatment.  Using vitamin K1 with Warfarin in rats, however, has been 
reported to result in arterial calcification.115  When the rats were fed Warfarin and vitamin 
K2, contrastingly, no arterial calcification was demonstrated.19  This can be explained 
because K2 is preferentially taken up in non-liver tissues, but can be used by the liver to 
carboxylate vitamin K-dependent proteins to provide satisfactory therapeutic results.  To 
effectively target anticoagulants against VKOR, a greater understanding of VKOR structure 
and protein complexation must be investigated. 
 
1.5 Thesis Scope 
The objective of this thesis is to investigate the structural and functional properties of 
the integral membrane proteins Gamma-Glutamyl Carboxylase (GGCX) and Vitamin K 
Epoxide Reductase (VKOR) in the vitamin K cycle.  In the presence of cofactors, GGCX 
carboxylates selected glutamic acid residues in vitamin K-dependent proteins to gamma-
carboxy glutamic acids.  Simultaneous with carboxylation, vitamin K hydroquinone is 
converted to vitamin K epoxide.  VKOR then functions to catalyze the reduction of vitamin 
K epoxide and vitamin K to vitamin K hydroquinone and the cycle continues.   
20 
The vitamin K cycle including the mechanism for carboxylation and epoxidation has 
been studied for over thirty years with the majority of protein characterization resulting from 
mutational analysis or chemical modeling.  Our approach to such biological problems 
attempts to evaluate the structure and function of GGCX and VKOR using analytical 
methodology including ultra performance liquid chromatography (UPLC) and mass 
spectrometry (MS).  In Chapter 2, we begin by introducing an optimized bottom-up 
proteomics approach for maximizing topological peptide recovery in purified GGCX.  From 
there, we design and characterize a series of photoactive cross-linker substrates for 
determination of the catalytic GGCX carboxylation domain (Chapter 3) followed by the 
identification of cross-linked complexes by LC-MS in Chapter 4.  Chapter 5 evaluates an 
alternative strategy for studying GGCX and VKOR using synthetic nanoscale phospholipid 
structures termed Nanodiscs.  Nanodiscs permit the incorporation of integral membrane 
proteins into a monomeric and reproducible water-soluble membrane environment for single-
molecule characterization.  Finally, in Chapter 6, GGCX embedded Nanodiscs are coupled 
with hydrogen deuterium exchange mass spectrometry (HX MS), providing a novel platform 
in which to investigate protein dynamics.  The work provided here not only lends itself to 
significant advancements in the structural investigation of proteins involved in the vitamin K 
cycle, but presents methodology which can be applied towards investigation of other 
complex membrane protein systems. 
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Figure 1.1 Vitamin K analogs (A) Vitamin K1 phylloquinone, (B) Vitamin K2 menaquinone, 
and (C) Vitmain K3 menadione. 
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Figure 1.2 The Vitamin K Cycle.  Gamma glutamyl carboxylase (GGCX) carboxylates 
selected glutamic acid residues (Glu) in vitamin K-dependent proteins (VKD) to 
gamma-carboxy glutamic acid (Gla) in the presence of cofactors: vitamin K 
hydroquione (KH2), carbon dioxide (CO2), and oxygen (O2).  During this process, 
KH2 is converted to vitamin K epoxide (KO) through a strong base intermediate 
vitamin K alkoxide.  Vitamin K Epoxide Reductase (VKOR) then converts KO to 
vitamin K.  In the process of KO conversion to vitamin K, the active site thiol in 
VKOR is oxidized.  For functional activity of VKOR to be restored, VKOR must be 
reduced to its native form allowing the vitamin K cycle to continue.  To date, the 
exact mechanism for the reduction of vitamin K to KH2 is unknown, but is thought to 
involve either a secondary quinone reductase or VKOR itself.   
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Figure 1.3 Proposed membrane topology for Gamma-Glutamyl Carboxylase (GGCX).  
GGCX is predicted to be a five transmembrane domain integral membrane protein 
with the N-terminus in the cytoplasm and the C-terminus in the endoplasmic 
reticulum (ER) lumen.  The five transmembrane domains of GGCX are labeled with 
Roman numerals with the boundary residues indicated.  A single disulfide bond is 
between cysteine residues 99 and 450 and functional glycosylation sites are 
designated by a Y. 
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Figure 1.4 The Dowd mechanism of carboxylation.  GGCX uses vitamin K hydroquinone 
(KH2) oxygenation to drive the conversion of glutamic acid (Glu) residues to gamma-
carboxy glutamic acid (Gla).  The active site catalytic base (B:) is a weak base that 
deprotonates KH2 to form a strong base alkoxide (K-), which abstracts a proton from 
the gamma position of glutamic acid.  The Glu carbanion then reacts with carbon 
dioxide (CO2) to form a Gla residue while K- is converted to the vitamin K epoxide 
product (KO) 
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Figure 1.5 Proposed membrane topology of Vitamin K Epoxide Reductase (VKOR).  VKOR 
is predicted to be a three transmembrane domain integral membrane protein with the 
N-terminus in the endoplasmic reticulum (ER) lumen and the C-terminus in the 
cytoplasm.  Active site cysteines, Warfarin binding, and interfacial tryptophans are 
distinguished with different shadings.  Figure adapted from Dr. Jian-Ke Tie. 
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Figure 1.6 Proposed mechanism of Vitamin K Epoxide Reductase (VKOR). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2: Improved Digestion Conditions for Integral Membrane 
Protein Gamma-Glutamyl Carboxylase 
________________________________________________________ 
2.1 Introduction 
2.1.1 Evolution of Mass Spectrometry 
The determination of molecular weight is among the first measurements used to 
characterize biomolecules.  Up to the end of the 1970s, the only techniques that provided this 
information were electrophoretic, chromatographic, or ultracentrifugation methods.  These 
results were not very precise because they also depended on characteristics other than the 
molecular weight, such as conformation, Stokes’ radius and hydrophobicity.  Thus, the only 
possibility of knowing the exact molecular weight of a macromolecule remained its 
calculation based on its chemical structure.   
At that time, the mass spectrometric ionization techniques of electron ionization (EI)1 
and chemical ionization (CI)2 required the analyte molecules to be present in the gas phase 
and thus were suitable only for volatile compounds.  This considerably limited applications 
of mass spectrometry for large non-volatile biological molecules that are often thermolabile.  
The development of desorption ionization methods based on the emission of pre-existing ions 
from a liquid or solid surface such as plasma desorption (PD),3, 4 fast atom bombardment 
(FAB),5 or laser desorption (LD)6 allowed the first breakthrough for mass spectrometry in the 
field of biomolecule analysis.  Finally, at the beginning of the 1990s, two new ionization 
methods: electrospray ionization (ESI)7 and matrix-assisted laser desorption ionization 
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(MALDI) coupled to time-of-flight (TOF) analyzers8 were developed and revolutionized the 
role of mass spectrometry in biological research.  These methods allowed the high-precision 
analysis of biomolecules in complex mixtures.  Today, the classic method for peptide and 
protein identification is by reverse phase liquid chromatography (LC) separations coupled to 
electrospray ionization mass spectrometry (MS). 
2.1.2 Mass Spectrometry for Protein Investigation 
Proteomics is the large scale study of proteins including structural variations and 
functional roles in biological pathways.  The field of proteomics encompasses a vast number 
of methodologies ranging from classical investigations by Edman degradation and 2D-PAGE 
(polyacrylamide gel electrophoresis) to cell imaging by electron microscopy.  The 
complexity of cellular proteomes and the low abundance of many proteins necessitates highly 
sensitive analytical techniques for proteomic applications.  Throughout the years, the field of 
mass spectrometry in concert with a wide variety of separation methods has advanced to 
increasingly become the method of choice for the analysis of complex protein samples.   
Two major strategies exist for proteomic studies: bottom-up and top-down.9  In top-
down proteomics, intact proteins are separated and analyzed by mass spectrometry for gas-
phase fragmentation.  Fragmentation patterns are then studied to identify the protein as well 
as characterize structural variations within a protein complex.  In the bottom-up approach, on 
the other hand, purified proteins or complex protein mixtures are subjected to proteolytic 
cleavage resulting in peptide formation.  The mixture of peptides is then separated using a 
variety of separation modes and analyzed by mass spectrometry.  Protein identification can 
be determined by comparison of the peptide mass spectra with theoretical peptide masses 
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calculated from a proteomic or genomic database.  The work in this thesis is based on a 
bottom-up proteomics approach. 
Typically, there are two methods for protein identification using bottom-up 
proteomics: peptide mass fingerprinting (PMF) and tandem MS (or MSMS).  In peptide mass 
fingerprinting, peptide masses are generated from an MS scan and are compared to calculated 
peptide masses generated by a theoretical “in silico” cleavage of protein sequences in the 
database using the same specificity as the enzyme that was employed in the experiment.10  
Here the profile of peptide masses is compared to a database of proteins.  A protein generally 
can be identified using the mass of four to six of its cleavage peptides having masses in the 
range of 700 to 3000 Daltons and determined with an accuracy of 0.1 to 0.01%.11-14  The 
specificity and reliability can be improved by increasing the number of peptide masses, 
improving the precision of the measured masses, and by using different digestion enzymes 
with different specificities.  Various algorithms have been developed for the identification of 
proteins by peptide mass fingerprinting such as MASCOT, MOWSE, MS-FIT, and Profound.  
A disadvantage of PMF, however, requires pure proteins or simple mixtures of proteins that 
limit the likelihood that multiple peptides could be identified for a given mass.  Tandem MS 
on the other hand, allows dissociation of a precursor peptide to product ion fragments.  Using 
data processing algorithms, the amino acid sequence of the original precursor ion can be 
deduced from fragment ions, adding greater confirmation to protein identification. 
There are advantages and disadvantages to both the top-down and bottom-up 
methodologies of proteomics.  The bottom-up strategy has been most successful in the 
identification of proteins in digests derived from very complex mixtures such as cell lysates.  
Moreover, quantitative techniques have been developed using affinity tags and stable isotope 
38 
labels for determination of up- and down-regulated proteins in expression proteomics.  A 
limitation of bottom-up proteomics, however, is that only a fraction of the total peptide 
population for a given protein is identified.  Proteolytic digestion may limit the number of 
peptides that can be resolved for a given protein preventing knowledge of protein isoforms, 
alternative splicing products, and locations of post-translational modifications (PTMs).  In 
additional to structural modifications, low abundant peptide species may be lost in bottom-up 
proteomic approaches preventing identification of particular proteins in complex mixtures.  
Top-down proteomics, on the other hand, provides potential access to the complete sequence 
of a given protein and allows the ability to locate and characterize PTMs.15  Complexity 
arises, however, in the generation of very complicated mass spectra often limiting the study 
of proteins to a simplified mixture.  To aid in spectral deconvolution, favored instrumentation 
includes high resolution mass spectrometers such as Fourier transform-ion cyclotron 
resonance (FT-ICR) instruments.  Influences of charge state, protein dynamics and structure, 
as well as contributions by PTMs further complicate data analysis providing a greater need 
for bioinformatic analysis.  Ultimately, the choice between a bottom-up and top-down 
approach is dictated by the type of information desired from the study. 
2.1.3 Tandem Mass Spectrometry of Peptides 
In order to generate structural data by mass spectrometry, the molecule that is studied 
must undergo fragmentation.  The most common method of fragmentation for tandem mass 
spectrometry of peptides is collision-induced dissociation (CID).  This technique consists of 
selecting the ion to be fragmented using a mass analyzer and sending it into a collision cell 
where it collides with uncharged gas atoms.  Here kinetic energy results in an increase in 
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internal energy of the precursor ion inducing fragmentation to product ions that can be 
analyzed by a second spectrometer.   
The tandem mass spectra may be obtained using many different instruments such as 
magnetic analyzers, ion traps, quadrupoles, etc.  The main difference lies in the kinetic 
energy of the ions.  For sector instruments the precursor ion kinetic energy is several kilo-
electronvolts (keV) whereas ion traps and quadrupoles maintain ion kinetic energies below 
100 electronvolts (eV).  This difference is shown to drastically influence the fragmentation 
process.16   
The tandem MS analysis of many peptides with known and unknown sequences allows 
one to identify the various existing fragmentation processes.  The nomenclature suggested by 
Roepstorff and Fohlman17 and later modified by Biemann18 allows the labeling of various 
fragments obtained in a peptide digest.  The first peptide fragments identified were produced 
by cleavage of a bond in the main chain where fragmentation can occur in either of three 
types of bonds C-C, C-N or N-C generating six different types of fragments labled an, bn, 
and cn when a positive charge is kept by the N-terminal side and xn, yn, and zn when the 
positive charge is kept by the C-terminal side.  Here the subscript n indicates the number of 
amino acids contained in the fragment.  Figure 2.1 illustrates the various types of fragments 
produced through the cleavage of a bond in a peptidic chain where the mass difference 
between consecutive ions within a series allows one to determine the identity of the 
sequential amino acids and therefore deduce the peptide sequence.  Variations in peptide 
fragmentation are shown to result from differences in collision energy applied to a peptide 
during tandom MS analysis.  At high energy, all the fragmentation possibilities can be 
generated in principle.  At low energy, the observed fragments are mostly bn and yn.  These 
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fragments are also typically seen to experience a neutral loss of water or ammonia from the 
functional groups on the side chains of the amino acids. 
Two other types of fragments found in most spectra result from cleavage of internal 
bonds in the peptidic chain.  Internal source fragment ions result from loss of the initial N- or 
C-terminal amino acids and are often weak in ion abundance, rarely containing more than 
three or four amino acid residues.  The second type of internal fragmentation results from 
cleavage of immonium ions.  These ions appear in the low mass end of the spectrum and 
yield information concerning the amino acid composition of the sample.   
2.1.4 Separation Technology for Proteomics 
Separations are the key to almost all proteomics studies.  Classical bottom-up 
proteomic analysis favors one dimensional (1-D) or two dimensional (2-D) gel 
electrophoresis.  Gel electrophoresis resolves proteins based upon their different rates of 
migration through a polymeric gel in the presence of an applied electric field.  First reported 
in 197519, 2D-PAGE resolves proteins using isoelectric focusing (IEF) in the first dimension 
and sodium dodecyl sulfate (SDS) detergent facilitated size-dependent separation in the 
second dimension.  Protein bands of interest may be cleaved out of the gel matrix followed 
by proteolytic digestion and peptide extraction.  Peptides are then typically separated by 
reverse phase LC-MS/MSMS for protein identification.  Although labor intensive in sample 
preparation, gel electrophoresis provides a universal means for studying a wide variety of 
proteins. 
While gel electrophoresis is traditional for bottom-up proteomics, a preferred 
separation mechanism for studying complex protein mixtures is by liquid chromatography.  
When appropriate conditions are used, liquid chromatography can separate a broader range 
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of proteins than 2D-PAGE including large proteins that are highly acidic or basic in nature.  
In addition, liquid chromatography provides a sensitive means to detect small quantities of 
low abundant proteins using varying modes of detection such as UV absorbance, laser-
induced fluorescence, or mass spectrometry.  One strategy in developing an LC method to 
rival the resolving power of 2D-PAGE is to use long columns with extended gradients.20  
While successful, this approach results in a drastic increase in run time limiting the 
practicality of high-throughput experimentation.  To attain separation efficiency within time 
constraints, multidimensional separations have lead to vast improvements for the analysis of 
complex protein mixtures 
2.1.5 Proteomic Study of  Membrane Proteins 
One of the biggest challenges in proteomic research today is the study of membrane 
proteins.  Membrane proteins represent a large class of biologically relevant target receptors 
and enzymes that are largely under represented in their biophysical characterization due to 
complexities involving the availability of a reproducible and naturally occurring membrane-
like environment.  The study of membrane proteins offer significant promise in the 
understanding of fundamental biological processes such as cell signaling, cell-cell 
interactions, and intracellular compartmentalization.  The importance of membrane proteins 
cannot be overemphasized, with membrane proteins accounting for ~70% of all known 
pharmaceutical drug targets.21 
Assuming a suitable system for membrane protein investigation, the next challenge 
arises in means of studying these structures.  Common biophysical techniques such as X-ray 
crystallography, NMR, fluorescence, circular dichroism, and liquid chromatography are ideal 
when investigating soluble proteins of interest.  Membrane proteins, however, are inherently 
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insoluble and prone to aggregation, oligomerization, or precipitation in solution.  Thus 
despite the vital roles of membrane proteins in biological processes, most membrane proteins 
remain resistant to structural elucidation and dynamic investigation. 
As mentioned previously, traditional methods of complex protein samples involve 
resolution of proteins using two-dimensional gel electrophoresis followed by identification 
by mass spectrometry.  The major obstacles experienced by 2D gel electrophoresis for 
membrane proteins are related to protein solubility in the isoelectric focusing dimension.22  
Limited dynamic range of detection is also an issue because membrane proteins are typically 
lower in abundance when compared to soluble proteins.  As a result, many investigators 
return to the ageless methodology of one-dimensional gels.23-26  Once proteins are resolved 
on gels, they can be visualized using various stains and the selected protein band(s) of 
interest may be excised for proteolytic digestion.  While having limitations, in-gel digestions 
allow ease in the analysis of difficult transmembrane protein samples limiting issues of 
membrane protein solubility.   
Recently, shotgun bottom-up proteomics have emerged as a powerful technique for 
membrane proteome identification.27-34  Shotgun proteomics requires the generation of 
peptides from proteins via protein degradation techniques such as enzyme or chemical 
digestion.  Prior to digestion, however, conditions for protein solubility must be optimized.  
To address issues of solubility, membrane fractions are often enriched using detergents, 
organic solvents, and organic acids.35  The drawback of this approach is that denaturants 
often reduce the proteolytic activity of enzymes and interfere with mass spectrometry and 
liquid chromatography requiring sample cleanup prior to analysis. 
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Washburn et al.,32  provided the first large-scale proteomic analysis by enriching yeast 
membrane fractions solublized with 90% formic acid in the presence of cyanogen bromide.  
The concentrated organic acid provides the solubilization agent, and the cyanogen bromide, 
functional under acidic conditions, allows many embedded membrane proteins to be cleaved.  
These large fragments are then further digested with a serial digestion using endoproteinase 
LysC and trypsin to produce smaller peptide fragments more amenable to analysis by tandem 
mass spectrometry.   
Another method by Hans et al.29 uses detergent to solublize the membrane proteins.  A 
membrane-enriched microsomal fraction is solubilized by boiling in 0.5% SDS.  As an 
anionic detergent, SDS firmly binds to cationic protein/peptide side chains causing effective 
solubilization.  After dilution, SDS concentrations are reduced for compatibility with trypsin 
digestion and cation-exchange chromatography is employed to remove interfering SDS prior 
to reverse phase LC-MS analysis.  Although successful solubilization can be achieved with 
SDS, removal of this tight binding detergent is never 100% complete resulting in column 
fouling.  Other detergents have been evaluated, however, the presence of detergent often 
interferes with enzymatic digestion, chromatographic separation, in addition to suppression 
of analyte ion signals during MS analysis.36  Although detergents present an ideal situation 
for protein solubilization, their complications are often found to outweigh their advantages. 
Membrane proteins can also be solubilized using organic solvents, as shown by Blonder 
et al.,27 in the study of proteins in Deinococcus radiodurans.  Using an enriched membrane 
sample, the proteins are thermally denatured and sonicated in a 60% methanol solution in the 
presence of trypsin.  The resultant peptide mixture is then analyzed by LC-MS.  An 
alternative approach addresses a strategy of ‘shaving’ solubile domains of membrane 
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proteins using proteolytic cleavage.33  Here sealed membrane vesicles are agitated at high pH 
to produce intact membrane sheets.  Proteinase K, is then used to cleave exposed soluble 
domains on the integral membrane proteins.  Despite improved recovery of membrane 
proteins using enriched methodologies, method development for the separation of membrane 
proteins are still far from being comprehensive.  In each case, the membranes are 
solubililized and topology is lost.   
2.1.6 Recent Advances in In-Gel Digestion of Membrane Proteins 
Current in-solution enzymatic digestions for membrane proteins are inherently limited 
by the time spent to optimize conditions for membrane protein solubilization that allow for 
analysis by LC-MS.  Even under solubilized conditions, inadequate digestions often 
compromise the topological characterization of hydrophobic and proteolytic resistant 
proteins.  A common alternative is to isolate target proteins by gel electrophoresis followed 
by in-gel digestion and analysis by LC-MS.  Gel electrophoretic separations minimize issues 
involved with protein solubility and focus primarily on optimization of digestion conditions.  
Similar to solution phase protein digestion enhancement strategies, peptide extraction from a 
gel matrix is improved using surfactants and organic solvents. 
One approach involves the use of an acid-labile surfactant (ALS), sodium 3-[(2-methyl-
2-undecyl-1,3-dioxolan-4-yl)methyoxyl]-1-propansulfonate during protein digestion.37, 38  
The ALS denaturant is an anionic surfactant, which structurally resembles SDS, given that it 
is composed of an ionic moiety (sulfonate) and a hydrophobic alkyl chain (undecyl).  A 0.1% 
(w/v) ALS solution is shown to be sufficient in solubilizing globular proteins without 
inhibition of enzymatic proteolysis.  Prior to LC analysis, ALS can be degraded at low pH 
creating a soluble product eluting at the void volume of a chromatographic separation and a 
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precipitated product that can be removed by centrifugation.  An alternative to ALS 
surfactants is the use of MS compatible detergents such as non-ionic octyl--glucopyranoside 
(OBG) that can be incorporated during peptide extraction after in-gel digestion.24  OBG has 
been shown to aid in hydrophobic peptide removal without the need for detergent breakdown 
or interference in mass spectrometric analysis. 
Besides detergents, other peptide extraction conditions involving organic solvents,23, 39, 40 
high temperature extractions,41, 42 and multiple proteolytic enzyme cocktails25, 28, 43, 44 are 
often employed to improve topological peptide recovery.  A staple in protein digestion is 
peptide cleavage by trypsin.  The amino acids lysine and arginine, however, are less frequent 
in membrane proteins compared to cytosolic proteins.  Furthermore, these positively charged 
amino acids are not uniformly distributed along the protein sequence, having the highest 
abundance in the hydrophilic domains.  Thus, trypsin digestion often results in unfavorable 
peptide cleavage of integral membrane proteins where the size and hydrophobicity of peptide 
fragments limits proper gel excision and analysis by LC-MS.  Alternative cleavage 
conditions, such as the consecutive use of cyanogen bromide and trypsin,25 or trypsin and 
chymotrypsin28 as well as other proteases such a proteinase K,33, 45 Lys-C,43 and Asp-N43 
have been described and have proven superior to trypsin in practice.   
Van Montfort et al., coupled trypsin digestions with subsequent cyanogen bromide 
cleavage.25  When compared with individual cleavage methods, the sequence coverage of the 
hydrophobic-membrane domain doubled, whereas coverage of the soluble domain remained 
the same.  In addition, non-specific enzymes are gaining support in the study of membrane 
protein digestions.  Non-specific enzymes offer the unique advantage of creating overlapping 
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peptides throughout the protein sequence increasing the protein sequence coverage, but at the 
expense of complication in computational analysis.  
Similar to using organic solvents for protein solubilization, organic solvents or strong 
acids such as high percentages of acetonitrile,24 methanol,27, 46 isopropanol,23 or formic acid23 
can be incorporated after digestion to extract resistant hydrophobic peptides that prefer to 
reside in SDS gel bands.  After extraction, organic solvents can be removed by lyophilization 
providing an efficient means of sample cleanup.  Other solutions introduced for in-gel 
digestions include temperature extraction42 of hydrophobic peptides or microwave assisted 
acid hydrolysis.47   
 
2.2 Chapter Scope 
This chapter aims to characterize the in-gel digestion and topological mapping of the 
transmembrane protein GGCX after proteolytic digestion.  Percent coverage will be 
evaluated for different digestion conditions and peptide recovery will be reported by 
considering peptide hydrophobicitiy, size, and specificity.  Chromatographic analysis after 
in-gel digestion will be completed using a custom UHPLC or commercial UPLC system with 
mass spectrometric detection.  Peptide identification will be compared for two modes of 
fragmentation: data directed analysis (DDA) and data independent analysis (MSE).  The 
objective of this chapter is to optimized digestion conditions of GGCX providing 
comprehensive topological coverage for structural investigation. 
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2.3 Experimental 
2.3.1 Materials 
 Reagents used in Gamma-Glutamyl Carboxylase protein purification are as follows:  
1,2-dioleoyl-sn-glycero-3-phosphocholine [DOPC] (Avanti Polar Lipids, Alabaster, AL), 2-
(N-morpholino)ethanesulfonic acid [MES] (Sigma-Aldrich, St. Louis, MO), 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate hydrate [CHAPS] (Sigma-Aldrich), 
3-(N-morpholino)-propanesulfonic acid [MOPS] (Sigma-Aldrich), calcium chloride 
dihydrate [CaCl2.2H2O] (Fisher Scientific, Fair Lawn, NJ), ethylenediamine-tetraacetic acid 
[EDTA] (Mallinckrodt Chemicals, Raleigh, NC), glycerol (Fisher Scientific), and sodium 
chloride [NaCl] (Fisher Scientific).  Protease inhibitors including aprotinin, leupeptin, 
pepstatin, and phenylmethyl sulfonyl fluoride were purchased from Roche Applied Science 
(Indianapolis, IN).  Anti-HPC4 monoclonal antibody coupled Sepharose resin was obtained 
from Dr. Charles T. Esmon (Cardiovascular Biology Research Program, Oklahoma Medical 
Research Foundation, Oklahoma City, OK).48 
 For gel analysis of Gamma-Glutamyl Carboxylase, NU-PAGE Bis-Tris Gels were 
purchased from Invitrogen (Carlsbad, CA) along with a SeeBlue prestained protein ladder, 
Mark 12 unstained protein ladder, Simply Blue Safe Stain, and Sypro® Ruby protein gel 
stain.  SDS-PAGE buffers were prepared according to protocol derived from Invitrogen 
including a 4X SDS-PAGE loading buffer and a 20X MES running buffer.  Gel digestions 
were completed with LC-MS grade reagents as follows: acetic acid, optima grade 
acetonitrile, ammonium bicarbonate, and optima grade water purchased from Sigma-Aldrich.  
Other reagents for digestion include, 95% ethanol (Fisher-Scientific), dithiothreitol [DTT] 
(Roche Applied Sciences), and PNGaseF glycerol stabilized deglycosylation reagents from 
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New England Biolabs (Ipswich, MA).  Trypsin-Gold mass spectrometry grade and 
chymotrypsin sequencing grade proteolytic enzymes were purchased from Promega 
(Madwason, WI) and Roche Applied Sciences accordingly. 
Liquid chromatography mobile phase components were optima grade acetonitrile, 
LC-MS grade formic acid, and optima grade water from Sigma-Aldrich. 
2.3.2 Purification of Recombinant Wild-Type Gamma Glutamyl Carboxylase 
Wild-type human Gamma-Glutamyl Carboxylase (GGCX) with a carboxyl terminus 
12-amino acid epitope tag (EDQVDPRLIDGK) was isolated from Sf9 as previously 
described.49  Solubilized GGCX microsomes were purified using a calcium dependent HPC4 
antibody resin and eluted in 25 mM MOPS pH 7.5, 0.1 M NaCl, 0.5% CHAPS, 0.2% DOPC, 
10 mM EDTA, and 15% glycerol stabilized by a protease inhibitor cocktail.  Protein 
concentration and purity was determined by enzymatic activity assay measurements and 
SDS-PAGE.  A detailed protocol describing Gamma-Glutamyl Carboxylase protein 
purification is described in Appendix A1. 
2.3.3 In-Gel Digestion Protocol for Gamma-Glutamyl Carboxylase 
A modified in-gel digestion protocol was optimized for Gamma-Glutamyl 
Carboxylase (GGCX) to maximize topological peptide recovery.  For most typical 
digestions, 60 pmol of purified gamma glutamyl carboxylase was deglycosylated with 
PNGaseF (1 L) overnight at 4oC. PNGaseF (Peptide-N4-(acetyl--glucosaminyl)-
asparagine amidase N-Glycosidase F) functions as an amidase that cleaves the inner-most 
GlcNAc and asparagine residues of high mannose, hybrid, and complex oligosaccharides 
from N-linked glycoproteins.  N-linked glycans are attached to the protein backbone via an 
amide bond to an asparagine residue in an Asn-Xaa-Ser/Thr (NXS/T) motif, where X can be 
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any amino acid except proline.  After deglycosylation, GGCX was reduced using an excess 
of DTT at 1 M final concentration and allowed to incubate at 30oC for 30 minutes.  The 
concentration of DTT was tailored to optimize reduction of the single disulfide bond reported 
between residues cysteine 99 and cysteine 450 in GGCX.50  The sample was then mixed with 
a 4X SDS-PAGE loading buffer and loaded onto a NU-PAGE Bis-Tris gel at approximately 
35 pmol of target protein.  For most experimental evaluations either a 4-12% Bis-Tris 
gradient gel or 10% Bis-Tris gel was utilized.  Electrophoresis was completed using a MES 
running buffer at running voltage conditions ranging from 150 V to 200 V until the front of 
the migration band has reached the bottom of the gel cassette.   
For in-gel digestions, the cassette was quickly removed and the gel was briefly 
washed with deionized water for three-ten minute intervals prior to staining for 30 minutes 
using Simply Blue Safe stain (Invitrogen).  To visualize gel bands, the stained gel was 
destained for one hour with deionized water.  For more sensitive protein band visualization, a 
fluorescent based stain was used.  Sypro® Ruby stain requires that the gel first be fixed in a 
solution of 50% methanol and 7% acetic acid for 30 minutes prior to overnight staining with 
a fluorescent binding protein stain.  After staining, the gel was washed for 30 minutes with a 
solution containing 10% methanol and 7% acetic acid and imaged using an AlphaImager 
2200 programmed to UV transilluminator mode with interference wavelength filtering.   
Once destained, protein bands are excised and placed in a pre-treated Eppindorf tube 
with 50% acetonitrile in optima grade water.  As a control, a gel band free of loaded protein 
was also isolated to provide a background for digestion analysis.  Gel bands were cut into 
quarters using the tip of a pipette and washed in two 30 minute intervals with 40% ethanol in 
50 mM ammonium bicarbonate with constant vortexing.  Bands were then washed for 10 
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minute intervals with 50 mM ammonium bicarbonate and cut into <1mm3 pieces using a 
feather surgical blade to allow for maximum surface area exposure during digestion.  Buffer 
was removed from the gel through dehydration with 100% acetonitrile and gel bands were 
vacuum dried.  All gel work-up was completed in a laminar flow hood to reduce sample 
contamination.   
Proteolytic solutions of sequencing grade chymotrypsin or trypsin were prepared for 
protein in-gel digestion.  For trypsin digestion, Promega grade trypsin (100 g) was 
dissolved in 50 mM acetic acid at a final concentration of 1 g/L and diluted to the desired 
digestion concentration in 10% acetonitrile with 40 mM ammonium bicarbonate.  Similarly, 
for chymotrypsin digestion, Roche sequencing grade chymotrypsin (25 g) was dissolved in 
25 mM ammonium bicarbonate at a final concentration of 1 g/L and diluted to the desired 
digestion concentration in 10% acetonitrile with 40 mM ammonium bicarbonate.  To the 
dried protein gel piece, 30 L of proteolytic digestion solution was added to reswell the gel 
band on ice for 45 minutes.  An overlay of 10% acetonitrile in 40 mM ammonium 
bicarbonate was then added and digestion was allowed to take place in a water bath at 30oC.  
Digestion times varied according to proteolytic enzyme with chymotrypsin digestions taking 
place for 5 hr, 3 hr, or 1 hr time intervals and trypsin digestions allowed to incubate 
overnight.  To agitate digestion reactions, samples were sonicated for a period of five 
minutes in the first three hours of digestion.  After digestion, the supernant was immediately 
removed and digestion was quenched by freezing with liquid nitrogen.  The digestion 
supernant was stored at -80oC while the remaining gel band was extracted in the presence of 
60% acetonitrile in 40 mM ammonium bicarbonate overnight.  The extraction supernant was 
then removed and lyophilized to dryness before combining with the thawed digestion 
51 
supernant.  The sample was sonicated for 20 minutes prior to isolation for reverse phase 
liquid chromatographic separation. 
2.3.4 Modifications to In-Gel Digestion Protocol for Gamma-Glutamyl Carboxylase 
Digestion conditions were varied to maximize the percent peptide coverage of 
GGCX.  Proteolytic enzyme concentration (100 ng/L, 50 ng/L, 25 ng/L) were evaluated 
for both chymotrypsin and trypsin digestions.  For trypsin digestions, additional parameters 
including detergent incorporation and organic solvent extraction were evaluated for peptide 
recovery.  One such method, investigated peptide extraction using an acid-labile surfactant 
RapiGestTM SF during digestion.  A 0.1% RapiGestTM containing solution was added to a 
GGCX incorporated gel matrix prior to trypsin digestion.  After digestion, ALS was 
degrading using 1 L of 10% trifluoroacetic acid (TFA) resulting in detergent hydrolysis.  
For hydrophobic peptide extraction, gel bands were washed with 10% formic acid in 90% 
isopropanol or 60% acetonitrile with 0.1% OBG and 0.1% TFA (trifluoroacetic acid) after 
digestion. 
An alternative limited trypsin digestion approach was taken to reduce the sample 
complexity of GGCX.  Limited digestion is characterized by the cleavage of GGCX into a 
disulfide linked 30kDa amino-terminus and a 60kDa carboxy-terminus by cleavage between 
residues 349 and 351.  For limited trypsin digestion, conditions must be optimized for each 
purified protein fraction.  As a basic experimental outline, 60 pmol of purified GGCX was 
digested in solution with 1 g trypsin for four hours on ice.  To stop the digestion, Aprotinin 
and FPRCK (Phe-Pro-Arg-chloromethylketone) were added at a final concentration of 2 
g/mL and 2 M respectively.  Samples were analyzed by reduced SDS-PAGE to confirm 
limited digestion and evaluated for subsequent in-gel digestion. 
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Chymotrypsin digestions were evaluated according to proteolytic enzyme 
concentration as well as digestion times (5 hr, 3hr, 1 hr) to maximize peptide recovery while 
limiting non-specific cleavage.  For enchancement of hydrophobic peptide recovery, 
additional parameters evaluated included gel extraction temperature (4oC, 30oC, and 60oC) 
and chromatographic column temperature (35oC, 45oC, and 60oC). 
2.3.5 Bottom-Up Peptide Separation Using UHPLC/UPLC-MS 
2.3.5.1 Instrumentation and Run Conditions: UHPLC 
2.3.5.1.1 Reverse Phase Capillary Column Preparation 
Fused silica capillary columns with a 50-100 m inner diameter and 360 m outer 
diameter (Polymicro Technologies, Phoenix, AZ) of varied lengths were packed with 1.5 m 
bridged ethyl hybrid (BEH) particles with a C18 stationary phase (Waters Corporation, 
Millford, MA, Lot Number KHG687) as previously described.51  Briefly, a polymer frit was 
created at the outlet of the capillary using a 1:1 Kasil: Formamide mixture and allowed to dry 
in the oven at 60oC for several hours.  The reverse phase particles were suspended in a slurry 
with acetone at a concentration of 3 mg/mL and sonicated.  The particle suspension was then 
introduced into the bottom of a high pressure packing bomb and a stir bar was added to keep 
the particles suspended.  The inlet end of the capillary column was introduced into the 
packing bomb using a packing ferrule machined in house.  Once tightened, pressure can be 
steadily applied to the packing bomb by a pneumatic amplifier Haskel pump (Haskel Inc., 
Burbank, CA) to maintain a constant flow of particles into the column.  The typical 
maximum pressure used to achieve a packed column was 30,000 psi.  Upon depressurization, 
the column was removed from the packing bomb and allowed to flush at equivalent packing 
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pressures (30,000 psi) with acetonitrile.  Under pressure, a temporary frit was arced to hold 
the packed bed in place until a permanent inlet frit was created. 
2.3.5.1.2 UHPLC Instrumentation 
A custom-built LC system was designed to provide capillary reverse phase 
separations at ultra-high pressures (termed UHPLC).  The system was designed and 
constructed by Geoff Gerhardt and Keith Fadgen at Waters Corporation.  A schematic 
diagram of the instrumental set-up is shown in Figure 2.2.  The instrument consists of a 
Waters® CapLC conventional gradient pump with integrated autosampler.  The CapLC was 
responsible for injecting the sample and generating the reverse phase gradient.  For ultra-high 
pressure generation, a second Waters® 1525 HPLC pump was modified to pump automotive 
break fluid and be coupled with a hydraulic amplifier for pressure magnification.  From these 
modifications, the hydraulic amplifier hybrid pump was capable of generating pressures up to 
3100 bar (45,000 psi). 
A four-port low-dead volume high pressure stainless steel union and two air-actuated 
pin valves (Model ASFVO, Valco) were designed to control the fluidic flow path of the 
customized UHPLC system.  The outlets from the CapLC and hybrid hydraulic amplifier via 
a gradient storage loop (5 meters, 0.020” ID) were connected to two ports on the union with 
the capillary column and an open-tubular split flow capillary (10 m ID) in positions three 
and four.  A pin valve was placed between the CapLC and four-port union and a second 
valve was located at the pressure vent on the hydraulic amplifier pump.  The instrumentation 
was controlled using both custom and commercial MassLynx 4.1 (Waters) software. 
With valves one and two in the open position, the CapLC generates a gradient at 40 
L/minute which travels through the four-port union onto the gradient storage tubing.  Since 
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the hydraulic amplifier pump is responsible for generating the ultra-high pressure for gradient 
separation through the capillary column, the gradient must be loaded by the CapLC in 
reverse configuration beginning with the highest desired acetonitrile content and ending with 
the lowest.  Once the gradient was generated, a plug of sample was the last component to be 
loaded into the storage loop.  Although the column and splitter were not blocked while the 
gradient was being loaded, both capillaries have a very high flow resistance in comparison to 
the storage tubing resulting in almost no loss in flow.   
After gradient and sample loading, valve 1 was closed in order to isolate the CapLC 
from the system.  Valve 2 was also closed and the ultra-high pressure pump was activated 
until desired running pressures were achieved (approximately 1600 bar or 23,000 psi).  The 
hydraulic amplifier pumps at a constant flow rate of 4 L/min using the open tubular splitter 
capillary in the four-port union to divert the majority of the flow.  The flow through the 
capillary column was dependent on the pressure generated by the hydraulic amplifier, the 
diameter of the packing material, and the dimensions of the column.  For a 50 m ID x 45 cm 
capillary column, a flow rate of 100 nL/min was desirable resulting in a split ratio of 40:1.  
The sample was loaded first onto the column and the gradient was played in the forward 
direction of low to high organic solvent content.   
The outlet of the capillary separation column was coupled end-to-end to a 20 m ID x 
360 m OD fused silica 10 m PicoTip nano-electrospray emitter (New Objective, Woburn, 
MA) using a Waters® Universal Nanoflow Spray.  The electrospray emitter was pulled to a 
10 m tip to provide optimal nanospray conditions.  The Universal Nanoflow stage was 
composed of stainless steel providing an electrical contact to the fluid inside the emitter when 
the capillary voltage from the mass spectrometer was applied.  The tip of the emitter was 
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oriented in a perpendicular fashion with respect to the orifice of the sample cone.  The 
precise position of the emitter was optimized by manual adjustment to generate the best 
signal intensity and a gentle sheath of nano-flow nitrogen gas was applied around the tip 
emitter to improve stability of Taylor cone formation 
For reverse phase separations, mobile phase A was prepared with 0.2% (v/v) LC-MS 
grade formic acid in optima grade water and mobile phase B with 0.2% (v/v) LC-MS grade 
formic acid in optima grade acetonitrile.  Peptide separation was performed as a linear 
gradient from 5 to 50% mobile phase B over 60 minutes, followed by a steep ramp and hold 
at 85% acetonitrile for five minutes before returning to initial conditions. 
2.3.5.2 NanoACQUITYTM UPLC Instrumentation 
The nanoACQUITYTM Ultra Performance LC (UPLC) system is designed for nano-
scale, capillary separations providing high chromatographic resolution, sensitivity, and 
reproducibility.  The system is operated under single-pump trapping mode where samples are 
loaded onto a trap column (180 m ID x 20 mm; 5 m C18 Symmetry particles) at 15 
L/minute with 99.5% optima grade water, 0.1% formic acid, and 0.5% acetonitrile.  The 
trapping time is recommended to be set based on three times the loop volume.  For this study, 
the sample loop was 5 L so sample loading time was allowed to continue for 1.0 minute.  
The trapping mechanism allows peptides to be concentrated on the head of the column, while 
salts and impurities to elute to waste.  After loading, the trapping valve was closed and 
reconnected to the flow path allowing the gradient generated by the binary solvent manager 
(BSM) to elute the sample from the trap column onto the analytical column at a flow rate of 
300 nL/minute (75 m ID x 250 mm; 1.7 m C18 BEH particles).  The analytical column 
was typically maintained at 35oC (unless specified) and eluted with a linear gradient of 5-
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50% B in 60 minutes where mobile phase A was prepared with 0.1% (v/v) LC-MS grade 
formic acid in optima grade water and mobile phase B with 0.1% (v/v) LC-MS grade formic 
acid in optima grade acetonitrile.  Sample volumes were loaded in partial loop mode with 3 
L sample injection volumes.   
The binary solvent manager (BSM) is a high pressure pump capable of providing a 
pulse-free solvent flow at flow rates ranging from 0.20 to 5.00 L/minute under closed loop 
control at 690 bar or 10,000 psi.  The BSM is engineered to have two independent pump 
systems each containing two linear driven actuators.  To create gradients, the mixing ratio is 
varied by the flow of pump A relative to that of pump B.  A pressure transducer in each 
pump head relays pressure data to the solvent manager, whose firmware measures pump head 
pressures during the pumping cycle.  The solvent manager adjusts the precompression to 
ensure consistent solvent delivery and minimize pump-induced baseline disturbances.  
Solvents are mixed in the flow control module which allows corrections due to temperature 
fluctuations and pumping inconsistencies.  While the BSM is generating the gradient, the 
auxillary solvent manager is used to provide flow for NanoLockSpray reference solution (0.5 
L/minute).  A diagram of the nanoACQUITYTM trapping mechanism is shown in Figure 
2.3. 
2.3.5.3 MS Instrumentation: DDA 
The MassLynx program that controls MS data acquisition allows for MSMS 
fragmentation known as data directed analysis (DDA).  The program begins with an MS 
survey acquisition.  In MS mode, the collision energy of the mass spectrometer was kept low 
at 7 V (QTof Micro) or 4 V (QTof Premier) and the quadrupole was set to pass all ions over 
the mass range of 400-1600 m/z (QTof Micro) or 50-1990 m/z (QTof Premier) at a scan time 
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of 1.1 seconds.  When the intensity of an individual ion in the MS survey scan rises above 20 
counts/second, the MS survey scan was stopped and switched to MSMS mode.  As a result, 
the quadrupole was set to only allow ions above the set peak threshold to pass to the TOF 
analyzer.   
When an ion is submitted for MSMS fragmentation each scan applies a different 
collision energy where every scan is 1.1 seconds including the interscan delay.  The resulting 
fragment ions are then detected over the mass range 50-1990 m/z.  The precursor mass 
continues to cycle through a collision energy profile until the target ion intensity drops below 
2 counts/second or after a time period of 3.3 seconds regardless of intensity.  For optimal 
quality in MSMS fragmentation, the collision energy can be stepped through varying energy 
voltages depending upon the m/z of the precursor ion.  A typical collision energy profile is 
shown in Table 2.1 where the collision energy was ramped between three voltages for a 
given mass range.  This collision energy profile was referred to as MLH scanning or 
Medium-Low-High sequential variation in collision energy.  Once all MSMS scans are 
complete, the instrument returns to the survey scan until another precursor ion exceeds the 
intensity threshold.  The method can be programmed such that two co-eluting peptides can be 
submitted for MSMS at a given time.  A schematic cartoon of DDA acquisition is illustrated 
in Figure 2.4 (A).  To prevent redundant data acquisition, the instrument was programmed to 
exclude from MSMS acquisition any precursor ion already analyzed within the last 15 
seconds.  Similarly, to prevent fragmentation on isotope peaks of the same peptide 
component, a mass range of +/- 2.3 Da from the monoisotopic peak was also excluded for the 
same period of time. 
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The Waters® Micromass QTof MicroTM and Waters® QTof PremierTM instruments 
are both capable of conducting DDA acquisition fragmentation on peptide digests in positive 
ion electrospray mode.  Tune page parameters varied slightly for the two mass spectrometers 
such that the QTof Micro demonstrates optimal ionization with a capillary voltage of    
+2000 V, sample cone voltage of +40 V, extraction cone voltage of +3V, and source 
temperature of 100oC.  For mass accuracy correction, a dynamic external calibration (DXC) 
probe was used such that the instrument was calibrated to control for mass fluctuations due to 
temperature drift.  The QTof Premier was operated in V-mode with a capillary voltage of 
+3000V, sample cone voltage of +35V, extraction cone voltage of +4V, and source 
temperature of 100oC.  For mass accuracy correction, a nanoflow lock spray source was 
implemented where two orthogonal electrospray probes are used for simultaneous 
introduction of both sample and a standard reference solution.  Here a 200 fmol/mL reference 
solution of [Glu1]-fibrinopeptide B was prepared in 70% acetonitrile and 30% water with 
0.1% formic acid.  The reference solution was constantly infused at a flow rate of 500 
nL/minute, however, for the majority of the time a rotational baffle blocks the access of 
reference ions into the source.  At thirty second time intervals throughout a chromatographic 
analysis the baffle rotates to allow for a single scan (0.6 seconds) of reference solution to 
pass into the mass spectrometer as the spray from the sample capillary becomes blocked.  
[Glu1]-fibrinopeptide B is a preferred reference source due to the strong signal intensity of its 
doubly charged ion at an m/z 786.8426 Daltons and the lack of adduct formation or other ion 
influences.  The lockspray signal is collected as a separate analyte channel during sample 
acquisition and allows for mass correction throughout a chromatographic analysis using 
Waters® Protein Lynx Global Server software (PGLS). 
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2.3.5.4  MS Instrumentation: MSE 
Waters Corporation pioneered a new approach for collection of fragmentation 
information by mass spectrometry in the identification of complex peptide and protein 
mixtures.  This technology, termed MSE is designed by acquiring exact mass data at high and 
low collision energies simultaneously.52, 53  In low energy MS mode, data are collected with a 
constant collision energy of 4eV at a scan time of 0.7 seconds.  On alternating scans, the 
system switches to an elevated energy mode where the collision energy is ramped from 15 to 
40 eV.  One cycle of low and elevated energy data are acquired every 1.4 seconds.  The RF 
applied to the quadrupole mass analyzer is adjusted such that ions from m/z 50 to 1990 were 
efficiently transmitted.  Every thirty seconds a 0.6 second scan of the reference solution was 
sampled allowing for accurate lock mass correction.  A schematic cartoon of MSE acquisition 
is illustrated in Figure 2.4 (B). 
The Waters® QTof PremierTM instrument is capable of conducting MSE acquisition 
on peptide digests.  For all measurements, the mass spectrometer was operated in V-mode 
with a typical resolution of at least 10,000 FWHM.  The tune page parameters for the QTof 
Premier were set to apply a capillary voltage of +3000V, sample cone voltage of +35V, 
extraction cone voltage of +4V, and source temperature of 100oC.  For mass accuracy 
correction, a nanoflow lock spray source was implemented with a 200 fmol/mL reference 
solution of [Glu1]-fibrinopeptide B in 70% acetonitrile and 30% water with 0.1% formic 
acid.   
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2.3.6 Data Processing 
2.3.6.1   Protein-Lynx Global Server-DDA 
Waters® ProteinLynx Global Server 2.4 (RC7) is a software package that automates 
processing of LC-MSMS or MSE data for proteomics.  PLGS allows data acquired in 
MassLynx to be loaded directly into a data analysis software package that will identify mass 
corrected peptide ions and match these peptides against a protein database for identification.  
Data analysis using PLGS requires two main method processing components: the data 
preparation file and the workflow template.  The data preparation file applies a lockmass 
correction on the data acquired, addresses background subtraction and noise reduction while 
automating peptide deconvolution and centroiding to generate a peak list.   Conditions for 
electrospray DDA data preparation method development were evaluated where the 
electrospray survey and MSMS processing parameters were kept constant.  Lock spray 
calibration was enabled for [Glu1]-fibrinopeptide B lock mass correction m/z at 785.8426 
Daltons for two consecutive scans within a mass tolerance of 0.25 Daltons for all methods 
generated.  Methods were varied both in noise reduction parameters as well as deisotoping 
and centroiding settings to maximize efficient data analysis.  The four data preparation 
conditions investigated were as follows: (a) adaptive background subtraction and slow 
deisotoping where the number of iterations were set to 40; (b) no background subtraction and 
slow deisotoping; (c) no background subtraction fast deisotoping of centroided data; and (d) 
no background subtraction with Savitzky-Golay smoothing (two iterations and a half-width 
window of three channels) with fast deisotoping of centroided data.  After data treatment, 
peptide lists were processed with a fragment ion search workflow designer to search a 
particular databank of interest. 
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Databanks were created to include proteins encompassed during sample preparation.  
To include contaminant proteins, samples were first processed with both a compiled Swiss-
Prot database as well as a databank specialized in the Spodoptera frugiperda (Sf9) insect cell 
line reported proteome.  From this evaluation, a specialized databank was created from the 
ExPASy proteomics server of the Swiss Institute of Bioinformatics (http://www.uniprot.org) 
of the most abundant proteins identified.  UniProtKB provides a protein knowledgebase 
consisting of two sections: Swiss-Prot which is manually annotated and reviewed and 
TrEMBL which is automatically annotated but not reviewed.  Swiss-Prot strives to provide 
reliable protein sequences associated with a high level of annotation such as the description 
of the function of a protein, its domains structure, post-translationalmodifications and 
variants with a minimal level of redundancy.  The work presented was processed from the 
Swiss-Prot curated biological database of protein sequences.  The databank created for 
GGCX proteolytic peptide identification included the following proteins listed by accession 
number: P38435-Homo Sapiens (Human) Vitamin K-dependent Gamma-Glutamyl 
Carboxylase modified with the HPC4 C-terminus epitope tag (EDQVDPRLIDGK), Q8I866- 
Spodoptera frugiperda (Sf9) Heat shock cognate 70 protein, P00766 and P00767-Bos Taurus 
(Bovine) Chymotrypsinogen A and B respectively, P00761-Sus Scrofa (Porcine) Trypsin, 
P04264 and P04259-Homo Sapiens (Human) Keratin type II cytoskeletal proteins 1 and 6B 
respectively.  To identify false positive protein selection, the specialized databank was 
randomized. 
The databank of choice was uploaded into the workflow designer for peptide and 
protein sample identification.  Here, both the MS and MSMS spectra were matched with a 
selected databank to identify the protein(s) in the original sample.  The peptide and fragment 
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ion tolerances were set to 20 ppm and 0.5 Daltons respectively with an estimated calibration 
error of 0.05 Daltons.  Digestions were completed with trypsin, chymotrypsin, modified 
chymotrypsin_NS, or nonspecific cleavage parameters with anywhere from one to three 
missed cleavages.  Trypsin proteolytic cleavage was specified C-terminal to lysine (K) and 
arginine (R) not before proline (P).  For chymotrypsin digestions, digestion parameters were 
modified to create a chymotrypsin_NS reagent tool to cleave peptides C-terminal to 
methionine (M) and leucine (L) in addition to the traditional phenylalanine (F), tyrosine (Y), 
and tryptophan (W).  A nonspecific digest reagent was also evaluated where peptide cleavage 
could occur at any given amino acid.  Conditions for peptide scoring for nonspecific 
digestions must be more stringent as a greater number of theoretical peptides may be 
generated.  To account for any sequence variability or post-translational adaptations, several 
common peptide modifications were added to the search parameters: N-terminus acetylation 
( 42.011 Daltons), deamidation of asparagine and glutamine (0.984 Daltons), and 
oxidation of methionine (15.995 Daltons).  Results were validated to limit peptide 
identification to only peptides with three or more consecutive fragment ions from the same 
series.  An example of data preparation and workflow parameter conditions for DDA 
analyzed samples is represented in Table 2.2. 
In addition to the databank search for DDA processed samples, AutoMod processing 
allows for peptides with modifications, substitutions, or greater than three missed cleavages 
to be identified with the same databank selected.  If there are peptides that are identified that 
do not meet the search criteria of the specified databank, a De Novo query can be applied that 
allows for sequence information to be extracted from the MSMS data and searched via a 
BLAST tool (Basic Local Alignment Search Tool) to match homologous proteins.   
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For most data sets, DDA PLGS2.4 processing is programmed using a lock mass 
corrected data preparation file with no background subtraction under fast deisotoping of 
centroided data.  The workflow template fragment ion preparation is limited to a databank 
search under appropriate proteolytic digestion conditions with peptide and fragment ion 
tolerance set to 20 ppm and 0.5 Daltons accordingly.  Variable peptide modifications 
including N-terminus acetylation, deamidation of asparagines and glutamine, and oxidation 
of methionine are also evaluated. 
2.3.6.2 Protein-Lynx Global Server-MSE 
MSE sample acquisitions were processed using ProteinLynx Global Server 2.4 (RC7).  
Experimental setup for data analysis was very similar to that for DDA processing, with 
generation of both the data preparation and workflow template files.  The data preparation 
file applies a lockmass correction on the data acquired and addresses threshold parameters 
for ion identification.  For MSE sample analysis, lock mass correction was enabled (m/z 
785.8426 Daltons) for a doubly charged ion with a correction window of 0.25 Daltons.  Here 
the chromatographic peak width (FWHM), MS TOF resolution, and retention time window 
parameters were set to automatic detection.  Thresholds for peak processing were set at 200 
counts, 75 counts and 1500 counts for the low energy, elevated energy, and intensity 
threshold values respectively.  The low and high energy ion detection threshold corresponds 
to the total ion volume over the mass spectrometric and chromatographic volume of a single 
peak and is set slightly lower than the default value to increase, within reason, the number of 
ions detected.  The intensity threshold, however, is the minimum integrated intensity that a 
precursor exact mass retention time must have for it to be submitted to the ion accounting 
search algorithm.  This value was set to a default of 1500 counts.   
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After data preparation processing, the aligned and corrected low energy precursor 
ions and high energy fragment ions can be matched against a protein databank in a designed 
workflow profile.  Here the GGCX specialized databank was searched for peptide and 
protein identification using automatic peptide and fragment tolerances for peptide 
identification after trypsin, chymotrypsin, chymotrypsin_NS, or nonspecific digestion.  The 
search criteria was set to match a minimum of three fragment ion matches per peptide, seven 
fragment ion matches per protein, and one peptide match per protein with a false positive rate 
of 4.  N-terminal acetylation, deamidation of asparagine and glutamine, and oxidation of 
methione were set as potential variable modifications.  Since GGCX was deglycosylated with 
PNGaseF, N-linked glycosylation sites were not specified in the search parameters.  An 
example of data preparation and workflow parameter conditions for MSE analyzed samples is 
presented in Table 2.3. 
2.3.6.3 Peptide Identification 
Samples were run in triplicate analysis to confirm peptides that replicated in two of 
three sequential chromatographic injections.  Peptide replicates helped to rule out 
misidentification as well as to provide support for peptides identified in regions where no 
additional overlapping protein fragments are found.  To identify replicating peptides, data is 
pooled from either the peptide workpad generated after PLGS processing or from the ion 
accounting output from MSE processed samples. 
The identified peptides of a triplicate analysis for a given sample are compiled and 
matched for replication in peptide sequence, retention time (within 0.5 minutes), mass 
accuracy (10 ppm), variable modification, and peptide type (digest peptides, variable 
modification, neutral loss, or source fragment).  A peptide must be present in two of three 
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replicate sample injections to be considered a reproducible peptide match.  Once these 
peptides are identified, a topology mapping can be generated to determine percent coverage 
of GGCX.  Here sequence coverage is defined as the ratio of the sum of amino acids in every 
detected peptide divided by the total number of amino acids in the protein sequence.  In the 
case of missed cleavages, peptides may oftentimes overlap resulting in each amino acid 
contributing only once to the calculated percent coverage. 
Simulated in silico digestions for GGCX are completed using the Peptide Mass tool 
available on the ExPASy proteomics server (www.expasy.org).  Digestion conditions are 
completed assuming cysteines are reduced in trypsin (cleavage C-terminal to R/K not before 
P) or chymotrypsin (cleavage C-terminal to F/Y/W/M/L not before P) digestions with three 
missed cleavages.  Scores for GRand AVerage hydropathY (GRAVY) are performed by the 
ProtParam ExPASy tool.  GRAVY values of peptides are determined according to the Kyte 
Doolittle54 scale where a hydropathy score is determine for each amino acid.  To calculate the 
hydropathy index for a given peptide, the GRAVY score is summed for each amino acid in 
the peptide sequence and divided by the total number amino acids in that peptide.  When 
determining the hydropathy plot for an entire protein, a moving average amino acid 
summation is calculated for every 7 amino acids in the protein sequence where hydropathy 
index was plotted against residue number. 
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2.4 Results and Discussion 
2.4.1 Sample Acquisition: Data Independent LC-MS versus Data Dependent LC-
MSMS 
Mass spectrometry has evolved into a powerful tool for the analysis of protein 
mixtures due to its speed of analysis, sensitivity, and accuracy.  As biological sample 
complexity increases, dynamic range and molecular weight limits the use of protein mass 
fingerprinting (PMF) for protein identification.  As a result, samples are typically analyzed 
by electrospray LC-MSMS using a precursor selected data dependent acquisition (DDA) 
method.  The major advantage of this approach is the generation of primary structural 
information from the peptide precursor ion selected for fragmentation.  The added specificity 
provided by the fragment ion information increases the quality of peptide identification in 
complex protein mixtures.   
 A DDA experiment is a cyclical process.  The series starts by acquiring an MS survey 
over a designated mass range in which the quadrupole is set to pass all ions to the TOF 
analyzer unaffected by ion fragmentation.  Set thresholds of ion intensity, charge state, or 
adduct formation can be configured such that when an ion meets the conditions determined, 
the instrument switches to MSMS mode applying an increase in collision energy and thus 
resulting in peptide fragmentation.  The number of selected precursor ions and the allocated 
MSMS acquisition time are optimized for a given sample type and complexity.  For DDA 
experiments conducted in this work, a collision energy profile was employed where 
fragmentation was primarily selected by ion intensity.  When ions breach a current threshold, 
the selected precursor ion is ramped through a series of three collision energies until the 
intensity of the precursor ion drops below a given threshold or after a period of 3.3 seconds 
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has passed.  After fragmentation, the system switches to continue in MS mode until 
conditions for precursor fragmentation are again met.  At any given time there can be up to 
two precursor ions being selected for fragmentation.  An experimental peptide digest of a 
DDA acquired chromatogram is shown in Figure 2.5.  Eluting precursor ions are recorded in 
a MS survey scan (A) with corresponding MSMS component chromatograms in (B and C).   
An inherent disadvantage of DDA intensity selection is that precursor ions are 
selected for fragmentation immediately after passing a predetermined ion current threshold, 
which may or may not be at their chromatographic apex.  Typically the number of selected 
precursor ions will increase and the MSMS acquisition time for each ion will decrease with 
increasing sample complexity.  This creates a fundamental problem for the identification of 
proteins over a wide dynamic range or generation of extensive sequence coverage for a single 
protein.  Fast separations with narrow, rapidly eluting peaks result in significant loss of data 
in MS mode when MSMS data is being acquired.  As a result, precursor ion sampling 
drastically suffers.  While DDA is sufficient in providing sequence information for 
identification of proteins, topology peptide mapping for individual peptides is severely 
under-sampled since only the two most intense ions at a given time are selected for MSMS 
fragmentation.  Many of these limitations described have a direct effect on the lack of 
reproducibility, low sequence coverage, and large number of single peptide-based protein 
identifications present in the literature.55, 56 
 To overcome some of these problems, a data independent mode of acquisition was 
introduced by Waters Corporation for label-free quantitative LC-MS studies.52, 53  This 
process, termed MSE, takes advantage of a high-peak capacity chromatographic separation 
coupled with the high sampling-rate of an orthogonal acceleration TOF mass spectrometer 
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providing a rapid and parallel generation of peptide precursor and product ion detections on 
all eluting species within a chromatographic separation.  Maximizing the duty cycle, MSE is 
programmed in such a way to acquire two functions during alternating scans.  The first 
function is set at a low collision energy during which no fragmentation occurs to the 
precursor ions.  Contrastingly, the second function is acquired during which the collision 
energy is linearly ramped between two user defined energies inducing fragmentation of any 
species present in the gas cell at that time.  The resulting low collision energy and elevated 
collision energy chromatograms for a peptide digest are shown in Figure 2.6 (A and B) 
respectively.  For optimal determination of m/z values, retention times, and peak volumes of 
all detectable ions, the acquisition time of the scan speed is set in proportion to the 
chromatographic peak width allowing a sufficient number (approximately 10) of scans to be 
collected from each precursor ion.  Figure 2.7 compares preservation of the chromatographic 
fidelity between the low collision energy scans in MSE (A) mode compared to DDA (B) 
mode for the same peptide digest sample.  Here one can note the preservation in peak 
geometry in the MSE sample chromatogram as low and high collision energy functions are 
acquired simultaneously by alternating 0.7 second scans.  Product ion information is obtained 
from all the isotopes and charge states of a given precursor peptide as fragmentation occurs 
in parallel.  The DDA chromatogram, on the other hand, loses the ability to accurately 
determine chromatographic peak profiling parameters as data acquisition is spread over three 
collection channels.  The DDA MS chromatogram, therefore, is depicted as a smoothed 
representation of only the ions present when the collision energy is switched low.  Precursor 
ions in the low intensity regime of a peptide digest not only lack in MSMS sequence 
information, but are often completely lost from the MS scan due to the timing of 
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fragmentation periods.  Both methods of precursor fragmentation allows for improvements in 
peptide identification compared to peptide mass fingerprinting.  While DDA allows for 
highly confident selected precursor fragmentation with minimal product ion impurities, MSE 
results in complex fragmentation patterns of all precursor ions at a given time.  Data 
processing algorithms, therefore, must be designed to appropriately interpret peptide 
identification for complex sample analysis.  
2.4.2 Peptide Detection: Data Independent LC-MS versus Data Dependent LC-MSMS 
Novel database algorithms were designed by Waters Corporation to allow for MSE 
and DDA processing using ProteinLynx Global Server 2.4 (RC7).  PLGS is a software 
package designed to automate the processing of MassLynx acquired LC-MS data for 
proteomic applications.  In either data acquisition mode, processing allows for accurate mass 
peptide and protein identification based upon matches to a user-defined database. 
PLGS uses a probability based scoring algorithm both for peptides and proteins 
identified in data dependent (DDA) MSMS fragmentation.  Figure 2.8 presents an 
experimental flow diagram for DDA peptide selection and identification by PLGS.  Figure 
2.8 (A) identifies the selection of a chromatographic peak in a peptide digest.  After MS 
acquisition for the indicated m/z of 635.8 Daltons (B) the system is triggered for MSMS 
fragmentation (C) in the second component scan to generate the product ion spectrum (D).  
During processing, PLGS matches the associated fragment ion spectrum to the peptide 
sequence (L)MVLDIPQERGL(S) identified in Gamma-Glutamyl Carboxylase.  For peptide 
identification, PLGS uses a probability based methodology to identify theoretical cleavages 
with experimental mass spectra.  
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For each precursor ion, a set of peptide sequences are constructed by synthetic 
digestion of the protein sequences in the database, matching within the user-defined peptide 
tolerance of the precursor mass.  The peptide score is based upon the natural logarithm of the 
likely probability of a given peptide sequence to match the calculated sequence based upon a 
stochastic model for fragmentation.  The weight of the peptide probability is determined by 
the site specificity, the number of missed cleavages, and the number of variable 
modifications.  ProteinLynx then matches the probabilistic models against fragmentation 
characteristics of peptides that incorporate a, b, y, and z immonium ions, fragment ions from 
modifications, internal cleavages, and neutral losses to produce a given score.  The combined 
probability of correlating peptides contributing to percent recovery is then used to calculate 
the associated protein score for identification.   
 Since MSE acquisition simultaneously collects both precursor and product ion 
information, data processing algorithms must be modified to distinguish between peptide 
overlap.  The algorithm employs a hierarchical database search strategy that manages the 
physiochemical attributes associated to a given precursor mass and then identifies the peptide 
according to an ion accounting depletion algorithm.57  The raw data was initially treated to 
locate peak apeces and apply a lock-mass corrected calibration (Apex3D output).  Peptide 3D 
follows Apex3D in the identification process as a deconvolution algorithm that collapses the 
ions of a single peptide to a single exact mass retention time (EMRT).  Included for both the 
low and elevated energy component scans is the monoisotopic accurate mass, an average 
charge state biased by intensity, the summed peak area for all isotopes of all charge states, a 
calculated area deviation, and the apex retention time.  After ion detection, a time alignment 
correlation is then applied to identify product ions to corresponding precursor masses.58  In 
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the case of coeluting peptides, the same fragment ions will be initially assigned to multiple 
precursors.  This theory is based on the principle that the chromatographic behavior of all 
ions associated with an eluting parent peptide are similar such that the calculated apex 
retention times should equal plus or minus one-tenth of the chromatographic peak width of 
the low energy component.57  The time aligned precursor/product ion tables are then filtered 
and modeled before submission to the search algorithm.  Using a specified database modified 
with randomized decoy protein sequences, theoretical peptide digestions and optimized 
fragmentation models can be created from processing query parameters to aid in peptide 
assignment.  
Ion accounting represents an iterative databank search stage of the processing where 
peptides and proteins are identified according to the deconvoluted precursor and product ions 
in the sample spectrum.  During the first iteration (Pass 1), each parent/product ion is queried 
against the protein sequence database.  For a peptide to be identified it has to fit within the 
precursor ion mass tolerance and contain at least three fragment ions within the product ion 
mass tolerance.  These tentative peptide identifications are scored based on how well the 
peptide correlates to a number of different models using the physiochemical attributes of the 
peptides determined during Apex3D processing.  After ranking, the tentative peptide 
identifications are collated into potential protein identifications.  A second pass is designed to 
identify peptide modifications (in-source fragmentation, neutral loss, variable modifications) 
and nonspecific cleavage products to proteins positively identified in the first pass.  The 
software realigns the low and elevated energy accurate mass retention time components that 
were not identified in pass one and conducts a search for pass two peptides.  Once a protein 
has been securely identified, a depletion algorithm is applied to remove all top ranked 
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precursor ions and their corresponding product ions from subsequent identification.  Finally, 
the remaining data is realigned for pass three identification where ion intensity is no longer 
restricted, multiple variable modifications are searched per peptide, and single-point amino 
acid modifications are incorporated.  The work in this study ignores identified pass three 
peptides. 
The final output is a table containing proteins identified with corresponding precursor 
peptide outputs.  A score is provided for each protein and peptide based on a series of 
fourteen parameters.57  Those peptides with low probability are indicated by peptides in red 
on the protein workpad output of PLGS.  These peptides are deleted for each replicate 
injection.  An experimental flow diagram for MSE acquisition is illustrated in Figure 2.9.  At 
a given point in a chromatogram, a mass spectrum can be isolated for each a low energy (A) 
and elevated energy (C) component scan where the simultaneous fragmentation of all the 
precursor ions in (B) are shown as product ions in (D). EMRT coupled with ion accounting 
algorithms in PLGS software processing identifies the peptide sequence at MH+ 1270.7 
Daltons as (L)MVLDIPQERGL(S) in Gamma-Glutamyl Carboxylase. 
This chapter will focus on the peptide digestions of Gamma-Glutamyl Carboxylase 
(GGCX) and peptide identification using both DDA and MSE fragmentation.  Samples were 
run in triplicate analysis for identification of topology mapping.  Reproducibility in 
chromatographic retention as well as peptide identification is compared and only those 
peptides that are identified in two out of three replicate runs are collated for percent coverage 
calculations.  Figure 2.10 demonstrates the correlation of three sequential injections of the 
same digest sample.  Chromatographic profiles between the three injections show almost no 
visual evidence of deviation (A).  Comparing the total peptides identified corresponding to 
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GGCX in each replicate, a relative percent standard deviation of only 3.8% is determined 
(B).   Here the total peptides are identified by all peptide types: pass one, pass two, neutral 
loss, source fragmentation, and variable modification containing peptides with removal of 
low probability peptides and pass three peptides.  For a peptide to be considered the same in 
replicate injections, the peptide must match not only in peptide sequence, type, and variable 
modification, but the retention time and precursor mass must match within 0.5 minutes and a 
10 ppm error threshold.  142 peptides were found to replicate in all three injections with 278 
peptides replicating in two out of the three sequential runs.  Reporting peptide identification 
by replication provides further confirmation of probable identification for low scoring 
peptides.  Often such low scoring peptides result from poor fragmentation limiting the ability 
of the peptide to match modeled systems.  Throughout the remainder of this chapter, 
digestion protocols will be discussed for the optimized percent recovery of the target 
transmembrane protein GGCX.  While much of the development work on GGCX digestion 
protocols were completed using a custom built UHPLC system and DDA MSMS 
fragmentation on a Waters® QTof MicroTM, the data reported herein is represented primarily 
from a Waters® nanoACQUITYTM liquid chromatography system with mass analysis using a 
Waters® QTof PremierTM mass spectrometer capable of exact mass lock spray calibration for 
both DDA and MSE acquisitions.  
2.4.3 Optimization of In-Gel Digestions for Gamma-Glutamyl Carboxylase 
Vitamin K-dependent Gamma-Glutamyl Carboxylase (GGCX) is a 758 amino acid 
integral membrane glycoprotein that catalyzes the post-translational conversion of specific 
glutamic acid residues in vitamin K-dependent proteins to gamma-carboxy glutamic acid.  A 
two-dimensional topology mapping of GGCX is shown in Figure 2.11.  Despite purification 
74 
and cloning, the structural analysis of GGCX is solely dependent on functional studies.  For 
example, regions characterized by highly conserved homology (highlighted in red) and 
propeptide binding (highlighted in blue) were accomplished by site-specific mutagenesis59 
and affinity labeling respectively.60  Topological studies have predicted GGCX to span the 
membrane between the cytoplasm and endoplasmic reticulum (ER) lumen five times, with its 
N-terminus in the cytoplasm and C-terminus in the lumen.61  Despite the abundance of 
information obtained in biological characterization of GGCX, studies have been severely 
limited in structural investigations due in part to problems associated with poor solubility and 
protein aggregation.  To identify characteristic attributes regarding the protein structure of 
GGCX, a bottom-up proteomics approach was investigated with the objective of optimizing 
digestion conditions to maximize topology recovery using in-gel digestions.   
Affinity purified recombinant GGCX isolated from Sf9 insect cells was solubilized in 
buffer containing 0.2% DOPC and 0.5% CHAPS to maintain catalytic functionality.  Prior to 
in-gel digestion, GGCX must be reduced and deglycosylated to promote partial protein 
unfolding and easy access for proteolytic digestion.  A study of the glycosylation sites in 
GGCX identified N-linked glycosylation using mass spectrometry by performing in-gel 
deglycosylation of GGCX by PNGaseF in the presence of 50% 18O water.62  Further 
confirmation by mutational analysis concluded N-linked glycosylation sites in GGCX to 
exist on residues N459, N525, N550, N605, and N637 in human GGCX.  It was also 
determined that a glycosylation site is present on residue N570 only when all five of the 
natural glycosylation sites are removed.  This may be explained by the influence of 
glycosylations for stable protein structure formation.  Figure 2.12 illustrates an SDS-PAGE 
gel representing purified GGCX after treatment with PNGase (lane 2) at an apparent 
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molecular weight of 87 kDa compared to unmodified GGCX (lane 1) at ~94 kDa.  
Electrophoretic migration of the GGCX protein band after PNGaseF treatment confirms 
human GGCX is an N-linked glycoprotein.  Furthermore, modification to the traditional 
digestion protocol allows for limited digestion of GGCX into a disulfide-linked 30 kDa 
amino-terminal and a 60 kDa carboxy-terminal fragment (lane 3).  Treatment of GGCX with 
PNGaseF after limited trypsin digestion, results in band migration only of the 60 kDa tryptic 
fragment of GGCX (lane 4) confirming N-linked glycosylation in the C-terminal domain. 
Figure 2.13 demonstrates an optimized flow diagram for proteolytic in-gel digestion 
of GGCX.  This protocol was modeled after a conventional digestion procedure based on 
Wilm et al.63 and was adjusted to limit sample handling and maximize peptide recovery.  
Several parameters were investigated throughout method development including gel staining, 
washing procedures, gel dehydration, and gel extraction in addition to digestion protocols.  
During gel work-up stages it is important to minimize sample handling to prevent 
contamination as well as pre-treat all Eppindorf tubes and tips with a solution containing 
50% acetonitrile to prevent peptide loss by adsorption.  In agreement with Hellman et al.,64 
yields in dry gels were generally about 30-50% higher, suggesting more efficient penetration 
of protease solution into the gel piece after reconstitution.  To aid dehydration and provide 
maximal surface area for proteolytic digestion, the gel band was cut into small pieces <1mm3 
and treated with 100% acetonitrile prior to drying by lyophilization. 
After dehydration, the gel is reconstituted in a minimal volume of buffer containing 
proteolytic enzyme and kept on ice to allow rehydration. Excess enzyme containing solution 
was removed from the gel and a small amount of buffer in the absence of enzyme was added 
to provide a concentrated environment for digestion.  To optimize recovery of hydrophobic 
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peptides while maintaining proteolytic activity, 10% acetonitrile was incorporated into the 
digestion buffer.  After digestion, the supernant was removed and the gel band was further 
extracted overnight with 60% acetonitrile in 40 mM ammonium bicarbonate.  It is reported 
that the major cause of low peptide recovery is the unsuccessful peptide extraction from a 
polyacrylamide gel where losses vary anywhere from 15-50% depending on peptide 
properties and concentration.65  Extraction with high concentration of organic solvents aid in 
peptide extraction from the gel matrix further improving peptide recovery. 
Proteolytic digestion was evaluated using trypsin, chymotrypsin, pepsin, cyanogen 
bromide, and a combined digestion with both trypsin and chymotrypsin.  Traditionally, 
specific proteases such as trypsin have been used almost exclusively in protein digestions for 
bottom-up proteomics.  The stringent specificity of trypsin provides reproducible cleavage at 
the carboxylic side of lysine (K) and arginine (R) residues to promote protein identification.  
The specificity of trypsin can be further improved to inhibit chymotrypsin contaminants and 
prevent enzyme autolysis eliminating additional peptide fragments that could interfere with 
mass analysis of the target peptide sequence.   
Nonspecific enzymes, however, offer the unique advantage of digesting smaller 
peptide fragments thus creating overlapping peptides throughout the protein sequence.  These 
overlapping peptides greatly improves the protein sequence coverage, but at the expense of 
icreased sample complexity.  A compromise between specific and nonspecific proteolytic 
enzymes is chymotrypsin.  Chymotrypsin is a serine endoproteinase which predominately 
cleaves peptide bonds at the carboxyl side of phenylalanine (F), tyrosine (Y), and tryptophan 
(W).  In addition, chymotrypsin also catalyzes the nonspecific hydrolysis of peptide bonds at 
the carboxyl side of methione (M) and leucine (L) at lower rate of cleavage.  For peptide 
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mapping of GGCX, trypsin and chymotrypsin digestion conditions will be evaluated in this 
chapter. 
2.4.4 Modeling of In-Gel Digestions for GGCX 
To pre-screen for cleavage outcomes of a target protein, in silico digestions can be 
completed.  Using computational simulations, the suitability of a single cleavage reagent may 
be evaluated.  One important point to consider when creating theoretical peptide digestions, 
however, is the hydrophobic nature of the target GGCX transmembrane protein.  The 
GRAVY (Grand Average of HydropathY) score for a peptide or protein is based on 
principles developed by Kyte and Doolittle54 detailing an elaborate study investigating 
protein correspondence of a given amino acid residue to location between the hydrophobic 
interior structure or hydrophilic exterior.  Hydropathy values ranging from -4.5 to +4.5 can 
be calculated for a given peptide or protein sequence and can be used to characterize 
hydrophobic (+) or hydrophilic (-) domains.  Figure 2.14 illustrates a plot of the hydropathy 
index values for a moving peptide average of human GGCX.  Here it can be demonstrated 
that the N-terminal doman of GGCX represents a concentrated hydrophobic region of the 
protein compared to that of the C-terminus illustrated by plotting the five predicted 
transmembrane domains in red.  Despite the strong hydrophobic influence of GGCX, an 
averaged GRAVY value for the entire protein is calculated to be -0.156.   
Simulated peptide digestions of GGCX by trypsin or chymotrypsin can also be used 
to predict the relative hydrophobicity of extracted peptides.  Figure 2.15 demonstrates a 
predicted histogram for the number of peptides identified at corresponding hydropathy index 
values.  Chymotrypsin, characterized by a theoretical digestion of 746 peptides, has a median 
hydropathy index of -0.050, indicating that the predicted peptides are closely centered around 
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an average zero-point index.  Trypsin, on the other hand, has a simulated digestion of 268 
peptides in which the median hydropathy is -0.382 indicating digested peptides favor 
hydrophilic characteristics.  When evaluating these results, it is important to consider 
differences in digestion specificity between the two proteolytic enzymes evaluated.  
Characteristically, trypsin is known to produce longer cleavage fragments compared to that 
of chymotrypsin, cleaving at hydrophilic charged residues, which are likely not located in 
transmembrane domains.  Chymotrypsin, on the other hand, cleaves smaller peptides 
terminating in hydrophobic residues, theoretically promoting greater coverage of 
transmembrane domains.   
Using the same theoretical digestion and principles of digestion specificity, we can 
evaluate the distribution in peptide frequency as a function of peptide precursor mass as 
shown in Figure 2.16.   The more frequent cleavage at F/Y/W/M/L terminating residues in 
chymotrypsin digestions produce an abundance of low molecular weight peptides even when 
considering up to three missed cleavages.  Trypsin on the other hand, demonstrates a 
digestion with longer peptide sequences having a wide dynamic range in molecular mass, 
where the median molecular mass is 2192 Daltons for trypsin compared to 952 Daltons for 
chymotrypsin.  For hydropathy plots and fragment ion histograms, it must be noted that 
variable modifications are not included in peptide calculations.  Using simulated digestions 
for human GGCX as an evaluation of proteolytic performance prior to experimentation can 
greatly reduce experimental workload during method development.  From these studies, it 
can be predicted that trypsin, which produces long peptides upon digestion, will be limited in 
peptide recovery due to the inability to extract peptides from the gel matrix.  Although 
slightly more hydrophobic in total peptide characterization, chymotrypsin peptides may be 
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easier to recover due to their shorter peptide sequence and thus will produce more 
comprehensive peptide mappings. 
2.4.5 In-Gel Chymotrypsin Digestions 
Characteristic GGCX experimental in-gel digestion MSE chromatograms are 
displayed in Figure 2.17 for both a chymotrypsin digestion (A) and trypsin digestion (B).  In 
both chromatograms an LC gradient of 5-50% acetonitrile over 60 minutes was evaluated.  
Both spectra represent a complex chromatographic representation of GGCX peptidic 
digestions with little correlation with one another.  To rule out the possibility that the 
digestion spectrum is dominated by proteolytic autolysis or environmental contaminations, a 
control was evaluated where a piece of SDS-PAGE gel was digested under the same set of 
conditions except in the absence of target protein.  Figure 2.18 displays the comparison 
between a characteristic chymotrypsin digestion (A) and that of a chymotrypsin control (B).  
The scarcity of peptides in the control digestion indicates that the majority of the peptides 
identified in the chromatogram above correlates to GGCX. 
2.4.5.1 Specificity of Chymotrypsin Digestions 
During data evaluation, the specificity of proteolytic digestion must be considered.  
Chymotrypsin digestion is predicted to occur at a high frequency due to the abundance of 
F/Y/W sites throughout the protein.  The abundance of cleavage sites lends itself to an 
increase in sequence coverage when the data is processed with three missed cleavages as 
shown in Figure 2.19.  In this figure, a two dimensional topological diagram of GGCX is 
evaluated for site specific peptide recovery.  The residues highlighted in purple are those 
residues that have been confirmed by peptide identification when data is processed using a 
specific chymotrypsin digestion and considering only one missed cleavage.  Residues 
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highlighted in green are additional amino acids identified when up to three missed cleavages 
are incorporated.  When comparing percent peptide recoveries for both processing conditions 
it is shown that only a slight increase in percent coverage for three missed cleavages (42.5%) 
is shown over one missed cleavage (40.5%).   
In addition to missed cleavages that must be considered, nonspecific digestion plays a 
larger role in identifying peptides where proteolytic digestion results in cleavage at additional 
unspecified residues.  Chymotrypsin is shown to mostly cleave at F/Y/W aromatic residues 
but with cleavage at methionine and leucine C-terminating peptides to a lesser extent.  
Looking at the sequence structure of GGCX, the number of potential cleavage sites can be 
compared for each target amino acid, where 44 (5.8%) GGCX residues are phenylalanines, 
35 (4.6%) tyrosines, 18 (2.4%) tryptophans, 18 (2.4%) methionines, and 114 (15.0%) 
leucines.  From residue abundance alone, it is predicted that a modified chymotrypsin 
digestion incorporating M/L cleavage sites will improve peptide recovery if chymotrypsin 
shows nonspecific behavior during in-gel digestion.  Figure 2.20 summarizes these results 
demonstrating an increase in percent coverage from 42.5% coverage when processing 
conditions were limited to F/Y/W cleavage residues and three missed cleavages to 73.5% 
coverage when additionally incorporating M/L.  Those amino acid residues that are not 
identified in the modified chymotrypsin digestion (F/Y/W/M/L), but do appear under site 
specific processing (F/Y/W) are illustrated in light blue.  Leucine residues in particular are 
very abundant throughout the GGCX sequence and allows for drastic improvements in 
percent recovery in both the N-terminal and C-terminal domains of the protein.   
Going one step further, the same data set can now be processed using completely 
nonspecific cleavage parameters.  In this scenario, depicted in Figure 2.21, percent recovery 
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is seen to increase totaling 86.1% of the total protein sequence.  Again it must be noted that 
in order for a peptide to be identified as contributing to the percent coverage of the protein, 
the peptide must be sequenced successfully in two out of three replicate runs under the same 
peptide conditions (pass match, variable modifications, source fragmentation, or neutral 
loss).  Here we can demonstrate excellent recovery of the protein sequence where the largest 
gap between two neighboring peptide residues is 19 amino acids.  Only a small percentage of 
the residues identified in the nonspecific processing do not overlap with peptides identified in 
the chymotrypsin modified processing.  Those residues are highlighted in yellow on the 
topology diagram.  Comparing amino acid cleavage specificity for chymotrypsin digestions 
(Figure 2.22), it can be seen that although the majority of digestions terminate in 
F/Y/W/M/L, cleavage is also seen in elevated yields at glutamine, alanine, histidine, and 
glutamic acid residues. 
Taking the same processing conditions of a nonspecific digestion, we can evaluate 
variations in sequence coverage dependent on data acquisition in either MSE or DDA mode.  
To this point in the chapter all topology diagrams and percent coverage has been reported 
when the data is acquired using alternating low/elevated collision energies in MSE.  The 
advantages and disadvantages of the two data acquisition techniques have previously been 
evaluated and can be compared with experimental results to further support the argument.  
Figure 2.23 reports the topology diagrams for comparison between the two fragmentation 
methods where MSE coverage (86.1%) drastically outnumbers that of DDA (43.1%) for 
GGCX peptide recovery.  The sampling inefficiency in DDA acquisition coupled with the 
number of peptides identified in the low intensity region of the chromatogram make it 
difficult to identify a large number of small peptides created during chymotrypsin digestion.  
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By sheer numbers alone, the number of peptides identified to replicate in the MSE acquisition 
was 278 peptides and only 41 peptides in the case of DDA.  For applications involving 
protein identification where only a few peptides for each protein need to be confirmed to 
validate identity, DDA acquisition often proves to be sufficient.  When the objective, 
however, is for optimal peptide recovery DDA does not lend itself to provide sufficient 
means for identification.  The majority of the development work for in-gel digestions was 
initially completed on a customized UHPLC system coupled to a mass spectrometer only 
capable of DDA acquisition.  Although this system was sufficient for characterizing 
digestion trends, it did not provide an adequate means for protein representation.  From this 
point forward in this thesis, the remainder of data presented will consist of MSE acquired data 
for peptide sequence identification. 
2.4.5.2 Evaluation of Chymotrypsin In-Gel Method Variations 
High sequence coverage is key when analyzing samples for covalent modifications 
and Chapters 3 and 4 will focus on the identification by LC-MS of substrate binding by 
covalent attachment.  A number of conditions for chymotrypsin in-gel digestions were 
evaluated including: concentration of digestion solution upon gel-rehydration, duration of 
digestion at 30oC, gel extraction temperature with 60% acetonitrile in 40 mM ammonium 
bicarbonate, and column temperature during chromatographic separation.  A table listing 
these conditions is presented in Table 2.4.  In all studies, the experimental in-gel digestion 
methodology was compared to an optimized standard: 3 hour chymotrypsin digestion at 30oC 
with 100 ng/L proteoloytic solution, overnight extraction at 4oC, and a chromatographic 
column temperature at 35oC.  When varying an experimental parameter, the remaining 
conditions were held consistent with the standard system. 
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Chymotrypsin concentrations (100 ng/L, 50 ng/L, or 25 ng/L) and digestion times 
(5 hour, 3 hour, 1 hour) were evaluated.  The concentration of proteolytic solution and 
duration of digestion is thought to impact the specificity of digestion.  Conditions were 
considered such that a high concentration of enzyme could be applied to rehydrate the gel 
and allow specific digestion in a shorter time compared to longer digestion times with lower 
concentrations.  The results are illustrated in Figure 2.24 (A).  As the concentration of 
proteolytic enzyme increases, the percent coverage increases accordingly.  Comparing the 
percent coverage between a nonspecific processed digestion and a chymotrypsin modified 
digestion (F/Y/W/M/L), there is on average an 18  5 % increase in percent recovery by 
incorporating a nonspecific digestion. 
In terms of chymotrypsin digestion time (Figure 2.24, B), it was seen that the highest 
percent peptide recovery was achieved when digesting with a concentrated chymotrypsin 
solution for three hours.  Only minor differences in peptide recover were seen depending on 
digestion time variations.  For a chymotrypsin modified processing results, an average 
increase of 12.1  0.8% recovery is reported when incorporating nonspecific cleavages.   It is 
believed that for the longer digestion time point of 5 hours, peptide digestion resulted in 
cleavage of peptides into smaller sequences that could not be properly identified by MSE.  
Since the average peptide length in most peptide digestions centers around 11 residues, 
peptides that are cleaved to sequences spanning only three or four residues may likely be 
missed through peptide filtering during processing. 
To increase the recovery of hydrophobic fragments during sample extraction, 
temperatures were evaluated ranging from 4oC, 30oC, and 60oC.  It is hypothesized that 
higher temperatures coupled with extraction with organic solvent improves recovery of 
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hydrophobic peptides from the gel matrix.  Figure 2.25 (A) illustrates the percent peptide 
recovery as a function of extraction temperature showing the highest topological coverage at 
4oC.  When the gel was incubated overnight at 60oC with extraction solution, dehydration of 
the gel band was observed preventing peptide extraction from the gel matrix.  At 4oC, on the 
other hand, the gel maintains hydration during overnight incubation thus demonstrating 
optimal percent coverage conditions.  A plausible test for further experimentation would be 
to again monitor extraction at 60oC but for a shorter time period. 
Similarly, the influence of column temperature on peptide recovery is evaluated 
during a chromatographic separation.  As the temperature of the column increases, analytes 
exchange faster between the stationary and mobile phase making hydrophobic entities less 
likely to ‘stick’ during reverse phase separation.  In addition to preventing peptide 
adsorption, the higher temperature lowers the viscosity of the mobile phase allowing 
separations to proceed at lower pressures with the ability to move to faster separations.  In 
this scenario, the flow rate of the chromatographic separation was held constant to maximize 
the alternating channel sampling for low and elevated collision energies.  Figure 2.26 
illustrates chromatograms of the same peptide digestion at three different column 
temperatures, but with the same linear velocity for separation.  At higher temperatures, the 
peak profiles are slightly modified displaying overall a decrease in peak resolution.  
Considering the kinetics behind thermodynamic influenced exchange, some peptides change 
in retention time as the column temperature is increased from 35oC to 60oC.  Identifying 
replicate peptides for each running condition (Figure 2.25, B) demonstrates that at higher 
column temperatures, the peptide recovery decreases, with the optimal performance at 35oC.  
One plausible explanation for this occurrence is that at higher temperatures, resolution is lost 
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resulting in peptide co-elution.  As the chromatographic elution window narrows for peptide 
separation, MSE software has a increasingly difficult time deciphering between precursor 
products for one peptide compared to another resulting in inconsistent identification and a 
lack of reproducibility in positively matched peptides between multiple injections. 
From this experimental method validation, the optimal percent recovery for GGCX 
digestions was achieved under standard digestion conditions using a 100 ng/L proteolytic 
solution for a 3 hour digestion and 4oC gel extraction.  Chromatographic separations were 
completed at 35oC.  Incorporating nonspecific cleavage sites further increases our peptide 
recovery of GGCX, but at the expense of enhanced sample complexity during processing.  
To compare the distribution of peptides recovered during chymotrypsin digestion, we can 
compare our results to simulated in silico digestions.  Figure 2.27 (A) demonstrates the 
distribution of chymotrypsin modified and nonspecific peptides identified for a given 
precursor mass compared to a theoretical digestion.  Simulated digestion conditions assume 
cleavage at F/Y/W/M/L not before proline with up to three missed cleavages.  Compared to 
predicted results, experimental sample evaluation confirmed that the majority of peptides 
being identified are below 2000 Daltons.  Here multiple overlapping small peptides 
contribute largely to the extended percent coverage of GGCX.  Looking at the hydropathy 
index of peptides recovered (Figure 2.27, B), there appears to be a preferential distribution of 
hydrophilic peptides identified when incorporating only chymotrypsin cleavage domains.  
When adjusting the search parameters to include nonspecific digestions, the histogram shifts 
to provide a more balanced distribution.  The median hydropathy results of the experimental 
digestion were determined to be -0.071 and -0.443 for nonspecific and chymotrypsin 
modified digestion conditions respectively.  Thus, it may be concluded that chymotrypsin 
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GGCX digestions provide optimal peptide recovery allowing for overlapping peptides in 
multiple regions through the protein topology.  So long as sufficient data processing software 
is provided and stringent conditions for peptide verification are implemented, nonspecific 
peptide cleavages can be identified with a considerable degree of certainty. 
2.4.6 In-Gel Trypsin Digestions 
Trypsin digestions are the gold standard for shotgun proteomics of complex protein 
samples.  When considering a broad range of proteins, only a few peptides need to be 
identified to confirm protein identification and trypsin is often the proteolytic enzyme of 
choice due to its inherent specificity during digestion.  For membrane proteins, however, 
trypsin does not present optimal conditions for protein digestion.  For GGCX, the number of 
lysine and arginine residues in the protein sequence represent 3.6% and 6.5% of the total 
protein sequence respectively.  In comparison to chymotrypsin modified digestions alone 
(F/Y/W/M/L), trypsin digestions are expected to produce considerably lower number of 
peptides recovered.  Coupling the low number of accessible cleavage sites with the enhanced 
peptide length, it is predicted that trypsin digestions will present greater difficulty for 
extraction of peptides from the gel matrix leading to a lower percent total peptide recovery.  
Results can be illustrated in Figure 2.28 demonstrating the peptide recovery on the 
topology of GGCX for a trypsin digestion incorporating three missed cleavages.  It can be 
shown that the majority of topological domains are not recovered with a total percent 
coverage of only 38.3%.  This compares similarly to a protein mass fingerprinting GGCX 
topology previously reported in the literature.50  Varying the concentration of proteolytic 
enzyme for overnight digestion shows little change in peptide recovery (Figure 2.29).  
Evaluating the peptide recovery in terms of precursor mass (Figure 2.30, A) and 
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hydrophobicity (Figure 2.30, B), it can be seen that experimental results do not provide a 
good representation of desired theoretical digestion conditions.  For simulated digestions, a 
histogram represents a multitude of potential peptide fragments over a wide mass range 
distribution.  Experimental cleavage for these results, however, demonstrates a higher 
representation of small molecular weight cleavage peptides with no peptide identification 
above 2500 Daltons.  Similar to in silico predictions, hydropathy plots identify peptide 
recovery to be centered on slightly hydrophilic peptides with a median value of -0.543.  Thus 
it may be concluded that although trypsin provides reproducible site specific digestions, 
limited peptide recovery does not provide adequate peptide representation for structural 
comparisons.  Figure 2.31 further confirms the significant improvements in comprehensive 
topological representation by chymotrypsin digestion of GGCX over trypsin. 
Several attempts were made in an effort to improve the peptide recovery by trypsin 
digestion.  This included incorporating a higher concentration of organic solvent content 
during digestion as well as investigating extracting solvents for hydrophobic peptide 
recovery.  It is reported that trypsin can tolerate up to 65% methanol during digestion and 
still maintain enzymatic activity.27, 39, 66  Varying the concentration of organic solvent 
content, however, did not improve peptide identification with the optimal recovery being 
obtained for a digestion with 10% acetonitrile in 40 mM ammonium bicarbonate.  
Incorporation of an acid labile surfactant (ALS) was another point of experimental 
investigation.  ALS is thought to improve peptide recovery by encouraging hydrophobic 
peptides to be extracted from the gel matrix.  After digestion, the surfactant can be degraded 
by acid hydrolysis producing a solid precipitate that can be removed by centrifugation and a 
soluble by-product that is removed at the void volume during chromatographic separation.  
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The advantage of using RapiGestTM ALS over standard protein denaturants, such as sodium 
dodecyl sulfate or urea, is that RapiGestTM does not modify peptides or suppress 
endoprotease activity and it can be easily removed after use by hydrolysis under acidic 
conditions.  Investigation of the Waters® RapiGestTM ALS, however, demonstrated no 
improvement in peptide recovery.  A final attempt, investigated a limited trypsin digestion in 
solution.  Under modified trypsin digestion conditions, GGCX can be cleaved between 
residues 349 and 351 to achieve a 30 kDa N-terminal fragment and a 60 kDa C-terminal 
fragment upon reduction of the disulfide bond.  The 60 kDa portion of GGCX isolates a very 
soluble portion of the protein with only one transmembrane pass domain.  This protein 
fragment can then be isolated by reducing SDS-PAGE for further treatment of in-gel 
digestion by trypsin.  The hypothesis was that reducing the hydrophobicity of GGCX by 
removing the 30 kDa fragment will allow for better digestion by trypsin further increasing 
the coverage in the C-terminal domain.  This, however, was not the case and limited trypsin 
digestions followed similar digestion patterns consistent with previously observed results.  It 
may be concluded that despite modifications, trypsin provides less than ideal digestion 
conditions of the transmembrane protein GGCX by in-gel digestion. 
2.4.7 Sample Preparation Reproducibility 
A final point of consideration that was evaluated with sample preparation 
reproducibility is the influence of sample-to-sample digestion reproducibility and the 
influence of contaminant proteins during proteolytic digestion.  Previously (Figure 2.10), 
sample injection replicates were considered demonstrating good correlation in retention time 
and peak profile reproducibility while maintaining consistent peptide identifications.  These 
findings confirm that the experimental system for analyzing protein digests provides 
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reproducible performance on a run-to-run basis.  Here we evaluated duplicate sample digest 
preparations of two separate GGCX protein fractions.  Figure 2.32 displays the 
chromatographic reproducibility between sample preparations as well as compares the 
peptide recovery for each sample.  In each set of experiments, three replicate injections were 
made and the peptides identified in two out of the three replicate runs were reported for each 
sample and illustrated on respective topology diagrams.  In addition to evaluating topology 
coverage, the number of peptides identified in each sample replicate set is compared using a 
Venn diagram.  In sample 1, 220 GGCX peptides were matched in two out of the three 
replicate injections.  Of these 220 peptides, 129 matched with the peptide replicates 
identified in sample 2.  Although only a little over fifty percent of the peptides identified in 
the two samples were exact matches based on peptide sequence, type, variable modification, 
and precursor mass, the average peptide recovery between the two samples was reported as 
86.5 ± 0.5%.  Comparing a total of six sample injections between two different sample 
preparations provides a valid means for evaluating reproducibility of topology recovery in 
GGCX chymotrypsin digestions. 
Throughout this investigation, we have focused on the peptide recovery of GGCX.  
Other contaminant proteins, however, are shown to be present in the digest samples further 
complicating data analysis.  Figure 2.33 demonstrates the consistency of contaminant protein 
identification between two individual sample preparations where the percentage reported is 
the average peptide count for each protein identified between three triplicate injections.  The 
main contribution in both samples was that of GGCX with 55 ± 0.7% total peptides 
identified.  Of that percentage, 34 ± 6% accounts for peptides that replicated in two out of 
three of the replicate runs.  Other contaminant proteins identified were chymotrypsinogen 
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A/B contributing from proteolytic autolysis, human keratin from sample handling, and 
HSP70 (heat shock protein 70 from Spodoptera frugiperda).  Populating the processing 
database with contaminant proteins as well as a randomized decoy database, will identify 
processing discrepancies in the identification of false positive peptide and protein matches. 
2.4.8 Conclusions 
This chapter focused on the optimization of proteolytic digestion of the 
transmembrane protein GGCX.  Integral membrane proteins inherently present problems in 
separation science due to difficulties in protein solubility.  As a result, it becomes very 
difficult to study such proteins using analytical techniques such as liquid chromatography 
and mass spectrometry.  To optimize topology recovery, an in-gel digestion of GGCX was 
completed with varying proteolytic enzymes and enzymatic methodologies.  In combination 
with data acquisition and sample preparation, it was determined that an optimal method for 
GGCX digestion involves an in-gel chymotrypsin digestion (100 ng/L) for 3 hours followed 
by extraction by 60% acetonitrile in 40 mM ammonium bicarbonate overnight at 4oC.  
Results demonstrate up to 86% recovery for GGCX for peptides that replicate in two out of 
three injections.  In comparison to standard trypsin digestions, chymotrypsin tremendously 
improves the ability to recover a comprehensive peptide mapping of the transmembrane 
protein GGCX.  While nonspecific cleavages are shown to occur with chymotrypsin 
digestions, improved peptide recovery is preferred at the expense of sample complexity.  
Excellent reproducibility is demonstrated between replicate injections and between multiple 
sample preparations further validating method robustness.  In moving forward, hopes are to 
apply this structural model of GGCX for identification of substrate binding domains in 
covalent modifications.   
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2.6 Tables 
 
 
 
 
 
 
 
 
 
 
 
 
 
From m/z To m/z CE1 (eV) CE2 (eV) CE3 (eV)
400.0000 500.0000 28 22 38
500.0001 600.0000 30 24 40
600.0001 700.0000 32 26 42
700.0001 800.0000 32 28 38
800.0001 900.0000 35 30 40
900.0001 1000.0000 37 32 42
1000.0001 1600.000 37 32 45
 
 
Table 2.1 Collision energy profile for data directed analysis (DDA) MSMS acquisition.  
Three collision energy voltages applied in sequential order over given m/z range 
where voltages ramp from medium, low, high values (MLH).  
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Data Preparation Workflow Template
*Chymotrypsin_NS: Modified Digest Reagent
Cleave C-term to F/Y/W/M/L not before P
Electrospray DDA
Processing Parameters
Value
Mass Accuracy Lock Spray Calibration
785.8426 Da/e
Lock Spray Scans: 2
Lock Mass Tolerance: 0.25 Da
Noise Reduction 
-Background Subtraction
None
Noise Reduction
-Smoothing
Savitzky-Golay
Smoothing Iterations: 2
Smoothing Window: 3 channels
Deisotoping Fast Deisotoping
Threshold 3%
Centroiding Minimum Peak Width: 4 channels
Centroid Top: 80%
Tof Resolution: 10000
Np Multiplier: 0.7
Fragment Ion
Databank Search
Value
Databanks GGCX_HPC4_1XRandom-1.0
Species NA
Peptide Tolerance 20 ppm
Fragment Tolerance 0.5 Da
Estimated Calibration Error 0.05 Da
Molecular Weight Range 0 to 200000 Da
pI Range 0 to 14
Minimum Peptides to Match 1
Maximum Hits to Return 20
Primary Digest Reagent Nonspecific, Chymotrypsin, 
Chymotrypsin_NS, or Trypsin
Secondary Digest Reagent None
Missed Cleavages 1 or 3
Fixed Modifications None
Variable Modifications Acetyl N-term; Deamidation N; 
Deamidation Q; Oxidation of M
Validate Results Yes
Filter None
 
 
Table 2.2 Data preparation and workflow template ProteinLynx Global Server (PLGS) 
processing parameters for data directed analysis (DDA) MSMS files. 
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Data Preparation Workflow Template
*Chymotrypsin_NS: Modified Digest Reagent
Cleave C-term to F/Y/W/M/L not before P
Electrospray-MSE
Apex3D
Value
Chromatographic Peak Width Automatic
MS TOF Resolution Automatic
Lock Mass for Charge 1 NA
Lock Mass for Charge 2 785.8426 Da/e
Lock Mass Window 0.25 Da
Low Energy Threshold 200.0 counts
Elevated Energy Threshold 75.0 counts
Retention Time Window Automatic
Elution Start Time NA
Elution End Time NA
Intensity Threshold 1500 counts
Electrospray-MSE
Databank Search Query
Value
Databanks GGCX_HPC4_1XRandom-1.0
Peptide Tolerance Automatic
Fragment Tolerance Automatic
Min Fragment Ion Matches Per Peptide 3
Min Fragment Ion Matches Per Protein 7
Min Peptide Matches Per Protein 1
Maximum Protein Mass 250000
Primary Digest Reagent Nonspecific, Chymotrypsin, 
Chymotrypsin_NS, or Trypsin
Secondary Digest Reagent None
Missed Cleavages 1 or 3
Fixed Modifications None
Variable Modifications Acetyl N-term; Deamidation N; 
Deamidation Q; Oxidation of M
Enriched Variable Modifications NA
Variable Glycosylation Modifications NA
False Positive Rate 4
Calibration Protein NA
Calibration Protein Concentration NA
Manual Response Factor NA
 
 
Table 2.3 Data preparation and workflow template ProteinLynx Global Server (PLGS) 
processing parameters for data independent analysis (MSE) files. 
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Concentration
(ng/L)
Digestion Time
(hours)
Extraction 
Temperature 
(oC)
Column 
Temperature 
(oC)
100 5 4 35
100 3 4 35
100 1 4 35
100 3 30 35
100 3 60 35
100 3 4 45
100 3 4 60
50 3 4 35
25 3 4 35
 
 
Table 2.4 Chymotrypsin in-gel digestion parameters for Gamma-Glutamyl Carboxylase 
(GGCX).  Method development included variations in proteolytic enzyme 
concentration, digestion time, gel extraction temperature, and column temperature.  
Standard protein digestion protocol highlighted in yellow. 
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2.7 Figures 
 
 
 
 
 
a2  b2 c2
x2  y2 z2
C
H
R1
H2N C
H
N C
H
R2
C
H
N C
H
C
R3
H
N CH
R4
COOH
O O O
C
H
R1
H2N C NH
CH
R2O
a2 x2
C
H
R1
H2N C
H
N C
H
R2
C
O
O
b2 y2
c2 z2
C
H
R1
H2N C
H
N C
H
R2
C NH3
O O
HC C
R3
H
N C
H
R4O
COOH
H3N C
H
C
R3
H
N C
H
R4O
COOH
C
H
N C
H
C
R3
H
N C
H
R4O
O COOH
 
 
Figure 2.1 Common fragmentation pattern for low energy collision induced dissociation 
(CID) during MSMS acquisition. 
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Figure 2.2 Systematic diagram illustrating operation of UHPLC custom system.  When both 
pin valves are open, the system is operated in the LOAD position.  The CapLC 
generates the gradient and injects the sample passing through the four-port union and 
onto the gradient storage tubing.  When the pin valves are closed, the hydraulic 
amplifier supplies the pressure to run the gradient and INJECT the sample onto the 
column. 
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Figure 2.3 nanoACQUITYTM UPLC system module.  The binary solvent manager (BSM) 
provides flow rates and pressures amenable to capillary liquid chromatography 
separations.  A trapping column allows for sample desalting and concentration prior 
to separation on an analytical capillary column packed with 1.7 m BEH C18 
particles.  The column is housed in a thermally controlled sleeve allowing 
thermostated separations.  Detection is completed using a Waters® QTof PremierTM 
with electrospray ionization. 
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Figure 2.4 Schematic comparison of data directed analysis (DDA) and data independent 
analysis (MSE) fragmentation modes.  (A) DDA fragmentation follows a traditional 
MSMS methodology, where precursor ions are targeted for selected ion 
fragmentation.  Acquisition in DDA mode incorporates time-dependent scanning 
between a MS channel and two component precursor MSMS fragmentation channels.  
(B) MSE fragmentation allows for simultaneous acquisition of low and elevated 
collision energy scans resulting in fragmentation of all precursor ions present in a 
chromatographic separation.   
 
 
 
 
 
 
 
103 
 
 
 
 
 
 
 
100
90
80
70
60
50
40
30
20
10
0
In
te
ns
ity
 (%
 B
PI
)
60565248444036322824201612
Time (minutes)
A.
B. C.
100
75
50
25
0
In
te
ns
ity
 (%
 B
PI
)
60565248444036322824201612
Time (minutes)
100
75
50
25
0
In
te
ns
ity
 (%
 B
PI
)
60565248444036322824201612
Time (minutes)  
 
Figure 2.5 Experimental overview of DDA MSMS acquisition.  In-gel digest samples are 
subjected to reverse phase liquid chromatographic separations with mass 
spectrometric detection.  (A) MS survey scan mode is used to detect peptide 
components.  When a peptide increases above a user-defined threshold, the 
instrument switches to MSMS mode.  The selected precursor mass is fragmented by 
ramping through a collision energy profile for a given time interval or until the 
selected mass falls below a user-defined intensity threshold (B).  At any given time 
up to two precursor masses are fragmented (C).  Upon MSMS commencement, the 
instrument returns to MS survey mode until the cycle is repeated. 
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Figure 2.6 Experimental overview of MSE acquisition.  In-gel digest samples are subjected to 
reverse phase liquid chromatographic separations with mass spectrometric detection.  
Alternating scan mass spectra are collected in parallel at low (A) and elevated (B) 
collision energies to provide simultaneous collection of precursor and product ion 
fragmentation for every ion detected. 
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Figure 2.7 Comparison of MSE (A) and DDA (B) chromatograms for a GGCX protein digest 
sample. Separation completed on Waters® nanoACQUITYTM system with 75 m ID 
x 250 mm analytical column packed with 1.7m BEH C18 particles under gradient 
conditions of 5 to 50% acetonitrile in 60 minutes.  Mass spectrometric detection 
performed on Waters® QTof PremierTM in MSE acquisition mode. 
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Figure 2.8 Experimental peptide detection by DDA acquisition.  Peptide is detected above 
user-defined intensity threshold in MS survey scan (A) and selected for 
fragmentation.  Precursor mass is defined in mass spectrum by (*) corresponding to 
m/z 635.8 Daltons (CS+2).  MSMS component scan two (C) ramps collision energy 
through three programmed values producing a summed spectrum (D) for the selected 
precursor ion.  PLGS processing matches the y-ions (red), b-ions (blue), and 
immonium ions (green) in the fragmentation spectrum to theoretical models to 
identify the corresponding GGCX peptide (L)MVLDIPQERGL(S). 
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Figure 2.9 Experimental peptide detection by MSE acquisition.  System alternates between 
low (A) and elevated (C) collision energy scans.  PLGS time alignment algorithms 
match the precursor mass MH+ 1270.7 Daltons (B) defined as (*) with product ion 
fragments (D) to identify the corresponding GGCX peptide (L)MVLDIPQERGL(S). 
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Figure 2.10 Evaluation of experimental reproducibility of triplicate MSE injections for a 
single peptide digest sample of GGCX.  (A) Chromatographic retention time and 
peak profile comparison for three sequential injections.  (B) Venn diagram illustrating 
PLGS peptide processing for triplicate sample injection displaying total GGCX 
peptides identified.  Peptide must match in sequence, precursor mass (± 10 ppm), 
retention time (± 30 seconds), variable modification, and peptide type for replicate 
identification.  Separation completed on Waters® nanoACQUITYTM system with 75 
m ID x 250 mm analytical column packed with 1.7m BEH C18 particles under 
gradient conditions of 5 to 50% acetonitrile in 60 minutes.  Mass spectrometric 
detection performed on Waters® QTof PremierTM in MSE acquisition mode. 
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Figure 2.11 Predicted planar topology for transmembrane protein GGCX.  GGCX 
represented as 758 amino acid integral membrane protein with five membrane 
spanning domains between the cytoplasmic N-terminus and lumen containing C-
terminus.  Residues conserved among varying taxonomies depicted in red, cysteine 
containing residues in yellow, and predicted substrate binding domain in blue. 
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Figure 2.12 SDS-PAGE 4-12% Bis Tris gel with MES running buffer.  Invitrogen Mark 12 
protein ladder represents protein molecular weight standards for estimated mass 
calibration.  Lane 1: Purified GGCX; Lane 2: Purified GGCX treated with PNGaseF 
for removal of N-linked glycosylation; Lane 3: Limited trypsin digestion of purified 
GGCX into 30 kDa N-terminal domain and 60 kDa C-terminal domain; Lane 4: 
Deglycosylation of purified GGCX after limited trypsin digestion.  Gel confirms that 
GGCX is a glycoprotein with N-linked glycosylation sites in the C-terminal 60 kDa 
domain. 
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Figure 2.13 Experimental flow diagram for in-gel digestion of GGCX followed by LC-MS 
analysis. 
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Figure 2.14 GRand AVerage of HydropathicitY (GRAVY) index scoring of amino acid 
hydrophobicity.  Hydropathy index, based on the work by Kyte and Doolittle, scores 
individual amino acids from -4.5 (hydrophilic) to +4.5 (hydrophobic) to determine 
probabilistic topology based on modeled behavior.  Hydropathy profile for GGCX 
calculated from moving average summation of every seven amino acid residues in 
protein sequence.  Red boxes represented predicted transmembrane domains. 
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Figure 2.15 In silico digestion of GGCX by chymotrypsin (C-terminal cleavage at 
F/Y/W/M/L not before proline) or trypsin (C-terminal cleavage at R/K not before 
proline) incorporating three missed cleavages.  Hydropathy index values for 
simulated digestion peptides calculated and plotted based on peptide frequency.  
Histogram represents theoretical distribution of peptides based on hydrophobicity. 
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Figure 2.16 In silico digestion of GGCX by chymotrypsin (C-terminal cleavage at 
F/Y/W/M/L not before proline) or trypsin (C-terminal cleavage at R/K not before 
proline) incorporating three missed cleavages.  Peptide molecular mass plotted based 
on peptide frequency.  Histogram represents theoretical distribution of peptides 
according to precursor mass. 
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Figure 2.17 Experimental GGCX digestion chromatograms for (A) chymotrypsin and (B) 
trypsin in-gel digestions.  Separation completed on Waters® nanoACQUITYTM 
system with 75 m ID x 250 mm analytical column packed with 1.7m BEH C18 
particles under gradient conditions of 5 to 50% acetonitrile in 60 minutes.  Mass 
spectrometric detection performed on Waters® QTof PremierTM in MSE acquisition 
mode. 
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Figure 2.18 Chromatographic comparison of in-gel GGCX chymotrypsin digestion (A) with 
chymotrypsin digested gel control (B).  Separation completed on Waters® 
nanoACQUITYTM system with 75 m ID x 250 mm analytical column packed with 
1.7m BEH C18 particles under gradient conditions of 5 to 50% acetonitrile in 60 
minutes.  Mass spectrometric detection performed on Waters® QTof PremierTM in 
MSE acquisition mode. 
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Figure 2.19 Peptide recovery topology for GGCX upon chymotrypsin in-gel digestion.  
Peptide identification resulting from peptides matched in two out of three replicate 
MSE injections.  Evaluate missed cleavages (MC) identified for single sample 
preparation using PLGS processing.  Residues identified by chymotrypsin selected 
digestion [C-terminal to F/Y/W not before proline; one missed cleavage (MC)] are 
highlighted in purple.  Additional amino acids recovered after extending search 
parameters to include up to three missed cleavages represented in green.  Reported 
topological coverage is 40.5% for chymotrypsin processing with one missed cleavage 
and 42.5% recovery incorporating three missed cleavages. 
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Figure 2.20 Peptide recovery topology for GGCX upon chymotrypsin in-gel digestion.  
Peptide identification resulting from peptides matched in two out of three replicate 
MSE injections.  Evaluate nonspecific cleavages identified for single sample 
preparation using PLGS processing.  Residues identified by chymotrypsin selected 
digestion [C-terminal to F/Y/W not before proline; three missed cleavages(MC)] 
highlighted in green.  Additional amino acids recovered after extending search 
parameters to include chymotrypsin cleavage at M/L C-terminating residues in 
addition to F/Y/W with up to three missed cleavages represented in blue.  Amino 
acids not recovered in modified search parameters (F/Y/W/M/L) distinguished in 
light blue.  Reported topological coverage is 42.5% for chymotrypsin processing with 
three missed cleavages and 73.5% recovery incorporating modified cleavage residues. 
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Figure 2.21 Peptide recovery topology for GGCX upon chymotrypsin in-gel digestion.  
Peptide identification resulting from peptides matched in two out of three replicate 
MSE injections.  Evaluate nonspecific cleavages identified for single sample 
preparation using PLGS processing.  Residues identified by chymotrypsin modified 
digestion [C-terminal to F/Y/W/M/L not before proline; three missed cleavages 
(MC)] highlighted in blue.  Additional amino acids recovered after extending search 
parameters to include all nonspecific digestions represented in red.  Amino acids not 
recovered in modified search parameters distinguished in yellow. Reported 
topological coverage is 73.5% for chymotrypsin modified digestion with three missed 
cleavages and 86.1% recovery incorporating nonspecific digestion. 
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Figure 2.22 Amino acid preferential C-terminal cleavages upon chymotrypsin in-gel 
digestion of GGCX.  Peptide identification resulting from peptides matched in two 
out of three replicate MSE injections using nonspecific enzymatic specificity in PLGS 
processing.  Amino acids represented as single letter abbreviations.   
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Figure 2.23 Peptide recovery topology for GGCX upon chymotrypsin in-gel digestion.  
Peptide identification resulting from peptides matched in two out of three replicates 
by MSE (A) or DDA (B) analysis and nonspecific enzymatic specificity in PLGS 
processing.  Same digest sample utilized for both MSE and DDA acquisition modes.  
Reported topological coverage is 86.1% for MSE sampled data and 43.1% recovery 
for DDA acquired data. 
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Figure 2.24 Peptide percent recovery for GGCX upon varying chymotrypsin in-gel digestion 
conditions.  Peptide identification resulting from peptides matched in two out of three 
MSE injections and PLGS processing by nonspecific or chymotrypsin _NS [C-
terminal cleavage F/Y/W/M/L; three missed cleavages (MC)] enzymatic digest 
reagents.  (A) Variations in GGCX coverage at increasing chymotrypsin 
concentrations for 3 hr protein digestion.  (B) GGCX coverage for a 100 ng/L 
chymotrypsin digestion at varying digestion periods.  Gel control prepared in the 
absence of target protein. 
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Figure 2.25 Peptide percent recovery for GGCX upon varying chymotrypsin in-gel digestion 
conditions.  Peptide identification resulting from peptides matched in two out of three 
MSE injections and PLGS processing by nonspecific enzymatic digest reagent.  All 
chymotrypsin digestions conducted for 3 hours at a stock concentration of 100 ng/L.  
(A) Variations in GGCX coverage at increasing gel extraction temperatures.  (B) 
GGCX coverage at varying column temperatures.  Gel control prepared in the 
absence of target protein. 
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Figure 2.26 Chromatographic comparison of in-gel GGCX chymotrypsin digestions 
evaluated at varying column temperatures.  Separation completed on Waters® 
nanoACQUITYTM system with 75 m ID x 250 mm analytical column packed with 
1.7m BEH C18 particles under gradient conditions of 5 to 50% acetonitrile in 60 
minutes and a constant flow rate of 300 nL/minute.  Mass spectrometric detection 
performed on Waters® QTof PremierTM in MSE acquisition mode. 
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Figure 2.27 Experimental peptide recovery compared to in silico digestion of GGCX by 
chymotrypsin [C-terminal cleavage at F/Y/W/M/L not before proline; three missed 
cleavages (MC)].  Experimental peptide identification resulting from peptides 
matched in two out of three MSE injections and PLGS processing by nonspecific 
(black) or chymotrypsin _NS [C-terminal cleavage F/Y/W/M/L not before proline; 
three missed cleavages (MC)] (blue) enzymatic digestion.  Comparative histograms 
evaluated for (A) peptide precursor and (B) hydropathy recovery. 
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Figure 2.28 Peptide recovery topology for GGCX upon trypsin in-gel digestion.  Peptide 
identification resulting from peptides matched in two out of three replicate MSE 
injections.  Residues identified by trypsin selected digestion [C-terminal to R/K not 
before proline; three missed cleavages(MC)] are highlighted in green.  Reported 
topological coverage is 38.3% for trypsin processing with three missed cleavages. 
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Figure 2.29 Peptide percent recovery for GGCX upon in-gel digestion with varying 
concentration of trypsin proteolytic enzyme concentrations.  Peptide identification 
resulting from peptides matched in two out of three MSE injections and PLGS 
processing by trypsin (C-terminal cleavage R/K; three missed cleavages) enzymatic 
digest reagent.  Gel control prepared in the absence of target protein. 
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Figure 2.30 Experimental peptide recovery compared to in silico digestion of GGCX by 
trypsin [C-terminal cleavage at R/K not before proline; three missed cleavages (MC)].  
Experimental peptide identification resulting from peptides matched in two out of 
three MSE injections and PLGS processing by trypsin [C-terminal cleavage R/K not 
before proline; three missed cleavages (MC)] (green) enzymatic digestion.  
Comparative histograms evaluated for (A) peptide precursor and (B) hydropathy 
recovery. 
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Figure 2.31 Comparison of peptide recovery topology for GGCX upon chymotrypsin (A) or 
trypsin (B) in-gel digestion.  Peptide identification digestion resulting from peptides 
matched in two out of three replicate MSE injections.  PLGS processing was 
completed for each sample set utilizing nonspecific enzymatic cleavage or trypsin 
specific digestion (C-terminal cleavage at R/K not before proline; three missed 
cleavages) for topology diagrams A and B respectively  Reported topological 
coverage is 86.1% for chymotrypsin digested GGCX and 38.3% recovery for trypsin 
digested GGCX. 
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Figure 2.32 Evaluation of sample preparation reproducibility of triplicate MSE injections for 
two independent chymotrypsin peptide digest samples of GGCX.  Chromatographic 
retention time and peak profile comparison for both sample preparations evaluated in 
overlaying chromatograms.  Venn diagram compares PLGS nonspecific peptide 
processing for triplicate sample injection of each sample.  Peptide identification based 
on peptide replication in two out of three sequential injections.  Peptide must match in 
sequence, precursor mass (± 10 ppm), variable modification, and peptide type for 
replicate identification.  Comparative topology diagrams for peptide recovery in each 
GGCX digestion displayed.  Separation completed on Waters® nanoACQUITYTM 
system with 75 µm ID x 250 mm analytical column packed with 1.7 µm BEH C18 
particles under gradient conditions of 5 to 50% acetonitrile in 60 minutes.  Mass 
spectrometric detection performed on Waters® QTof PremierTM in MSE acquisition 
mode. 
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Figure 2.33 Evaluation of sample contaminant reproducibility for two independent 
chymotrypsin peptide digest samples of GGCX.  Sample processing completed by 
PLGS using nonspecific enzymatic cleavage.  Peptide identification in triplicate 
injection averaged for each protein and represented in pie diagram for each sample 
preparation. 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3: Identifying the Catalytic Active Site of GGCX – Biological 
Development of Cross-linker Substrates 
________________________________________________________ 
3.1 Introduction 
3.1.1. Catalytic Carboxylation Domain 
Despite the well-proclaimed evidence that vitamin K-dependent proteins are required for 
carboxylation, the mechanism by which glutamate carboxylation occurs is not well 
understood.  From Chapter 1, in the presence of cofactors vitamin K hydroquinone (KH2), 
oxygen (O2) and carbon dioxide (CO2), Gamma-Glutamyl Carboxylase (GGCX) converts 
selected glutamic acid residues (Glu) to gamma-carboxy glutamic acid (Gla) in vitamin K-
dependent proteins (VKD).  Most VKD proteins are characterized by an eighteen amino acid 
highly conserved propeptide adjacent to the Gla domain.  After post-translational 
modification, the propeptide of the VKD protein is cleaved, and the Gla domain undergoes 
calcium dependent conformational reorientation allowing association with phospholipids on 
the membrane surface near damaged vascular tissue. 
Current understanding suggests that VKD proteins bind GGCX primarily through the 
propeptide domain.  Presumably, the propeptide anchors the VKD protein to GGCX allowing 
the tethered Gla domain to arrange itself in the catalytic active site of GGCX.  The binding of 
the propeptide is relatively tight and all of the carboxylations that occur for a given substrate 
take place in a single binding event with product release being the rate-limiting step in the 
mechanism.1-3  Figure 3.1 illustrates the processive mechanism of carboxylation where a 
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VKD protein binds GGCX in two locations, a high affinity propeptide binding site and a low 
affinity catalytic domain.  Once associated, GGCX carboxylates all of the necessary glutamic 
acid residues in the VKD protein before substrate release.  In support of the processive 
carboxylation model, it has also been shown that the occupancy of the active site by a Glu 
residue directly affects the binding of propeptide.  The dissociation rate, koff, of factor IX 
propeptide is reduced three-fold by the small pentapeptide substrate FLEEL and nine-fold by 
the Gla domain (residues 1-46) of factor IX.  When investigating a covalently linked 
propeptide (factor IX) to the first 41 residues of the corresponding Gla domain 
(FIXproGla41), the koff is reported as 30 times slower compared to the propeptide alone.1  
The presence of a Gla domain, thus exerts an allosteric influence on the binding of the 
propeptide to GGCX. 
Wu et al. were the first to report that the amino acid residues 438-507 on the carboxyl-
terminal of GGCX are important in propeptide binding.4  Here it was experimentally 
demonstrated that the propeptide of factor IX is cross-linked to a segment of GGCX cleaved 
by cyanogen bromide originating at residue 438.  Later Lin et al. demonstrated that the 
amino acid residues from 495-513 play a critical role in propeptide binding to carboxylase.5  
Mutations of amino acids in this designated GGCX region were seen to alter propeptide 
binding indicating a site-specific model for propeptide interaction with GGCX. 
In contrast to the clear role of the propeptide in carboxylation, the contribution of Gla 
domain binding has not been well defined.  After showing that the carboxylation reaction is 
inhibited by sulfhydryl-specific reagents, it was initially assumed that cysteines were the 
catalytic residue on GGCX responsible for KH2 deprotonation.6, 7  In keeping with Dowd’s 
theory, Pudota et al. reported that modification of cysteine residues 99 and 450 resulted in 
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the loss of carboxylation, indicating that these two cysteine residues are involved as active 
site residues.8  In 2003, Tie et al. provided evidence that cysteines are not involved in the 
active glutamate recognition site,9 however, Cys99 and Cys450 were involved in disulfide 
linkage crucial for GGCX activity.10  As a result of these findings, other residues in GGCX 
were investigated.  Rishavy et al. demonstrated that when GGCX was incubated with diethyl 
pyrocarbonate, a histidine-specific reagent, carboxylase activity was decreased.11  From these 
studies, the authors concluded that a histidine was likely the active site residue of GGCX.  
Further investigations by the same laboratory reported that lysine 218 was the catalytic base 
to deprotonate KH2.  This work evaluated the ability of exogenous amines to restore activity 
of the mutated K218A and concluded that recovery of activity was not only feasible but 
dependent on the basic form of the amine.12  This scenario is consistent with previous reports 
demonstrating loss of carboxylase activity in the mutation of L21813, 14 as well as quantum 
calculations.15-17   
The most groundbreaking research involves the use of a naturally-occurring mutation of 
the leucine residue at position 394 to arginine.18-20  The L394R mutation is evolutionarily 
highly conserved within the amino acid region 374-418 in carboxylase and impairs both Glu 
and propeptide interactions.  Patients with this mutation suffer from decreased coagulation 
activity of all clotting factors.  Mutucumarana et al. showed the mutation resulted in reduced 
affinity for a glutamate-containing substrate.20  They concluded L394R might be directly 
involved in the binding of Glu residues, therefore providing evidence that this region is 
involved in catalytic binding or allosteric influences to the active site domain.   
Throughout the years, numerous experiments have been carried out to obtain a greater 
understanding of the structure and function of GGCX in its native environment.  Much of the 
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structural studies regarding the glutamate binding site in GGCX are limited based on 
previous work using binding and kinetic assays of mutant GGCX.  Understanding the 
location and mechanism by which Glu residues are modified to Gla, however, is crucial to 
form a complete picture of GGCX and its role in the vitamin K cycle.  To approach this 
challenge, a substrate cross-linking methodology was investigated. 
3.1.2 Chemical Cross-linkers 
3.1.2.1 Reactivity 
Protein-protein interactions are involved in performing and regulating a multitude of 
biological processes.  Accordingly, a number of methods have been developed to identify, 
map, and potentially inhibit these interactions in the hope of modulating biological function.  
If non-covalent protein-protein interactions are strong enough to survive cell lysis, they can 
be directly captured by affinity purification assays such as co-immunoprecipitation.21  This 
classic approach is straightforward, but can miss transient protein interactions which are 
more difficult to discern using in vitro methods.  Alternative analytical techniques used to 
address the questions of spatial and topological organization of proteins and protein 
complexes are primarily X-ray crystallography and NMR spectroscopy.  Both techniques 
yield detailed information on the protein structure; however, NMR spectroscopy requires 
large quantities of pure protein in a specific solvent.  For X-ray studies, the protein has to be 
crystallized which is often difficult especially when dealing with membrane proteins.  As a 
result, mass spectrometric analysis is increasingly becoming the standard practice to map 
protein-protein interactions providing a sensitive technique with low sample volume 
requirements and high throughput analysis.  The mass spectrometric techniques used for 
structural studies of proteins are typically hydrogen deuterium exchange, the analysis of non-
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covalent complexes in the gas phase, and chemical cross-linking followed by enzymatic 
digestion. 
The first step in cross-linking mass spectrometry is the selection of chemical cross-
linkers appropriate for the given protein or protein complex.  There are hundreds of reagents 
described in the literature22, 23 or offered commercially which are based on a small number of 
organic chemical reactions.  The most widely used class of cross-linker reagents can be 
categorized into three main divisions: (1) amine reactive cross-linkers, (2) sulfhydryl reactive 
cross-linkers, and (3) photoreactive cross-linkers.24 
Amine reactive cross-linkers can typically be characterized as N-hydroxysuccinimide 
esters or imidoesters.  N-hydroxysuccinimide esters (NHS) react with nucleophiles to release 
the NHS group and to create stable amide and imide bonds with primary or secondary 
amines, such as the free N-terminus and -amino groups in the lysine side chain of proteins.  
NHS esters exhibit half-lives in the order of hours under physiological pH conditions with 
hydrolysis and amine reactivity increasing when the pH is raised.22, 25-27  A common 
difficulty experienced with NHS esters, however, is the frequent side reaction products with 
sulfhydryl groups in cysteines, hydroxyl groups in serine or theonine, or imidazole nitrogens 
of the histidine ring.   
The imidate functional group is one of the most specific acylating groups to modify 
primary amines and among the oldest cross-linking reagents used for protein conjugation.  
Unlike most other cross-linking reagents, imidoesters possess minimal cross reactivity 
towards other nucleophiles.  Another advantage of imidoesters is that the positive charge is 
maintained on the lysine group preventing distortion of protein three-dimensional structure.  
This cross-linker functional group, however, is prone to continuous degradation due to 
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hydrolysis reducing the half-life of the imidate group to less than 30 minutes28, 29 thus 
preventing high efficiency during protein covalent linkage.  The final classification of 
imidoesters are carboiimides which are used to mediate amide bond formation between 
spatially close (< 3Å) groups such as a carboxylate and an amine group.30,31 
The second category of reagents are maleimide reactive sulfhydryl reactive cross-
linkers.  Maleimide reactions are sulfhydryl specific in the pH range between 6.5 and 7.5, 
however, at more basic pH values side reactions with amines or hydrolysis of the maleimide 
group are also shown to take place.32-36  Besides the pH requirements for maleimides, 
sulfhydryl targeting should only be implemented when targeting the SH group of cysteines 
not involved in disulfide-bond formation.  Reduction of disulfide bonds to create free SH 
groups imply the danger of distorting the three dimensional structure.  
Lastly, photoreactive cross-linkers are induced to react with target molecules by 
exposure to UV light.  The ideal photoreactive agent should be of high reactivity, capable of 
indiscriminating association into any type of residue, stable in the dark, and used at a 
wavelength that does not cause any photolytic damage to the biological sample.  Moreover, 
the reaction with proteins should lead to stable and unique products to enable their isolation, 
purification, and subsequent mass spectrometric analysis.  Photolysis results in the creation 
of highly reactive intermediates, mainly carbenes and nitrenes, which will form covalent 
bonds with receptor proteins at the receptor-binding site.  Three types of photoactivating 
probes are mainly used in photoaffinity labeling: aryl azides, diazirenes, and 
benzophenones.24 
Phenyl- and nitro-substituted phenyl azides have played a leading role in 
photochemical labeling.  Upon photolysis, phenyl azide groups form short-lived nitrenes that 
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can insert nonspecifically into chemical bonds of target molecules.37  A disadvantage of aryl 
azides, however, is that they are activated by shortwavelength UV irradiation (<280 nm).  
Diazirines, on the other hand, are remarkably stable providing photolysis at wavelengths 
around 360 nm to generate a highly reactive carbene that can insert into a heteroatom-H or C-
H bond.  Photolysis of diazirines, however, may lead to diazo isomers resulting in undesired 
reactions in the dark.   
Benzophenones are a class of photoreactive cross-linkers that follow a completely 
different photochemistry mechanism compared to aryl azides and diazirines.38-40  Upon 
irradiation, biradical formation permits covalent linkage between the photophore and the 
receptor protein.  Additional discussions regarding the photochemistry of a benzophenone 
analog are reported in greater detail in section 3.1.3.  The final class of reactivity is photo-
induced cross-linking of unmodified proteins (PICUP).  PICUP mediates oxidative cross-
linking by creating high valent-metal-chelate complexes.  The main advantage of this type of 
reaction is that cross-linking takes place very quickly without requiring chemical 
modification of the protein.41  When photo-excitation is performed in the presence of an 
electron acceptor, a radical forms preferentially at aromatically stabilized side chains 
allowing an intermolecular cross-link with a neighboring protein.  In addition to the short 
time periods necessary for the reaction to take place, cross-linking also occurs across a wide 
pH range.   
3.1.2.2 Cross-Linker Design 
Once the reactivity of the cross-linker group is determined, the type of cross-linker 
design must then be evaluated.  The three main classes of cross-linker design are: 
homobifunctional, heterobifunctional, and zero-length cross-linkers.24  Homobifunctional 
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cross-linking reagents contain identical functional groups at both reactive sites, which are 
connected with a carbon chain spacer bridging a defined distance.  The length of the spacer 
arm and reactivity of the cross-linker is key in developing an optimized system.  The main 
disadvantage of using homobifunctional reagents originates in the variability of reaction 
products.  The cross-linking reagent reacts initially with a protein forming an intermediate.  
This complex can then react with neighboring proteins to form a high molecular mass 
aggregate or adversely react intramolecularly with neighboring functional groups on the 
same polypeptide chain.42  
Heterobifunctional cross-linking reagents, on the other hand, contain two different 
reactive groups that target different functional groups on the protein, for example an amine 
and a sulfhydryl group.  These cross-linking reagents favorably associate with proteins in two 
or three step protocols to minimize the degree of aggregate formation.  For addition of a third 
functional group, specificity is often introduced using affinity tags or isotopic labeling.  The 
final classic design of cross-linkers are zero-length reagents.  These compounds mediate 
cross-linking between two proteins by creating a bond without an intervening linker.  
Carbodiimides are probably the most widely used type of zero-length cross-linkers.   
3.1.3 Benzoylphenylalanine 
Benzophenone (BP) photochemistry has attracted the attention of biochemists for 
over three decades.  The first application of the photogenerated triplet state of BPs in 
biological systems was reported in 1974.43  Several years later, the BP photophore was 
employed as a tethered, photoactive reagent used to functionalize specific remote C-H bonds 
in steroids and to map conformations of flexible chains in solution, micelles, and 
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membranes.44, 45  In 1986, the development of the photolabile amino acid analog p-benzoyl-
L-phenylalanine (Bpa) led to an increase in new studies of protein-protein interactions.46   
The photoactive cross-linker Bpa is an aryl ketone moiety used to preferentially 
attack weak C-H bonds with high selectivity and yield for covalent cross-linking of protein-
protein complexes.  Numerous advantages of benzophenone photophores (BP) make them a 
more attractive candidate for photoactive cross-linking than aryl azides, and diazirines.38  In 
addition to being more chemically stable than other common cross-linking agents, BPs can 
be manipulated in ambient light and activated at 350-360 nm to avoid protein damaging 
wavelengths.  BPs also respond preferentially with unreactive C-H bonds, even in the 
presence of solvent water and bulk nucleophiles, forming a covalent bond.  These properties 
combine to produce highly efficient covalent modifications of macromolecules with 
remarkable site specificity.47 
An advantage of the Bpa cross-linking mechanism is the inherent site specific 
reactivity of the photophore.  The reaction is based on the observation that cross-linking can 
only attack geometrically accessible C-H bonds.  The reactant and substrate must spend 
sufficient time in the active site domain for covalent cross-linking to be successful.  The 
selectivity is also increased by stereoelectronic factors influencing orientation of molecular 
orbitals during cross-linking.  If proper conformation is not achieved, the BP probe will 
undergo many excitation and relaxation cycles until a favorable geometry for covalent 
modification is achieved.  For biochemical studies, the selection of linker size and orientation 
is crucial, since the primary goal is to label the binding site for the ligand while minimizing 
nonspecific modifications.48 
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3.1.4 Additional Cross-linking Strategies 
When designing a chemical cross-linker, in addition to reaction specificity other 
considerations involve minimizing steric hindrance to enable optimal reactivity.  In hetero- 
and homobifunctional cross-linkers this involves selecting an appropriate arm-length 
between the two functional groups.  Short cross-linkers may have low reaction efficiency and 
are limited by steric hindrance.  This is often dependent on surrounding amino acids that may 
provide steric or electrostatic interference.  If a cross-linker arm is too long, conjugation to 
virtually any two reactive amino acids becomes possible limiting the amount of useful 
structural information.  Solubility is another important factor when studying protein 
complexes.  Oftentimes cross-linker reagents may have limited solubility in aqueous solution 
preventing the protein from maintaining an active environment during cross-linking. 
Despite the apparent straightforwardness of the cross-linking approach, cross-linking is 
typically a trial and error process for a particular protein or protein complex where 
identification of cross-linking products can be hampered by the complexity of the cross-
linking reaction mixture.  To aid in cross-linked product identification, a number of strategies 
have been developed by enriching cross-linker containing species using affinity, fluorescent, 
or isotopic labeling.24  Such enrichment methods provide the opportunity to selectively target 
the cross-linked product of interest using pull-down methods, specific physiochemical 
properties, or signature mass fingerprinting for mass spectrometric detection. 
 
3.2 Chapter Scope 
Cross-linking mass spectrometry has enormous potential to impact structural proteomics.  
To aid in the identification of the catalytic carboxylation domain of the transmembrane 
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protein Gamma-Glutamyl Carboxylase (GGCX), we devised a chemical cross-linking 
scheme utilizing both biochemical and mass spectrometric applications.  Synthetic 
photoactive cross-linkers were developed mimicking sequence homology of a typical vitamin 
K-dependent protein (VKD).  To aid in cross-linker identification, photoactive substrates 
were modified with either a fluorescent tag or isotopic label.  In this chapter we present the 
biological validation of cross-linker functionality and site-specific covalent attachment to 
GGCX upon irradiation.  Chapter 4 will continue to investigate the catalytic domain of 
GGCX by photoactive cross-linking, using mass spectrometric characterization and 
identification of targeted active site domains. 
 
3.3 Experimental 
3.3.1 Materials 
Reagents used for Gamma-Glutamyl Carboxylase purification and evaluation are as 
follows: 1,2-dioleoyl-sn-glycero-3-phosphocholine [DOPC] (Avanti Polar Lipids, Alabaster, 
Al), 2-(N-morpholino)ethanesulfonic acid [MES] (Sigma-Aldrich, St. Louis, MO), 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate hydrate [CHAPS] (Sigma-Aldrich), 
3-(N-morpholino)-propanesulfonic acid [MOPS] (Sigma-Aldrich), bovine serum albumin 
(BSA) fraction V, heat shock (Roche Applied Science, Indianapolis, IN), calcium chloride 
dihydrate [CaCl2.2H2O] (Fisher Scientific, Fair Lawn, NJ), dithiothreitol [DTT] (Roche 
Applied Science), ethylenediamine-tetraacetic acid [EDTA] (Mallinckrodt Chemicals, 
Raleigh, NC), glycerol (Fisher Scientific), 14C labeled sodium bicarbonate [NaH14CO3] 
specific activity, 55 mCi/mmol (MP Biomedicals, Solon, OH), sodium chloride [NaCl] 
(Fisher Scientific), tris(hydroxymethyl)aminomethane hydrochloride [Tris-HCl] (Sigma 
143 
Aldrich), and Vitamin K1(25) purchased from Hospira Incorporated (Lake Forest, IL) as 10 
mg/mL single dose ampules stabilized with phytonadione injectable emulsion.  Protease 
inhibitors including aprotinin, leupeptin, pepstatin, and phenylmethyl sulfonyl fluoride were 
purchased from Roche Applied Science.  Anti-HPC4 monoclonal antibody coupled 
Sepharose resin was obtained from Dr. Charles T. Esmon (Cardiovascular Biology Research 
Program, Oklahoma Medical Research Foundation, Oklahoma City, OK).49  The 
pentapeptide Gla domain FLEEL (Phe-Leu-Glu-Glu-Leu) was purchased from Bachem 
(Philadelphia, PA) and the propeptide modified peptides factor IX propeptide [pFIX] 
(TVFLDHENANKILNRPKR), consensus propeptide [pCon] 
(AVFLSREQANQVLQRRRR), and fluorescein-labeled consensus propeptide [FpCon] (Fl-
AVFLSREQANQVLQRRRR) were synthesized and purified by Chiron Mimotopes 
(Calyton, Victoria, Australia).  FIXQ/S, a 59 residue recombinant peptide whose sequence is 
derived from the propeptide and the first 41 residues of the Gla domain of human factor IX 
was prepared and purified as described by Wu, et al.50 
3.3.2 Gamma-Glutamyl Carboxylase – Recombinant, Mutant, and Construct 
Modifications 
Wild-type human Gamma-Glutamyl Carboxylase (GGCX) with a carboxyl terminus 
12-amino acid epitope tag (EDQVDPRLIDGK) was isolated from Sf9 as previously 
described.51  Solubilized GGCX microsomes were purified using a calcium dependent HPC4 
antibody resin and eluted in 25 mM MOPS pH 7.5, 0.1 M NaCl, 0.5% CHAPS, 0.2% DOPC, 
10 mM EDTA, and 15% glycerol stabilized by a protease inhibitor cocktail.  Protein 
concentration and purity was determined by enzymatic activity assay measurements and 
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SDS-PAGE.  A detailed protocol describing Gamma-Glutamyl Carboxylase protein 
purification is described in Appendix A1. 
The cDNA for human Gamma-Glutamyl Carboxylase,52 cloned into the pSK- vector, 
was modified by site-directed mutagenesis to construct the Y395A mutant.  The construct 
contains the FLAG epitope (DYKDDDDK sequence) at the amino terminus and the HPC4 
epitope sequence at the carboxyl terminus.  The construct was subcloned into the pVL1392 
vector, and the protein was expressed in baculovirus-infected High Five cells.  The protein 
was purified using the HPC4 antibody affinity resin.  The Y395A mutant of GGCX was 
provided by Dr. Vasantha P. Mutucumarana for cross-linking studies. 
Construction of the two-chain C+N GGCX construct was outlined previously.53  
Briefly, wild-type human GGCX cDNA was engineered into the pFastBac1 baculovirus 
expression vector.  Full-length GGCX is split at amino acid residue 345 to form the two-
chain construct.  For co-expression of both peptides, the PCR-amplified coding sequence of 
the N-terminal peptide (1-345) of GGCX with a FLAG tag at its amino terminus and the 
coding sequence for the C-terminal peptide (346-758) with a HPC4 tag at its carboxyl 
terminus were cloned into the pFastBacDual vector.  The C+N construct was purified using 
the HPC4 antibody affinity resin.  The two-chain GGCX construct was provided by Dr. Jian-
Ke Tie for cross-linking experimentation. 
3.3.3 Synthetic Vitamin K-Dependent Peptides 
33mer and 27mer vitamin K-dependent peptides were synthesized by Chiron 
Mimotopes (Australia) and Synthetic Biomolecules (San Diego, CA) respectively.  The 
33mer peptide (H-AVFLSREQANQVLQRRRRANAFLEEBpaVQGNLEKfl-OH) was 
purified to >95% purity determined by LC-MS with a free amine N-terminus and a free acid 
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C-terminus containing two modified amino acids, the p-benzoylphenylalanine (Bpa) and the 
5(6)-carboxyfluoresceine (Kfl).  In a similar peptide design, two 27mer peptide substrates 
were synthesized (H-AVFLSREQANQVLQRRRRANAFLEEBpaA-NH2 and H-
AVFLSREQANQVLQRRRRANAFLEEBpaAd3-NH2) with a free amine N-terminus and an 
amide C-terminus.  The photoactive Bpa cross-linker residue is maintained in position 26 as 
previously positioned in the 33mer peptide.  Incorporation of an isotopic label on the side 
chain of the C-terminal alanine [Ad3] (Cambridge Isotope Cat # DLM-7316-1) provided 
selective mass spectrometric patterning between both the labeled and unlabeled forms of the 
peptide.  The 27mer peptides constructed by Synthetic Biomolecules were prepared to >95% 
purity determined by LC-MS. 
3.3.4 Photochemical Cross-linking Experimentation 
GGCX was preincubated with an experimentally determined concentration of cross-
linker substrate at 4oC for 45 minutes.  The sample was placed in a small polystyrene 1.5 x 1” 
weigh boat (Fisher Scientific) and positioned on a bed of ice to minimize temperature 
fluctuations during irradiation.  A 100W spot bulb UVP lamp (Model B-100AP) was placed 
6 cm above the center of the sample and used for sample irradiation at 365 nm.  The sample 
was irradiated for an experimentally defined period of time and the ice was changed every 15 
minutes throughout the duration of irradiation to maintain temperature control and prevent 
GGCX activity loss.  Before and after irradiation, a sample aliquot was pooled to evaluate 
cross-linking efficiency. 
3.3.5 Confirmation of Fluorescent Covalent Cross-linking by SDS-PAGE  
For gel analysis of Gamma-Glutamyl Carboxylase, NU-PAGE Bis-Tris Gels were 
purchased from Invitrogen (Carlsbad, CA) along with the Mark 12 unstained protein ladder, 
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and SYPRO® Ruby protein gel stain.  SDS-PAGE buffers were prepared according to 
protocol derived from Invitrogen including a 4X SDS-PAGE loading buffer and a 20X MES 
running buffer. 
SYPRO® Ruby protein stain requires that the gel first be fixed in a solution of 50% 
methanol and 7% acetic acid for 30 minutes prior to overnight staining with a fluorescent 
protein stain.  After staining, the gel was washed for 30 minutes with a solution containing 
10% methanol and 7% acetic acid and imaged using a blue light UV transilluminator (Alpha 
Innotech AlphaImagerTM 2200) with interference wavelength filtering. 
For detection of fluorescently cross-linked proteins, the gel is imaged directly after 
electrophoresis using an AlphaImagerTM 2200 set to UV transilluminator mode with 
fluorescein wavelength filtering.  Detection of fluorescent bands were captured using a CCD 
camera.   
3.3.6 In Vitro Carboxylation Assay 
To determine the activity concentration of GGCX, an in vitro radioactivity assay was 
performed.  Here, the carboxylation of a synthetic vitamin K-dependent substrate (FLEEL, 
33mer, 27mer, or FIXQ/S) in the presence or absence of excess propeptide (pFIX or pCon) 
was measured after incorporation of cofactors vitamin K hydroquinone (KH2), O2, and 
radiolabeled CO2 in the form of NaH14CO3.  Vitamin K1(25) phylloquinone was reduced to 
vitamin K hydroquinone by overnight incubation with buffer containing 25 mM Tris-HCl pH 
8.5, 0.5 M NaCl, and 0.2 M DTT at 37oC.  KH2 is very light and air sensitive and must stored 
accordingly in a dark enclosure.   
A reagent mixture was prepared containing 25 mM MOPS pH 7.5, 500 mM NaCl, 
0.16% CHAPS, 0.16% DOPC, 30 mM FLEEL, and 2.4 M pFIX or pCon (if present) and 
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allowed to incubate with GGCX for 30 minutes on ice.  For cross-linker inhibition studes, 
additional propeptide was not supplemented into the reaction mixture as the cross-linker 
substrate itself provided the propeptide substrate for GGCX activation.  An excess of 5.5 mM 
KH2 and 18.4 mM NaH14CO3 in a 1:1 (v/v) ratio was added to the sample assay for a final 
volume of 125 L.  The carboxylation assay was allowed to proceed for 30 minutes at 20oC.  
If desired to achieve a higher concentration of carboxylated product, the reaction can be 
incubated for a longer period of time.  To precipitate the carboxylated product, 100 L of the 
reaction mixture was quenched with 800 L of 5% trichloracetic acid.  The samples were 
boiled to remove excess 14CO2 and radioactivity was determined by scintiallation counting 
(Beckman LS5000TD).  To determine the final concentration of carboxylated material, the 
following ratio was used where 92 counts per minute (cpm) were equal to 1 picomole of 
14CO2 incorporated.  In a typical in vitro reaction using FLEEL and a 30 minute incubation 
period, approximately 2% of the starting material was carboxylated. 
3.3.6.1 FLEEL Inhibition 
To determine the efficiency of carboxylation, the ability of the synthetic 
photochemical cross-linker substrate to inhibit FLEEL carboxylation was measured.  Here 
the carboxylation assay was carried out as described above for samples before and after 
irradiation.  The percent inhibition was calculated by dividing the counts per minute after 
irradiation by the counts per minute before irradiation and subtracting this value from one.  
To account for sample evaporation during irradiation, a correction factor for the change in 
volume was applied. 
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3.3.6.2 Determination of Km 
To approximate the binding kinetics of cross-linker substrates to GGCX, a Michaelis-
Menten kinetics model was evaluated.  The reaction rate, v, is defined as the number of 
reactions per second catalyzed per mole of the enzyme.  The reaction rate increases with 
increasing substrate concentration, [S], asymptotically approaching the maximum rate or 
Vmax.  The substrate concentration at which the reaction rate reaches half of its maximum 
value is defined as Km.  Substrates evaluated for GGCX binding were FIXQ/S and the 33mer 
and 27mer cross-linker peptides.  Carboxylation of each model substrate was monitored at 
increasing concentrations until saturation was achieved.  The Km and Vmax constants were 
calculated accordingly by fitting a regression to the Michaelis-Menten equation. 
3.3.6.3 Consensus Propeptide Inhibition 
To evaluate cross-linking specificity, a consensus propeptide inhibition study was 
investigated.  For this experiment, an excess of consensus propeptide was pre-incubated with 
purified GGCX at 4oC.  After equilibration, the 33mer synthetic cross-linker was added and 
irradiation was conducted to encourage covalent attachment.  The efficiency of cross-linking 
was monitored by in vitro carboxylation activity and fluorescence intensity by SDS-PAGE. 
3.3.7 Circular Dichroism 
An Applied Photophysics Pistar-180 CD/Fluorescence Spectrometer was used for 
circular dichroism (CD) measurements of synthetic vitamin K-dependent substrates FIXQ/S, 
33mer, 27mer-AH3 and 27mer-AD3.  A 0.05 mg/mL solution of each sample in water or 2 
mM MOPS (FIXQ/S) was measured at 25oC from 185 to 260 nm with a step width of 0.5 
nm.  The scan rate was set to 2.5 seconds/wavelength.  A CD spectrum for each peptide was 
collected.  Data was smoothed and baseline subtracted to remove residual interference from 
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background contaminants.  For ideal CD measurements, the absorbance of the sample must 
be less than one and buffer solutions must not contain halide salts or DTT.   
3.3.8 Fluorescence Anisotropy 
A T-format SLM-Aminco 8100 spectrofluorometer equipped with Glan-Thompson 
polarizers and Olis Global Works Software system was used for fluorescence anisotropy 
experiments.  Measurements were made in a quartz cuvette (Starna Cells, Atascadero, CA) at 
4oC with a final volume of 300 L.  The temperature was controlled with a Quantum 
Temperature Controller (Vancouver, Canada).  A nitrogen purge in the sample holder was 
used for sample temperatures lower than 10oC to prevent condensation from forming on the 
cuvette.  The excitation and emission wavelengths were 490nm and 520 nm respectively with 
the band-pass slits set at 4 nm.  Assay conditions were set for 300 increments with an 
integration time of 2.0 seconds.  Experiments were performed in buffer containing the 
following reagents: 50 mM MOPS pH 7.5, 500 mM NaCl, 0.18% CHAPS, 0.12% DOPC, 
5% glycerol, 2 mM DTT, 0.2% BSA, and 10 nM purified GGCX.  Five anisotropy values 
were recorded for each sample after the 200 second time point allowing for equilibration due 
to sample temperature fluctuations.  For all experiments, enzyme and substrate were allowed 
to incubate for 45 minutes at 4oC prior to analysis.  Fluorescence anisotropy values were 
recorded for each sample as the substrate concentration increased from 2 nM to 200 nM.  
Anisotropy curves were compared for fluorescently labeled consensus propeptide (FpCon), 
the 33mer cross-linker peptide, and the 33mer cross-linker peptide after irradiation with 
GGCX. 
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3.4 Results and Discussion 
3.4.1 Development of Synthetic Vitamin K-Dependent Cross-linker Substrates 
The identification of catalytic residues in GGCX that play a role in the conversion of 
selected glutamic acids (Glu) to gamma-carboxy glutamic acids (Gla) in vitamin K-
dependent (VKD) proteins has been a topic of interest for almost thirty years.  Various 
studies involving site directed mutations, quantum mechanical models, and other biochemical 
investigations of GGCX have provided basic insight regarding theories of catalysis.  Despite 
these extensive studies, a consensus regarding the mechanism of VKD carboxylation has not 
been achieved.  Here we provide an alternative approach to the steadfast question of isolating 
the glutamate binding domain in GGCX, using liquid chromatography and mass 
spectrometry to identify the site of catalytic conversion by covalent cross-linking. 
The binding of carboxylase to a particular VKD substrate is dictated by the enzyme’s 
relative affinity for a particular propeptide.  Although propeptide domains have similar 
sequences, their affinities are seen to vary more than 100 fold51 with the consensus and factor 
X propeptides showing the highest affinity (lowest Kd) and prothrombin with the lowest 
affinity (Table 3.1).  In Table 3.1, it is shown that the propeptide domain demonstrates a high 
degree of sequence homology with three highly conserved amino acids: phenylalanine at -16, 
alanine at -10, and leucine at -6.54  Comparatively, investigating the small pentapeptide 
FLEEL as a substrate Gla domain, Km values are reported as 0.54 ± 0.10 mM in the absence 
of propeptide.19  Although the contribution of a specific Gla domain sequence is still in 
question, evidence clearly suggests that covalent attachment of the propeptide and Gla 
domains induce a conformational change enabling further stability of the carboxylase 
complex.1 
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The design of GGCX covalent cross-linkers were mimicked after a vitamin K-
dependent protein containing both an eighteen amino acid propeptide binding domain and a 
truncated Gla domain.  Comparing the dissociation constants (Kd) for propeptide sequences 
in Table 3.1, it can be shown that the consensus propeptide domain exhibits the tightest 
binding to GGCX.  Modeling the synthetic cross-linker substrates with the high affinity 
consensus propeptide, encourages the propeptide to tightly anchor itself to GGCX allowing 
the Gla domain of the substrate to occupy the catalytic active site and reside there for an 
extended period of time.   
The Gla domain of mammalian VKD proteins are also found to exhibit considerable 
sequence homology as shown in Table 3.2.  Here the first eighteen amino acids of several 
VKD Gla domains are aligned for sequence comparison.  Following the highly conserved 
propeptide binding domain, the covalent cross-linker substrates were designed with a Gla 
domain that combined both the sequences of factor VII and factor IX.  Within this Gla 
domain, the cross-linker residue, p-benzoylphenylalanine (Bpa), was introduced into the 
peptide sequence at position 26 adjacent to two glutamic acid residues.  The cross-linker Bpa 
is a photoaffinity label that preferentially attacks weak C-H bonds of GGCX upon irradiation 
to encourage covalent linkage.  Maintaining a consistent arm length between the propeptide 
domain and the first highly conserved glutamic acid residue in the Gla domain, allows for the 
synthetic substrate to anchor GGCX at the propeptide binding site permitting the Gla domain 
to reside in the the catalytic pocket.  Once the substrate has equilibrated into a correct 
orientation, the sample complex can be irradiated to encourage covalent cross-linking at the 
catalytic active site.  In our model system, Bpa promotes site-directed attachment in a 
chemically stable environment avoiding protein damaging wavelengths during irradiation.  
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Due to the steric hindrance of the Bpa structure, radial recombinations are frequently 
suppressed.  As with most peptide-based photoaffinity labels, the mapping of ligand-receptor 
interactions by liquid chromatography and mass spectrometry can be quite challenging.  To 
aid methods for photochemical cross-linker detection, a reporter group is added to the C-
terminal residue of the synthetic VKD substrates. 
In the development of a photoactive cross-linker substrate for GGCX, two reporter 
approaches were investigated: (1) derivatizing the C-terminal lysine with 5(6)-
carboxyfluorescein in the 33mer substrate; and (2) isotopically labeling the C-terminal 
alanine in the 27mer substrate.  Sequence representations of the cross-linker VKD synthetic 
substrates including structural information regarding modified residues are shown in Figure 
3.2.  Following the Bpa residue in the substrate sequence the 33mer cross-linker is designed 
with a six amino acid spacer arm before addition of a fluorescent tag.  The reasoning behind 
this is that both the benzoylphenylalanine and 5(6)-carboxylfluorescein exhibit steric 
hindrance that may prevent reactivity.  Placing six residues in between the site of covalent 
attachment and the reporter allows for greater substrate flexibility.  The downside of this 
approach, however, is that the separation of the cross-linker and the reporter group provides 
greater access for enzymatic cleavage further complicating identification of the ligand 
binding site.  When considering proteolytic digestion conditions, amino acid specificity must 
be selected to prevent separation of the photoactive Bpa residue and the fluorescent reporter. 
Synthesis of the 27mer cross-linker substrates follows a similar platform for 
development.  Here, however, the Gla domain has been shortened to terminate only one 
amino acid after the photoactive Bpa residue.  Directly following the Bpa, an alanine residue 
is placed in the C-terminal position.  Unlike the peptide sequence of the 33mer substrate, the 
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27mer substrates are terminated with an amide bond compared to a free acid.  This design 
prevents any electrostatic repulsion between the C-terminal end of the synthetic substrate and 
the neighboring glutamic acid residues associated with the catalytic domain of GGCX.  The 
reporter domain of the 27mer substrate is an isotopically labeled alanine residue.  The side 
chain protons of this alanine are exchanged for a stable deuterium label creating a peptide 
whose mass shift is three Daltons greater than that of an undeuterated peptide.  For substrate 
design, both the deuterated and undeuterated forms of the peptide are synthesized.  The two 
peptide forms can be mixed in a 1:1 (w/w) ratio creating a 50% deuterated sample 
population.  Since the ionization efficiencies are the same for both peptide analogs, the 
response signal in the mass spectrometer will only vary by the mass difference introduced by 
the stable deuterium label.  The signature mass fingerprint will allow for peptide 
identification at the site of covalent attachment to carboxylase.  In addition, the shortened 
substrate sequence prevents proteolytic digestion between the Bpa cross-linker residue and 
the reporter tag. 
The development of 33mer and 27mer cross-linker substrates will aid in the 
identification of the catalytic active site of GGCX.  Prior to identification of this cross-linked 
complex, however, a systematic evaluation of substrate functionality must be conducted.  
The remainder of this chapter will focus on the verification of the 33mer and 27mer cross-
linker substrates to behave similarly to native vitamin K-dependent proteins.  Substrate 
structure, catalytic efficiency, and site-directed specificity will be evaluated for cross-linker 
selectivity.  In Chapter 4, we will combine the method validation of our synthetic cross-linker 
substrates (Chapter 3) with the development of a comprehensive peptide mapping for in-gel 
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digestions of GGCX (Chapter 2) to identify a potential domain for VKD carboxylation using 
liquid chromatography and mass spectrometry. 
3.4.2 Confirmation of Structure and Catalytic Activity 
Cross-linker substrates were compared against a modeled VKD substrate, FIXQ/S, to 
evaluate structural similarities and catalytic efficiency.  FIXQ/S is a 59 amino acid derived 
substrate containing both a propeptide domain and the first 41 amino acid residues of the 
factor IX Gla domain with five modifications in sequence homology.  FIXQ/S has been 
evaluated in vitro as a substrate to aid in further understanding of the processive mechanism 
of carboxylation demonstrating anywhere from 1 to 12 carboxylated Gla residues.2, 50   
To compare similarities in secondary structure, VKD substrates including the 33mer, 
27mer AH3 (d0), 27mer AD3 (d3), and FIXQ/S were evaluated by circular dichroism (CD).  
CD spectroscopy measures the differences in the absorption of left-handed polarized light 
versus right-handed polarized light which arise due to structural asymmetry.  In the far-UV 
spectral region (190-250 nm), peptide bonds show characteristic absorbance profiles 
indicative of secondary structure (α-helix, β-sheet, and random coils).  The approximate 
fraction of each secondary structure type that is present in a protein can thus be determined 
by analyzing the CD spectrum as a sum of its fractional components.  Figure 3.3 illustrates 
overlaying CD spectra for each of the four VKD synthetic substrates.  Using background 
subtraction and smoothing algorithms, characteristic features indicating primarily random 
coil orientation in secondary structure is observed for all substrates evaluated.  The larger 
amplitude deviation in the FIXQ/S spectrum results from the extended amino acid sequence 
of the FIXQ/S substrate compared to the cross-linker substrates.  Thus, despite a truncated 
Gla domain and structural modifications through incorporation of a reporter tag and the 
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photoactive Bpa residue, the cross-linker substrates demonstrate similar structural profiles to 
FIXQ/S as measured by circular dichroism.   
 In addition to structural similarities, the cross-linker substrates were evaluated based 
upon catalytic efficiency.  Assuming carboxylase functions as a single-substrate simple 
system, the Michaelis-Menten model (Equation 3.1) can be used to describe the relationship 
between the reaction velocity of an enzymatic process and the substrate concentration.   
     v =   Vmax [S]                        Equation 3.1 
            Km + [S] 
In this equation, the observed rate (v) is recorded for increasing substrate concentrations 
([S]), where Vmax is the maximum velocity at substrate saturation and Km is the substrate 
concentration at ½Vmax.  Km is not a binding constant; however, it is a value that can be used 
to approximate the affinity of substrate for enzyme.  To calculate Km for each of the VKD 
substrates evaluated, an activity assay was completed where carboxylation was measured by 
the incorporation of radiolabeled 14CO2.  In an appropriately buffered solution stabilized with 
detergent and phospholipid, purified GGCX is incubated with a VKD substrate containing a 
both a propeptide and Gla domain.  The carboxylase reaction is initiated upon the addition of 
cofactors vitamin K hydroquinone (KH2), oxygen (O2), and carbon dioxide in the form of 
sodium bicarbonate (NaH14CO2).  The reaction proceeds for a set period of time at 20oC and 
the incorporation of 14C is measured for each concentration interval.  The resulting plot is fit 
to a Michelis-Menten regression curve to calculate values for Vmax and Km.   
Figure 3.4 illustrates the reaction velocity plot for the VKD substrate FIXQ/S.  
FIXQ/S is characterized with a maximum of twelve potential carboxylation sites in the Gla 
domain of the VKD substrate.  The sequence of the 59 amino acid FIXQ/S is reported in 
Figure 3.4 where the propeptide domain is highlighted in blue and modified residues varying 
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in homology from the blood clotting protein factor IX are underlined.  Compared to the Gla 
domain alone, attachment of the propeptide sequence considerably improves the apparent 
binding efficiency of this VKD substrate with a calculated Km constant of 0.18 M.  Using 
the FIXQ/S substrate as a control of expected VKD substrate binding, Km curves were 
evaluated for the 33mer cross-linker substrate (Figure 3.5) and the 27mer cross-linker 
substrates (Figure 3.6) with Km values of 11.5 M and 32 M respectively.  Although the 
cross-linker peptides are predicted to exhibit very strong binding affinity from the consensus 
propeptide domain, it appears as though modifications to the Gla domain reduce overall 
substrate binding affinity.   
The Gla domain is characterized with several regions of high sequence homology 
similar to that seen for the propeptide sequence.  Modifications or truncations to the Gla 
domain, thus may modify the strength to which the substrate associates with GGCX.  
Considerable efforts have also been made to determine the influence of chimeric VKD 
substrates.  For example, binding studies have been conducted to evaluate the combination of 
a low affinity prothrombin propeptide with a factor X Gla domain compared to a factor X 
propeptide with factor X Gla domain.  These mixed VKD substrates are investigated to 
observe Gla domain influences on propeptide affinity for GGCX.  Although no definite 
conclusion has been made, the mechanism behind VKD substrate binding appears much 
more complicated than propeptide governed control.  Despite the higher than expected 
relative binding constants for the synthetic cross-linker substrates, carboxylation is observed 
for each substrate with relative binding efficiencies in a manageable range. 
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3.4.3 Optimization of Covalent Attachment 
3.4.3.1 33mer Cross-linker Substrate 
After confirming the ability of the cross-linker substrates to bind GGCX and become 
carboxylated, the next problem at hand was to evaluate the specificity of covalent 
attachment.  Since the 33mer substrate is characterized by a fluorescent receptor tag, 
visualization of photochemical cross-linking could be demonstrated by SDS-PAGE.  A 
purified sample of GGCX was equilibrated with the 33mer cross-linker substrate for 45 
minutes on ice prior to irradiation at 365 nm.  To prevent sample evaporation or loss of 
activity, the sample solution was kept on ice throughout the irradiation time period.  The 
sample was collected after irradiation and pooled for SDS-PAGE analysis as shown in Figure 
3.7.  Figure 3.7(A) represents a fluorescently imaged gel without prior staining confirming 
selective covalent cross-linking of the fluorescent 33mer substrate to GGCX only after 
sample irradiation.  If the gel is then stained to view the remaining lanes (Figure 3.7, B) it is 
apparent that the fluorescence for the GGCX band is specific to the photochemically cross-
linked complex. 
In addition to evaluating photochemical cross-linking by SDS-PAGE, the carboxylase 
activity assay is another means by which the efficiency of covalent attachment may be 
assessed.  Here we investigate the competitive inhibition of FLEEL carboxylation.  A cartoon 
outlining the potential mechanism of carboxylation is shown in Figure 3.8.  In panel A, an 
excess of factor IX propeptide and the Gla domain FLEEL is added to the assay 
reconstitution mixture.  FLEEL, represented by very low affinity binding to GGCX, will 
exchange very rapidly with the active site while the high affinity propeptide domain remains 
mostly bound.  This high turnover in substrate exchange, produces very high carboxylation 
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counts as measured by the incorporation of radiolabeled 14C.  When the 33mer substrate, or 
other cross-linking substrate, is evaluated without irradiation (panel B), both FLEEL and the 
cross-linker substrate contribute to carboxylation, where the propeptide domain is provided 
by the 33mer substrate.  Again, this scenario is characterized by a very high magnitude of 
carboxylation counts.  If the 33mer substrate, however, is covalently cross-linked to GGCX 
after irradiation (panel C), then the carboxylation of FLEEL will be inhibited as the cross-
linker substrate is now completely occupying the active site reducing the carboxylation 
counts.  In theory, the more efficient the covalent linkage, the less FLEEL that can access the 
catalytic active site, and the lower the incorporation of 14C upon carboxylation.  Since 
FLEEL is a very small Gla domain substrate, even in the presence of very good covalent 
attachment, there is evidence of FLEEL carboxylation resulting in a maximum percent 
inhibition less than 100%. 
To optimize cross-linking efficiency, cross-linker concentration and irradiation time 
are evaluated for the 33mer substrate in Figure 3.9 and Figure 3.10 respectively.  Figure 3.9 
(A) illustrates the fluorescently imaged gel after covalent cross-linking of the 33mer substrate 
at substrate concentrations ranging from 1.0 M to 33 M.  The corresponding stained gel in 
panel B confirms that the same concentration of GGCX was loaded for each sample.  
Activity measurements in the presence of FLEEL were recorded before and after sample 
irradiation and the %FLEEL inhibition (C) was reported for each sample concentration 
corresponding to the gel lanes in panels A and B.  For each cross-linker concentration 
evaluated, the total time of irradiation was 45 minutes.  The results in Figure 3.9 demonstrate 
that the maximum %FLEEL inhibition (75  5%) for the 33mer substrate is observed at a 
cross-linker concentration of 16.5 M, slightly above that determined as the Km value.  One 
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explanation for a decrease in FLEEL inhibition at higher 33mer concentrations is due to 
issues resulting in cross-linker solubility.   
Using the 16.5 M 33mer concentration, irradiation time was evaluated in Figure 
3.10 where panel A is the fluorescently imaged gel, panel B is the stained gel, and panel C is 
the corresponding activity assay results reporting the % FLEEL inhibition for irradiation 
times varying from 0 minutes to 60 minutes.  As the irradiation time increases, the percent 
FLEEL inhibition increases accordingly, where only a small difference was noted between 
the 45 minute and 60 minute time points.  To reduce sample exposure, 45 minutes was 
selected as the optimal irradiation time with a percent FLEEL inhibition of 75  5%.  In an 
effort to prevent an increase in sample temperature from prolonged irradiation times and 
maintain the height distance of 6 cm between the ultraviolet lamp and the sample, the ice 
bath was replenished every 15 minutes.  As a control to confirm sample temperature was 
maintained throughout the experiment and loss of activity was not experienced, a purified 
sample of carboxylase was irradiated under the same conditions as outlined for the cross-
linking experiment but in the absence of the 33mer substrate.  Activity counts reported before 
and after irradiation demonstrated almost no deviation, indicating GGCX stability (data not 
shown).  Although conditions have been optimized for both 33mer concentration and 
irradiation time, some experimental refinement must be completed when switching to a new 
purified GGCX protein fraction. 
3.4.3.2 27mer Cross-linker Substrate 
Similar experimental parameters of concentration and irradiation time were evaluated 
for the 27mer AH3 (d0) and 27mer AD3 (d3) cross-linker substrates.  Since the 27mer 
substrates are no longer characterized with a fluorescent tag, the efficiency of photochemical 
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cross-linking is evaluated solely by the % FLEEL inhibition calculated from activity 
measurements before and after irradiation.  Figure 3.11 illustrates % FLEEL inhibition for 
increasing concentrations of 27mer cross-linker substrate (A) and increasing irradiation times 
(B).  The 33mer substrate data is overlaid for each bar graph to provide a comparison 
between the two substrate designs.  Whereas the 33mer cross-linker correlated well between 
the apparent Km affinity and the optimal FLEEL inhibition, the 27mer substrate required a lot 
higher concentrations to maximize inhibition values.  Even at maximum inhibition, 27mer 
substrate concentrations of 85 M were required to obtain only 49.6  0.8 % FLEEL 
inhibition whereas 75  5% inhibition was achieved with 16.5 M of the 33mer cross-linker.  
When evaluating substrate concentration, a 45 minute irradiation time was utilized.  No 
deviation in cross-linking efficiency was observed between isotopic pairs (27mer AD3 and 
27mer AH3) or a combined 1:1 (w/w) mixture of the 27mer substrates.   
Figure 3.11 (B) follows more closely with the results observed for the 33mer 
substrate where the optimal % FLEEL inhibition is achieved at a 45 minute irradiation time.  
27mer substrate analogs were combined in a 1:1 (w/w) ratio totaling a final substrate 
concentration of 85 M.  The percent FLEEL inhibition was recorded before and after 
sample irradiation.  Similar to the 33mer substrate, FLEEL inhibition for the 27mer (d0/d3) 
substrate was maximized at 49.6  0.8 % after a 45 minute irradiation period. 
Cross-linker substrate combinations were investigated where the source of covalent 
attachment was facilitated by a photoaffinity Bpa residue and the reporter tag was varied 
between fluorescent or isotopically modified residue.  In addition to variations in the reporter 
tag, the spacer arm between the cross-linking agent and the reporter was modified to limit 
proteolytic cleavage during digestion.  The resulting sequence modification, however, 
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seemed to impact the efficiency by which the cross-linker substrate binds GGCX and 
covalently attaches.  Despite previous theory that VKD substrate affinity is influenced solely 
by the binding of the propeptide domain to GGCX, the influence of the Gla domain in VKD 
substrate binding is beginning to gain further attention in understanding the mechanism of 
carboxylation.   
3.4.4 Specificity of Covalent Attachment 
3.4.4.1 Cross-linking to Inactive GGCX 
Thus far, we have confirmed the binding of synthetic cross-linker substrates to 
GGCX and successful carboxylation of corresponding Gla catalytic domains.  We now 
switch the focus back to the 33mer fluorescently labeled photochemical cross-linker substrate 
in an attempt to verify specificity for site-directed covalent attachment.  Experimental 
parameters for photochemical cross-linking were based upon optimized conditions tested 
above.  Figure 3.12 illustrates a SDS-PAGE gel evaluating the cross-linking of the 33mer 
substrate to active and inactive samples of purified GGCX.  Activity in the sense of GGCX is 
defined as the ability to bind propeptide and catalytically convert glutamic acid to gamma-
carboxy glutamic acid.  Without the influence of propeptide, purified GGCX has very low 
stability at room temperature resulting in loss of activity in less than an hour after incubation 
at 25oC.  To test the specificity of the 33mer cross-linker substrate to bind inactive GGCX, a 
purified sample of GGCX was allowed to incubate at room temperature for several hours.  
The loss of catalytic activity was confirmed by the absence of FLEEL carboxylation in the 
presence of factor IX propeptide and cofactors KH2, O2, and 14CO2.  The catalytically 
inactive GGCX was then photochemically cross-linked with the 33mer substrate and 
fluorescence intensity was compared to an active fraction of GGCX by SDS-PAGE.  If the 
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33mer substrate binds specifically to the Gla catalytic domain of GGCX, it should be unable 
to covalently cross-link to an inactive fraction of the protein.  Confirmation of this result is 
shown in Figure 3.12 (A) lane 5 where there is an absence of fluorescently labeled GGCX 
after cross-linking with inactive GGCX.  Panel B of that same figure illustrates the stained 
gel where the intensity of GGCX maintains consistency whether the protein was active or 
inactive.  One potential hypothesis for loss in protein activity is due to the aggregation of 
GGCX at elevated temperatures in the absence of bound substrate.  It will later be 
demonstrated that when propeptide is present, the stability of GGCX improves dramatically 
by protecting the protein from aggregation.   
3.4.4.2 Cross-linking Investigated by Fluorescence Anisotropy 
An alternative means to evaluate nonspecific binding is by fluorescence anisotropy.  
Fluorescence anisotropy is a method for studying the binding interaction between two 
molecules by measuring the partially polarized fluorescence emission of a fluorophore.  In 
solution, free fluorophores have randomly aligned transition moments.  When impinged upon 
with polarized light, the fluorophore whose absorbance transition moments are aligned with 
the electric vector of the polarized light are selectively excited.  The intensities of both the 
parallel and perpendicular emission are used to calculate the anisotropy (r) as shown in 
Equation 3.2. 
r = (I║ - I┴ )/(I║+ 2I┴)                        Equation 3.2 
Fluorescence anisotropy measurements are sensitive to the rotational diffusion of a 
fluorophore.  Small fluorophores in solution can rotate many times during an excited state 
resulting in randomly oriented emission and a small anisotropy value.  When bound to larger 
macromolecules, however, the bound complex has a much slower rotational diffusion 
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therefore resulting in a higher anisotropy value.  If the 33mer substrate nonspecifically binds 
several locations on GGCX upon irradiation, we would expect that the fluorescence 
anisototropy of this complex to continue to increase with increasing substrate concentrations 
of the 33mer cross-linker.  Figure 3.13 (A) evaluates anisotropy curves for both a 
fluorescently labeled consensus propeptide (FpCon) and the fluorescently tagged 33mer 
substrate.  At very low concentrations of fluorescent substrate, all substrate is bound by a set 
concentration of GGCX and anisotropy levels are elevated.  As the concentration of substrate 
increases, GGCX becomes the limiting reagent.  The anisotropy now decreases due to a large 
excess of substrate free in solution with only a very small percentage bound to GGCX.  The 
profiles for both the FpCon and 33mer substrates are very similar.  The higher anisotropy 
values experienced for the 33mer substrate is likely due to the longer peptide sequence thus 
impeding rotational diffusion compared to the shorter FpCon.   
Using this same technique, the 33mer substrate can be evaluated with and without 
covalent cross-linking to GGCX.  With irradiation, the anisotropy binding curve appears very 
similar with a distinct leveling off at higher concentrations of 33mer substrate.  If the 
photochemical cross-linker substrate was attaching to GGCX at multiple nonspecific 
locations we would expect to see a continued increase in anisotropy with increase substrate 
concentration.  A possible explanation for the decrease in anisotropy values of the irradiated 
sample compared to the non-irradiated sample is likely a result of fluorophore 
photobleaching upon ultraviolet irradiation.  Thus, it may be concluded that the 33mer cross-
linker substrate is likely binding specifically to a single domain on GGCX. 
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3.4.4.3 Competitive Inhibition of Photochemical Cross-linking  
 In addition to FLEEL inhibition, we can also conduct studies in which competitive 
inhibition by excess propeptide is evaluated.  Figure 3.14 displays an SDS-PAGE gel 
indicating the competitive inhibition by excess consensus propeptide (pCon) to prevent 
covalent cross-linking at varying concentrations of the 33mer substrate.  The fluorescently 
imaged gel in Figure 3.14 (A) illustrates that the fluorescence intensity dramatically reduces 
when the purified GGCX sample has been pre-equilibrated with pCon prior to incorporation 
of the 33mer cross-linker and substrate irradiation.  This phenomenon is evident for multiple 
concentrations of the 33mer cross-linker (16.5 M, 4.0 M, and 1.0 M).  The stained gel in 
panel B confirms the correlation of similar sample loading indicating that the change in 
fluorescent intensity is dependent on the amount of cross-linked product that is produced.  
Although slight remnants of fluorescence intensity is present in lane 6 after competitive 
inhibition with pCon, activity assay results confirm that there continues to be evidence of 
FLEEL inhibition indicating the presence of a covalent complex (data not shown).  One 
explanation for this occurrence is that covalent cross-linking alters the equilibrium of a 
competitive inhibition mechanism.  Even though the consensus propeptide is in large excess 
and binds GGCX with a much higher affinity compared to the 33mer substrate, the reaction 
is still represented as an equilibrium.  The difference, however, is when the 33mer substrate 
binds, covalent cross-linking prevents substrate release creating a redistribution of the 
equilibrium conditions.  Since there is always propeptide bound in some form to GGCX, the 
protein maintains an active conformation promoting covalent cross-linking to the Gla 
catalytic domain in some small amount.  
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3.4.4.4 Cross-linking to Mutant GGCX 
 The last two examples aimed to investigate the specificity of the 33mer cross-linker 
substrate to selectively bind GGCX, attempt to evaluate the precise location of cross-linker 
binding compared with previous reports in the literature.  Figure 3.15, compares wild-type 
GGCX to a Y395A single amino acid mutation.  Mutucumarana et al. reported the Y395A 
mutant to have good propeptide binding, with reduced carboxylation efficiencies.19  Cross-
linking the 33mer fluorescent substrate to the mutant GGCX, however, demonstrates 
covalent cross-linking that is only slightly reduced in fluorescent intensity despite the 
absence of catalytic activity.  To explain this phenomenon, we can revisit results from the 
2003 Mutucumarana et al. manuscript.19  Here GGCX mutants W390A, Y395A, S398A, 
W399A, and H404A were expressed and purified.  Three of the five mutations investigated, 
W390A, S398A, and H404A exhibited normal activity, whereas Y395A and W399A 
experienced reduced GGCX activity similar to the natural mutant L394R.  Relative to wild-
type GGCX, L394R, Y395A, and W399A all have high Km values for FLEEL indicative of 
low affinity substrate binding.  In parallel with reduced activities for FLEEL carboxylation, 
L394R and W399A also have high Km values for FIXproGla compared to wild-type.  The Km 
for Y395A carboxylation of propeptide containing FIXproGla, however, is quite similar to 
wild-type with reported values of 0.20  0.04 M and 0.23  0.03 M respectively.19  Here, 
similar to the 33mer substrate, the kinetic constants for FIXproGla are dependent on both the 
interaction at the propeptide and Glu binding sites.  Unlike the L394R and W399A mutants 
which experience reduced affinities for both the propeptide and Gla domains, the Y395A 
mutant is characterized with affinity for the propeptide similar to wild-type.  Thus, the ability 
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of the Y395A mutant to bind propeptide may stabilize the 33mer in a geometric orientation 
to promote covalent attachment at the catalytic active site. 
3.4.4.5 Cross-linking to Two-Chain GGCX 
 As mentioned in Chapter 2, GGCX can be digested under limited trypsin conditions 
to yield an N-terminal 30 kDa domain and a C-terminal 60 kDa domain.  Similar to the 
limited trypsin digestion, a two-chain C+N construct may be generated which expresses both 
the 30 kDa and 60 kDa domains separately, but provides an active GGCX complex linked by 
a disulfide bond.  A stained SDS-PAGE gel illustrated in Figure 3.16 A compares wild-type 
GGCX (lane 1) to the intact two chain construct (lane 2).  After reduction with DTT (lane 3) 
the construct separates into a 60 kDa and 30 kDa band.  The cross-linking efficiency of wild-
type GGCX (lane 4) upon irradiation with the 33mer substrate compared to irradiation of the 
two-chain GGCX with the 33mer substrate (lane 5) display very similar intensity profiles in 
both panels A and B of Figure 3.16.  When the photochemical cross-linked two-chain 
construct is reduced with DDT and concentrated, it can be shown that the large majority of 
the fluorescence intensity is localized in the C-terminal 60 kDa of the protein (lane 6).  From 
previous literature it is predicted that the catalytic conversion site for GGCX is located within 
the lumen containing segment of the C-terminal branch.  Confirmation of this localized 
region further validates the method for the specificity of the photoactive 33mer cross-linker 
substrate to covalently bind the Gla catalytic domain of GGCX. 
3.4.5 Conclusions 
Despite numerous experiments designed to investigate the catalytic binding domain of 
GGCX, a consensus on the precise location of carboxylation has not yet been concluded.  To 
approach this problem, we developed synthetic photoactive cross-linker substrates modeled 
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after natural vitamin K-dependent proteins with a highly conserved consensus propeptide 
domain followed by a truncated Gla domain.  In both substrate sets, a photoactive 
benzoylphenylalanine (Bpa) is positioned adjacent to two conserved glutamic acids.  Upon 
irradiation, the Bpa moiety will form a diradicaloid intermediate that will covalently attach to 
a geometrically accessible C-H proton of GGCX, ideally in the catalytic binding pocket of 
glutamic acid carboxylation.  To identify the site of covalent attachment, a reporter tag is 
modified to the C-terminal residue of the substrate sequence.  For the 33mer substrate this is 
a 5(6)-carboxyfluorescein attached to the side chain of a lysine residue, whereas, the 27mer 
substrates differentiate covalent attachment through isotopic labeling.  Two 27mer substrates 
are synthesized with and without a deuterium labeled alanine (d0/d3).  When the substrates 
are mixed in a 1:1 (w/w) ratio, a 50% deuterated complex will offer a signature isotopic 
distribution in the mass spectrum that differs by three Daltons.  Biochemical evaluation of 
these substrates conclude that both the 33mer and 27mer cross-linkers bind GGCX and 
become carboxylated.  The binding efficiency is determined by inhibition of the small Gla 
domain FLEEL and is seen to vary depending on cross-linker concentration and irradiation 
time.  Optimal conditions for covalent attachment are achieved demonstrating 75  5% 
FLEEL inhibition with 16.5 M 33mer substrate after a 45 minute irradiation and 49.6  
0.8% FLEEL inhibition with 85 M 1:1 (w/w) 27mer in 45 minutes of irradiation.  
Variations in binding efficiency between the two cross-linker substrates can be explained by 
modifications to the Gla domain sequence.  The specificity of covalent attachment was 
evaluated for the 33mer cross-linker substrate.  From these studies it was concluded that 
covalent attachment occurred at a single site of active GGCX in the 60 kDa C-terminal 
domain of the protein.  These findings agreed nicely with previous reports indicating that 
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residues 393-404 in GGCX are important for interaction with glutamate substrates.  Using 
the methodology developed to achieve a photochemically crosslinked VKD-GGCX complex, 
Chapter 4 will attempt to identify the site-specific catalytic domain of carboxylation by liquid 
chromatography coupled to mass spectrometry. 
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3.6 Tables 
 
 
 
 
 
 
 
 
 
 
 
 
 
Propeptide Sequence Kd at 4oC (nM)
Consensus 0.083 + 0.005
Factor X 0.593 + 0.040
Protein Z 1.80 + 0.04
Protein S 2.28 + 0.05
Factor VII 2.34 + 0.08
Factor IX 4.97 + 0.10
Protein C 18.6 + 0.6
Prothrombin 25.8 + 0.4
A V F L S R E Q A N Q V L Q R R R R
S L F I R R E Q A N N I L A R V T R
S V F L P A S K A N D V L V R W K R
A N F L S K Q Q A S Q V L V R K R R
R V F V T Q E E A H G V L H R R R R
T V F L D H E N A N K I L N R P K R
S V F S S S E R A H Q V L R I R K R
H V F L A P Q Q A R S L L Q R V R R
 
 
Table 3.1 Relative Kd values and sequence alignment for human vitamin K-dependent 
propeptides.   
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Gla Domain Sequence
Factor X
Protein Z
Protein S
Factor VII
Factor IX
Protein C
Prothrombin
A N S F L E E M K K G H L E R E C
A G S Y L L E E L F E G N L E K E C
A N S L L E E T K Q G N L E R E C
A N A F L E E L R P G S L E R E C
Y N S G K L E E F V Q G N L E R E C
A N S F L E E L R H S S L E R E C
A N T F L E E V R K G N L E R E C
 
 
Table 3.2 N-terminal sequence alignment for human vitamin K-dependent Gla domains 
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3.7 Figures 
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Figure 3.1 Schematic diagram of processive mechanism of carboxylation.  Vitamin K-
dependent proteins (VKD) bind Gamma-Glutamyl Carboxylase (GGCX) at a high 
affinity propeptide binding site and a lower affinity Gla catalytic domain.  In the 
presence of CO2, O2, and vitamin K hydroquinone (KH2), selected glutamic acids 
residues (Glu) in the Gla domain of the VKD protein are converted to gamma-
carboxy glutamic acid (Gla) in a single binding event where the rate of substrate 
release is the rate limiting step. 
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Figure 3.2 Photoaffinity cross-linker vitamin K-dependent substrates.  33mer and 27mer 
substrates are synthesized with a high affinity N-terminal consensus propeptide 
sequence (dark blue) followed by a truncated Gla domain.  Adjacent to two conserved 
glutamic acid residues in the Gla domain, a photoactive p-benzoylphenylalanine 
(Bpa) cross-linker residue is inserted to promote covalent attachment upon irradiation 
to the catalytic binding domain of GGCX.  Reporter peptides were varied between the 
two substrates.  A 5(6)-carboxyfluorescein modified lysine occupied the C-terminal 
position for the 33mer substrate, whereas the 27mer substrate was terminated with an 
isotopically labeled alanine.  A 1:1 (w/w) mixture of the undeuterated (d0) and 
deuterated (d3) 27mer substrate analogs generate a signature mass profile that differs 
by three Daltons. 
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Figure 3.3 Circular dichroism overlaid spectra comparing the synthetic vitamin K-dependent 
substrates: 33mer cross-linker, 27mer AH3 (d0) cross-linker, 27mer AD3 (d3), and 
FIXQ/S.  Baseline subtraction and Savinsky-Golay smoothing algorithms have been 
applied to each data set to remove background buffer influences. 
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Figure 3.4 Reaction velocity curve at increasing concentrations of FIXQ/S with calculated 
Vmax and Km values.  Corresponding FIXQ/S sequence reported with propeptide 
domain highlighted in dark blue.  The Gla domain contains twelve potential glutamic 
acid residues capable of carboxylation shown in bold.  Residues that differ from the 
wild-type factor IX are underlined. 
 
 
 
 
 
 
 
179 
 
 
 
 
 
 
Vmax =    8.9e4 + 2e3 cpm
Km =    11.5 + 0.8 M
R2 =    0.998
AVFLSREQANQVLQRRRR
ANAFLEEBpaVQGNLEKfl
80x103
70
60
50
40
30
20
10
0C
or
re
ct
ed
 c
pm
 (8
0 
m
in
ut
es
; 2
0o
C
)
6050403020100
[33mer] M  
 
Figure 3.5 Reaction velocity curve at increasing concentrations of 33mer cross-linker 
substrate with calculated Vmax and Km values.  Corresponding 33mer sequence 
reported with propeptide domain highlighted in dark blue.  The Gla domain contains 
three potential glutamic acid residues capable of carboxylation shown in bold.  
Modified residues are underlined in position 26 (p-benzoylphenylalanine) and 
position 33 (5(6)-carboxyfluorescein). 
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Figure 3.6 Reaction velocity curve at increasing concentrations of 27mer cross-linker 
substrates with calculated Vmax and Km values.  Corresponding 27mer sequences 
reported with propeptide domain highlighted in dark blue.  The Gla domain contains 
two potential glutamic acid residues capable of carboxylation shown in bold.  
Modified residues are underlined in position 26 (p-benzoylphenylalanine) and 
position 27 (deuteroalanine).  27mer AH3 undeuterated substrate represented in green 
and 27mer AD3 deuterated substrate represented in red. 
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Figure 3.7 SDS-PAGE gel confirming 33mer photoactive cross-linking efficiency.  
Corresponding fluorescently imaged gel (A) and SYPRO® Ruby stained gel (B).  
The presence (+) or absence (-) of reported conditions are represented in table format 
for each gel lane.   
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Figure 3.8 Schematic cartoon representing carboxylation mechanism for GGCX.  (A) 
Carboxylation of small pentapeptide substrate FLEEL in the presence of factor IX 
propeptide.  FLEEL, with very low affinity binding for the catalytic domain of 
GGCX, exchanges very quickly with GGCX resulting in a high carboxylation 
efficiency.  (B) The 33mer substrate alone experiences a very low carboxylation 
turnover, as the consensus propeptide is bound very tightly to GGCX and substrate 
release is the rate limiting step.  In combination with FLEEL carboxylation, both the 
33mer substrate and FLEEL substrate become carboxylated.  (C)  If the 33mer 
substrate is covalently cross-linked to the active site of the GGCX complex, however, 
the FLEEL substrate will have very limited access to the catalytic domain of GGCX 
preventing substrate carboxylation and reducing the overall carboxylation efficiency.  
The determination of %FLEEL inhibition is used to assess the relative effectiveness 
of covalent cross-linking. 
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Figure 3.9 SDS-PAGE gel confirming photoactive cross-linking efficiency at varying 
concentrations of the 33mer substrate.  Corresponding fluorescently imaged gel (A) 
and SYPRO® Ruby stained gel (B). (C) Percent FLEEL inhibition calculated for 
each sample concentration by measuring the competitive inhibition of FLEEL 
carboxylation before and after a 45 minute irradiation period.  Number above each 
bar correlates to corresponding gel lane for given concentration. 
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Figure 3.10 SDS-PAGE gel confirming photoactive cross-linking efficiency at varying 
irradiation times for the 33mer substrate.  Corresponding fluorescently imaged gel 
(A) and SYPRO® Ruby stained gel (B). (C) Percent FLEEL inhibition calculated for 
each irradiation time by measuring the competitive inhibition of FLEEL 
carboxylation before and after irradiation with 16.5 M 33mer substrate.  Number 
above each bar correlates to corresponding gel lane for given irradiation period. 
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Figure 3.11 Percent FLEEL inhibition for 27mer and 33mer photoactive cross-linker 
substrates under varying conditions of cross-linker concentration (A) and irradiation 
time (B).  Concentration variations compared the 27mer AH3 (d0) and 27mer AD3 (d3) 
independently after irradiation for 45 minutes.  A 1:1 (w/w) mixture of both the 
deuterated and undeuterated substrate analogs (d0/d3) was additionally verified to 
confirm optimal FLEEL inhibition at a combined concentration of 85 M.  Irradiation 
time variations evaluated a 1:1 (w/w) d0/d3 isotopic mixture of the 27mer substrates 
(85 M) to have a maximum inhibition at 45 minutes.  For comparison, representative 
FLEEL inhibition for the 33mer substrate and overlaided for each graph. 
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Figure 3.12 SDS-PAGE gel confirming 33mer cross-linking specificity requires catalytically 
active GGCX.  Corresponding fluorescently imaged gel (A) and SYPRO® Ruby 
stained gel (B).  The presence (+) or absence (-) of reported conditions are 
represented in table format for each gel lane.   
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Figure 3.13 Fluorescent anisotropy binding curves confirming site-directed specificity for 
33mer cross-linking.  (A) At a constant concentration of GGCX, fluorescently labeled 
substrate [consensus propeptide-(FpConsensus) or 33mer] was titrated and 
corresponding anisotropy values were recorded.  (B) The binding curves for the 
33mer substrate were compared before and after covalent cross-linking to GGCX.  
Similarity in binding profiles confirm specificity in 33mer covalent binding. 
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Figure 3.14 SDS-PAGE gel confirming 33mer cross-linking competitive inhibition with 
excess consensus propeptide.  Corresponding fluorescently imaged gel (A) and 
SYPRO® Ruby stained gel (B).  The presence (+) or absence (-) of reported 
conditions are represented in table format for each gel lane.  For this experiment three 
concentrations of 33mer substrate were evaluated: 16.5 M, 4.0 M, and 1.0 M. 
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Figure 3.15 SDS-PAGE gel confirming inhibition of the 33mer cross-linker to the Y395A 
single-point GGCX mutant.  Corresponding fluorescently imaged gel (A) and 
SYPRO® Ruby stained gel (B).  The presence (+) or absence (-) of reported 
conditions are represented in table format for each gel lane.   
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Figure 3.16 SDS-PAGE gel confirming 33mer cross-linking site-specific covalent attachment 
to the 60 kDa C-terminal domain of GGCX.  Corresponding SYPRO® Ruby stained 
(A) and fluorescently imaged gel (B).  The presence (+) or absence (-) of reported 
conditions are represented in table format for each gel lane.  GGCX two chain C+N is 
an active protein construct that when reduced by DTT separates into an N-terminal 30 
kDa and C-terminal 60 kDa domain. 
 
 
 
 
 
CHAPTER 4: Identifying the Catalytic Active Site of GGCX –Cross-linker 
Substrate Identification by LC-MS 
________________________________________________________ 
4.1  Introduction 
4.1.1 Mass Spectrometric Determination of Protein Cross-linking  
Closely related to protein function is the analysis of three dimensional structure and the 
identification of substrate binding domains.  The two most common methods for high 
resolution determination of protein structure include X-ray crystallography and nuclear 
magnetic resonance (NMR) spectroscopy.  For membrane proteins, however, it is difficult to 
obtain large sample quantities of purified protein necessary for such classical structural 
methods without complications in sample solubility or protein aggregation.  Alternatively, 
chemical cross-linking in conjunction with mass spectrometry (MS) is a very promising tool 
to yield structural information on proteins and protein complexes that are difficult to address.  
Cross-linking MS is an attractive technique allowing high sensitivity coupled to rapid 
analysis, requiring very low amounts of purified protein.  In addition, the specificities of the 
cross-linking reagents are very broad, resulting in a wide variety of experiments that can be 
performed.   
A typical approach for mass spectrometric analysis of cross-linked products is bottom-up 
proteomics.  Here protein complexes are generated after induced covalent attachment of a 
functionalized substrate molecule to a target protein of interest.  They are then digested using 
proteolytic enzymes and analyzed by mass spectrometry followed by MSMS identification of 
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potential cross-linked sequences.  Despite the straightforwardness of the cross-linking 
approach, product identification can be quite cumbersome due to the complexity of the 
reaction mixtures.  Frequently, chemically cross-linked complexes generate altered 
proteolytic or chemical fragmentation patterns resulting in very low abundance precursor 
ions.1  Thus, searching for cross-linked peptides in a complex bottom-up digestion mixture is 
comparable to looking for the infamous “needle in the haystack.”  To locate the “needles” or 
cross-linked products, a number of strategies have been developed that aim to selectively 
isolate covalent complexes.  Commonly employed enrichment strategies include isolation by 
affinity chromatography or the incorporation of reporter tags including: isotope labeled 
residues, fluorophores, or cleavable cross-linkers.   
Affinity modified cross-linkers provide a means to selectively isolate a protein complex.  
When incorporating affinity recognition, the cross-linker is often designed as a multi-
functional substrate.  In this approach, the cross-linker substrate is defined with selective 
residues for covalent attachment in addition to a secondary affinity recognition domain.  For 
example, a biotinylated affinity stubstrate provides enrichment of the cross-linker containing 
species by affinity purification on avidin beads.2   
Application of 1:1 (w/w) mixtures of stable isotope-labeled cross-linking reagents allows 
low-abundance cross-linked peptides to be detected by their distinctive isotopic patterns after 
enzymatic digestion.3, 4  For identification of the cross-linked precursor by mass 
spectrometry, a signature isotopic doublet will be introduced into every cross-linker 
containing species.  MSMS fragmentation can then be utilized to confirm the sequence 
identity of the cross-linked complex.  The first report of isotope facilitated identification of 
cross-linked protein products involved a rather complicated labeling procedure.5  In this 
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study, all primary amine groups in the protein were reductively methylated followed by 
enzymatic hydrolysis.  The newly formed N-termini of the peptides were then derivatized 
with a 1:1 (w/w) mixture of 2,4-dinitrofluorobenzene-d0/d3 (DNFB).  Cross-linked peptides 
could be discriminated in the mass spectra by a 1:2:1 or 1:1 isotopic pattern for the doubly 
and singly labeled peptides after chromatographic separation.  Besides using DNFB for 
chemical sequencing, other commercially available isotopic cross-linkers (e.g. BS3-d4, BS2G-
d4) are also popular for investigating site-specific protein interactions.  For example, the 
homo-bifunctional amine reactive NHS esters BS3 (bis[sulfosuccinimidyl]suberate) and 
BS2G (bis[sulfosuccinimidyl]glutarate) were examined for complex mapping between 
calmodulin and a peptide derived from the C-terminus of adenylyl cyclase 8.6   
Mass spectral detection of cross-linked peptides have also been developed using 
mixed isotope cross-linking (MIX).  In one study, the MIX strategy is exemplified in a 1:1 
(w/w) 15N-labeled and 14N-unlabeled protein mixture of cytokine interleukin 6 homodimers 
for cross-linking identification.7  Inter-molecular cross-linked peptides were identified by 
distinctive triplets or quadruplets in the mass spectra.  In contrast, intra-molecular cross-
linked or non-cross-linked peptides appeared as doublets in the mass spectra, thus offering 
the possibility to discriminate between variations in molecular cross-linked species.  
Incorporation of 18O from isotopically enriched water into the C-termini of proteolytic 
peptides also presents a valuable means to discriminate cross-linked products.8, 9   
An alternative approach to selective cross-linker enrichment is the incorporation of a 
fluorogenic reagent as a signature tag.  Here a fluorophore is incorporated into the cross-
linker substrate where peptides containing the covalently linked complex can be isolated 
using fluorescence detection prior to mass spectrometry.  Cleavable cross-linkers are another 
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popular choice for simplified identification by mass spectrometry through production of 
signature cleavage fragmentation.  The thiol-cleavable cross-linking reagent 3,3’-dithio-
bis(succinimidylpropionate) (DTSSP) has been applied to map interfaces of a number of 
protein complexes.10-12  In these experiments, peptides not observed in the mass spectrum 
following reduction of DTSSP were assigned as putative cross-linker complexes.  In contrast 
to chemical cleavage cross-linkers, collision energy induced cleavage provides a useful 
methodology for the mass spectrometric detection of covalent cross-linked complexes.  First 
reported by Back and co-workers in 2001,13 an amine-reactive, homobifunctional cross-linker 
N-benzyliminodiacetoyloxysuccinimide (BID) was designed and applied to the cross-linking 
of model peptides as well as protein complexes.10, 13  BID uniquely yields a stable tropylium 
ion marker at m/z 91 upon low-energy collision induced dissociation indicative of cross-
linker incorporation. 
Currently, the greatest limitation of chemical cross-linking by mass spectrometry is 
the lack of computer software that can effectively analyze the enormous complexity of 
reaction mixtures.  Commercial and web-based cross-linking software includes the 
Automated Spectrum Assignment Program (ASAP),14-17 SearchXLinks,18 and the General 
Protein/Mass Analysis for Windows (GPMAW) program19 to name a few.  Most commercial 
cross-linking software functions under the same general processing platform with minor 
deviations designed to target specific cross-linker variations.  Using a bottom-up approach, a 
comprehensive peptide list of potential cross-linked targets are generated for a given protein 
sequence based upon user defined information regarding the cross-linker sequence, the 
protease used for enzymatic digestion, as well as potential post-translational modifications.  
A report matching predicted results against an experimental mass list identifies potential 
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cross-linker candidate complexes.7, 8, 11, 17, 20-22  Further sequence confirmation is made at the 
MSMS level where fragmentation pattern interpretation and simulations can be investigated.  
Despite the advancements in cross-linking software, however, all existing programs exhibit 
some level of user limitation.  Thus for final confirmation, manual assignment of cross-
linked products must be made.   
4.1.2 Benzoylphenylalanine Photophore Cross-linking 
The photoactive amino acid p-benzoylphenylalanine (Bpa) has proven to be extremely 
useful in identifying peptide-protein interactions.23-27  In addition to chemical stability, Bpa 
produces highly efficient covalent modifications of macromolecules with remarkable site 
specificity.  Bpa covalent cross-linking is analogous to a carbonyl photochemistry 
concomitant with proton transfer reactions.  The basic mechanism of Bpa carbonyl photo 
cross-linking is illustrated in Figure 4.1.  Upon irradiation of the Bpa photophore (1), photon 
absorption results in the promotion of one electron from a nonbonding n-orbital on oxygen to 
an anti-bonding *-orbital of the carbonyl group (2).  In the diradicaloid triplet state, the 
electron-deficient oxygen n-orbital is electrophilic and therefore reacts with weak C-H -
bonds in neighboring molecules (3) to abstract a proton.  The ketyl (4) and alkyl (5) radicals 
formed then readily recombine to generate a new C-C bond (6).  After recombination, the 
cross-linked complex is covalently stable.  If the target of recombination is a proton donor 
lacking a chiral center, the resulting benzhydrol is capable of generating a highly conjugated 
dehydration species (7).23   
The lifetime and geometric accessibility of the diradicaloid excited species are the 
primary sources of cross-linking site specificity.  The lifetime of the exited state containing 
two unpaired electrons is much longer than that of a singlet state promoting sufficient 
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diradicaloid attack of geometrically accessible C-H bonds.  The regiochemical and 
stereoelectronic control of the recombination, however, is further challenged by the rigidity 
of the benzoylphenylalanine ring system to maintain a planar orientation.  If a suitable proton 
donor is not identified, the excited triplet-state Bpa electronically relaxes back to the ground 
state.  In contrast to other photoreactive groups that are irreversibly activated, the Bpa probe 
is capable of undergoing several excitation and relaxation cycles until a favorable geometry 
for covalent modification is achieved.  Unlike Bpa excitation, the lifetime of covalent 
recombination is considerably shorter.  Here the transition state radicals formed by proton 
abstraction remain in close proximity to one another where only minimal motion is required 
to fulfill the stereoelectronic requirements for bond formation.   
The probability of achieving an optimal geometry for covalent attachment can be further 
improved by using an appropriate linker sequence.  For biochemical studies, the selection of 
linker size and orientation is crucial, since the primary goal is to label the binding site for the 
ligand while maintaining nonspecific modifications.  Linkers are characterized with either 
moderately flexible (repeating CH2, O, NH) or moderately rigid (C=O, COO) 
functionalities.23  Although a long flexible linker provides a greater probability of achieving 
optimal geometry for covalent attachment, excessive nonspecific labeling is more likely to 
occur.  Thus, when investigating the topographic mapping of a peptide-protein active site, 
more rigid linkers are recommended.23 
Apart from the geometric factors, the efficiency of covalent attachment strongly depends 
on the chemical and electronic environment of the photophore and the proton donor moiety.28  
The strength of the bond being broken and the relative stabilities of the resulting alkyl 
radicals indicate that the homolytic cleavage of C-H bonds induced by the triplet biradical is 
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favored over O-H or N-H bonds.  In biological systems, the most effective proton donors 
include backbone C-H bonds in all amino acids (except proline), polypeptides, and 
carbohydrates.  In addition to C-H peptide bonds, other particularly reactive sites include the 
electron rich tertiary centers such as C-H of leucine and C-H of valine and CH2 groups 
adjacent to heteroatoms in lysine, arginine, and methionine.29  Figure 4.2 illustrates a 
modified reaction mechanism of Bpa covalently cross-linked to the side chain of a leucine 
residue.  Despite the affinity of Bpa for alternative C-H donors, insertion into vinylic or 
aromatic C-H bonds has not been reported.23   
In the absence of any orientational preference, the reactivity order for proton abstraction 
can be largely affected by functional group influences of the targeted protein.  For Bpa 
photochemical reactions, electron-withdrawing groups are shown to increase the efficiency 
of proton abstraction whereas, electron donating or electron delocalized conjugated systems 
are much less reactive towards H-abstraction.  In addition to the chemical environment, the 
selectivity of Bpa photochemical covalent attachment is further influenced by 
stereoelectronic factors.  For proline crosslinking, radical recombination product formation is 
suppressed due to additional steric hindrance.  Similarly, radical recombinations between 
alkyl radicals or triplet state Bpa biradicaloids are prevented due to steric restrictions (Figure 
4.3) 
The benzoylphenylalanine (Bpa) photoaffinity cross-linker has been reported in several 
studies as a valuable probe for ligand-receptor interactions.  In combination with 
biotinylated,30 deuterated,30 tritiated,31 or 125I radiolabeled27, 32, 33 enrichment methods, mass 
spectrometric detection has enabled targeted binding domain identification for Bpa 
containing cross-linkers.  Based upon both geometric and chemical reactivity of Bpa proton 
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abstraction, several studies concluded a preference for covalent attachment to the side chain 
of methionine residues.29, 32-34  In one study, Egnaczyk et al. demonstrated the use of a 
photoaffinity Bpa cross-linker to determine high-resolution structural constraints on the 
assembly of -amyloid (A) monomers into amyloids fibrils in the pathogenesis of 
Alzheimer’s disease.34  The photochemically activated amyloid complex was isolated by 
SDS-PAGE followed by enzymatic digestion and mass spectrometric analysis.  Localized 
covalent attachment of the Bpa residue was confirmed to be cross-linked to the -methyl 
group of the Met35 side chain confirming an antiparallel alignment of the A peptides within 
amyloid fibrils. 
 
4.2 Chapter Scope 
Structural analysis of proteins by chemical cross-linking combined with mass 
spectrometric analysis is a rapidly developing area.  In contrast to biological techniques 
including immunoprecipitation, mass spectrometry provides a high resolution and high mass 
accuracy method for the assignment of cross-linker containing species.  In Chapter 3, 33mer 
and 27mer photoactive cross-linkers were developed and evaluated for selective binding to 
Gamma-Glutamyl Carboxylase (GGCX).  The cross-linker substrates were modeled with a 
high affinity consensus propeptide domain followed by a truncated Gla domain to mimic a 
modified vitamin K-dependent protein (VKD).  For covalent attachment, a photoactive 
benzoylphenylalanine (Bpa) was positioned adjacent to two glutamic acid residues in the Gla 
domain in each substrate to encourage cross-linking to the catalytic active site of GGCX 
upon irradiation.  Extensive biological validation of cross-linker specificity for GGCX and 
catalytic functionality was confirmed for both the 33mer and 27mer substrates.  For substrate 
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enrichment, the VKD substrates were synthesized with a C-terminal 5(6)-carboxyfluorescein 
modified lysine (Kfl) or a deuterated alanine (Ad3) in the 33mer and 27mer substrates 
respectively.  Combining the biological development of the photoactive cross-linker 
substrates (Chapter 3) with the optimized proteolytic digestion conditions for GGCX 
(Chapter 2), Chapter 4 will focus on the identification of the covalently cross-linked substrate 
by capillary liquid chromatography coupled to mass spectrometry.   
Transmembrane proteins such as GGCX, provide extreme challenges for separation 
scientists due to limitations in solubility and protein aggregation.  To date, much of the work 
investigating the catalytic binding domain of GGCX is based upon mutational analysis or 
biochemical assays.  Probing the catalytic active site of GGCX with a photoactive cross-
linker modified substrate provides a novel approach to identifying protein interactions by 
mass spectrometry.  With covalent cross-linking, however, comes additional obstacles in the 
complexity of the cross-linking reaction and the cumbersome nature of mass spectral 
identification.  To approach this challenge, several data mining algorithms were created to 
identify potential peptides for covalent attachment.  In addition to identification of covalent 
cross-linking in GGCX, the data analysis methodology developed in this chapter can be 
further applied as a platform for cross-linking in other target protein complexes.   
 
4.3 Experimental 
4.3.1 Materials 
Reagents used for Gamma-Glutamyl Carboxylase purification and evaluation are as 
follows: 1,2-dioleoyl-sn-glycero-3-phosphocholine [DOPC] (Avanti Polar Lipids, Alabaster, 
AL), 2-(N-morpholino)ethanesulfonic acid [MES] (Sigma-Aldrich, St. Louis, MO), 3-[(3-
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cholamidopropyl)dimethylammonio]-1-propanesulfonate hydrate [CHAPS] (Sigma-Aldrich), 
3-(N-morpholino)-propanesulfonic acid [MOPS] (Sigma-Aldrich), bovine serum albumin 
(99% Purity) [BSA] (Sigma-Aldrich), bovine serum albumin-fluorescein isothiocyanate 
conjugate [BSA-FITC) (Sigma-Aldrich), calcium chloride dihydrate [CaCl2.2H2O] (Fisher 
Scientific, Fair Lawn, NJ), dithiothreitol [DTT] (Roche Applied Science), ethylenediamine-
tetraacetic acid [EDTA] (Mallinckrodt Chemicals, Raleigh, NC), glycerol (Fisher Scientific), 
14C labeled sodium bicarbonate [NaH14CO3] specific activity, 55 mCi/mmol (MP 
Biomedicals, Solon, OH), sodium chloride [NaCl] (Fisher Scientific), 
tris(hydroxymethyl)aminomethane hydrochloride [Tris-HCl] (Sigma Aldrich), and Vitamin 
K1(25) purchased from Hospira Incorporated (Lake Forest, IL) stabilized with phytonadione 
injectable emulsion.  Protease inhibitors including aprotinin, leupeptin, pepstatin, and 
phenylmethyl sulfonyl fluoride were purchased from Roche Applied Science (Indianapolis, 
IN).  Anti-HPC4 monoclonal antibody coupled Sepharose resin was obtained from Dr. 
Charles T. Esmon (Cardiovascular Biology Research Program, Oklahoma Medical Research 
Foundation, Oklahoma City, OK).35  The pentapeptide Gla domain FLEEL (Phe-Leu-Glu-
Glu-Leu) was purchased from Bachem (Philadelphia, PA) and the propeptide modified factor 
IX propeptide [pFIX] (TVFLDHENANKILNRPKR) was synthesized and purified by Chiron 
Mimotopes (Calyton, Victoria, Australia) 
For gel analysis of Gamma-Glutamyl Carboxylase, NU-PAGE Bis-Tris Gels were 
purchased from Invitrogen (Carlsbad, CA) along with a SeeBlue prestained protein ladder 
and Simply Blue Safe Stain.  SDS-PAGE buffers were prepared according to protocol 
derived from Invitrogen including a 4X SDS-PAGE loading buffer and a 20X MES running 
buffer.  Gel digestions were completed with LC-MS grade reagents as follows: acetic acid, 
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optima grade acetonitrile, ammonium bicarbonate, and optima grade water purchased from 
Sigma-Aldrich.  Other reagents for digestion include, 95% ethanol (Fisher-Scientific), 
dithiothreitol (Roche Applied Sciences), and PNGaseF glycerol stabilized deglycosylation 
reagents from New England Biolabs (Ipswich, MA).  Trypsin-Gold mass spectrometry grade 
and chymotrypsin sequencing grade proteolytic enzymes were purchased from Promega 
(Madwason, WI) and Roche Applied Sciences accordingly. 
 Liquid chromatography mobile phase components were optima grade acetonitrile, 
puriss LC-MS grade ammonium acetate, LC-MS grade formic acid, and optima grade water 
from Sigma-Aldrich. 
4.3.2 Purification of Recombinant Wild-type Gamma-Glutamyl Carboxylase 
Wild-type human Gamma-Glutamyl Carboxylase (GGCX) with a carboxyl terminus 
12-amino acid epitope tag (EDQVDPRLIDGK) was isolated from Sf9 as previously 
described.36  Solubilized GGCX microsomes were purified using a calcium dependent HPC4 
antibody resin and eluted in 25 mM MOPS pH 7.5, 0.1 M NaCl, 0.5% CHAPS, 0.2% DOPC, 
10 mM EDTA, and 15% glycerol stabilized by a protease inhibitor cocktail.  Protein 
concentration and purity was determined by enzymatic activity assay measurements and 
SDS-PAGE.  A detailed protocol describing Gamma-Glutamyl Carboxylase protein 
purification is described in Appendix A1. 
4.3.3 Synthetic Vitamin K-Dependent Peptides 
33mer and 27mer vitamin K-dependent peptides were synthesized by Chiron 
Mimotopes and Synthetic Biomolecules (San Diego, CA) respectively.  The 33mer peptide 
(H-AVFLSREQANQVLQRRRRANAFLEEBpaVQGNLEKfl-OH) was purified to >95% as 
determined by LC-MS.  The peptide was synthesized with a free amine N-terminus and a free 
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acid C-terminus containing two modified amino acids, the p-benzoylphenylalanine (Bpa) and 
the 5(6)-carboxyfluorescein (Kfl).  In a similar peptide design, two 27mer peptide substrates 
were synthesized (H-AVFLSREQANQVLQRRRRANAFLEEBpaA-NH2 and H-
AVFLSREQANQVLQRRRRANAFLEEBpaAd3-NH2) with a free amine N-terminus and an 
amide C-terminus.  The photoactive Bpa cross-linker residue is maintained in position 26 as 
previously tested with the 33mer peptide.  Incorporation of an isotopic label on the side chain 
of the C-terminal alanine [Ad3] (Cambridge Isotope Cat # DLM-7316-1) provides a signature 
isotopic pattern in the mass spectrum for a 1:1 (w/w) mixture of the labeled (d3) and 
unlabeled (d0) forms of the peptide.  The 27mer peptides were prepared to >95% purity as 
measured by LC-MS.  Concentration determination for cross-linker solutions were calculated 
from reported extinction coefficients for the 5(6)-carboxyfluorescein (492nm = 78,000M-1cm-
1, pH 9.0) and the p-benzoylphenylalanine (262nm = 18,000M-1cm-1). 
4.3.4 Photochemical Cross-linking Experimentation 
Photochemical cross-linking of GGCX with the 33mer substrate or 1:1 (w/w) 27mer 
substrates (d0/d3) was performed as described in Chapter 3.  In brief, a pre-incubated mixture 
of GGCX with cross-linker substrate was irradiated at 365 nm for 45 minutes on ice.  The 
lamp distance, sample temperature, and irradiation time were optimized to provide maximum 
cross-linking efficiency.  To determine the efficiency of covalent cross-linking, an in vitro 
radioactivity assay measuring the percent inhibition of FLEEL carboxylation was evaluated.  
Details regarding the in vitro inhibition assay are outlined in Chapter 3.  The percent FLEEL 
inhibition was calculated for the GGCX-cross-linker containing samples before and after 
irradiation.  If site-specific covalent cross-linking of GGCX was achieved, carboxylation of 
the small peptapeptide substrate FLEEL would be completely inhibited.  To account for 
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sample evaporation during irradiation, a correction factor for the change in volume was 
applied. 
4.3.5 Proteolytic Digestions 
4.3.5.1 In-Gel Digestion Protocol for Gamma-Glutamyl Carboxylase 
In-gel proteolytic digestions were completed for cross-linked GGCX substrate complexes 
as well as uncross-linked GGCX controls.  The details regarding an optimized in-gel 
digestion are reported in Chapter 2.  In brief, 60 pmol of purified Gamma-Glutamyl 
Carboxylase (GGCX) was deglycosylated with PNGaseF overnight at 4oC followed by 
reduction with 1 M dithiothreitol (DTT) for 30 minutes at 30oC.  The sample was 
concentrated (4x) with Millipore Microcon YM-30 MWCO centrifugal spin filters and 
loaded onto a NU-PAGE Bis-Tris gel.   
For in-gel digestions, gel bands were cleaved and placed in a pre-treated eppindorf tube 
with 50% acetonitrile in optima grade water.  The 33mer-GGCX complex, characterized by a 
fluorescent gel band, can be visualized using an AlphaImagerTM 2200 UV transilluminator 
with a fluorescein filter and extracted without staining.  Contrastingly, the 27mer isotopically 
labeled GGCX complex required protein gel staining using simply Blue Safe stain prior to 
gel band removal.  As a control, a gel band free of loaded protein was also isolated to provide 
a background for digestion analysis.  The gel bands were cut into quarters using the tip of a 
pipette and washed in two 30 minute intervals with 40% ethanol in 50 mM ammonium 
bicarbonate and constant vortexing.  Once destained, bands were washed for 10 minute 
intervals with 50 mM ammonium bicarbonate, cleaved into <1mm3 pieces, dehydrated with 
100% acetonitrile, and vacuum dried.  All gel work-up was completed in a laminar flow hood 
to prevent sample contamination.   
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To the dried protein gel piece, 30 L of proteolytic digestion solution (100 ng/L) was 
added to reswell the gel band on ice for 45 minutes.  An overlay of 10% acetonitrile in 40 
mM ammonium bicarbonate was then added and digestion was carried out at 30oC for three 
hours (chymotrypsin) or overnight (trypsin).  After digestion, the supernant was immediately 
removed and the remaining gel band was extracted in the presence of 60% acetonitrile in 40 
mM ammonium bicarbonate overnight at 4oC.  The extraction supernatant was removed and 
lyophilized to dryness before combining with the digestion supernatant for liquid 
chromatographic analysis. 
4.3.5.2 In-Gel Digestion Protocol for Bovine Serum Albumin 
Bovine serum albumin (BSA) and fluorescein modified BSA (BSA-FITC) samples 
were evaluated for method validation of peptide extraction after proteolytic in-gel digestion.  
In-gel digestions were modeled after GGCX where the fluorescence intensity after each 
digestion step was monitored using AlphaImager® 2200 UV transilluminator with a 
fluorescein filter.  Chromatographic separations and mass analysis were completed on a 
capillary liquid chromatography system coupled to a Waters® QTof MicroTM mass 
spectrometer.   
4.3.5.3 In-Solution Digestion of 27mer and 33mer Cross-linker Substrates 
The 33mer cross-linker substrate and the 1:1 (w/w) 27mer d0/d3 isotopically labeled 
substrates were individually investigated by in-solution proteolytic digestion to characterize 
peptide fragmentation patterns of target cross-linker substrates prior to incorporation with 
GGCX.  Digestions were completed at 30oC in a 1:50 ratio of proteolytic enzyme to target 
protein.  Similar to in-gel digestions, both chymotrypsin (3 hours) and trypsin (overnight) 
digestions were examined for peptide mapping using capillary liquid chromatography and 
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mass spectrometry.  To improve recovery of fluorescein labeled peptides, low pH quench 
conditions were avoided during digestion.  After incubation at 30oC, samples were 
immediately frozen in liquid nitrogen to stop digestion and stored at -80oC until analysis by 
UHPLC-MS. 
4.3.6 Bottom-Up Peptide Separation and Mass Spectrometric Detection 
4.3.6.1.1 Reverse Phase Capillary Column Preparation 
Fused silica capillary columns with a 50-100 m inner diameter and 360 m outer 
diameter (Polymicro Technologies, Phoenix, AZ) of varied lengths were packed with 1.5 m 
bridged ethyl hybrid (BEH) C18 particles (Waters Corporation, Millford, MA, Lot Number 
KHG687) as previously described in Chapter 2.37   
4.3.6.2 UHPLC Instrumentation 
A custom-built LC system was designed to provide capillary reverse phase 
separations at ultra-high pressures (UHPLC).  The instrument consisted of a Waters® CapLC 
conventional gradient pump with integrated autosampler pumping at a flow rate of 40 
L/minute.  For ultra-high pressure generation, a second Waters® 1525 HPLC pump was 
coupled with a hydraulic amplifier for pressure magnification up to 3100 bar (45,000 psi).  
The outlets from the CapLC and hybrid hydraulic amplifier were connected via a gradient 
storage loop to two ports on a low-dead volume high pressure stainless steel union along with 
the capillary separation column and an open-tubular split flow capillary (10 m ID).  The 
instrumentation was controlled using both custom and commercial MassLynx 4.1 (Waters) 
software.  A detailed description of the UHPLC system is provided in Chapter 2.   
For a 100 m ID x 41.5 cm capillary column, a flow rate of 400 nL/min was desirable 
resulting in a backpressure of 1400 bar (20,000 psi) and a split ratio of 10:1.  The outlet of 
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the capillary column was coupled through a Teflon junction to a 20 m ID, 360 m OD open 
tube capillary (OTC) with a 75m ID bubble cell for UV-Vis detection (Linear Model 200 
Variable UV-Vis Spectrophotometer, Linear Instruments, Reno, NV).  UV detection of the p-
benzoylphenylalanine residue was monitored at 262 nm while visible detection of the 5(6)-
carboxyfluorescein absorbance was monitored at 492 nm (actual 410 nm on Linear Model 
200 Variable UV-Vis detector) with a range of 0.02.  The maximum absorbance wavelength 
was determined by migrating a sample front through the UV-Vis detector until the signal 
intensity reached a maximum (data not shown).  A modified version of Stripchart Recorder 
XP (LabVIEW VI, written by Matthew Monroe) was used to record the signal from the UV-
Vis detector.  The outlet of the UV-Vis OTC capillary was coupled end-to-end to a 20 m ID 
x 360 m OD fused silica 10 m PicoTip nano-electrospray emitter (New Objective, 
Woburn, MA).  Mass analysis was completed using a Waters® QTof MicroTM mass 
spectrometer. 
For reverse phase separations, mobile phase A1 was prepared with 0.2% (v/v) LC-MS 
grade formic acid in optima grade water and mobile phase B1 with 0.2% (v/v) LC-MS grade 
formic acid in 80% optima grade acetonitrile.  Similarly, mobile phase A2 was prepared with 
10 mM ammonium acetate LC-MS grade in optima grade water and mobile phase B2 with 10 
mM ammonium acetate LC-MS grade in 80% optima grade acetonitrile. Peptide separation 
was performed as a linear gradient under varying conditions. 
4.3.6.3 Capillary LC Instrumentation 
A customized low pressure LC system was designed to provide capillary reverse phase 
separations with greater sample loading capacity.  The instrument consisted of a Waters® 
CapLC conventional gradient pump operated at a flow rate of 5 L/minute.  A constant back-
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pressure regulator was used as a pre-injection splitter providing direct sample injection onto a 
reverse phase capillary column.  A two-port low-dead volume (18 nL) stainless steel union 
was used to couple the gradient flow to an analytical capillary column.  The instrumentation 
was controlled using both custom and commercial MassLynx 4.1 (Waters) software.  For a 
100 m ID x 8 cm capillary column, a flow rate of 400 nL/min was desirable with a 
backpressure of 276 bar (4000 psi) and a pre-injection split ratio of 1/10.  The outlet of the 
capillary column was coupled through a Teflon junction to a 20 m ID, 360 m OD open 
tube capillary (OTC) with a 75m ID bubble cell detection window for UV-Vis absorbance.  
Mass analysis was completed using a Waters® QTof MicroTM mass spectrometer.  Reverse 
phase gradient conditions and mobile phase preparations for capillary LC separations are 
consistent with reported conditions for UHPLC separations. 
4.3.6.4 nanoACQUITYTM UPLC Instrumentation 
The nanoACQUITYTM Ultra Performance LC® (UPLC) system is designed for nano-
scale, capillary separations providing high chromatographic resolution, sensitivity and 
reproducibility.  The system is operated under single-pump trapping mode where samples are 
loaded for one minute (5 L sample loop) onto a trap column (2 cm x 180 m ID; 5 m C18 
Symmetry particles) at 15 L/minute with 99.5% optima grade water with 0.1% formic acid 
and 0.5% acetonitrile.  Reverse phase separation are completed on a 25 cm x 75 m ID 
analytical capillary column packed with 1.7 m C18 BEH particles.  Column flow rate and 
temperature is maintained at 300 nL/minute and 35oC respectively.  Peptides are eluted with 
a linear gradient of 5-50% MP B in 60 minutes where mobile phase A was prepared with 
0.1% (v/v) LC-MS grade formic acid in optima grade water and mobile phase B with 0.1% 
(v/v) LC-MS grade formic acid in optima grade acetonitrile.  Sample volumes were loaded in 
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partial loop mode.  While the binary solvent manager is generating the gradient, the auxiliary 
solvent manager is used to provide flow (0.5 L/minute) for a [Glu1]-fibrinopeptide 
NanoLockSpray reference solution (200 fmol/mL).  The nanoACQUITYTM system is further 
reviewed in Chapter 2. 
4.3.6.5 MS Instrumentation: DDA and MSE 
Mass identification of peptide digests was completed using Waters® QTof MicroTM 
and QTof PremierTM mass spectrometers.  The MassLynx program that controls MS data 
acquisition for both instrumental systems allows for peptide fragmentation in both data 
directed analysis (DDA) (MicroTM and PremierTM) and MSE (PremierTM) modes.  An 
overview of DDA and MSE data acquisition and processing is described in Chapter 2.   
DDA provides MSMS precursor fragmentation of selected ions above a user defined 
threshold.  In MS mode, the collision energy of the mass spectrometer is kept low at 7 V and 
the quadrupole is set to pass all ions over the mass range of 400-1600 m/z at a scan time of 
1.1 seconds.  When the intensity of an individual ion in the MS survey scan rises above 20 
counts/second, the MS survey scan is stopped and switched to MSMS mode.  For MSMS 
fragmentation, the collision energy is ramped until the target ion intensity drops below 2 
counts/second or after a time period of 3.3 seconds regardless of intensity.  For a given mass 
range, the collision energy is varied between three defined energy values.  The resulting 
fragment ions can then be detected over the mass range 50-1990 m/z.  The QTof MicroTM 
was tuned in positive electrospray mode to provide optimal ionization with a capillary 
voltage of +2000 V, sample cone voltage of +40 V, extraction cone voltage of +3 V, and 
source temperature of 100oC.  For mass accuracy correction, a dynamic external calibration 
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(DXC) probe was used such that the instrument was calibrated to control for mass 
fluctuations due to temperature  
MSE is represented by using acquisition of exact mass data at high and low collision 
energies simultaneously38, 39 and is outlined in greater detail in Chapter 2.  In low energy 
+ESI MS mode, data is collected with a constant collision energy of 4eV.  For ion 
fragmentation, the collision energy is elevated and ramped from 15 to 40 eV during each 0.7 
second integration.  The fast switching time for the MSE analysis thus allows for a low and 
elevated energy scan to be acquired for all ions (m/z 50 to 1990) every 1.4 seconds.  A 
reference sample was scan every thirty seconds allowing for accurate lock mass correction.  
For all measurements, the QTof PremierTM mass spectrometer was operated in V-mode with 
a typical resolution of at least 10,000 FWHM.  The tune page parameters for the QTof 
PremierTM were tuned to apply a capillary voltage of +3000V, sample cone voltage of +35 V, 
extraction cone voltage of +4V, and source temperature of 100oC.  For mass accuracy 
correction, a nanoflow lock spray source was implemented with a 200 fmol/mL reference 
solution of [Glu1]-fibrinopeptide B in 70% acetonitrile and 30% water with 0.1% formic 
acid.   
4.3.7 Data Processing 
4.3.7.1   Protein-Lynx Global Server-DDA 
Data directed analysis (DDA) MSMS runs were processed using ProteinLynx Global 
Server 2.4 (RC7).  Data analysis using PLGS requires two main method processing 
components: the data preparation file and the workflow template as previously outlined in 
Chapter 2.  The data preparation file applies a lockmass correction ([Glu1]-fibrinopeptide B, 
m/z 485.8426 Daltons, ± 0.25 Daltons) on the data acquired, addresses background 
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subtraction (none) and noise reduction (none) while automating peptide deconvolution and 
centroiding (fast with automatic thresholds) to generate a peak list.   Databanks were created 
to include proteins encountered during sample preparation.  The databank created for GGCX 
digestions included the following proteins listed by accession number: P38435-Homo 
Sapiens (Human) Vitamin K-dependent Gamma-Glutamyl Carboxylase modified with the 
HPC4 C-terminus epitope tag (EDQVDPRLIDGK), Q8I866- Spodoptera frugiperda (Sf9) 
Heat shock cognate 70 protein, P00766 and P00767-Bos Taurus (Bovine) Chymotrypsinogen 
A and B respectively, P00761-Sus Scrofa (Porcine) Trypsin, P04264 and P04259-Homo 
Sapiens (Human) Keratin type II cytoskeletal proteins 1 and 6B respectively.  The synthetic 
27mer and 33mer cross-linker sequences were also appended to the databank to identify 
corresponding cross-linker peptide fragments.  To identify false positive protein selections, 
the specialized databank was randomized. 
The databank was uploaded into the workflow designer for peptide and protein 
sample identification.  The peptide and fragment ion tolerances were set to 20 ppm and 0.5 
Daltons respectively with an estimated calibration error of 0.05 Daltons.  Digestions were 
completed with trypsin or nonspecific cleavage parameters with three missed cleavages.  
Here trypsin proteolytic cleavage was specified C-terminal to lysine (K) and arginine (R) not 
before proline (P) whereas a nonspecific peptide cleavage could occur at any given amino 
acid.  To account for any sequence variability or post-translational adaptations, common 
variable peptide modifications were added to the search parameters: N-terminus acetylation 
( 42.011 Daltons), deamidation of asparagine and glutamine (0.984 Daltons), and 
oxidation of methionine (15.995Daltons).  Results were validated to limit peptide 
identification to only peptides with three or more consecutive fragment ions.   
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4.3.7.2 Protein-Lynx Global Server-MSE 
MSE acquired samples were processed using ProteinLynx Global Server 2.4 (RC7).  
Experimental setup for data analysis was very similar to that for DDA processing, with 
generation of both the data preparation and workflow template files.  The data preparation 
file applies a lockmass correction ([Glu1]-fibrinopeptide B, m/z 485.8426 Daltons, ± 0.25 
Daltons) on the data acquired and addresses threshold parameters for ion identification: 200 
counts, 75 counts, and 1500 counts respectively for the low energy, elevated energy, and the 
intensity threshold value.  The chromatographic peak width (FWHM), MS TOF resolution, 
and retention time window parameters were set to automatic detection.   
After data preparation processing, the time aligned precursor and product ions can be 
matched against the GGCX specialized databank for peptide identification.  The workflow 
template was created to search the GGCX databank using automatic peptide and fragment 
mass tolerances for trypsin or nonspecific peptide digestions.  The search criteria were set to 
match a minimum of three fragment ion matches per peptide, seven fragment ion matches per 
protein, and one peptide match per protein with a false positive rate of 4.  N-terminal 
acetylation, deamidation of asparagine and glutamine, and oxidation of methionine were set 
as potential variable modifications.   
4.3.8 Photoaffinity Cross-linker Identification 
Photo cross-linked GGCX peptide digests were searched for potential cross-linker 
modifications to identify the site of covalent attachment.  Several web-based algorithms were 
evaluated for cross-linker identification in addition to PLGS2.4 RC7 processing and manual 
investigation.  The PLGS2.4 workflow template can be modified to search for user defined 
variable modifications. Using in-solution proteolytic digestions of the 33mer and 1:1 (w/w) 
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27mer d0/d3 cross-linker substrates as a fingerprint of expected proteolytic peptide fragments, 
variable modifications can be incorporated into the ProteinLynx peptide search criteria.  
Cross-linker variable modifications are defined as side-chain amino acid additions with a 
calculated peptide mass difference.  The delta mass values are derived from the monoisotopic 
peptide mass with the following mass additions: 104.0262 Daltons, 358.0477 Daltons, 
+3.0185 Daltons, and -0.9840 Daltons for the p-benzoylphenylalanine (Bpa), 5(6)-
carboxyfluorescein (Kfl), alanine-d3, and amide C-terminus respectively.  For example, the 
27mer cross-linker peptide fragment LEEBpaAd3 can be added as a variable modification 
into the workflow search parameters.  The monoisotopic mass of the raw peptide sequence 
(H-LEEFA-OH) is 607.2853 Daltons and can be modified with mass additions from 
incorporation of a Bpa residue, an alanine-d3 isotopic tag, and an amide C-terminus to give a 
final peptide mass of 713.3494 Daltons.  The dehydration products for each modified cross-
linker peptide fragment must also be considered with a mass loss of (18.0106 Daltons).  A 
total of 34 variable modifications were evaluated during PLGS processing for both the 33mer 
and 27mer cross-linker substrates (5 modified 33mer cross-linker peptides with 
corresponding dehydration products = 10; 6 modified 27mer cross-linker peptides with 
complementary d3 modified sequences and associated dehydration products = 24). 
Covalent attachment of Bpa is facilitated through abstraction of a proton from the 
target protein C-H peptide backbone.  Previous studies have reported that, in addition to 
geometric accessibility, Bpa photo cross-linking demonstrates preference based upon amino 
acid side-chain functionality.23  Thus, variable modifications were specified to form covalent 
attachments between Bpa and the following amino acid residues: N, Q, E, D, C, R, K, M, L, 
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V, I, G.  Identification of cross-linked substrate-protein complexes by PLGS2.4 RC7 were 
manually confirmed through evaluation of peptide score and fragmentation efficiency. 
Inherent complications in automated data processing programming require that 
manual investigation of experimental cross-linking must be completed for sample validation.  
Focusing on the 33mer cross-linker substrate modified with a C-terminal fluorophore, time 
alignment between the visible spectrum and mass spectrum provides a perspective list of 
potential cross-linked peptide candidates.  Further confirmation of cross-linked peptides can 
be provided by evaluating MSMS fragmentation patterns characterized by the loss of a 
modified 5(6)-carboxyfluoresein modified C-terminal lysine residue (505.16 Daltons) and the 
absence of targeted cross-linker precursor masses in the GGCX digestion control.   
Modification of the photoaffinity cross-linker with an isotopic label as in the 27mer 
substrates (d0/d3) provides a signature mass pattern in the MS spectrum of a peptide 
separation when the peptides are mixed in a 1:1 (w/w) ratio.  Manual interrogation of 
complex cross-linked GGCX digestions utilize data processing algorithms which search the 
raw data for precursor ions that differ in mass by three Daltons but are found to elute at the 
same retention time in a chromatographic separation.  The candidate precursor cross-linked 
peptides can be plotted on a three dimensional chromatospectrum where retention time is 
plotted on the x-axis, precursor mass on the y-axis, and mass intensity illustrated in false 
color.  Since the d0/d3 labeled substrates are mixed in a 1:1 (w/w) ratio, it is expected that the 
precursor intensity remains conserved.  Thus, the candidate precursor cross-linked complex 
must not only maintain a mass difference of three Daltons at a given retention time, but also 
be present in a 1:1 mass intensity ratio.  For peptide validation, potential cross-linkers must 
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be absent from the GGCX control sample digestion and be well-sequenced by high collision 
energy fragmentation. 
Identification of GGCX peptides or potential cross-linked complexes requires 
replication to validate peptide existence.  For a peptide to be confirmed, a precursor ion must 
match in two out of three sample injections and be identified in two different sample 
preparations analyzed under the same chromatographic and mass spectrometric conditions.  
Peptide or precursor mass data was pooled from either the peptide workpad generated after 
PLGS processing or from the apex3D Pep3DAMRT output from MSE processed samples.  
Identified peptides are matched for replication in peptide sequence, retention time (within 0.5 
minutes), mass accuracy (10 ppm), and variable modification. 
 
4.4 Results and Discussion 
Covalent chemical cross-linking combined with mass spectrometry provides a highly 
sensitive means for identification of site-specific protein interactions.  In this chapter, 
photochemical cross-linking is investigated in an effort to determine the catalytic active site 
domain of Gamma-Glutamyl Carboxylase (GGCX).  Despite the abundance of biochemical 
studies regarding the active site recognition of GGCX, the precise mechanism for vitamin K-
dependent (VKD) protein carboxylation is not fully understood.  The most promising work to 
date identifies the highly conserved region in human GGCX between residues 393 and 404 to 
exhibit biological significance in the conversion of select glutamic acids (Glu) to gamma-
carboxy glutamic acids (Gla) in VKD substrates.  To mimic the carboxylation mechanism 
and identify the precise location of catalytic conversion, synthetic substrates were modeled 
after VKD proteins with a highly conserved consensus propeptide and a truncated Gla 
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domain.  A photoactive p-benzoylphenylalanine and a fluorescent (33mer) or isotopic 
(27mer) C-terminal reporter tag are incorporated into the peptide sequence to provide site-
specific identification of covalently cross-linked GGCX active site complexes by liquid 
chromatography and mass spectrometry.   
4.4.1 Identification of Characteristic 33mer Cross-linker Peptides 
The 33mer cross-linker substrate is enriched with a 5(6)-carboxyfluorescein (Kfl) C-
terminal reporter tag to provide identification of the Bpa containing cross-linked peptides in a 
complex proteomic digestion mixture.  Due to the steric hindrance of both the Bpa and the 
fluorescein reporter, however, the separation distance between the Bpa and Kfl residues was 
extended to seven amino acids.  The flexible arm length of the extended peptide allows the 
Bpa molecule to have geometric access to the catalytic active site of GGCX initiating 
covalent attachment.  The downside of this substrate design, however, is that proteolytic 
digestion must be controlled to eliminate cleavage between the Bpa and Kfl residues.  To 
further improve identification of the 33mer-GGCX complex, sample conditions must be 
tuned to maximize fluorescein absorbance at 492 nm.   
It is commonly recognized that fluorescein and many of its derivatives exhibit 
multiple pH dependent ionic equilibria as shown in Figure 4.4.  Above pH 9.0, both the 
phenol and carboxylic acid functional groups of fluorescein are almost totally ionized in 
aqueous solutions.  Acidification of the fluorescein-dianion first protonates the phenol (pKa 
~6.4) to yield the fluorescein monoanion, then protonates the carboxylic acid (pka ~5.0) to 
produce a neutral species.  Further acidification generates a fluorescein cation (pKa ~2.1).  
As the pH of the solution changes, the absorbance pattern for fluorescein is affected 
accordingly.  Maximum absorbance is achieved at 492 nm between pH 7-9.  When the pH is 
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lowered, a decreased absorptivity and a blue shift in absorbance maxima is indicative of the 
formation of protonated species with maximum absorbance at 478 nm and 456 nm at pH 5.0 
and 440 nm at pH 2.0.  Typical chromatographic separations are conducted at low pH in the 
presence of 0.2% formic acid to provide optimal charge carrier properties for electrospray 
ionization.  At such low pH mobile phase conditions, however, the absorbance of the 
fluorescein reporter tag on the 33mer cross-linker is at a minimum intensity.  To compromise 
ionization efficiency with fluorescein absorbance, chromatographic mobile phase conditions 
were modified to include 10 mM ammonium acetate. 
In-solution digestions of the 33mer cross-linker peptide substrate with trypsin and 
chymotrypsin are illustrated in Figures 4.5 and 4.6 respectively.  Peptide separations were 
completed over a 25 minute gradient from 1-65% acetonitrile on a customized UHPLC 
system (100 m x 41.5 cm capillary column packed with 1.5 m BEH C18 particles) at a 
flow rate of 400 nL/minute.  In addition to the MS chromatogram in each panel, absorbance 
at 492 nm and 262 nm was also monitored to detect characteristic peptide fragments 
containing Kfl and Bpa residues respectively.  For both Figures 4.5 and 4.6, panel A 
represents the corresponding peptide separation and absorbance under mobile phase 
conditions containing 0.2% formic acid (pH 2.5), while panel B evaluates chromatographic 
performance with mobile phase containing 10 mM ammonium acetate (pH 7.5).  Alignment 
of both the absorbance and MS chromatograms permit identification of 33mer cross-linker 
containing peptides.   
From these results, it may be concluded that controlled peptide digestion with trypsin 
or chymotrypsin prevents peptide cleavage between the photoactive Bpa residue and the Kfl 
fluorescent reporter tag in the 33mer substrate.  Absorbance conditions at both 492 nm and 
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262 nm are maximized when the mobile phase is modified with 10 mM ammonium acetate 
despite the lower efficiency in sample ionization compared with 0.2% formic acid.  Although 
Bpa containing peptides are identified at 262 nm at pH 2.5, no evidence of Kfl modified 
peptides are observed at 492 nm. Figure 4.7 summarizes the cross-linker peptides identified 
and sequenced by MSMS in chymotrypsin (A) and trypsin (B) in-solution digestions under 
chromatographic running conditions containing 10 mM ammonium acetate.  As observed in 
Chapter 2, chymotrypsin digestion often results in non-specific cleavages.  Despite the 
unpredicted behavior of chymotrypsin, several overlapping fragments are identified 
providing ample opportunity for identification of 33mer containing cross-linker peptides.  
Proteolytic digestion of the 33mer substrate prior to incorporation of GGCX thus provides a 
method of profiling covalently cross-linked complexes using experimentally observed 33mer 
digestion patterns. 
4.4.2 Validation of In-Gel Digestion Methodology for Fluorescein Labeled Substrates 
Unlike in-solution digestions, identification of fluorescently labeled peptides after in-
gel digestion proves much more challenging.  In addition to the hydrophobicity of a bulky 
fluorescein residue, proteolytic cleavage is often altered for modified peptides as a result of 
proteolytic inaccessibility during digestion.  As a result, in-gel digestions with a fluorescein 
isothiocyanate BSA conjugate (BSA-FITC) were performed to optimize in-gel digestion 
condition and maximize recovery of fluorescein modified peptides.  In BSA-FITC, the 
fluorescein conjugate is coupled to BSA through the -amino group of lysines in albumin 
where the degree of substitution is 13 moles of FITC per mole of albumin (data not shown).  
Throughout the in-gel digestion protocol, sample fluorescent intensity was periodically 
evaluated using AlphaImagerTM 2200 UV transilluminator with a fluorescein filter.  
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Optimized conditions for BSA-FITC fluorescent recovery after in-gel digestion were then 
applied for 33mer-GGCX photo cross-linked complexes.   
To maximize the sample loading of the peptide digest, a modified capillary liquid 
chromatography system was assembled for low pressure chromatographic separations.  
Unlike the UHPLC system which splits the flow and sample injected prior to loading onto 
the analytical capillary column, the low pressure capillary LC system controls the flow rate 
with a constant backpressure regulator prior to sample injection such that all of the sample 
being injected is loaded onto the column.  BSA-FITC and BSA in-gel chymotrypsin 
proteolytic digestion extractions were separated on an 100 m x 8 cm capillary column 
packed with 1.5 m BEH C18 particles using a 25 minute gradient from 1-50-65% 
acetonitrile and a column flow rate of 400 nL/minute.  Mobile phase compositions were 
modified to include 10 mM ammonium acetate (pH 7.5) providing optimal conditions for 
fluorescein absorbance at 492 nm.  Mass analysis was completed using a Waters® QTof 
MicroTM mass spectrometer with MSMS acquisition in DDA mode.   
Corresponding mass and absorbance chromatograms for in-gel digested BSA-FITC 
(A) and BSA (B) are illustrated in Figure 4.8.   As expected, fluorescently labeled peptides in 
only the BSA-FITC peptide digest are identified in the absorbance chromatogram at 492 nm.  
Aligning the retention times of fluorescently labeled peaks in the visible spectrum with 
peptides in the MS chromatogram, a potential list of modified peptides could be generated.  
To validate experimental findings and identify site-specific modifications, a comprehensive 
mass list was generated from a theoretical chymotrypsin digestion of BSA where peptides 
containing a lysine residue were modified by the monoisotopic addition of 389.4 Daltons, 
corresponding to the FITC reporter.  For example, if a digested peptide fragment contained 
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three lysine residues, four different corrected masses were generated for the single peptide 
moiety.  Aligned precursor peptides correlating with the absorbance spectrum at 492 nm 
were then compared to the theoretical peptide list to confirm FITC modified peptides.  
MSMS fragmentation further validated the presence of a fluorescein reporter tag attached to 
lysine residues.  Combining the optimized conditions for in-gel digestion of BSA-FITC with 
analytical capillary liquid chromatographic separations, site-specific lysine residues modified 
with a fluorescein reporter tag can be identified by MSMS sequencing.   
4.4.3 Identification of Photochemically Cross-linked 33mer-GGCX Complex 
The BSA-FITC model system outlined above provides validation for fluorescent 
peptide extraction and mass spectrometric identification after proteolytic in-gel digestion.  A 
flow diagram illustrated in Figure 4.9 outlines the experimental conditions for in-gel 
digestion and LC-MS analysis of the 33mer-GGCX cross-linked complex.  Photochemical 
cross-linking of GGCX with the 33mer synthetic substrate is confirmed through a 
carboxylation inhibition assay.  If covalent attachment of the cross-linker substrate is 
successful, then carboxylation of the small pentapeptide substrate FLEEL will be inhibited.  
The fluorescently labeled cross-linked GGCX complex is then concentrated and isolated on a 
SDS-PAGE gel.  The fluorescence intensity of the isolated gel band is monitored throughout 
gel washing (Figure 4.9 images A and B) and proteolytic digestion (Figure 4.9 images C and 
D) prior to analysis by LC-MS.  Sample chromatograms illustrating an in-gel chymotrypsin 
digestion of the 33mer-GGCX complex (A) compared to uncross-linked GGCX (B) are 
represented in Figure 4.10.  Peptide separation was completed on a 100 m x 8 cm capillary 
column packed with 1.5 m BEH C18 particles over a 25 minute gradient from 1-50-65% 
acetonitrile.  To optimize the absorbance of Kfl at 492 nm, 10 mM ammonium acetate was 
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incorporated as a mobile phase component.  Time aligned visible spectra and MS 
chromatograms confirm the identification of fluorescently labeled GGCX modified peptides 
in the covalently cross-linked sample.  Due to the complexity of the sample system, mass 
alignment with peaks in the visible spectrum serves only as a tool in cross-linker validation 
and cannot be used to precisely identify fluorescein labeled complexes. 
The proteolytic digestion of covalently cross-linked 33mer-GGCX generates a very 
complicated chromatographic separation.  Manual interpretation alone would be a very 
cumbersome feat, so a combination of commercial and user-defined algorithms must be 
created to assist in data mining.  The general workflow for cross-linker identification in 
regards to the 33mer substrate involves the following four steps: (1) identification of 
characteristic uncross-linked 33mer peptide fragments in a GGCX complex sample digestion; 
(2) PLGS processing to identify potential variable cross-linker modifications; (3) correlation 
of theoretical 33mer mass modified peptides to an experimental 33mer-GGCX complex 
digestion; and (4) identification of characteristic product ion fragmentation patterns.   
From Figure 4.7, eight reported 33mer peptides were identified in the chymotrypsin 
digested 33mer substrate alone.  Using these peptides as an initial search platform, the 
33mer-GGCX digestion complex was investigated for uncross-linked 33mer peptide 
fragments.  Figure 4.11 (A) identifies the two 33mer cleavage peptides LSREQANQVL and 
SREQANQVL confirming covalent incorporation of the cross-linker substrate into the 
GGCX complex.  Using the LSREQANQVL cross-linker fragment (*) as an example, 
peptide confirmation can be validated by the absence of the selected precursor ion in the 
uncross-linked GGCX mass spectrum (B) in addition to MSMS fragmentation (C).  
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In the next step of cross-linker identification, the 33mer-GGCX digest is processed 
using Waters® ProteinLynx Global Server (PLGS2.4 RC7).  Variable modifications are 
added to the workflow template to search for side-chain modifications with calculated 
monoisotopic mass additions corresponding to the remaining peptide sequence of the 33mer 
substrate: QRRRRANAFLEEBpaVQGNLEKfl, RANAFLEEBpaVQGNLEKfl, 
ANAFLEEBpaVQGNLEKfl, AFLEEBpaVQGNLEKfl, and LEEBpaVQGNLEKfl.  
Preferential functional group reactivities for Bpa proton abstraction were incorporated into 
the search parameters in addition to considering the possibility of product dehydration.  
Successfully matched cross-linked products must be identified in two out of three replicate 
injections as well as acknowledged in a duplicate sample preparations.   
In PLGS processing, an Apex3D Pep3DAMRT output file is created.  The 
Pep3DAMRT output applies lockmass correction to all ions and reports time aligned 
precursor and product ions identified in the sample mass spectrum.  Using the GGCX peptide 
digestion as a control, precursor ions identified in two out of three replicate injections are 
compared to replicate precursor ions in a 33mer-GGCX cross-linked sample digest (Figure 
4.12, A).  For the unprocessed comparison, 2004 precursor ions match between the two 
samples within a 0.5 minute retention time window and a 10 ppm mass error.  To reduce 
sample complexity, any precursor ions that were identified as peptides in the GGCX control 
digestion are removed.  Peptides must replicate in sequential sample injections and can be 
isolated from any protein sequence in the specified GGCX database (Figure 4.12. B).  
Removing precursor ions corresponding to identified peptides lowers the number of 
unmatched 33mer-GGCX precursor ions from 2501 to 2068.  The filtered precursor ion 
output can then be matched against a theoretical peptide list of potential cross-linked 
222 
complexes.  Candidate photo cross-linked complexes are calculated by adding potential 
33mer cross-linker peptide fragments as modifications to an in silico chymotrypsin digestion 
of GGCX (C-terminal cleavage of F/Y/W/M/L not before proline; 3 missed cleavages).  
Cross-linker peptide complexes are identified if the theoretical mass matches the 
experimental precursor ion within 10 ppm.  Peptide confirmation is validated by MSMS 
sequencing and correlation with an identified peak in the absorbance spectrum at 492 nm.   
To simplify data analysis, a histogram of peptide precursor mass can be plotted where 
only the unmatched precursor ions that overlap with theoretically modified GGCX peptides 
need to be considered (Figure 4.12, C).  In this example, the 33mer cross-linker sequence 
LEEBpaVQGNLEKFL is taken into account.  LEEBpaVQGNLEKfl is the smallest 33mer 
peptide fragment identified during in-solution chymotrypsin digestion with a precursor mass 
of 1766.7352 Daltons.  From a chymotrypsin in silico digestion (red bars), a shift in peptide 
precursor mass is shown upon addition of the 33mer LEEBpaVQGNLEKfl peptide 
modification (green bars) to predicted GGCX peptides.  The overlap between the 
unidentified precursor ions in the 33mer-GGCX complex and the theoretically modified in 
silico digestion reduces the sample searching to 491 potential peptides.  Similarly, this 
protocol is completed for the QRRRRANAFLEEBpaVQGNLEKfl, 
RANAFLEEBpaVQGNLEKfl, ANAFLEEBpaVQGNLKEfl, and AFLEEBpaVQGNLEKfl 
33mer cross-linker modifications. 
As a final method of cross-linker identification and validation, the fragmentation 
spectrum for a potentially cross-linked 33mer-GGCX complex is evaluated.  It is proposed, 
that the fragmentation pattern of the cross-linked 33mer-GGCX peptide will be expressed 
with y- and b-ions from both the GGCX active site peptide and the 33mer cross-linker 
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peptide fragment.  In studying the fragmentation pattern of the 33mer peptides containing 
both a Bpa and Kfl residue, it is concluded that a characteristic product ion at an m/z of 
505.16 Daltons is the most prominent ion in the fragmentation spectrum corresponding to the 
loss of the Kfl C-terminal residue.  To prove this concept, method validation was performed 
on a 33mer chymotrypsin in-solution peptide digest (Figure 4.13) separated on a 75 m x 
250 mm capillary column packed with 1.7 m BEH C18 particles.  The nanoACQUITYTM 
UPLC system was operated in single trapping mode at a flow rate of 300 nL/minute and 
gradient conditions of 5-50% acetonitrile in 60 minutes.  Mass analysis was completed with a 
Waters® QTof PremierTM mass spectrometer operated in MSE fragmentation mode (Figure 
4.13, A).  Using the elevated collision energy fragmentation scan, a selected ion 
chromatogram (SIC) was generated to identify the presence of the m/z 505.16 Dalton product 
ion.  Each precursor ion and corresponding fragmentation spectrum identified from the SIC 
corresponds to a successfully sequenced 33mer cross-linker containing peptide.  Figure 4.13 
(B) provides an example of the sequenced LEEBpaVQGNLEKfl cross-linker peptide and 
verification of the characteristic m/z 505.16 Dalton product ion.   
The four data processing methods were evaluated for several 33mer-GGCX 
complexes digested with either chymotrypsin or trypsin proteolytic enzymes.  Despite the 
extensive search for the GGCX cross-linked peptide complex, there was little reproducible 
evidence to confirm probable identification.  One of the major limitations of cross-linker 
identification is the likely size of the GGCX peptide complex.  Several studies have reported 
that after covalent cross-linking, peptide digestion patterns may vary due to the 
inaccessibility of the proteolytic enzyme to targeted digestion sites.1, 40  As a result, the 
expected peptide sequence is often represented as an extended missed cleavage sequence.  
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Evaluating a typical GGCX in-gel digestion, the peptides identified in two out of three 
replicate injections have an average precursor mass of 1285.46 Daltons (data not shown).  
Considering the LEEBpaVQGNLEKfl peptide as the smallest identified 33mer cross-linker 
fragment with a precursor mass of 1766.7352 Daltons, a potential cross-linked GGCX 
peptide complex is likely to have a combined mass of 3052.20 Daltons.  For peptides 
identified and sequenced in two out of three replicate injections for a GGCX peptide digest 
alone, only four peptides were confirmed greater than 3000 Daltons.  Even if the cross-linked 
GGCX peptide is present in the digestion mixture, the low ion abundance coupled with poor 
MSMS fragmentation will likely hinder the ability to identify the peptide complex and 
provide adequate sequence validation. 
The non-specific nature of chymotrypsin proteolytic digestions further complicates 
cross-linker identification.  Although chymotrypsin provides excellent sequence coverage of 
GGCX compared to other common proteolytic enzymes such as trypsin, the abundance of 
missed and nonspecific cleavages makes it difficult to predict theoretical cleavage sites and 
forecast potential cross-linked complexes.  Additional possibilities of GGCX modifications 
such as acetylation, methionine oxidation, deamidation, or phosphorylations in the modified 
GGCX cross-linked complex will also add a level of uncertainty to cross-linker 
identification.  The improvement of cross-linker substrate design in combination with data 
processing algorithms may provide considerable improvements for identification of the 
GGCX catalytic active site cross-linked domain. 
4.4.4 Characterization of 1:1 (w/w) 27mer (d0/d3) Cross-linker by LC-MS 
Improvements to the 33mer cross-linker design were made in creation of a pair of 
isotopically modified 27mer substrates.  The 27mer substrates are characterized by a high 
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affinity propeptide domain followed by a truncated Gla domain.  Sequence homology with 
the 33mer cross-linker is consistent for the first 26 amino acid residues where a Bpa 
photoactive cross-linker residue is positioned adjacent to two glutamic acid residues 
providing covalent attachment to the catalytic active domain of GGCX.  To overcome 
limitations in cross-linker peptide identification and fragmentation, the 27mer substrate was 
characterized with an isotopically labeled reporter tag, alanine-d3 at position 27.  Unlike the 
bulky 5(6)-carboxyfluorescein reporter in the 33mer cross-linker, the alanine-d3 residue is 
less likely to experience steric interference and therefore can be positioned adjacent to the 
Bpa photoactive cross-linker.  The shortened cross-linker peptide sequence in combination 
with a d0/d3 signature mass fingerprint in the mass spectrum of a peptide digest provides an 
improved system for identification of the GGCX-cross-linked peptide complex. 
Similar to the 33mer cross-linker, the 27mer substrate was initially evaluated by in-
solution proteolytic digestions with chymotrypsin (Figure 4.14, A) or trypsin (Figure 4.14, 
B).  A 1:1 (w/w) mixture of the undeuterated (d0) and three-times deuterated (d3) 27mer 
cross-linker was digested in a 50:1 peptide to enzyme ratio.  Digestion supernatants were 
separated on a 75 m x 250 mm capillary column packed with 1.7 m BEH C18 particles.  
The nanoACQUITYTM UPLC system was operated in single pump trapping mode where 
peptides were separated over a 60 minute gradient from 5-50% acetonitrile at a flow rate of 
300 nL/minute.  Mass analysis was completed using a Waters® QTof PremierTM with MSE 
mass fragmentation.  Characterization of Bpa containing peptides were identified by a 
signature three Dalton spacing between the undeuterated (d0) and deuterated (d3) substrate 
analogs in a low collision energy MS scan.  Since the isotopic modification is limited to a 
mass difference of only three Daltons, the d3/d0 peptide counterparts are seen to elute at the 
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same retention time in a reverse phase chromatographic separation.  Sample mass spectra for 
identified peptides (*) in both the chymotrypsin (A) and trypsin (B) digestion chromatograms 
are displayed.  For a singly charged peptide (e.g. m/z 714.3/711.3), the d0/d3 intensity ratio 
will equal 1 and the peptide m/z values will vary by three Daltons.  Similarly for a doubly 
charged cross-linker peptide (e.g. m/z 637.3/6.35.8), the peptide m/z values will vary by 1.5 
Daltons.  Peptide fragments corresponding to the digestion of the 1:1 (w/w) 27mer d3/d0 
cross-linker substrate are summarized in Figure 4.15.  For each cross-linker peptide 
identified, the sequence was validated by MSE elevated collision energy fragmentation.   
For complex GGCX digestions, manual identification of 27mer d0/d3 peptides is a 
very intricate and time-consuming process.  To expedite cross-linker identification, data 
processing algorithms were designed to identify signature peptide masses that elute in 1:1 
mass intensity ratios at the same retention time but vary in mass by three Daltons.  
Pep3DAMRT Apex3D outputs generated by PLGS compile lockmass corrected and time 
aligned precursor ions identified in a chromatographic separation.  Ion filtering results in an 
unprocessed chromatospectrum where an identified precursor ion at a given retention time 
and mass is plotted in three dimensional space with ion intensity being represented in false 
color (Figure 4.16, A).  Time and mass slice windows (Figure 4.16, B) can then be evaluated 
to identify and compare precursor ions of interest.  The unprocessed data is next filtered to 
plot only precursor ions that vary in mass by three Daltons but elute at the same retention 
time (Figure 4.17, A).  Although a reduction in sample complexity is noted for both 
representative chromatospectra, the plotted data indicates very little about the intensity of the 
3 Dalton spaced peptides relative to one another.  The final data filter, is applied to ratio the 
intensity of the peptide (IM) to the intensity of the peptide +3 Daltons (IM+3) using the 
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following the algebraic function 1/[abs(log(IM/IM+3))] (Figure 4.17, B).  If the peptides are 
present in a 1:1 mass intensity ratio, then the inverse log of mass intensity ratio will be 
amplified correlating to a potential 27mer cross-linked complex.  In the example illustrated in 
Figures 4.16 and 4.17, precursor ions were selected from an in-solution digestion of the 
27mer cross-linker substrate.  The LEEBpaA/Ad3 ([M] = 710.3/713.3) and 
RANAFLEEBpaA/Ad3 ([M = 1269.6/1273.6) selected ion chromatospectra indicate 
amplified ion intensity after processing, thus validating the methodology of the data 
processing algorithm.  The advantage of this technique is that as long as the precursor ion can 
be identified by PLGS, the magnitude of the raw precursor intensity does not influence mass 
identification.  Thus, chromatospectral analysis for isotopically labeled cross-linker 
substrates provides an excellent methodology for detecting low intensity candidate precursor 
ions that vary in mass by three Daltons but elute at the same retention time and mass 
intensity. 
4.4.5 Identification of Photochemically Cross-linked 27mer-GGCX Complex 
Minor modifications to the in-gel digestion and cross-linking sample analysis flow 
chart were made for the 27mer cross-linker substrate (Figure 4.18).  Since the 27mer-GGCX 
protein complex is no longer characterized by a fluorescent tag, the gel must be stained prior 
to proteolytic digestion and cross-linker recovery can not be evaluated based upon visual 
inspection alone.  As an improvement to peptide identification, sample digestions were 
analyzed using a nanoACQUITYTM UPLC system coupled to a Waters® QTof PremierTM 
mass spectrometer operated in MSE fragmentation mode.  MSE data acquisition is 
characterized by simultaneous acquisition of precursor and product ions for all ions in 
alternating low and elevated collision energy scans.  Using a scan rate of 0.7 seconds enables 
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efficient switching between component scans with almost no deviation experienced in peak 
profiles and ion intensities.  As a result, a low energy MS scan can be used to identify 
potential cross-linked GGCX peptides eluting at the same retention time but varying in 
precursor intensity by three Daltons, while the high collision energy scan provides 
fragmentation data for potential peptide sequence verification of all precursor ions.   
A comparison of proteolytic chymotrypsin in-gel digestions for the 1:1 (w/w) 27mer 
d0/d3-GGCX complex (A) and the GGCX control (B) are illustrated in Figure 4.19.  Visual 
comparisons of the two peptide chromatographic separations show very little variation.  To 
identify potential GGCX cross-linkers, data is filtered and processed into chromatospectra 
plots (Figure 4.20).  In order for a peptide to be considered a candidate cross-linker match, a 
signature 1:1 isotopic doublet must appear in the low energy mass spectrum at a given 
retention time and vary in precursor mass by three Daltons.  For candidate cross-linker 
validation, the potential precursor ion pairs must replicate in two out of three sequential 
injections as well as be identified in a duplicate sample preparation.  Final peptide 
verification is confirmed by MSE fragment ion peptide sequencing.   
 The total ion chromatospectrum for the 1:1 (w/w) 27mer d0/d3-GGCX chymotrypsin 
digest sample (Figure 4.20, A) is reported for each of three replicate sample injections.  Mass 
slice windows can be compared for the unprocessed (Figure 4.20, B) and processed (Figure 
4.21, A) data sets where sample filtering identified only precursor ions eluting at the same 
retention time and differing in mass by three Daltons.  The processed chromatospectra plots 
filter the mass list of candidate cross-linkers from 12275, 13885, and 14171 precursor ions to 
205, 220, and 267 candidate ions respectively for each trial injection (I, II, III).  Peptide 
precursor ion pairs are then amplified if the mass intensity ratio for the two peptides are in a 
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1:1 ratio by applying an inverse log function (Figure 4.21, B).  Comparing candidate 
precursor lists between each trial, 36 potential precursor ions are found to replicate in two out 
of three injections.  Considering the in-solution digestion of the 1:1 (w/w) 27mer d0/d3 
peptide, the smallest potential cross-linker containing peptide fragment is the LEEBpaA/Ad3 
peptide with a precursor mass of 710.3/713.3 Daltons.  Therefore, any GGCX peptide 
covalently cross-linked to a 27mer fragment, must be greater than 710.3 Daltons.  This 
reduces the candidate precursor ion list down to 20 potential targets.  To validate peptide 
identification, a second 1:1 (w/w) 27mer d0/d3-GGCX chymotrypsin digestion sample was 
prepared and analyzed in triplicate MSE analysis using the nanoACQUITYTM QTof 
PremierTM.  Of the 20 precursor ions replicating in three Dalton mass pairs between sample 
injections only four peptide were found in duplicate sample preparation.  The most promising 
candidate cross-linked peptide is highlighted in Figure 4.21 (boxed region) where the peptide 
amplification after data processing validates the methodology for potential cross-linker 
identification.   
Raw peptide data was then compared between the 1:1 (w/w) 27mer d0/d3-GGCX 
complex and the uncross-linked GGCX digestion.  At a retention time of 29.4 minutes, the 
mass spectra for both samples show a number of overlapping peptides (Figure 4.22, A and 
B).  Zooming in on the candidate precursor ion pair (Figure 4.22, B, C and D) at an m/z of 
587.7 and 589.3 Daltons (CS 2+), it can be shown that the selected peptide is only present in 
the 27mer containing sample.  Overlaying the two mass spectra (Figure 4.22, E) confirm the 
absence of the overlapping target peptide.  Although this candidate cross-linker peptide has 
been detected, the intensity of the peptide complex drastically reduces the ability to obtain 
meaningful fragmentation data.  Although promising, the reduced precursor intensity makes 
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it difficult to distinguish peptide peak features from background noise.  Therefore, to 
effectively verify this potential cross-linked complex further validation must be provided by 
MSMS peptide sequencing. 
4.4.6 Conclusions 
Combining the information provided in Chapters 2 and 3, a covalent cross-linking 
approach was developed to identify the site-specific catalytic active site domain of GGCX by 
liquid chromatography and mass spectrometry.  Synthetic cross-linker substrates were 
designed to mimic the peptide sequence of a vitamin K-dependent (VKD) protein with a 
high-affinity propeptide coupled to a truncated Gla domain.  Adjacent to two glutamic acid 
residues in the Gla domain of each cross-linker peptide sequence is a photochemical p-
benzoylphenylalanine (Bpa) residue that will form a covalent complex through proton 
abstraction of a neighboring GGCX peptide.  Covalent attachment is verified by modifying 
the cross-linker to include a C-terminal fluorogenic (33mer) or isotopic (27mer) reporter tag.  
The biological validation and site-specific covalent attachment of both the 33mer and 27mer 
cross-linker peptide designs were extensively investigated in Chapter 3.  Modeling optimized 
in-gel GGCX digestions investigated in Chapter 2, GGCX-cross-linker complexes were 
evaluated by liquid chromatography coupled to mass spectrometry.   
Despite the straightforward approach of chemical cross-linking, identification of 
candidate peptide complexes by mass spectrometry is not a trivial task.  Combinations of 
both commercial and manual data software algorithms were designed to identify cross-linker 
site-specific attachment.  To validate candidate cross-linkers, the peptide must exhibit the 
following four requirements: (1) reproducible identification by precursor mass and retention 
time within experimental tolerance values; (2) correlation of precursor mass with 
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characteristic reporter recognition; (3) absence of candidate peptide in uncross-linked GGCX 
controls; (4) sequence verification by high collision energy fragmentation.   
One of the inherent problems with the 33mer substrate is that peptide sequence must 
remain intact between the photoactive Bpa residue and the Kfl fluorescein reporter.  When 
cross-linked to GGCX, the length of peptide sequence coupled to the bulky modified residues 
creates a very large precursor ion that will most likely be characterized by low signal 
intensity and poor fragmentation.  Substrate modifications to improve identification of the 
GGCX active site domain, resulted in the design of an isotopically labeled 27mer d0/d3 cross-
linker substrate.  When mixed in a 1:1 (w/w) ratio, Bpa containing peptides of the 27mer 
d0/d3 substrate elute at a given retention time varying in mass by three Daltons .  
Chromatospectra plots were generated to identify potential 27mer-GGCX cross-linked 
complexes; however, further validation by MSMS fragmentation is required for site-specific 
peptide validation.   
From these studies, it may be concluded that improvements of cross-linking GGCX 
experimentation is dependent on in-solution protein processing strategies promoting more 
efficient peptide recovery.  As shown from in-solution digestions of the 33mer and 27mer 
substrates, Bpa containing peptides are easily identified using fluorescein absorbance at 492 
nm or isotopic chromatospectrum processing respectively.  Efforts made to improve 
membrane protein in-solution digestion, however, include enhancing sample solubility with 
phospholipid and detergent components which further complicates data analysis.  Difficulties 
in sample handling coupled with challenges involved in chemical cross-linking, thus presents 
a very arduous approach for investigating the active site domain of GGCX.  Chapters 5 and 6 
will investigate alternative strategies for incorporating GGCX into soluble nanoscale 
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membranes.  These nano-systems will not only provide a protected membrane structure 
where GGCX can be incorporated into a near-native environment, but also facilitate the 
ability to study protein dynamics and substrate interactions using mass spectrometry. 
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4.6 Figures 
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Figure 4.1 Photochemistry of p-benzoylphenylalanine (Bpa) and radical recombination 
mechanism.  Upon irradiation of the Bpa (1) photoaffinity cross-linker, the 
diradicaloid (2) transition state complex abstracts a weak C-H proton from a 
neighboring peptide backbone (3).  Ketyl (4) and alkyl (5) generated radicals 
recombine to form a new C-C covalent bond (6).  If the proton donor lacks a chiral 
center, the resulting benzhydrol can undergo dehydration producing a highly 
conjugated species (7) 
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Figure 4.2 Photochemistry of p-benzoylphenylalanine (Bpa) and modified radical 
recombination mechanism where proton abstraction occurs at the electron rich tertiary 
C-H center of leucine.  A similar mechanism is also observed for the C-H of valine 
and CH2 groups adjacent to heteroatoms in lysine, arginine, and methionine. 
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Figure 4.3 Photochemistry of p-benzoylphenylalanine (Bpa) and inhibited radical 
recombination.  Product formation is suppressed if radical recombination of ketyl or 
alkyl radicals occurs due to steric interference. 
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Figure 4.4 Fluorescein ionization equilibrium and correlation of pH variations in visible 
absorbance spectra. 
 
 
 
 
 
 
 
 
 
240 
 
 
 
 
 
 
 
 
A. B.
Abs 492nm
Abs 262 nm
MS Scan
33mer
Abs492 nm = Kfl
Abs262 nm = Bpa
Trypsin Solution Digestion
LC-MS/DDA
-15x10-3
-10
-5
0
5
A
bsorbance (A
U
)
6050403020100
Retention Time (minutes)
150
125
100
75
50
25
0
%
 B
PI
 In
te
ns
ity
150
125
100
75
50
25
0
%
 B
PI
 In
te
ns
ity
6050403020100
Retention Time (minutes)
-15x10-3
-10
-5
0
5
A
bsorbance (A
U
)
Abs 492nm
Abs 262 nm
MS Scan
 
 
Figure 4.5 In-solution trypsin digestion of the 33mer cross-linker substrate and evaluation of 
mobile phase modifiers.  Peptide separations completed on a modified UHPLC 
system using a 00 m x 41.5 cm capillary column packed with 1.5 m BEH C18 
particles at a flow rate of 400 nL/minute and a pre-column split ratio of 1/10.  
Capillary UV-Vis chromatograms were collected at 492 nm or 262 nm corresponding 
to the absorbance of the 5(6)-carboxyfluorescein (Kfl) and p-benzoylphenylalanine 
(Bpa) residues respectively.  Mass analysis on a Waters® QTof MicroTM.  Mobile 
phase modifiers varied as follows: (A) 0.2% formic acid; (B) 10 mM ammonium 
acetate. 
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Figure 4.6 In-solution chymotrypsin digestion of the 33mer cross-linker substrate and 
evaluation of mobile phase modifiers.  Peptide separations completed on a modified 
UHPLC system using a 100 m x 41.5 cm capillary column packed with 1.5 m BEH 
C18 particles at a flow rate of 400 nL/minute and a pre-column split ratio of 1/10.  
Capillary UV-Vis chromatograms were collected at 492 nm or 262 nm corresponding 
to the absorbance of the 5(6)-carboxyfluorescein (Kfl) and p-benzoylphenylalanine 
(Bpa) residues respectively.  Mass analysis on a Waters® QTof MicroTM.  Mobile 
phase modifiers varied as follows: (A) 0.2% formic acid; (B) 10 mM ammonium 
acetate. 
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Figure 4.7 In-solution chymotrypsin (A) and trypsin (B) digestion of the 33mer cross-linker 
substrate in 10 mM ammonium acetate.  Cross-linker peptide fragments validated by 
MSMS sequencing.  Peptide separations completed on a modified UHPLC system 
using a 100 m x 41.5 cm capillary column packed with 1.5 m BEH C18 particles at 
a flow rate of 400 nL/minute and a pre-column split ratio of 1/10.  Mass analysis was 
completed on a Waters® QTof MicroTM mass spectrometer. 
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Figure 4.8 In-gel chymotrypsin digestion of BSA-FITC (A) and BSA (B).  Peptide 
separations completed on a capillary LC system using a 100 m x 8 cm capillary 
column packed with 1.5 m BEH C18 particles at a flow rate of 400 nL/minute and a 
pre-injection split ratio of 1/10.  Mobile phase was supplemented with 10 mM 
ammonium acetate (pH 7.5) to maximize absorbance of fluorescein containing 
peptides.  Capillary UV-Vis absorbance was collected at 492 nm prior to mass 
analysis on a Waters® QTof MicroTM.  Digestion and chromatographic sample 
conditions modified to maximize recovery of fluorescently labeled peptides.  FITC 
modified peptides confirmed by MSMS sequencing and mass alignment with 
fluorescein containing peptides in the absorbance spectrum at 492 nm. 
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Figure 4.9 Experimental flow diagram for in-gel digestion of 33mer photo cross-linked 
GGCX.  Peptide separations completed on a capillary LC system using a 100 m x 8 
cm capillary column packed with 1.5 m BEH C18 particles at a flow rate of 400 
nL/minute and a pre-injection split ratio of 1/10.  Capillary UV-Vis absorbance was 
collected at 492 nm prior to mass analysis on a Waters® QTof MicroTM.  33mer-
GGCX peptide complex identified through commercial and manual data integration 
algorithms. 
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Figure 4.10 In-gel chymotrypsin digestion of 33mer-GGCX (A) and GGCX (B).  Peptide 
separations completed on a capillary LC system using an 8 cm x 100 m x 8 cm 
capillary column packed with 1.5 m BEH C18 particles at a flow rate of 400 
nL/minute and a pre-injection split ratio of 1/10.  Mobile phase was supplemented 
with 10 mM ammonium acetate (pH 7.5) to maximize absorbance of fluorescein 
containing peptides.  Capillary UV-Vis absorbance was collected at 492 nm prior to 
mass analysis on a Waters® QTof MicroTM.   
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Figure 4.11 (A). 33mer-GGCX screened chymotrypsin digestion identifying uncross-linked 
33mer peptide fragments.  (B) Confirmation of peptide (*) selectivity for the 33mer-
GGCX complex and absence in the control GGCX digest.  (C) MSMS sequence 
confirmation for the selected (*) 33mer peptide LSREQANQVL. 
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Figure 4.12 Evaluation of 33mer-GGCX sample digest and identification of cross-linked 
peptide complex.  (A) Unprocessed precursor masses identified in two out of three 
replicate injections for the GGCX (red) and 33mer-GGCX (blue) chymotrypsin 
digestion samples.  (B) Processed precursor masses filtered after removal of identified 
peptides.  (C) Histogram illustrating in silico chymotrypsin digestion (C-terminal 
cleavage at F/Y/W/M/L not before proline; 3 missed cleavages) of GGCX (red) 
overlaid with unmatched filtered precursor masses of the 33mer-GGCX (blue).  
Simulated cross-linker candidate mass list (green) generated upon addition of 
LEEBpaVQGNLEKfl 33mer peptide to in silico digestion GGCX peptides.  Area of 
overlap (491 peptides) isolates targeted precursor masses for cross-linker complex 
identification. 
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Figure 4.13 Identification of 33mer cross-linker peptides by fragment ion selection patterns.  
(A) 33mer MSE chymotrypsin digestion chromatograms illustrating low collision 
energy (red) and elevated collision energy (blue) scans.  A selected ion chromatogram 
(green) for m/z 505.16 Daltons identifies the characteristic peptide fragmentation loss 
of Kfl indicative of all 33mer cross-linker containing peptides identified.  (B) 
Confirmation of y-ion fragmentation pattern for 33mer cross-linker peptide (*) 
LEEBpaVQGNLEKfl. 
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Figure 4.14 In-solution chymotrypsin (A) and trypsin (B) digestion of the 1:1(w/w) 27mer 
d0/d3 cross-linker substrate.  Peptide separations completed on a nanoACQUITYTM 
UPLC system using a 75 m x 250 mm capillary column packed with 1.7 m BEH 
C18 particles at a flow rate of 300 nL/minute.  Mass analysis is completed on a 
Waters® QTof PremierTM operated in MSE mode.  Identification of Bpa cross-linker 
containing peptides are characterized by signature isotopic doublets spaced by 3 
Daltons for singly charged precursor ions or 1.5 Daltons for doubly charged ions. 
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Figure 4.15 In-solution chymotrypsin (A) and trypsin (B) digestion of the 1:1(w/w) 27mer 
d0/d3 cross-linker substrate.  Peptide separations completed on a nanoACQUITYTM 
UPLC system using a 75 m x 250 mm capillary column packed with 1.7 m BEH 
C18 particles at a flow rate of 300 nL/minute.  27 mer cross-linker peptide fragments 
validated by MSE sequencing. 
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Figure 4.16 (A) Total ion chromatospectrum for 1:1 (w/w) 27mer d0/d3 cross-linker 
chymotrypsin digestion.  Chromatospectra plots provide relationship between 
precursor mass and retention time with ion intensity being represented in false color.  
Mass slice windows evaluated (B and C) for assessment of Bpa containing precursor 
peptides LEEBpaA/Ad3 and RANAFLEEBpaA/Ad3 respectively.   
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Figure 4.17 (A) Selected ion chromatospectra for 1:1 (w/w) 27mer d0/d3 cross-linker 
chymotrypsin digestion.  Precursor ions matching in retention time and varying in 
mass by three Daltons are displayed in each mass slice window.  Bpa containing 
precursor peptides LEEBpaA/Ad3 and RANAFLEEBpaA/Ad3 are indicated in boxed 
regions.  (B) Chromatospectra plots for mass slice window after data treatment with 
inverse log intensity function.  Precursor ions exhibiting a 1:1 mass intensity ratio 
will be amplified in intensity indicative of candidate cross-linker complexes.   
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Figure 4.18 Experimental flow diagram for in-gel digestion of 1:1 (w/w) 27mer d0/d3 photo 
cross-linked GGCX.  Peptide separations completed on a nanoACQUITYTM UPLC 
system using a 75 m x 250 mm capillary column packed with 1.5 m BEH C18 
particles at a flow rate of 300 nL/minute.  Mass analysis is completed on a Waters® 
QTof PremierTM operated in MSE  mode.  27mer-GGCX peptide complex identified 
through commercial and manual data integration algorithms. 
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Figure 4.19 In-gel chymotrypsin digestion of 1:1 (w/w) 27mer d0/d3-GGCX (A) and GGCX 
(B).  Peptide separations completed on a nanoACQUITYTM UPLC system using a 75 
m x 250 mm capillary column packed with 1.5 m BEH C18 particles at a flow rate 
of 300 nL/minute.  Mass analysis is completed on a Waters® QTof PremierTM 
operated in MSE  mode.   
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Figure 4.20 (A) Total ion chromatospectrum for 1:1 (w/w) 27mer d0/d3-GGCX chymotrypsin 
digestion.  Mass slice windows (B) evaluated for three replicate injections (I, II, III 
respectively).   
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Figure 4.21 (A) Selected ion chromatospectra for 1:1 (w/w) 27mer d0/d3-GGCX 
chymotrypsin digestion.  Precursor ions matching in retention time and varying in 
mass by three Daltons are displayed in each mass slice window for three replicate 
sample injections (I, II, III respectively).  (B) Chromatospectra plots for mass slice 
window after data treatment with inverse log intensity function.  Precursor ions 
exhibiting a 1:1 mass intensity ratio will be amplified in intensity indicative of 
candidate cross-linker peptides (boxed precursor mass).   
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Figure 4.22 Validation of a potential 27mer-GGCX cross-linked peptide complex observed in 
the selected ion chromatospectra plots in Figure 4.21 (boxed region).  Mass scan for 
1:1 (w/w) 27mer d0/d3-GGCX (A) and GGCX (B) chymotrypsin digestion 
chromatogram at retention time of 29.4 minutes.  Precursor ions (m/z 587.73 and 
589.32; CS2+) of interest identified in cross-linked (C) mass spectrum but absent 
from uncross-linked (D) GGCX digestion.  Spectral overlap (E) confirms the 
presence of a candidate 27mer-GGCX cross-linker peptide complex.  Inverse log 
mass intensity values for a targeted precursor isotopic doublet are reported (F) for 
each of three 27mer-GGCX sample injections.  Similar values obtained for duplicate 
27mer-GGCX sample digest preparation (data not shown). 
 
 
 
 
 
 
 
 
 
CHAPTER 5: Nanodisc Formation – Biological Applications to the 
Vitamin K Cycle 
________________________________________________________ 
 
5.1 Introduction 
5.1.1 Development of Model Membranes 
Membrane proteins represent one of the biggest challenges in proteomic research today.  
Despite their abundance in biological systems, membrane proteins resist biophysical 
characterization due to complexities involving the availability of a model membrane system.  
Historically, membrane proteins are most often studied in unstructured detergent micelles or 
liposomes in which a controlled stable environment and solubilization is difficult to achieve.1  
Detergent solubilized micelles self-assemble when detergent is added above its critical 
micelle concentration.  As model membranes, micelles have the inherent disadvantage of 
lacking a lipid bilayer thus resulting in a poorly defined membrane environment.  Although 
detergents are somewhat reproducible in micelle formation, oftentimes the structure and 
activity of a protein is perturbed in the presence of detergent resulting in inactive or 
denatured entities.2-4  Liposomes, on the other hand, are vesicles of amphiphilic lipid 
bilayers.  Liposomes may occur as multilamellar vesicles (MLVs) with several concentric 
bilayers, or as small or large unilamellar vesicles (SUV or LUV respectively).  Numerous 
methods of liposome preparation have been described,5 however, most of these procedures 
generate a heterogenous population of vesicles resulting in unavoidable variability in 
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subsequent preparation.  Although liposomes do have the advantage of providing a 
compartmentalized membrane environment, the challenges involved with aggregate 
formation and controlled stoichiometry in sample preparation limit a reproducible study of 
protein behavior.  Thus, inherent complications in polydispersity result in an inconsistent 
model of native behavior preventing a meaningful assessment of the membrane protein’s 
structural dynamics. 
5.1.2 Overview of Nanodisc Technology 
To combat the challenges involving the investigation of membrane proteins, the 
Sligar group at the University of Illinois developed a technology to study membrane proteins 
in a controlled, monomeric, and native-like membrane environment.  Nanodiscs are soluble 
nanoscale particles of lipid bilayer surrounded by an amphipathic protein with a defined, 
homogenous size and composition.  Structurally, Nanodiscs strongly resemble nascent 
discoidal high-density lipoprotein (HDL) particles.6  HDL together with apolipoprotein A1 
(apoA1) participate in reverse cholesterol transport, a process by which accumulated 
cholesterol is transported from tissues all over the body to the liver for excretion.7, 8  HDL 
discoidal lipoprotein complexes have been the subject of study for nearly thirty years.9-13  
The extensive literature of lipoprotein self-assembly provides a rich pool of information for 
understanding the basics of Nanodisc formation where synthetic lipids and amphipathic α-
helical proteins are combined for selective isolation of target membrane proteins. 
Nanodiscs are assembled by adding an amphipathic membrane scaffold protein 
(MSP) to a detergent stabilized phosopholipid in a suitable molar ratio.  Upon removal of 
detergent from a solubilized lipid mixture, the target membrane protein self-assembles with 
the phospholipid into a discoidal bilayer encircled by the MSP scaffold protein.  Using 
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apoA1 as a template, a genetically modified coding sequence was developed for MSP 
production to encourage disc formation in the presence of phospholipids.14, 15  Two-copies of 
the MSP protein wrap around the periphery of the phosopholipid bilayer domain to stabilize 
the Nanodisc structure in a belt-like configuration where the size of the Nanodisc is strictly 
controlled by the length of the MSP protein (Figure 5.1, A).6, 15-17  The resultant structure 
creates a uniformly sized, water soluble nanoscale bilayer which mimics a stabilized native 
environment for a target membrane protein of choice to be incorporated (Figure 5.1, B). 
Nanodisc size can be precisely tuned by changing the sequence of the MSP construct.  
Denisov et al. prepared a library of MSP constructs of varying length to create Nanodiscs of 
different diameters.15  Nanodisc dimensions were measured by fitting small angle X-ray 
scattering (SAXS) data to cylindrical core-shell models where the homogeneity of disc 
formation was evaluated by size-exclusion chromatography (SEC).  MSP1D1 consists of 
22mer helical repeats punctuated by proline and glycine with an approximated diameter of 
9.8 nm.  Modifications to the scaffold protein sequence created variations with one 
(MSP1E1D1), two (MSP1E2D2), and three (MSP1E3D1) 22mer amphipathic extensions to 
give Nanodiscs 10.6, 11.9, and 12.9 nm in diameter respectively (Table 5.1).  MSP constructs 
were designed with an N-terminal hexahistidine tag, a TEV (Tobacco Etch Virus) cysteine 
protease site enabling cleavage of the histidine tag, and the main MSP sequence.   
Several experimental studies conducted by the Sligar group investigated Nanodisc 
formation with the lipids POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine), DPPC 
(1,2-dipalmitoyl-sn-glycero-3-phosphocholine), or DMPC (1,2-dimyristoyl-sn-glycero-3-
phosphocholine).  Phosphatidylcholine (PC) is a major constituent of cell membranes 
providing a structural framework for the membrane while maintaining a permeable barrier.  
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The length of the acyl chain and the degree of lipid saturation will affect the stability of the 
lipid complex and the number of lipid molecules that can be inserted in each Nanodisc 
leaflet.  POPC, a mixed unsaturated acyl phospholipid, has a larger surface area in the bilayer 
than DPPC, limiting the molar ratios of lipids used in reconstitution.  Comparing experiments 
with tritiated lipids, approximately 164 DPPC (82 DOPC molecules per leaflet) or 122 POPC 
molecules are experimentally determined to be incorporated into MSP1D1 Nanodiscs.15, 18  
Despite differences in phospholipid selection, size exclusion chromatography and atomic 
force microscopy confirmed similar Nanodisc dimensions for a particular MSP construct.  
These studies clearly indicate that the length of the protein’s amphipathic helix is the sole 
determinant of Nanodisc diameter.  The membrane scaffold construct, the type of 
phospholipid, and the number of phospholipid molecules per Nanodisc thus are concluded to 
all be interrelated. 
5.1.3 Nanodisc Formation  
Formation of Nanodiscs is an empirical process that requires optimum ratios of the 
constituents in a reconstitution mixture.  For empty Nanodisc characterization, a defined ratio 
of phospholipid to MSP is required during the assembly process.  If the lipid ratio during 
formation is too high, populations of large aggregate particles are formed and shown to elute 
in the void volume of a size exclusion separation.  MSP can also form lipid-poor particles if 
the ratio of lipid to MSP is too low or unfavorable conditions are used for disc formation.  
Molecular dynamic simulations demonstrate the deformation of discs containing too few 
phospholipids due to the energetic requirements of matching the length of the MSP belt to 
the length of the bilayer hydrophobic edge.19-21  Hence, when trying a new lipid or lipid 
mixture, it is imperative to determine the correct stoichiometry experimentally.   
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When including a target membrane protein into the reconstitution mixture, the ratio of 
phospholipid to MSP must be re-evaluated.  Here it is often not known how many lipids the 
target protein will displace when assembled into the bilayer, thus the optimal ratios of lipid to 
MSP are not known a priori.  Other difficulties arise if the membrane protein of interest is 
purified in the presence of phospholipid to maintain protein solubility and activity.  The total 
amount of phospholipid present in the reconstitution mixture must be accounted for to 
maximize Nanodisc incorporation.  One experimental solution is to reconstitute with a large 
excess of empty Nanodiscs to minimize the ill-effects of target protein to the membrane 
surface area.  Single monomeric membrane proteins will assemble into Nanodiscs as long as 
the ratio of MSP to target is high.  If an oligomeric membrane protein is desired then one 
must consider the strength of interaction, as increasing the phospholipid component can 
dissociate oligomers by a surface dilution effect.  For oligomeric assemblies, the ratio of 
MSP to target protein must be finely tuned to optimize Nanodisc formation.  In optimized 
preparations, transmembrane incorporated Nanodiscs will co-elute in a symmetrical peak 
ahead of the empty Nanodiscs in a size exclusion chromatogram. 
The detergent used for initial solubilization is also critical.  Sodium cholate is often 
used as the target detergent for Nanodisc solubilization and is present in a 2:1 mole ratio to 
total phospholipid.22  Depending on the target protein of interest, other detergents can work 
equally as well allowing phospholipid solubilization without disrupting the membrane 
protein dynamic conformation.  The choice and concentration of the secondary detergent 
depends entirely on the membrane protein and has to be worked out for every new target.  In 
general method development it is recommended that the detergent concentration be 
maintained above the critical micelle concentration.  In all cases, the assembly process is 
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initiated by removal of detergents by dialysis or treatment with polystyrene beads.  
Presumably, detergent removal creates a molecular scramble in which hydrophobic surfaces 
suddenly exposed to an aqueous environment are driven to cluster.23  The speed in which 
detergent is removed from the reconstitution mixture is also thought to influence the 
homogeneity of disc formation and must be considered during method validation.  Finally, 
the temperature during assembly is important with Nanodiscs forming most efficiently near 
the phase transition temperature of the phospholipid, where the phase behavior of the 
phospholipids may impact the size and organization of the phospholipid/detergent micelle 
during reconstitution.   
5.1.4 Nanodisc Applications 
The Nanodisc technology first pioneered in the Sligar Laboratory, has been extensively 
studied using model target proteins such a bacteriorhodopsin,24, 25 cytochrome P450,26-30 and 
tissue factor31, 32 to name a few.  Along with membrane protein structural dynamics, 
Nanodiscs provide a means to investigate substrate binding interactions using a variety of 
analytical techniques.  The robust structure of Nanodisc assembly coupled with the ability to 
isolate single-molecule membrane protein complexes in a water soluble environment opens 
the door for better understanding the role of membrane proteins in biochemical systems. 
5.1.4.1 Bacteriorhodopsin 
A particularly powerful aspect of the Nanodisc system is that it can be used to isolate a 
protein in a known monomeric or oligomeric state.  The light driven proton pump 
bacteriorhodopsin (bR) is considered the “gold-standard” of membrane protein research.  The 
seven transmembrane protein bacteriorhodopsin (bR) was incorporated monomerically into 
MSP1 containing Nanodiscs.25  The structural homogeneity and stability of bR-Nanodiscs 
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was evaluated by size exclusion chromatography, atomic force microscopy, and transmission 
electron microscopy to confirm monomeric incorporation of active bR.  Considering 2D 
crystal structures of bacteriorhodopsin, however, native conformation is composed of a 
trimeric protein state.  Trimers of bR show a positive and negative bilobed pattern in the 
circular dichroism spectrum due to exciton splitting arising from the geometry of the three 
chromophores.33  Nanodisc reconstitution was optimized to incorporate three bR molecules 
per Nanodisc by varying the phospholipid ratio and assessing the reconstitution by size 
exclusion.24  The smaller disc sizes were unable to incorporate trimer formation presumably 
due to insufficient amounts of phospholipids.  In larger Nanodiscs, however, trimer 
oligomerization was successful.  Ordered trimers of bR having 21 total transmembrane 
helices thus are shown to be affected by the stoichiometry of lipid to bR ratio during 
formation and the overall limitations of Nanodisc diameter. 
5.1.4.2 Cytochrome P450 
Nanodiscs have also found many applications in the study of microsomal chytochrome 
P450 (CYPs).  Chytochrome P450s are a class of heme-thiolate enzymes that activate 
molecular oxygen used in the oxidation of a variety of substrates.34  Despite the biological 
importance of these enzymes, structural characterization has been complicated by the fact 
that CYPs are integral membrane proteins with an N-terminal helical membrane anchor.  
Nanodiscs have been used to solubilize and functionally stabilize CYPs that are typically 
resistant to characterization due to their tendency to aggregate in the absence of detergents or 
lipids.   
Nanodiscs with incorporated cytochrome P450 proteins were analyzed by AFM in an 
effort to determine the orientation and depth of the membrane domain in the lipid bilayer.  
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Force-distance curves were collected and cantilever deflection was analyzed to estimate a 3.5 
nm height for CYP2B4 above the phospholipid-water boundary.27  The information obtained 
can be interpreted in terms of structural interactions with the membrane and with its 
membrane bound redox partner, cytochrome P450 reductase, providing a potential 
mechanism for catalysis.27, 35 
Nanodiscs have also been used to directly solubilize recombinant CYPs from an insect 
cell expression system without any intermediate purification steps.  CYP6B1 was expressed 
in Spodoptera frugiperda (Sf9) insect cells and ratios of MSP, lipid, and detergent were 
optimized to incorporate all of the Sf9 membrane proteins including the overexpressed 
CYP6B1 into Nanodiscs.28  CYP6B1 containing Nanodiscs were then purified by nickel 
affinity and fractionated by size-exclusion chromatography.  From this study, it was 
demonstrated that Nanodiscs can be used to isolate heterogeneously expressed membrane 
proteins and maintain them in a lipid bilayer throughout the purification process minimizing 
exposure of membrane proteins to detergents and any consequent structural disruption or 
functional interferences.   
Nanodiscs also provide promise for prototype biosensor development.  CYP3A4 is a 
promiscuous enzyme with major drug-metabolizing behavior.36  Nanodiscs provide a 
possible way to solubilize CYP3A4 and maintain monomeric isolation at high concentrations 
needed to investigate cooperativity in ligand binding and consequent allosteric kinetics in 
catalysis.  To study rapid screening of drug candidates against CYP3A4, localized surface 
plasmon resonance (LSPR) is investigated as a label-free technique which arises when light 
interacts with metal nanoparticles.  LSPR is highly dependent on the refractive index of the 
surrounding media and upon analyte binding, resulting in a shift in the extinction maximum 
266 
wavelength of the nanoparticle when a conformational change occurs in the local 
environment near the nanoparticle surface.37  CYP34A in Nanodiscs were covalently coupled 
using carbodiimide chemistry to silver nanoparticle surfaces generated using nanosphere 
lithography.  Drug binding to CYP3A4-Nanodiscs on the nanoparticle surface was detected 
using LSPR wavelength shifts where the type of shift can distinguish between different drug 
targets.29 
5.1.4.3 Tissue Factor 
An interesting use of Nanodiscs to control the microenvironment around a protein was 
realized in investigations of blood clotting where activity is dependent on the phospholipid 
compositions.  The complex of the integral membrane protein tissue factor (TF) together with 
the soluble factor VIIa initiates the blood coagulation cascade.  The activity of this enzyme 
complex is markedly influenced by lipid bilayer composition and further by tissue factor 
partitioning into membrane microdomains on a cell surface.  Membrane surfaces can only 
support the binding and assembly of clotting factors if they contain exposed anionic 
phospholipids, with phosphatidylserine (PS) being the most active.38  Membrane binding, 
however, is involved with more than just localizing enzymes and substrates to regions of 
tissue trauma.  The membrane also plays a critical role in catalysis.  In spite of the critical 
importance of membrane binding, classical membrane models prevent a complete 
understanding of how the membrane surface enhances blood clotting reactions.   
Nanodiscs have been used to study the effect of changing the local PS content on the 
assembly and function of the tissue factor (TF)-factor VIIa complex.32  It was concluded that 
the binding affinity of factor VIIa for TF increased as a function of local PS content.  In 
addition, the catalytic efficiency of this complex was seen to show maximum activity when 
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PS concentration was 70% or higher, compared to TF-liposomes containing 30% PS.  
Extended Nanodiscs studies have also investigated the phospholipid dependence of other 
protease-cofactor pairs in blood coagulation.31 
5.1.4.4 Future of Nanodiscs 
Microfluidic devices have been investigated for high-throughput screening techniques 
involving lipid bilayers and membrane associated proteins.  Specifically, a microfluidic 
device is employed to deliver Nanodiscs to a desired surface where analyte-Nanodisc 
interactions can be investigated in a multiplexed manner.  Two systems of lipid 
immobilization were evaluated.39  The first system employed Nanodiscs containing 
biotinylated lipids.  The delivery of biotinylated lipids was detected using streptavidin 
labeled quantum dots.  The second system involves Nanodiscs containing various amounts of 
phosphoserine (PS) lipids.  These Nanodiscs are screened with annexin, a family of proteins 
that play a significant role in various cellular functions involving apoptosis, an important 
biological process that malfunctions in many diseases such as cancer.  Binding of annexin V 
to negatively charged PS lipids was observed using fluorescence detection and validated 
using surface plasmon resonance (SPR).  Using microfluidics, a simple approach has been 
demonstrated for transporting, patterning, and assaying lipids in a multiplexed array for high-
throughput screening.   
These examples demonstrate that phospholipid bilayer Nanodiscs are a powerful and 
versatile model membrane system that can simplify investigations of the structure and 
function of a wide variety of biologically relevant membrane proteins.  Nanodiscs have been 
investigated using numerous analytical techniques including size exclusion chromatography, 
atomic force microscopy, small angle X-ray scattering, microfluidics, surface plasmon 
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resonance, and circular dichroism to investigate native state membrane environments.  
Nanodiscs thus provide a novel means for localized membrane protein investigations, 
opening the door for structural and functional studies that were previously limited to the class 
of soluble proteins and enzymes.   
 
5.2 Chapter Scope 
The study of membrane proteins has been hampered by the lack of a suitable well-
defined, soluble model membrane.  In the absence of a model membrane, even relatively 
soluble membrane proteins will tend to oligomerize and aggregate thereby impeding 
experimental investigation.  On the other hand, if liposomes or micelles are used to stabilize 
proteins, the situation is complicated by the system’s inherent polydispersity, inconsistency, 
and instability.  Nanodiscs, however, provide a general solution for membrane proteins 
enabling a reproducible phospholipid environment in which to study the structural and 
functional recognition of membrane proteins in a native-like environment.   
The focus of this chapter is to systematically evaluate and optimize incorporation of 
Gamma-Glutamyl Carboxylase (GGCX) and Vitamin K Epoxide Reductase (VKOR) into 
Nanodiscs for structural and functional investigations.  To date, a crystal structure topology 
of GGCX or VKOR has not yet been obtained and knowledge regarding substrate 
interactions, complex formations, and structural properties of these two membrane proteins 
has been severely limited based upon finding a suitable system for protein investigation that 
maintains protein activity.  To further complicate analysis, purification of both vitamin K-
dependent proteins incorporate precisely controlled ratios of lipid and detergent limiting the 
ability to study these proteins by common analytical techniques such as liquid 
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chromatography and mass spectrometry.  Incorporation of GGCX and VKOR into Nanodisc 
structures provides a novel means for investigating protein interactions in the vitamin K 
cycle. 
 
5.3 Experimental 
5.3.1 Materials 
Reagents used for Gamma-Glutamyl Carboxylase and Vitamin K Epoxide Reductase 
purification and evaluation are as follows: 1,2-diheptanoyl-sn-glycero-3-phosphocholine 
[DHPC] (Avanti Polar Lipids, Alabaster, AL), 1,2-dioleoyl-sn-glycero-3-phosphocholine 
[DOPC] (Avanti Polar Lipids), 2-(N-morpholino)ethanesulfonic acid [MES] (Sigma-Aldrich, 
St. Louis, MO), 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate hydrate 
[CHAPS] (Sigma-Aldrich), 3-(N-morpholino)-propanesulfonic acid [MOPS] (Sigma-
Aldrich), HPLC grade acetonitrile (Fisher Scientific, Fair Lawn, NJ), adenosine 5’-
triphosphate disodium salt solution [ATP] (Sigma Aldrich), bovine serum albumin (BSA) 
fraction V, heat shock (Roche Applied Science, Indianapolis, IN), calcium chloride dihydrate 
[CaCl2.2H2O] (Fisher Scientific), ultrapure dithiothreitol [DTT] (Roche Applied Science), 
ethylenediamine-tetraacetic acid [EDTA] (Mallinckrodt Chemicals, Raleigh, NC), glycerol 
(Fisher Scientific), HPLC grade isopropanol (Fisher Scientific), magnesium chloride [MgCl2] 
(Sigma Aldrich), silver nitrate [AgNO3] (Sigma Aldrich), 14C labeled sodium bicarbonate 
[NaH14CO3] specific activity, 55 mCi/mmol (MP Biomedicals, Solon, OH), sodium chloride 
[NaCl] (Fisher Scientific), sodium deoxycholate (Sigma-Aldrich), 
tris(hydroxymethyl)aminomethane hydrochloride [Tris-HCl] (Sigma Aldrich), N-
tris(hydroxymethyl)methyl-3-aminopropanesulfonic acid [TAPS] (Sigma-Aldrich), 
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tris(hydroxypropyl)phosphine [THP] (Calbiochem, San Diego, CA), Vitamin K3 menadione 
sodium bisulfite (Sigma Aldrich), Vitamin K1(20) (Abbott, Chicago, IL), Vitamin K1(25) from 
Hospira Incorporated (Lake Forest, IL) stabilized with phytonadione injectable emulsion, and 
Vitamin K epoxide [KO] provided by Paul Dowd (University of Pittsburg, Pittsburg, PA).  
Protease inhibitors including aprotinin, leupeptin, pepstatin, and phenylmethyl sulfonyl 
fluoride were purchased from Roche Applied Science.  Anti-HPC4 monoclonal antibody 
coupled Sepharose resin was obtained from Dr. Charles T. Esmon (Cardiovascular Biology 
Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK).40  The 
pentapeptide Gla domain FLEEL (Phe-Leu-Glu-Glu-Leu) was purchases from Bachem 
(Philadelphia, PA) and the propeptide modified peptides factor IX propeptide [pFIX] 
(TVFLDHENANKILNRPKR), consensus propeptide [pCon] 
(AVFLSREQANQVLQRRRR), and fluorescein-labeled consensus propeptide [FpCon] (Fl-
AVFLSREQANQVLQRRRR) were synthesized and purified by Chiron Mimotopes 
(Calyton, Victoria, Australia).  Additional reagents used in membrane scaffold protein 
purification and Nanodisc formation include: imidizole, sodium azide, and triton X-100 
purchased from Sigma-Adrich.  FIXQ/S, a 59 residue recombinant peptide whose sequence is 
derived from the propeptide and the first 41 residues of the Gla domain of human factor IX 
was prepared and purfied as described.41 
5.3.2 Purification of Recominant Wild-Type Gamma-Glutamyl Carboxylase  
Wild-type human Gamma-Glutamyl Carboxylase (GGCX) with a carboxyl terminus 
12-amino acid epitope tag (EDQVDPRLIDGK) was isolated from Sf9 cells as previously 
described.42  Solubilized GGCX microsomes were purified using a calcium dependent HPC4 
antibody resin and eluted in 25 mM MOPS pH 7.5, 0.1 M NaCl, 15% glycerol, 0.5% 
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CHAPS, 0.2% DOPC, and 10 mM EDTA, stabilized by a protease inhibitor cocktail.  
Purified protein was stored at -80oC.  Protein concentration and purity was determined by 
enzymatic activity assay measurements and SDS-PAGE.  A detailed protocol describing 
Gamma-Glutamyl Carboxylase protein purification is described in Appendix A1. 
5.3.3 Purification of Recombinant Wild-Type Vitamin K Epoxide Reductase 
Wild-type human Vitamin K Epoxide Reductase (VKOR) with a carboxyl terminus 
12-amino acid epitope tag (EDQVDPRLIDGK) was isolated from Sf9 cells as previously 
described.43  VKOR microsomes were prepared and solubilized in standard buffer (25 mM 
TAPS pH 8.6, 0.15 M NaCl, 30% glycerol) supplemented with 8 mM DHPC and 4 mM THP 
and stabilized by a protease inhibitor cocktail.  Solublized VKOR microsomes were purified 
using a calcium dependent HPC4 antibody resin.  Prior to elution, the resin was washed with 
ten column volumes of standard buffer containing 10 mM ATP, 2 mM CaCl2, 15 mM DHPC, 
10 mM MgCl2, and 4 mM THP followed by washing with ten columns of reconstitution 
buffer containing 2 mM CaCl2, 0.4% Deoxycholate, 0.4% DOPC, and 4 mM THP.  Purified 
protein was eluted in 25 mM TAPS pH 8.6, 0.15 M NaCl, 30% glycerol, 0.4% Deoxycholate, 
0.4% DOPC, 10 mM EDTA, and 4 mM THP stabilized by a protease inhibitor cocktail and 
stored at 4oC.  To recover VKOR activity, detergent must be removed by dialysis against 
standard buffer at 4oC for 72 hours with one buffer change every 24 hours followed by the 
addition of 4 mM THP for overnight incubation.  A modified VKOR purification included 
removal of DOPC from the reconstitution and elution buffer.  Protein concentration and 
purity was determined by enzymatic activity assay measurements and SDS-PAGE.  A 
detailed protocol describing Vitamin K Epoxide Reductase protein purification is described 
in Appendix A2. 
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5.3.4 Membrane Scaffold Protein (MSP1D1) Expression and Purification 
MSP1D1 expression and purification was carried out as previously described.15  In 
short, the MSP1D1 plasmid with a polyhistidine tag (Addgene plasmid 20061) was expressed 
in E.coli BL21 Codon Plus (DE3) cells.  For purification, the protein was isolated by Ni-
NTA Agarose (QIAGEN, Valencia, CA) affinity purification and purity was confirmed by 
polyacrylamide gel electrophoresis.  Fractions containing MSP1D1 were pooled and dialyzed 
against standard buffer (20 mM Tris/HCl pH 7.4, 0.1 M NaCl, 0.5 mM EDTA, and 0.01% 
NaN3).  Purified protein was lyophilized and stored at -20oC.  Reconstitution was facilitated 
by dissolving the lyophilized protein in sterile water for end-over-end rotation at 4oC 
overnight.  Protein concentration was determined by absorbance at 280 nm using calculated 
extinction coefficients (280nm = 21,000 M-1cm-1 for MSP1D1).  A detailed protocol 
describing MSP1D1 protein expression and purification is described in Appendix A3. 
5.3.5 Nanodisc Formation and Purification 
A DOPC/Deoxycholate solubilized mixture (2:1) was added to purified target protein 
(GGCX or VKOR) in experimentally determined ratios to optimize self-assembly.  The 
sample mixture was allowed to equilibrate for one hour at 4oC.  Purified MSP1D1 stock in 
standard buffer was then added to the reconstitution mixture and incubated for an additional 
hour at 4oC.  Void volume was supplemented with 50 mM Tris-HCl pH 7.4, 0.15 M NaCl, 
and 0.02% NaN3 (TBS) buffer.  After incubation, detergent was removed during a 2 hour 
gentle rotation with damp SM-2 BioBeadsTM (BioRad, Hercules, CA) or a 24-hour dialysis 
(10kDa MWCO Snakeskin dialysis tubing, Pierce, Rockford, IL) with three buffer changes at 
4oC.  When reported, glycerol removal was facilitated using gel filtration Macro spin 
columns with G25 packing material (Harvard Apparatus, Holliston, MA) 
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The disk preparations were purified by size exclusion chromatography by monitoring 
the absorbance at 280 nm on a Tosoh TSKgel BioAssist G3SWXL 7.8  300 mm (5 m, 250 
Å) column with 50 mM Tris-HCl pH 7.0, 0.15 M NaCl, 0.02% NaN3 (TBS) mobile phase at 
0.5 mL/minute.  Fractions containing purified Nanodiscs were isolated and concentrated by 
Millipore (Bedford, MA) Microcon YM-30 centrifugal filters.  The protocol for self-
assembly was consistent in preparation of empty Nanodiscs. 
5.3.5.1 Phosphate Analysis 
1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC) obtained from Avanti Polar 
Lipids (Alabaster, Al) was prepared in chloroform and the concentration determined by 
phosphate analysis.  The Fiske and Subbarow method44 as described by Chen et al.45 was 
utilized for concentration determination of phosopholipid stock solutions.  In this assay, 
phosphorous is released by evenly heating samples (300 L total volume) in 250 L 8.9 M 
H2SO4 (Mallinckrodt) to temperatures greater than 200oC for 25 minutes.  Once cooled, 75 
L of 30% H2O2 (Fisher Scientific) is added to each sample to oxidize phosphorous to 
inorganic orthophosphate (PO43-).  Samples are incubated at 200-215oC for 25 minutes and 
aliquots of H2O2 are sequentially added until all samples are colorless.  Addition of 1.95 mL 
MilliQ water and 250 L 2.5% w/v ammonium molybdate (Sigma-Aldrich) results in the 
formation of a heteropolyphosphomolybdate complex which upon reduction with ascorbic 
acid (Sigma-Aldrich) (250 L) has a distinct blue color that can be quantified 
spectrophotometrically at 820 nm.  Using a 0.65 mM phosphorous stock (Sigma Aldrich), a 
standard curve can be generated to determine lipid concentration of phospholipied solutions 
prepared in chloroform.  Phospholipid stock solutions can be stored at -20oC in Teflon 
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capped glass vials.  To enhance phospholipid stability, stock solutions were stored under 
nitrogen. 
5.3.5.2 SDS-PAGE 
For SDS-PAGE analysis of purified Nanodiscs, 4-12% gradient gels or 10% NU-PAGE 
Bis-Tris Gels were purchased from Invitrogen (Carlsbad, CA) along with the Mark 12 
unstained protein ladder, and SYPRO® Ruby protein gel stain.  SDS-PAGE buffers were 
prepared according to protocol derived from Invitrogen including a 4X SDS-PAGE loading 
buffer and a 20X MES running buffer. 
SYPRO® Ruby protein stain requires that the gel first be fixed in a solution of 50% 
methanol and 7% acetic acid for 30 minutes prior to overnight staining with a non-covalent 
fluorescent protein stain.  After staining, the gel was washed for 30 minutes with a solution 
containing 10% methanol and 7% acetic acid and imaged using a 300 nm blue light UV 
transilluminator (Alpha Innotech AlphaImagerTM 2200) with interference wavelength 
filtering. 
5.3.6 In Vitro Carboxylation Assay 
To determine the active concentration of GGCX, an in vitro radioactivity assay was 
performed.  Here, the carboxylation of a synthetic vitamin K-dependent substrate FLEEL in 
the presence of excess propeptide (pFIX) was measured after incorporation of cofactors 
vitamin K hydroquinone (KH2), O2, and radiolabeled CO2 in the form of NaH14CO3.  
Vitamin K1(25) phylloquinone or vitamin K3 menadione was reduced to vitamin K 
hydroquinone by overnight incubation with buffer containing 25 mM Tris-HCl pH 8.5, 0.5 M 
NaCl, and 0.2 M DTT at 37oC.  For both forms of vitamin K hydroquinone, stability is very 
light and air sensitive.  While KH2 phylloquinone can be prepared and stored in the dark at  
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-80oC, KH2 menadione was shown to be much more sensitive to air oxidation.  As a result, a 
fresh sample of KH2 menadione must be newly prepared before each experiment and stored 
for limited time periods at room temperature under nitrogen. 
A reagent mixture was prepared containing 25 mM MOPS pH 7.5, 0.50 M NaCl, 
CHAPS, DOPC, 30 mM FLEEL, and 2.4 M pFIX and allowed to incubate with purified 
GGCX or GGCX Nanodiscs for 30 minutes on ice.  The concentration of CHAPS and DOPC 
in the assay reaction mixture was modified to optimize conditions for sample carboxylation.  
Conditions reported include: 0.16% CHAPS-0.16% DOPC, 0.32% CHAPS-0.08% DOPC, or 
0% CHAPS-0% DOPC.  An excess of 222 M (5.5 mM stock) KH2 phylloquinone or 111 
M (2.75 mM stock) KH2 menadione with 5 L of an 18.4 mM NaH14CO3 stock solution 
was added to the reaction mixture for a final volume of 125 L.  The carboxylation assay 
was allowed to proceed for 120 minutes at 20oC.  The reaction can be allowed to incubate for 
a longer period of time if desired to achieve a higher concentration of carboxylated product.  
Since the stability of KH2 menadione is very sensitive to air oxidation, carboxylation counts 
were optimized by the addition of two-2 L aliquots of KH2 menadione throughout the 
carboxylation reaction.  The first aliquot was added with NaH14CO3 to initiate carboxylation 
and the second aliquot was to replish the reaction after one hour incubation at 20oC.  For each 
addition, a new sample of KH2 menadione was utilized.  To precipitate the carboxylated 
product, 100 L of the reaction mixture was quenched with 800 L of 5% trichloracetic acid.  
The samples were boiled to remove excess 14CO2 and radioactivity was determined by 
scintillation counting (Beckman LS5000TD).   
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5.3.7 Fluorescence Anisotropy of GGCX Nanodiscs 
A T-format SLM-Aminco 8100 spectrofluorometer equipped with Glan-Thompson 
polarizers and Olis Global Works Software system was used for fluorescence anisotropy 
experiments.  Measurements were made in a quartz cuvette (Starna Cells, Atascadero, CA) at 
4oC with a final volume of 300 L.  The temperature was controlled with a Quantum 
Temperature Controller (Vancouver, Canada).  A nitrogen purge in the sample holder was 
used for sample temperatures lower than 10oC to prevent condensation from forming on the 
cuvette.  The excitation and emission wavelengths were 490nm and 520 nm respectively with 
the band-pass slits set at 8 nm.  Assay conditions were set for 300 increments with an 
integration time of 2.0 seconds.  Experiments were performed in buffer containing the 
following reagents: 50 mM MOPS pH 7.5, 500 mM NaCl, 5% glycerol, 2 mM DTT, 0.2% 
BSA, and 14nM FpCon.  Unlike experiments for purified GGCX, no CHAPS detergent or 
DOPC phospholipids were present in the sample buffer.  Five anisotropy values were 
recorded for each sample after the 200 second time point allowing for equilibration due to 
sample temperature fluctuations.  For all experiments, enzyme and substrate were allowed to 
incubate for 45 minutes at 4oC prior to analysis.  Fluorescence anisotropy values were 
recorded as the GGCX purified Nanodisc concentration was titrated with increasing sample 
additions.  Anisotropy values were used to calculate a fraction bound value using 
experimental constants ro (anisotropy of the free ligand), rmax (anisotropy of ligand when 
bound to saturating amounts of GGCX), and R (fluorescence intensity of the free fluorophore 
saturated by GGCX divided by the intensity of the free fluorophore alone).  Fluorescence 
anisotropy experiments were modeled after Presnell et al.46 in which the stoichiometric ratio 
of purified GGCX to propeptide binding was determined. 
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5.3.8 In vitro VKOR Activity Assay 
VKOR enzyme activity was assayed using a modified HPLC method as described 
previously.43  Twenty microliters of purified protein or VKOR Nanodiscs were added to 180 
L of buffer containing 25 mM Tris-HCl, 0.15 M NaCl, and 30% glycerol.  Eight microliters 
of 1 mM vitamin K epoxide in isopropanol was added as substrate followed by 5 L of 
30mg/mL freshly prepared DTT was added to initiate the reaction during a 30 minute 
incubation in the dark at 30oC..  The reaction was quenched by adding 500 L 0.5 M AgNO3: 
isopropanol (5:9) followed by the addition of 500 L of 1.5 M K1(25) in hexane as an 
internal standard.  The mixture was vortexed for one minute followed by brief centrifugation 
to separate the aqueous and organic phases and precipitate a pellet.  Four hundred microliters 
of the upper organic phase was dried with a gentle stream of nitrogen.  To the dried samples, 
400 L of the HPLC mobile phase (91.8% acetonitrile, 6.4% isopropanol, 1.8% water) was 
added to dissolve the dried sample.  The sample was analyzed by HPLC on a Vydax 5 M 
C18 column (4.6 mm x 250 mm, Catalog Number 218TP54) at a flow rate of 2 mL/minute 
under isocratic conditions.  The production of vitamin K1(20) was detected by UV absorbance 
at 248 nm.  Nanomoles of vitamin K1(20) produced is calculated from experimental peak area 
fitting to a standard regression calibration for increasing concentrations of vitamin K1(20).  To 
correct for variations in experimental response factors, a normalization constant is applied 
using the K1(25) internal standard. 
5.3.9 Atomic Force Microscopy 
All force measurements were made in AFM imaging buffer using a Molecular Force 
Probe 3D instrument from Asylum Research (Santa Barbara, CA) controlled with Igor Pro 
5.03B (Wavemetrics, Lake Oswego, OR).  The laser was aligned on the D cantilever (60 
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pN/nm nominal spring constant) of a DNP-S AFM probe (Veeco Probes, Camarillo, CA) 
where the spring constant was determined experimentally after thermal calibration.  Force 
curves were collected over 5 x 5 m2 square areas.   
In substrate surface preparation, both a glass microscope slide (Electron Microscopy 
Sciences, Washington, PA) and a DNP-S AFM cantilever were modified.  Tips were cleaned 
and coated with 3 nm of chromium and 45 nm of gold as described previously.47  For 
covalent attachment of the HPC4 antibody, a carboxylic acid terminated self-assembled 
monolayer (SAM) was formed by immersing the gold-coated tips in 11-mercapto-undecanoic 
acid solution (2 mM in absolute ethanol) overnight.  All substrates were rinsed with ethanol 
and water and dried with nitrogen prior to use.  The carboxylic acid terminated tips were 
active for covalent attachment using a standard amine coupling procedure.  Briefly, the 
surfaces were exposed to equal volumes of 0.1 M N-hydroxysuccinimide (NHS) and 0.4 M 
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) (Pierce, Rockford, IL) in water for 
30 min and then rinsed.  Next the HPC4 antibody was coupled to the activated surface by 
incubating the surface with protein solution for 20 minutes.  To remove excess reagent, the 
covalently modified tip was washed with imaging buffer containing 50 mM Tris-HCl pH 7.4, 
0.15M NaCl, and 10 mM CaCl2.   
Glass slides were used to immobilize freshly cleaved mica on which GGCX purified 
Nanodiscs can be adsorbed.  Sample substrates were prepared by incubating 10 L GGCX 
Nanodiscs and 10 L imaging buffer (50 mM Tris-HCl pH 7.4, 0.15M NaCl, and 10 mM 
CaCl2) in the presence of 23 M consensus propeptide for 30 minutes on ice.  The consensus 
propeptide was added to stabilize the Nanodisc in fluid without having to control temperature 
fluctuations in the AFM chamber.  After incubation, the sample was washed with imaging 
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buffer to remove any unadsorbed material.  Contact mode force curves were collected in 
fluid to monitor GGCX unfolding upon recognition of the C-terminal HPC4 epitope tag with 
an antibody modified cantilever tip.  Assistance for AFM experimentation was provided by 
Dr. Laurel Averett.48 
 
5.4 Results and Discussion 
Nanodiscs are novel model membranes that provide a well-defined phospholipid bilayer 
for the study of incorporated membrane proteins.  Inherent limitations in micelle and 
liposomal incorporation of proteins involved in the vitamin K cycle have prevented an in 
vitro approach for studying Gamma-Glutamyl Carboxylase (GGCX) and Vitamin K Epoxide 
Reductase (VKOR) in a similar membrane environment.  Despite significant biological 
advancements in the isolation and solubilization of such vitamin K-dependent proteins for 
biochemical investigation, the lack of a robust native-like phospholipid environment restricts 
the ability to model membrane based enzymatic pathways.   
The underlying goal for Nanodisc assembly in this work is to provide a platform in 
which to investigate the role of GGCX and VKOR in the vitamin K cycle.  Using Nanodiscs 
as a microenvironment for protein complexation, we can begin to target the possibilities for 
observing substrate-protein interactions in an isolated membrane environment.  The use of 
analytical techniques such as atomic force microscopy can also be applied to our model 
system for future investigation of structural features unique to dynamic protein folding.  
Continuing with the structural analysis of membrane proteins, Chapter 6 will conclude with 
Nanodisc applications for hydrogen deuterium exchange mass spectrometry, a novel 
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approach for understanding the protein dynamics and structural configurations of a 
membrane protein in a near-native state. 
5.4.1 Optimized Empty Nanodisc Assembly 
When embarking on the incorporation of a new target into Nanodiscs, one must 
consider both the requirements for Nanodisc formation as well as any unique characteristics 
of the target protein of interest.  In this study, Nanodisc characterization was completed with 
the smallest MSP construct, MSP1D1, providing a 9.8 nm disc diameter for target protein 
assembly.  Initial phospholipid and detergent combinations were based upon purification 
protocols for both target membrane proteins GGCX and VKOR.  Deoxcycholate was used to 
solubilized the unsaturated phospholipid DOPC (1, 2-dioleoyl-sn-glycero-3-phosphocholine) 
in a 2:1 molar ratio.  For optimal solubilization, deoxycholate concentrations were 
maintained above the critical micelle concentration (CMC).  In the presence of precisely 
defined MSP to solubilized DOPC ratios, homogenous Nanodisc self assembly occurs as 
detergent is removed from the reconstitution mixture (Figure 5.2 A).  Nanodisc formation 
can be observed by monitoring peak symmetry using size-exclusion chromatography. 
In selecting a phospholipid for Nanodisc assembly there are several issues to 
consider.  The incubation temperature for Nanodisc formation is based upon the phase 
transition temperature for the phospholipid.  Here the phase transition is defined as the 
temperature required to induce a change in the lipid physical state from the ordered gel phase 
to the disordered liquid crystalline phase.  For Nanodisc formation, it is recommended to 
maintain operation above the lipid transition temperature.  Selection of DOPC as the targeted 
lipid construct, with a reported transition temperature of -20oC, allows for Nanodisc 
assembly at 4oC.  Operating at incubation temperatures of 4oC is not only ideal for 
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phospholipid handling but also allows a desired environment in which our purified target 
protein maintains catalytic activity.   
The stability of lipid species is another point of concern.  Generally, the more 
unsaturated a compound, the easier the product is oxidized and thus the shorter the shelf life 
of the phospholipid.  While saturated lipids offer the greatest stability in terms of oxidation, 
they also have much higher transition temperatures requiring more energy to disrupt the 
ordered packing structure.  Compromising transition temperature with stability, an ideal 
alternative is DOPC, characterized by eighteen carbon acyl chains with a cis double bond at 
position nine.  Considering the biological functionality of the targeted membrane 
environment, the surface charge of the phospholipid may also be critical.  In many cases, a 
single lipid species does not yield the exact physical properties needed for a particular 
system.  For these situations, a complex lipid mixture composed of two or more individual 
lipid species may be considered.  Although there are a multitude of phospholipid and 
detergent combinations to choose from, modeling initial Nanodisc formation from 
experimental purification parameters provide a starting point for Nanodisc assembly. 
To identify the optimum lipid-to-MSP ratio for the self-assembly of DOPC 
containing Nanodiscs, a stoichiometric titration was conducted and visualized by size 
exclusion chromatography (Figure 5.3).  As the phospholipid concentration is increased, the 
particle size coalesces into a symmetrical peak shape between 65 and 70 DOPC molecules 
per MSP1D1.  Narrowing in on the phospholipid distribution ratio, the optimal phospholipid 
concentration for empty Nanodisc formation was experimentally determined as 67:1 DOPC 
to MSP1D1.  Reinjection of isolated Nanodiscs and evaluation by size exclusion 
chromatography (SEC) confirms that empty Nanodisc formation is homogenous under these 
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conditions (data not shown).  In comparison, elution profiles of Nanodisc assemblies at 
higher or lower than optimal phospholipid concentrations show evidence of aggregate 
formation or mis-configuration in Nanodisc assembly respectively.  Revisiting Table 5.1, the 
optimum ratio of DOPC to MSP1D1 scaffold protein varies in comparison to other 
combinations of phospholipids.  Although the number of phospholipid molecules per 
Nanodisc will vary based on the type of phospholipid in study, the size of the Nanodisc 
structure is precisely tuned by the length of the membrane scaffold protein.  Figure 5.4 
compares the elution time for the free membrane scaffold protein (MSP1D1) in red to an 
optimized DOPC empty Nanodisc in blue.  The size of both of these structures may be 
estimated using calibrated molecular weight protein standards where the MSP1D1 protein 
migrates as a dimer complex and the empty Nanodisc is estimated at a molecular weight of 
150 kDa.  The narrow size distribution and direct correlation with predicted hydrodynamic 
diameter confirms successful formation of DOPC containing MSP1D1 Nanodiscs solubilized 
with deoxycholate detergent. 
5.4.2 Incorporation of Purified GGCX in Nanodiscs 
The need for optimized DOPC to MSP1D1 ratios for Nanodisc formation becomes 
even more important when the goal is to incorporate a target transmembrane protein.  In this 
study we aimed to incorporate the transmembrane protein Gamma-Glutamyl Carboxylase 
(GGCX).  GGCX is a 758 amino acid protein with five predicted transmembrane domains.  
To allow for protein solubilization while maintaining catalytic functionality a precise ratio of 
phospholipid and detergent are utilized during purification such that 2.54 mM DOPC (0.2%) 
phospholipid and 8.13 mM CHAPS (0.5%) detergent are incorporated into the elution buffer.  
The presence of phospholipid and detergent in purified GGCX adds another dimension in 
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which Nanodisc formation must be balanced.  Using phospholipid concentrations determined 
by phosphate analysis of purified GGCX, in combination with previously screened ratios of 
MSP and DOPC for empty Nanodisc formation, GGCX Nanodiscs can be systematically 
evaluated.  The GGCX target protein is incubated with supplemented additions of DOPC 
phospholipid in a 1:2 ratio with deoxycholate.  The solubilized mixture is incubated at 4oC 
for one hour to allow equilibration before the addition of the membrane scaffold protein.  To 
negate influences of the target GGCX on disc formation, a twenty-fold excess of the 
MSP1D1 protein is added to the reconstitution mixture to ensure monomeric target protein 
incorporation.  After a second incubation period at 4oC, spontaneous Nanodisc assembly is 
initiated by the rapid removal of detergent using polystyrene adsorbent BioBeadsTM.  A flow 
diagram summarizing target membrane protein formation is shown in Figure 5.2(B).    
Self-assembly of GGCX Nanodiscs can be evaluated by size exclusion 
chromatography (Figure 5.5) where GGCX Nanodiscs (Peak II), can be isolated from an 
unassociated aggregate shown at the void volume of the column (Peak I) and empty 
Nanodiscs (Peak III).  An overlaid injection of empty Nanodiscs is superimposed over Peak 
III confirming production of excess empty Nanodiscs during self-assembly.  Correlating 
purified standards for GGCX and MSP1D1 in SDS-PAGE lanes (A) and (B) respectively to 
concentrated SEC fractions, confirms Peak II corresponds to a complex between MSP1D1 
and GGCX.  The aggregate peak eluting at the void volume of the column is shown to be 
comprised of unassociated GGCX, lipid, and scaffold protein.  Comparing the intensity of the 
protein bands isolated by SEC to a series of protein concentration standards, a stoichiometric 
ratio of 2:1 MSP1D1 to GGCX confirms monomeric incorporation of GGCX into assembled 
Nanodiscs.  In determination of stoichiometric ratios, it is important to consider that both 
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active and inactive purification forms of GGCX will be incorporated into a Nanodisc 
structure.  When purified, GGCX is characterized with only a 50% active form capable of 
binding propeptide substrate.46  The exact reason for such deactivation is not yet known, but 
Nanodisc self-assembly can likely not distinguish between the two forms.  From this figure, 
it is concluded that we have achieved reproducible association of our target transmembrane 
protein GGCX into a controlled Nanodisc environment with appropriate concentration ratios 
of DOPC.   
The formation of GGCX Nanodiscs not only depends on a finely tuned ratio of 
phospholipid to scaffold protein, but is also highly dependent on the target membrane protein 
of interest.  The presence of phospholipid and detergent in the purified protein in 
combination with the number of transmembrane domains directly affect the ability of 
Nanodiscs to spontaneously form an energetically stable species.  A common challenge 
preventing Nanodisc formation is the inability to adequately solublize protein aggregates.  
When purified, GGCX is very sensitive to temperature fluctuations and is seen to experience 
total loss of catalytic activity if exposed to room temperature for any period of time.  The 
catalytic activity of GGCX or the ability to carboxylate selected glutamic acid residues in the 
Gla domain of vitamin K-dependent proteins can be monitored after protein incubation at 
25oC for up to 24 hours (Figure 5.6).  Whereas purified protein loses catalytic functionality 
almost immediately upon exposure to room temperature conditions, GGCX Nanodiscs are 
maintained in a protected environment preventing loss of activity for several hours at 25oC.  
Contrastingly, if the high affinity consensus propeptide substrate is incorporated into either 
purified or Nanodisc containing GGCX, carboxylation efficiency is maintained with almost 
no loss of activity after a 24 hour incubation at 25oC.  Observing the SDS-PAGE analysis of 
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protein samples at the 24 hour time point both with and without the incorporation of 
consensus propeptide shows the plausibility for loss of activity due to protein aggregation.  
Even under denaturing conditions, purified GGCX illustrates formation of several high 
molecular weight complexes after extended exposure to elevated temperatures.  Such 
aggregation is not evident, however, in the GGCX Nanodisc incorporated sample or the 
consensus propeptide incubated samples. Purified GGCX that results in protein aggregation 
upon incubation at room temperature further prevents successful GGCX Nanodisc formation 
(Figure 5.7) demonstrating the need for monomeric solubilization in disc assembly. 
5.4.2.1 Optimization of GGCX Reconstitution Mixture 
The current protocol for GGCX Nanodisc reconstitution provides a balance between 
phospholipid and detergent already present in the purified sample with a supplemented 
phospholipid environment, encouraging discoidal membrane formation controlled by the 
amphipathic scaffold protein MSP1D1.  To optimize formation of GGCX containing 
Nanodiscs, several parameters were evaluated including: concentration ratios of the 
membrane scaffold protein to target protein, phospholipid incorporation, the addition of 
detergent for protein solubilization, glycerol removal, and modes for detergent removal.  
These parameters are compared by elution profiles in size exclusion chromatography as well 
as activity measurements for isolated Nanodisc fractions to verify maximum GGCX 
incorporation into DOPC containing Nanodiscs.   
MSP1D1 concentration was initially evaluated (Figure 5.8), where both a ten and 
twenty fold excess of scaffold protein compared to the active target membrane protein was 
incorporated into the reconstitution mixture.  In optimal conditions, target protein disc 
formation is facilitated where two copies of the scaffold protein wrap around the periphery of 
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the phospholipid bilayer and monomeric incorporation of the target protein is encouraged.  
Fine tuning the concentration of scaffold protein, however, can be difficult when a precise 
phospholipid/detergent combination is not employed or protein aggregation prevents efficient 
membrane protein solubilization.  As a result, an excess of scaffold protein and phospholipid 
encourages Nanodisc formation with a single GGCX molecule.  The remaining MSP is then 
incorporated into an excess of empty Nanodiscs or an unassociated protein aggregate that can 
be separated by size exclusion or affinity chromatography.  In comparing elution profiles for 
varying ratios of the membrane scaffold protein in a GGCX reconstitution mixture, it is 
concluded that a twenty fold excess of MSP1D1 to target protein produces a greater 
abundance of GGCX incorporated Nanodiscs confirmed by both absorbance at 280 nm and 
catalytic activity (data not shown).   
In addition to membrane scaffold protein concentrations, DOPC and deoxycholate 
incorporation was also investigated.  For optimal empty Nanodisc formation, 67 molecules of 
DOPC per MSP1D1 resulted in a homogeneous disc population observed by size exclusion 
chromatography.  Using the ratio of 67:1 as a targeted starting point, an abbreviated titration 
of incorporated phospholipid was investigated (Figure 5.9, A).  Evaluating peak profiling in 
SEC in combination with carboxylation efficiency of GGCX, optimal GGCX Nanodisc 
formation was achieved at a concentration ratio of 60 DOPC molecules per MSP1D1.  Here 
the total phospholipid concentration was determined by subtracting out the phospholipid 
present in the elution buffer of the purified protein.  The presence of 2.54 mM DOPC was 
confirmed by phosphate analysis and can be used to contribute to the phospholipid bilayer 
constructed during Nanodisc formation.  Considering the topology predictions for GGCX 
that characterize our target membrane protein with five transmembrane domains49, the 
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overall concentration of DOPC phospholipid in the assembled Nanodisc structure is slightly 
less than that experimentally determined for the empty Nanodiscs.  Future modifications to 
evaluate mixed phospholipid systems may be another alternative to maximizing GGCX 
Nanodisc formation.  This may include incorporation of a shorter chained phospholipid, a 
negatively charged phospholipid such as phosphatidylserine, or a saturated phospholipid 
assembly.  For proof of concept, however, DOPC Nanodiscs allow for successful 
incorporation of GGCX. 
Since the concentration of solubilized phospholipid added to the reconstitution 
mixture must be modified to consider the phospholipid already present in the purified protein 
sample, the total amount of deoxycholate detergent added to the reconstitution mixture is 
significantly reduced.  For most Nanodisc protocols, it is recommended that the 
concentration of detergent is maintained above the critical micelle concentration.  For 
deoxycholate this concentration range is between 2-6 mM.50  Studies were investigated 
where excess deoxcycholate was supplemented into the reconstitution mixture to allow for 
protein solubilization by encouraging micelle formation (Figure 5.9, B).  It was concluded 
from this experiment, that the excess of deoxycholate did not improve GGCX incorporation 
into Nanodiscs and in fact reduced the number of GGCX Nanodiscs assembled.  One 
explanation for this occurrence is that in addition to deoxycholate providing phospholipid 
and membrane protein solubilization, CHAPS detergent (CMC ~6 mM)50 is also present in 
the elution buffer of the purified protein.  Although both detergent systems can be efficiently 
removed using dialysis or adsorption methods, the excess of detergent does not contribute to 
optimized GGCX incorporation.   
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Other conditions investigated to optimize GGCX Nanodisc formation included the 
removal of glycerol prior to GGCX reconstitution.  GGCX is purified with concentrations of 
15% glycerol present in the elution buffer.  It is reported that glycerol in relatively high 
concentrations, interferes with the self-assembly of Nanodiscs.  Lowering glycerol 
concentration to below 3% during assembly is preferred to enable efficient detergent 
removal.  To remove glycerol from the purified sample, either dialysis or a G25 gel filtration 
column was utilized prior to incorporation of GGCX into the reconstitution mixture.  The 
removal of glycerol, however, was not seen to influence the formation of Nanodiscs, and 
must be added back after self-assembly to promote protein catalytic activity.  For simplicity, 
glycerol was allowed to remain in the reconstitution mixture during Nanodisc formation.  
Detergent removal methods were next evaluated for GGCX Nanodisc formation including 
24-hour dialysis or 2-hour incubation with polystyrene beads.  The speed in which detergent 
is removed from the reconstitution mixture is believed to influence self-assembly, however, 
no difference in size exclusion peak profiles or catalytic activity was concluded.   
Under conditions investigated, it was determined that optimal GGCX Nanodisc 
formation was achieved when a twenty fold excess MSP1D1 compared to target GGCX 
protein was incorporated into the reconstitution mixture with a ratio of 60 DOPC molecules 
per MSP1D1.  Supplemented phospholipid concentration was back calculated from the total 
amount of DOPC present in the elution buffer without an excess of detergent needed for 
solubilization.  Efficient detergent removal was facilitated by a two hour gentle rotation of 
Nanodisc samples with damp BioBeadsTM in a 2:1 (v/w) ratio at 4oC.  GGCX containing 
Nanodiscs are isolated by size exclusion chromatography and fractions are concentrated 
using Millipore Microcon YM-30 molecular weight cut-off filters.  A size exclusion 
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chromatographic column was chosen such that optimal separation of GGCX and empty 
Nanodiscs could be achieved.  Using the C-terminal epitope tag on GGCX, affinity 
purification can be further pursued for complete empty Nanodisc removal.  Once isolated, the 
stability of GGCX containing Nanodiscs is maintained for at least a month at 4oC in both 
Nanodisc structure and catalytic functionality.   
5.4.2.2 Modifications to in vitro GGCX Activity Assay 
The main requirement in formation of GGCX Nanodiscs is evaluating substrate 
interactions and catalytic functionality.  GGCX post-translationally modifies selected 
glutamic acid residues in the Gla domain of vitamin K-dependent proteins to gamma-carboxy 
glutamic acid or Gla.  The precise mechanism for the carboxylation reaction is not quite yet 
understood, but it is believed that a high affinity propeptide domain anchors the vitamin K-
dependent protein in an optimized orientation to encourage processive carboxylation.  
Purified GGCX Nanodiscs, isolated by size exclusion chromatography, are studied in vitro to 
investigate propeptide binding by fluorescence anisotropy and carboxylation activity. 
Presnell et al.46 developed a novel florescence assay to determine the number of 
propeptide binding sites in a purified GGCX preparation.  In this study, fluorescently labeled 
consensus propeptide (FpCon) was titrated with increasing concentrations of purified GGCX.  
Results demonstrate the FpCon binds stoichiometrically to GGCX until a saturation point is 
reached indicating the high affinity FpCon substrate provides a sensitive means to determine 
the active site concentration of GGCX.  A similar study was modeled for GGCX purified 
Nanodiscs.  Unlike purified GGCX which is stabilized with a solubilized solution of 
phospholipid and detergent, GGCX Nanodiscs are in a detergent free environment.  Thus in 
the presence of a synthetic nanoscale phospholipid environment one may question the ability 
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of consensus propeptide substrate to interact efficiently with GGCX.  Figure 5.10 illustrates 
the binding curve for fluorescently labeled consensus propeptide to GGCX Nanodiscs in the 
absence of buffer solution containing detergent or excess phospholipid.  Here a fraction 
bound value is calculated from anisotropy values according to the following equation: 
    fb  =  robs - ro                  Equation 5.1 
            (robs – ro) + R(rmax - robs) 
where fb is the fraction of the ligand bound and robs, ro, and rmax are the observed anisotropy, 
the anisotoropy of the free ligand, and the anisotropy of the ligand when bound to saturating 
amounts of GGCX respectively.  R is the fluorescence intensity of the fluorophore saturated 
with carboxylase divided by the intensity of the free fluorophore and is included as a 
normalization factor.   
The equivalence point of GGCX concentration was determined from the intersection 
of a stoichiometric linear regression with the saturation point at a fraction bound value of 
one.  The system reaches an equilibration when the 14 nM solution concentration of FpCon is 
titrated with 28 nM of GGCX Nanodiscs.  Similar to the study with purified GGCX, an 
apparent FpCon-Nanodisc stoichimetry of 0.50 was determined.  Such a stoichiometric ratio 
could indicate that two GGCX molecules bind per molecule of propeptide.  From previous 
work, however, a more likely possibility is that the stoichiometry of the propeptide-GGCX 
interaction is 1:1, but approximately half of the enzyme preparation is comprised of an 
inactive form of GGCX that is unable to bind propeptide.  Sedimentation velocity 
experimentation further confirmed a 1:1 complex of GGCX with propeptide.46  Unlike 
temperature instabilities of GGCX resulting in protein aggregation, inactive entities from 
purification appear to be well behaved in both sedimentation studies and Nanodisc self-
assembly.  Thus the activity lost in purification is proposed to be a more subtle denaturation 
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potentially due to enzyme oxidation.  Regardless of the exact mechanism for inactivity, 
fluorescence anisotropy confirms a direct stoichiometric correlation between enzyme activity 
and propeptide binding for GGCX incorporated Nanodiscs. 
Taking this one step further, GGCX Nanodiscs can also be evaluated as a platform for 
GGCX-substrate complexation.  Figure 5.11 illustrates a size-exclusion chromatographic 
separation of GGCX Nanodiscs when an excess of fluorescently labeled consensus 
propeptide (FpCon) is incorporated into the reconstitution mixture.  For Nanodisc self-
assembly, FpCon is incubated with purified GGCX prior to addition of solubilized 
phospholipid and membrane scaffold protein.  Detergent removal facilitated using 
polystyrene adsorbent beads encourages GGCX Nanodisc formation of the propeptide bound 
complex.  Results confirming GGCX Nanodisc formation can be observed by monitoring the 
absorbance at 280 nm.  If the sample reconstitution mixture is also observed in the visible 
spectrum at 492 nm (410 nm for Linear 200 UV-Vis detectors), it is shown that the high 
affinity fluorescently labeled propeptide substrate selectively binds GGCX encouraging non-
covalent incorporation into the GGCX containing Nanodiscs.  While the majority of the 
consensus propeptide binds GGCX Nanodiscs, only a small fraction is seen to aggregate in 
an unassociated complex at the void volume of the chromatographic separation.  Complex 
formation of GGCX and propeptide substrates into a nanoscale phospholipid environment 
provides a controlled method for monitoring structural changes resulting from substrate 
interactions.  In Chapter 6 we will revisit this topic of propeptide incorporated Nanodiscs for 
structural studies using hydrogen deuterium exchange mass spectrometry.   
GGCX catalytic activity is measured by the incorporation of radiolabeled 14C upon 
carboxylation of a small pentapeptide substrate FLEEL in the presence of excess propeptide 
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(pFIX) and cofactors vitamin K hydroquinone (KH2), carbon dioxide in the form of 
NaH14CO3, and oxygen.  For purified GGCX, this assay is carried out in the presence of 
defined ratios of reagents to maximize catalytic efficiency.  Particularly, the magnitude of 
carboxylation counts are seen to be significantly influenced by the concentration of detergent 
and phospholipid present in the solubilized mixture.  Molecular dynamic simulations and 
small angle X-ray (SAXS) studies have revealed that the addition of cholate to preformed 
Nanodiscs results in disassembly.21  Disassembly proceeds with cholate insinuating itself 
between the MSP and the edge of the phopholipid bilayer domain.  Further additions of 
cholate result in a perturbation of the MSP, which starts to fluctuate in spatial structure.  
Thus, in devising assay conditions for GGCX purified Nanodiscs, we must remove the 
detergent component to allow for accurate assessment of substrate carboxylation by GGCX.  
The evaluation of detergent and phospholipid concentrations on carboxylation activity of 
both purified GGCX and GGCX Nanodiscs is represented in Figure 5.12 (A).  Here the 
hydrophobic cofactor substrate vitamin KH2 phylloquinone is investigated.   
Comparing the magnitude of carboxylation counts, it is concluded that the highest 
activity for purified GGCX is under conditions in which the detergent and phospholipid 
concentrations are maintained at an equal mass ratio of 0.16%.  GGCX Nanodiscs, in 
contrast, are characterized with the highest carboxylation efficiency when incorporating 
0.32% CHAPS detergent and 0.08% DOPC.  Accounting for the sensitivity in carboxylation 
efficiency upon precise ratios of detergent and phospholipid, it is not surprising that GGCX 
Nanodiscs require higher detergent concentrations to open up the Nanodisc structure 
providing adequate substrate access to the enzyme active site.  The high magnitude of 
carboxylation counts indicate that the FLEEL substrate is able to freely access GGCX 
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without any membrane hindrance.  In combination with elevated detergent concentrations 
(0.32% CHAPS) for maximum carboxylation counts, a reduced phospholipid concentration 
(0.08% DOPC) is incorporated into the sample buffer.  This can be explained by the presence 
of phospholipid already present in the Nanodisc structure.  Although the magnitude of 
carboxylation counts are greatest for the GGCX Nanodisc sample in a detergent to 
phospholipid ratio of 0.32% to 0.08% respectively, this system does not provide the most 
accurate representation of a controlled membrane environment.  Removing additions of 
detergent and phospholipid all together from the carboxylation assay, however, results in a 
dramatic reduction in carboxylation magnitude with vitamin K1 hydroquinone.  Thus it may 
be concluded that the magnitude of carboxylation counts is only a relative relationship for 
substrate activity depending on whether purified or Nanodisc GGCX is evaluated.  GGCX 
Nanodiscs, although capable of catalytic conversion of glutamic acid to gamma-carboxy 
glutamic acid, limit the ability for protein substrates to access protein catalytic domains in a 
nanoscale membrane environment.  Although the carboxylation efficiency is lower for the 
GGCX Nanodiscs compared to solubilized GGCX purifications in the absence of detergent, 
the results do not necessarily correlate with a reduced affinity for substrate binding. 
Another thought for potential reduction in catalytic efficiency is that the hydrophobic 
nature of vitamin K1 hydroquinone is hindered by limited access to the catalytic active 
domain.  As discussed in Chapter 1, an alternative vitamin K analog is vitamin K3 
menadione.  Vitamin K3 is a synthetic form of vitamin K that lacks the aliphatic side chain 
making it water soluble.  Although K3 is toxic to humans, it is given to animals as a source of 
vitamin K confirming that it is recognized by GGCX.  In correlation with Dowd’s proposed 
mechanism of carboxylation, the side chain on the vitamin K is not critical for successful 
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carboxylation.  Therefore, the vitamin K3 hydroquinone analog was also studied to determine 
if a water soluble substrate improved carboxylation efficiency for GGCX Nanodiscs.  Under 
the same detergent and phospholipid concentrations evaluated above, Figure 5.12 (B) reports 
carboxylation efficiencies for purified GGCX and GGCX containing Nanodiscs using 
vitamin K3 hydroquinone.  Overall, for both systems, the carboxylation counts are reduced 
greatly in magnitude.  This is not surprising for the detergent and phospholipid purified 
GGCX that maintains a very hydrophobic liposomal environment.  For the water solubilized 
GGCX Nanodiscs, however, we would expect the carboxylation efficiency to be improved by 
switching to the menadione analog of vitamin K hydroquinone.  One explanation for this 
occurrence is that vitamin K3 menadione is very sensitive to light exposure and air oxidation 
resulting in a charge transfer complex that results in a characteristic of purple coloration.51   
The activity assay reaction was modified to optimize carboxylation efficiency with 
vitamin K3 hydroquinone.  Maximum reagent stability and carboxylation counts were 
achieved when the stock concentration of vitamin K3 hydroquinone was lowered to 2.75 mM 
instead of 5.5 mM and aliquots of menadione hydroquinone were added in two 2 L aliquots 
instead of one 5 L addition.  Although the magnitude of carboxylation counts are not 
comparable with the phylloquinone analog in purified GGCX, this modified system evaluates 
the carboxylation by GGCX embedded into Nanodiscs with the absence of detergent in a 
very stabilized nanoscale structure.  In further reports of GGCX Nanodisc activity, assay 
conditions are modified to include vitamin K3 hydroquinone in the absence of additional 
detergent and phosopholipid to stabilize the reaction buffer. 
Figure 5.13 provides a systematic evaluation of GGCX Nanodisc formation where 
fractions are collected from a size exclusion chromatographic separation, concentrated by 
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centrifugal filtration and analyzed by both SDS-PAGE and activity assay analysis.  The 
percent activity is based upon the pre-SEC sample (P) for FLEEL carboxylation in the 
presence of factor IX propeptide.  The highest activity fractions are determined to be 
fractions B6 and B7 corresponding closely with the GGCX containing Nanodisc peak in the 
size exclusion chromatogram.  The aggregate peak containing unassociated phospholipid, 
detergent, and GGCX (fraction B3) is shown to have very little activity.  In addition, empty 
Nanodisc containing fractions (B8 and B9) have almost no activity with only residual activity 
remaining from low concentrations of co-eluting GGCX Nanodiscs.  Concentration estimates 
and stoichiometric ratios may be assessed by SDS-PAGE analysis where lanes (A) and (B) 
correspond to purified GGCX and MSP1D1 respectively.  Isolated GGCX Nanodiscs 
fractions are illustrated as having very high concentrations of GGCX with little evidence of 
protein contamination (ie Heat Shock Protein 70).  Thus, Nanodisc formation is selective for 
GGCX self-assembly enabling access for both propeptide binding and catalytic carboxylation 
of vitamin K-dependent substrates. 
In Figure 5.11, we reported the ability to incorporate fluorescently labeled propeptide 
substrate into GGCX containing Nanodiscs providing a platform in which to study substrate-
protein interactions of vitamin K-dependent proteins.  Figure 5.14 moves to extend 
possibilities of substrate interactions in GGCX Nanodiscs by incorporation of the synthetic 
FIXQ/S substrate.  FIXQ/S is characterized by a factor XI propeptide domain and the first 41 
residues of the factor IX Gla domain with five site specific mutations.  Reconstitution 
mixtures with an excess of FIXQ/S and purified GGCX were self-assembled into Nanodiscs 
for analysis by size exclusion chromatography.  Chromatographic separation is very similar 
to previously analyzed GGCX reconstitution mixtures.  Evaluating concentrated SEC 
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fractions by SDS-PAGE, GGCX Nanodiscs incorporated with the FIXQ/S substrate are 
verified by comparison with protein standards of GGCX (lane A), FIXQ/S (lane B), and 
MSP1D1 (lane C).  The concentration of FIXQ/S in Nanodiscs is very low in comparison to 
that of the standard protein but is estimated at a molecular weight of 6.9 kDa.  Further 
confirmation of FIXQ/S incorporation into GGCX Nanodiscs is illustrated by evaluating 
catalytic carboxylation.  The carboxylation assay was carried out in the absence of 
phospholipid and detergent using vitamin K3 hydroquinone as a cofactor substrate.  To 
confirm carboxylation resulted from the FIXQ/S alone, no additional propeptide or Gla 
substrates were incorporated into the reaction mixture.  The pre-SEC (p) sample was treated 
as the 100% activity control, where FIXQ/S was present in excess.  SEC fractions B6 and B7 
were combined to produce the highest activity GGCX Nanodisc fraction confirming 
successful incorporation of FIXQ/S into the Nanodisc structure.  Although this sample 
fraction was shown to have the highest activity, the 100% threshold was not obtained.  When 
incorporated into the Nanodisc, only one FIXQ/S substrate binds to each active GGCX, thus 
limiting the carboxylation efficiency.  The continued ability to incorporate vitamin K-
dependent substrates into GGCX Nanodiscs provides a novel methodology for studying 
GGCX-substrate protein interactions.  The possibility to facilitate nanoscale membrane 
platforms also encourages one to believe the possibility of creating an in vivo controlled 
vitamin K cycle where both GGCX and VKOR are incorporated into Nanodisc structures 
with corresponding cofactors allowing the facilitation of VKD carboxylation and the 
recycling of vitamin K. 
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5.4.3 Incorporation of Purified VKOR in Nanodiscs 
Concomitant with carboxylation of vitamin K-dependent substrates, GGCX releases 
vitamin K epoxide as a catalysis product.  It is then the role of Vitamin K Epoxide Reductase 
(VKOR) that converts vitamin K epoxide (KO) to vitamin (K).  VKOR is a major player in 
the vitamin K cycle and is characterized as a 163 amino acid protein with three predicted 
transmembrane domains.  Despite the importance of VKOR as target for Warfarin, 
challenges involving protein expression and solubility limited purification until 2006.43  
VKOR is purified from Sf9 insect cells using affinity chromatography.  1,2-dihexanoyl-sn-
glycero-3-phosphocholine (DHPC), a short chain phospholipid, was used for microsomal 
solubilization of VKOR followed by reconstitution in 0.4% 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC) and 0.4% deoxycholate.  Unlike GGCX, the addition of detergent to 
VKOR resulted in a decrease in activity compared to the microsomes alone.  Previous 
topology experimentation predicted that the active site of VKOR is located in the membrane 
portion of the protein, therefore, necessitating an intact membrane environment.  To maintain 
a liposomal environment for the recovery of VKOR activity, purified VKOR is dialyzed 
against buffer containing the reducing agent tris(hydroxypropyl)phosphine (THP) but neither 
DOPC nor deoxycholate.   
Similar to GGCX, purified VKOR was systematically evaluated for Nanodisc 
formation.  Back calculations were made to account for the presence of DOPC and 
deoxycholate present in the in elution buffer totaling concentrations of 5.09 mM and 9.65 
mM respectively.  Phosphate analysis reported phospholipid concentrations even slightly 
higher than calculated most likely resulting from concentrated lipid after dialysis or residual 
lipid remaining from microsomal purification.  Despite the successful purification of 
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catalytically functional VKOR, the excess of lipid concentration provides a significant 
problem for Nanodisc incorporation.  Since such a precise control over stoichiometric ratios 
of phospholipid, membrane scaffold protein, and target membrane protein are required for 
optimal Nanodisc formation, excess phospholipid may result in aggregate formation.  Two 
scenarios of VKOR purification were evaluated for Nanodisc incorporation including VKOR 
directly after purification (0.4% DOPC, 0.4% deoxcholate) or VKOR purified without the 
presence of DOPC in either the reconstitution or elution buffers (0.4% deoxycholate).  Figure 
5.15 (A) illustrates the size exclusion chromatographic separation of corresponding VKOR 
Nanodisc preparations with (blue) and without (red) DOPC during purification.  Similar 
stoichiometric ratios to GGCX Nanodisc preparations were evaluated incorporating an excess 
of the membrane scaffold protein MSP1D1 and varying DOPC concentrations.  For VKOR 
purified in the presence of DOPC, Nanodisc reconstitution is very similar to the recovery of 
activity in purified protein.  Since such a large quantity of phospholipid is present in the 
elution buffer, no additional phospholipid or detergent is supplemented for Nanodisc 
formation.  As a result, only the membrane scaffold protein is added to the sample in precise 
stoichiometric proportions before the sample is dialyzed to encourage spontaneous Nanodisc 
formation as detergent is removed.  Reconstitition mixtures were prepared both with and 
without the reducing reagent THP for evaluation.  The addition of THP to the reconstitution 
mixture reduces the disulfide bond between residues 132 and 135 shown to be involved as 
the active site domain of VKOR.52-55  Having this region of the protein embedded into a 
membrane domain may require disulfide reduction for active protein conformation.  Finally, 
for both situations the influence of glycerol was evaluated using removal strategies such as 
dialysis and G25 spin columns.   
299 
The size exclusion chromatogram for Nanodisc reconstitution of VKOR illustrates a 
large aggregate formation occurring when VKOR is purified in the presence of DOPC 
phospholipid.  The lack of control over phospholipid concentration during purification results 
in protein agglomeration and prevention of spontaneous Nanodisc self-assembly.  VKOR 
purified without DOPC in the elution buffer, however, provided a much more symmetrical 
elution profile.  Since VKOR is estimated at only 18 kDa, resolution between empty 
Nanodiscs and VKOR Nanodiscs will not be possible resulting in the two complexes to co-
elute.  Confirmation of VKOR incorporation into Nanodiscs can be provided by SDS-PAGE 
analysis or activity assay measurements.  The activity of VKOR is calculated using an HPLC 
assay where vitamin K epoxide is incubated with purified VKOR or VKOR Nanodiscs in the 
presence of DTT.  The DTT facilitates regeneration of reduced VKOR allowing continual 
production of vitamin K.  The assay is quenched, and the hydrophobic vitamin K1(20) analog 
is extracted into an organic separation phase.  The quantitation of nanomoles of vitamin 
K1(20) is based off of vitamin K peak area calibrations at an absorbance of 248 nm. 
Instrumental fluctuations are corrected by applying a normalization factor from a vitamin 
K1(25) internal standard.  Figure 5.16 illustrates a typical chromatographic separation for a 
VKOR assay sample where the excess KO reagent elutes at a retention time of ~3.2 minutes, 
the K1(20) product at a retention time of ~4.5 minutes, and the K1(25) internal standard at ~9.0 
minutes.  The inset of Figure 5.16 compares the signal response for vitamin K1(20) production 
from purified VKOR after detergent removal (solid red line) to the reconstitution mixture of 
VKOR for Nanodisc preparation (dotted red line).  In this example, VKOR was purified in 
the presence of phospholipid and detergent removal was facilitated by dialysis.  For 
background subtraction, the baseline signal is shown in blue.  From these results, it is 
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concluded that prior to size exclusion isolation, a significant loss in VKOR activity is 
experienced in the reconstitution mixture.   
Using the conventional HPLC methodology for VKOR Nanodisc assessment, Figure 
5.15 can be revisited to evaluate VKOR Nanodisc reconstitution when purification was 
facilitated with and without phospholipid present in the elution buffer.  Activity here, is 
reported in bar graph format where the concentration of vitamin K1(20) produced is compared 
for each sample set.   VKOR purified in the presence of phospholipid (Figure 5.15, B) shows 
as step-wise improvement in vitamin K production after a 72 hour dialysis period followed 
by overnight incubation in THP.  To reduce time constraints involved in VKOR evaluation, 
alternative sample modifications such as BioBeadsTM treatment for detergent removal or G25 
spin columns for glycerol entrapment are tested and shown to have comparable VKOR 
activity recovery.  Moving on to VKOR Nanodisc formation, prior to SEC, overall activity 
remains very low despite efforts to improve sample reconstitution.  In comparison, VKOR 
purified in the absence of phospholipid (Figure 5.15, C) is shown to have no activity until 
both phospholipid and THP are added back to the purified sample system.  Activity is further 
enhanced by dialysis, however, maximal activity does not reach complete recovery of 
vitamin K production compared to VKOR purified in the presence of phospholipid.  
Evaluating a VKOR Nanodisc reconstitution mixture, the vitamin K production was elevated 
compared to VKOR purified with DOPC, however, significant activity losses are still 
experienced.  Despite the reduction of activity, there is some hope that VKOR activity 
recovery can be achieved. 
 Overlaying the SEC chromatograms for VKOR Nanodisc formation without the 
phospholid and an empty Nanodisc separation (Figure 5.17), almost identical elution profiles 
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are achieved.  This indicates that although minimal activity is reported for the pre-SEC 
reconstitution mixture, the activity is resulting from the VKOR aggregate alone.  The 
speculation is further confirmed by SDS-PAGE analysis where lane (A) and lane (B) 
represent the purified VKOR and MSP1D1 proteins respectively and lanes (I) and (II) 
correspond to peaks in labeled in the size exclusion chromatogram, where the presence of 
VKOR is only identified in the aggregate peak eluting at the void volume in the SEC 
separation.  Modifications to DOPC concentration, MSP1D1 ratios (Figure 5.18), glycerol 
removal, deoxycholate supplementation, and methods for detergent extraction were all 
evaluated for VKOR purified without the presence of phospholipid.  Despite efforts to 
improve VKOR Nanodisc formation, most chromatographic separations matched closely 
with the representative chromatogram illustrated in Figure 5.19.  Here individual SEC 
fractions from VKOR Nanodisc formation were collected and concentrated for activity assay 
analysis where the percent activity was calculated based on vitamin K production of the pre-
SEC reconstitution mixture.  In all experimental situations, VKOR Nanodisc formation was 
inhibited by aggregate formation.   
A potential method investigated to reduce protein aggregation was to incorporate a 
100 m solution of Arginine into the reconstitution mixture.  Preliminary results indicated 
that VKOR activity was maintained in the pre-SEC Nanodisc sample after self-assembly in 
the presence of arginine.  It is generally observed that proteins tend to aggregate during in 
vitro refolding when denaturant such as detergent is being removed.  The exact mechanism 
of protein facilitated aggregation, however, it not yet known.  Arginine has been consistently 
shown to be helpful in preventing protein aggregation by arranging in molecular clusters in 
solution.56, 57  These clusters present a hydrophobic surface through the alignment of 
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arginine’s methylene groups preventing hydrophobic surface induced protein aggregation.  
Future studies in VKOR Nanodisc formation may aim to further investigate additions of 
amino acids such as arginine or salt modifiers to prevent VKOR aggregation prior to 
Nanodisc incorporation.  Since the catalytic active site of VKOR is believed to exist in the 
membrane domain of VKOR, precise conformational orientation may require the 
investigation of other detergent or phospholipid combinations.  Finally, an alternative means 
to encourage Nanodisc formation of VKOR may be to attempt reconstitution from the 
microsomal stage of purification.  Incorporation of all membrane protein components may be 
facilitated by optimizing phospholipid and scaffold protein ratios.  Using the affinity tag on 
VKOR, only VKOR Nanodiscs may be isolated for subsequent purification.   
One additional point to keep in mind for Nanodisc formation of GGCX and VKOR is 
the influence of the membrane scaffold protein or excess empty Nanodiscs in activity assay 
measurements.  Figure 5.20 evaluates percent changes in enzyme activity for purified protein 
when doped with a small concentration of the membrane scaffold protein MSP1D1 or empty 
Nanodiscs.  For both GGCX (A) and VKOR (B), activity is shown to decrease in both 
scenarios.  A potential explanation for a decrease in activity upon incorporation of empty 
Nanodiscs may be explained by the uptake of cofactor reagents providing limited diffusional 
access to the purified target protein.  The GGCX activity assay is shown to be less 
susceptible to empty Nanodisc influences compared to VKOR.  This may be explained by 
Nanodisc disassembly in GGCX purified protein activity assays by incorporation of 0.16% 
CHAPS detergent.  The incorporation of the membrane scaffold protein MSP1D1 into 
activity assay evaluation for purified protein does not provide as easy of an explanation.  The 
free scaffold protein is very α-helical in nature, but to our knowledge does not provide high 
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affinity for substrate binding.  Further investigation into the mechanism by which MSP 
inhibits protein activity may provide insight into a more optimal method of Nanodisc 
assembly. 
5.4.4 Future Applications of Nanodiscs in the Vitamin K Cycle 
Single molecule force spectroscopy is a bionanotechnologial approach that allows the 
detection of inter- and intra-molecular interactions of macromolecules such as native 
membrane proteins.  Force microscopy reveals intriguing insights into the strength of forces 
that stabilize biological structures, determine various biological interactions, and drive 
biological processes.  Using Nanodisc technology with force microscopy measurements 
provides a multitude of applications in which we can investigate the catalytic mechanism by 
which GGCX and VKOR interact in the vitamin K cycle.   
Atomic force microscopy (AFM) has been used in the study of membrane protein 
structural dynamics providing a free energy landscape which highlights structurally rigid and 
flexible regions in a protein.58-61  Oesterhelt et al. performed some of the first unfolding 
experiments of single-molecule bacteriorhodopsin in native purple membrane patches 
isolated from Halobacterium salinarium.62  The experiment was designed in which a 
cantilever probe was pushed onto a single bacteriorhodopsin molecule until adsorbed.  The 
AFM probe was pulled away from the membrane while recording the cantilever deflection 
(force) over the distance (d) (Figure 5.21, A).  When the externally applied force overcomes 
the strength of these molecular interactions, all amino acids unfold spontaneously up to the 
forthcoming unfolding barrier.  Force-distance curves can then be created that illustrate a set 
of force peaks describing the stretching of an unfolded polypeptide chain anchored to the 
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membrane.  The distance between two consecutive unfolding barriers allows one to estimate 
the minimum and maximum number of amino acids that establish a stable structural segment. 
Previous studies using AFM to characterize target membrane proteins have been 
reported for cytochrome P450 2B4 and cytochrome P450 reductase.27, 35  Here authors 
reported that a monolayer of Nanodiscs adsorb to mica with the plane of the phospholipid 
bilayer domain parallel to the mica surface.  Using force-dependent topographic information, 
the approximate position of the native membrane-bound enzyme normal to the bilayer is 
determined.  With the help of Dr. Laurel Averett, an experiment was designed that combined 
the tools of Nanodisc protein isolation with membrane protein AFM.   There are several 
considerations to keep in mind for fluid AFM particularly the substrate material, cantilever 
type, and buffer properties.  The adsorption of Nanodiscs to mica is controlled largely by the 
ionic strength and pH of the image buffer to optimize van der Waals interactions.  Maximum 
adsorption densities are achieved when divalent electrolyte concentrations are used with pH 
values between 7 and 8.63  To prevent aggregation of the 6xHis affinity tagged membrane 
scaffold protein, a wash buffer including 500 mM NaCl and 500 mM imidazole was used to 
treat the sample after plating the Nanodiscs.  The cantilever was chosen with an appropriate 
spring constant and functionalized with a HPC4 calcium dependent antibody for C-terminal 
GGCX affinity recognition.  The experiment is designed to allow the functionalized 
cantilever to approach the surface of the Nanodisc, equilibrate to intiate binding, and slowly 
retract.  An example force spectrum is shown in Figure 5.21 (B).  As GGCX begins to 
unfold, stretches in the force spectrum indicate energy barriers the protein must overcome 
which then can be used to calculate the number of amino acids for a given domain barrier.  
Although this is not a completed representation of the unfolding pathway for GGCX, there is 
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some evidence to support the notion that Nanodisc AFM can be utilized to learn more about 
the structural dynamics and folding pathway of GGCX.  Future improvements to this system 
may include adding a linker between the cantilever tip and the antibody tag, modifying the 
dwell time in which the tag can identify the C-terminal epitope tag of GGCX, and improving 
Nanodisc orientation. 
5.4.5 Conclusions 
Self-assembled phospholipid bilayer Nanodiscs have become an important and 
versatile tool among model membrane systems to functionally reconstitute membrane 
proteins.  In this chapter, we focus on the incorporation of Gamma-Glutamyl Carboxylase 
(GGCX) and Vitamin K Epoxide Reductase (VKOR) independently into synthetic Nanodisc 
structures.  Parameters for experimental self-assembly were fine tuned to optimize membrane 
protein incorporation.  For GGCX containing Nanodiscs, studies concluded successful 
monomeric incorporation of GGCX into a protected nanoscale environment allowing 
catalytic carboxylation of vitamin K-dependent proteins.  In addition to maintaining 
enzymatic activity, GGCX Nanodiscs were also constructed in which synthetic vitamin K-
dependent substrates including a fluorescently labeled consensus propeptide or FIXQ/S could 
be incorporated.  Complexation of GGCX with carboxylation cofactors provides a platform 
to study protein-substrate interactions and further model the carboxylation mechanism.  
Similar conditions for Nanodisc formation were completed for VKOR.  Limitations in 
protein aggregation and enzymatic activity prevented current studies from successful 
Nanodisc formation, however, future objectives aim to systematically investigate 
phospholipid and detergent combinations may prove beneficial.  Besides catalytic activity 
and protein complexation, Nanodiscs provide a toolbox by which membrane proteins can be 
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investigated using a variety of analytical techniques.  In this chapter alone we investigate 
applications of fluorescence anisotropy and atomic force microscopy to better understand 
substrate interactions and structural dynamics of GGCX.  Chapter 6 will continue with the 
study of GGCX Nanodiscs promoting structural studies of GGCX using hydrogen deuterium 
exchange mass spectrometry. 
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5.6 Tables 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MSP TYPE POPC
16:0-18:1 PC
DPPC
16:0 PC
DMPC
14:0 PC
Diameter 
(Å)
MSP1D1 61 82 77 98
MSP1E1D1 79 106 102 106
MSP1E2D1 103 134 122 119
MSP1E3D1 125 167 148 129
 
 
Table 5.1 Phospholipids per leaflet and diameter for corresponding membrane scaffold 
protein (MSP) constructs in Nanodisc formation.15, 18 
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5.7 Figures 
 
A.
B.
Phospholipid
Membrane Scaffold Protein
Target Membrane Protein
 
 
 
Figure 5.1 Illustration of Nanodisc structure for an (A) empty Nanodisc and (B) protein 
embedded Nanodisc.  Two monomers of the membrane scaffold protein (green) form 
an amphipathic helical belt around a phospholipid bilayer (coral and grey).  The target 
transmembrane protein (purple) inserts into the discoidal bilayer in such a way to 
provide solvent access to either side of the membrane.   
 
 
313 
 
 
 
 
 
 
 
 
 
 
Phospholipid + 
Detergent
Detergent Removal
4oC Incubation Temp
+
MSP1D1Solubilized
Target Protein
+
Phospholipid + 
Detergent
Detergent Removal
4oC Incubation Temp
+
MSP1D1
A.
B.
 
 
Figure 5.2 Flow diagram of Nanodisc formation for (A) empty Nandodiscs and (B) protein 
embedded Nanodiscs.  Detergent solubilized phospholipid is combined in precise 
ratios with purified target protein (if present) and MSP1D1 scaffold protein.  During 
detergent removal, Nanodisc structures spontaneously self-assemble. 
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Figure 5.3 Size exclusion chromatograms of self-assembled empty Nanodiscs.  Titration of 
increasing concentration of DOPC to MSP1D1 to determine optimal number of 
phospholipid molecules per Nanodisc leaflet.  SEC separations performed on a Tosoh 
TSKgel BioAssist G3SWXL (7.8 mm x 300 mm; 5 m particles; 250 Å) column 
equilibrated with 50 mM Tris-HCl pH 7.0, 0.15 M NaCl, 0.02% NaN3 (TBS) buffer 
at a flow rate of 0.5 mL/minute.  Absorbance detection completed at 280 nm. 
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Figure 5.4 Size exclusion chromatograms overlaying self-assembled empty Nanodiscs (blue) 
and free MSP1D1 protein (red). SEC separations performed on a standard protein 
calibrated Tosoh TSKgel BioAssist G3SWXL (7.8 mm x 300 mm; 5 m particles; 250 
Å) column equilibrated with 50 mM Tris-HCl pH 7.0, 0.15 M NaCl, 0.02% NaN3 
(TBS) buffer at a flow rate of 0.5 mL/minute.  Absorbance detection completed at 
280 nm. 
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Figure 5.5 Size exclusion chromatograms overlaying self-assembled empty Nanodiscs (blue) 
and GGCX Nanodiscs (red).  Chromatographic peaks labeled (I), (II), and (III) 
correspond with SDS-PAGE gel.  Identification of peak components confirmed by 
GGCX and MSP1D1 purified protein standards in gel lanes (A) and (B) respectively.  
SEC separations performed on a Tosoh TSKgel BioAssist G3SWXL (7.8 mm x 300 
mm; 5 m particles; 250 Å) column equilibrated with 50 mM Tris-HCl pH 7.0, 0.15 
M NaCl, 0.02% NaN3 (TBS) buffer at a flow rate of 0.5 mL/minute.  Absorbance 
detection completed at 280 nm. 
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Figure 5.6 GGCX stability at 25oC monitored by percent activity.  Activity was measured by 
the incorporation of radiolabeled 14C as GGCX carboxylates a small pentapeptide 
substrate FLEEL in the presence of factor IX propeptide, vitamin K hydroquinone, 
NaH14CO3, and oxygen.  In all sample systems, the 100% active control is recorded at 
time zero.  Compare stability of purified GGCX (blue) and GGCX embedded 
Nanodiscs (ND) (red) with () and without () consensus propeptide (pCon).  SDS-
PAGE illustrates 24 hour time point at 25oC for each sample. 
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Figure 5.7 Size exclusion chromatograms overlaying self-assembled GGCX Nanodiscs (red) 
and Nanodiscs in which GGCX is catalytically inactive (dark blue).  Inactivity results 
from room temperature (25oC) incubation of purified GGCX and is defined as the 
inability of GGCX to carboxylate select glutamic acids in vitamin K-dependent 
proteins.  SEC separations performed on a Tosoh TSKgel BioAssist G3SWXL (7.8 
mm x 300 mm; 5 m particles; 250 Å) column equilibrated with 50 mM Tris-HCl pH 
7.0, 0.15 M NaCl, 0.02% NaN3 (TBS) buffer at a flow rate of 0.5 mL/minute.  
Absorbance detection completed at 280 nm. 
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Figure 5.8 Size exclusion chromatograms overlaying self-assembled GGCX Nanodiscs 
prepared with MSP1D1 to GGCX ratios of 20:1 (red) and 10:1 (green). SEC 
separations performed on a Tosoh TSKgel BioAssist G3SWXL (7.8 mm x 300 mm; 5 
m particles; 250 Å) column equilibrated with 50 mM Tris-HCl pH 7.0, 0.15 M 
NaCl, 0.02% NaN3 (TBS) buffer at a flow rate of 0.5 mL/minute.  Absorbance 
detection completed at 280 nm. 
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Figure 5.9 Size exclusion chromatograms overlaying varied conditions for GGCX Nanodisc 
self-assembly.  (A) GGCX Nanodisc reconstitution mixtures prepared with varying 
concentrations of DOPC phospholipid: 1:67 MSP1D1:DOPC (light blue), 1:60 (red), 
and 1:50 (grey blue).  (B) GGCX Nanodiscs reconstitution mixtures prepared with 
(grey) and without (red) supplemented deoxcyholate concentrations.  SEC separations 
performed on a Tosoh TSKgel BioAssist G3SWXL (7.8 mm x 300 mm; 5 m 
particles; 250 Å) column equilibrated with 50 mM Tris-HCl pH 7.0, 0.15 M NaCl, 
0.02% NaN3 (TBS) buffer at a flow rate of 0.5 mL/minute.  Absorbance detection 
completed at 280 nm. 
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Figure 5.10 Titration of GGCX embedded Nanodiscs against a constant concentration (14 
nM) of a fluorescein-labeled consensus propeptide (FpCon) in standard buffer at 4oC.  
The fraction of FpCon bound was calculated from experimental fluorescence 
anisotropy values.  Stoichiometric ratio of FpCon binding to GGCX embedded 
Nanodiscs is determined from the intersection of linear regression to point of 
saturation.  The FpCon-GGCX Nanodisc stoichiometry was determined to be 0.50. 
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Figure 5.11 Size exclusion chromatograms of GGCX Nanodisc self-assembly with 
incorporated fluorescein labeled consensus propeptide (FpCon).  FpCon incorporated 
GGCX Nanodiscs are monitored at both 280 nm and 492 nm to confirm FpCon 
selectively binds GGCX embedded Nanodiscs.  SEC separations performed on a 
Tosoh TSKgel BioAssist G3SWXL (7.8 mm x 300 mm; 5 m particles; 250 Å) 
column equilibrated with 50 mM Tris-HCl pH 7.0, 0.15 M NaCl, 0.02% NaN3 (TBS) 
buffer at a flow rate of 0.5 mL/minute.   
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Figure 5.12 GGCX activity assay results for purified and GGCX embedded Nanodiscs.  
Activity was measured by the incorporation of radiolabeled 14C as GGCX 
carboxylates a small pentapeptide substrate FLEEL in the presence of factor IX 
propeptide, vitamin K hydroquinone, NaH14CO3, and oxygen.  Activity reported as 
carboxylation counts after 120 minutes at 20oC.  Carboxylation efficiency was 
compared under different buffer conditions and varying forms of vitamin K 
hydroquionone (A) phylloquinone or (B) menadione.  Vitamin K hydroquinone 
structures provided for comparison. 
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Figure 5.13 Characterization of fractionated GGCX Nanodiscs by SDS-PAGE and catalytic 
activity.  Fractions collected from SEC chromatographic separation and concentrated 
for SDS-PAGE analysis.  Sample lanes are labeled as follows: GGCX and MSP1D1 
standards in lanes (A) and (B) respectively, pre-SEC reconstitution mixture lane (P), 
and corresponding SEC fractions in lanes B3, B6, B7, B8, and B9.  Fractions also 
analyzed by carboxylation activity assay in the absence of phospholipid and detergent 
with menadione as the vitamin K hydroquinone analog.  Percent activity calculated 
using the pre-SEC reconstitution mixture as the 100% control.  Results confirm 
fractions B6 and B7 correspond to catalytically active GGCX embedded Nanodiscs. 
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Figure 5.14 Characterization of fractionated FIXQ/S embedded GGCX Nanodiscs by SDS-
PAGE and catalytic activity.  Fractions collected from SEC chromatographic 
separation and concentrated for SDS-PAGE analysis.  Sample lanes are labeled as 
follows: GGCX, FIXQ/S, and MSP1D1 standards in lanes (A), (B), and (C) 
respectively, pre-SEC reconstitution mixture lane (P), and corresponding SEC 
fractions in lanes B2/3, B6/7, B8/9.  Fractions also analyzed by carboxylation activity 
assay in absence of phospholipid and detergent with menadione as the vitamin K 
hydroquinone analog.  Since FIXQ/S was pre-equilibrated into the embedded GGCX 
Nanodiscs, no additional FLEEL or pFIX was incorporated.  Percent activity 
calculated using the pre-SEC reconstitution mixture as the 100% control.  Results 
confirm fractions B6/7 correspond to FIXQ/S incorporated GGCX embedded 
Nanodiscs. 
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Figure 5.15 Evaluation of VKOR Nanodisc preparation by (A) SEC chromatography and (B) 
activity assay measurements for VKOR purified with (light blue) or without (red) 
DOPC.  SEC separations performed on a Tosoh TSKgel BioAssist G3SWXL (7.8 mm 
x 300 mm; 5 m particles; 250 Å) column equilibrated with 50 mM Tris-HCl pH 7.0, 
0.15 M NaCl, 0.02% NaN3 (TBS) buffer at a flow rate of 0.5 mL/minute.  VKOR 
activity reported as nanomoles of vitamin K produced using a calibrated HPLC assay.   
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Figure 5.16 Chromatographic representation of purified VKOR activity assay designed to 
measure the production of vitamin K1(20) from vitamin K epoxide (KO) by VKOR.  
Vitamin K1(25) was spiked into sample as internal standard to normalize peak area 
response factors.  Separation completed on a Vydax 5 m C18 column (4.8 mm x 250 
mm) at a flow rate of 2 mL/minute under isocratic conditions (91.8% acetonitrile, 
6.4% isopropanol, 1.8% water).  The production of vitamin K1(20) was detected by UV 
absorbance at 248 nm.  Inset compares purified VKOR (solid line) absorbance 
response for K1(20) to pre-SEC VKOR (dotted line) reconstitution mixture.  A buffer 
blank (blue) was included to differentiate baseline fluctuations.   
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Figure 5.17 Size exclusion chromatograms overlaying self-assembled empty Nanodiscs 
(blue) and a VKOR Nanodisc preparation (red) in the absence of phospholipid during 
purification.  Chromatographic peaks labeled (I) and (II) correspond with SDS-PAGE 
gel.  Identification of peak components confirmed by VKOR and MSP1D1 purified 
protein standards in gel lanes (A) and (B) respectively.  SEC separations performed 
on a Tosoh TSKgel BioAssist G3SWXL (7.8 mm x 300 mm; 5 m particles; 250 Å) 
column equilibrated with 50 mM Tris-HCl pH 7.0, 0.15 M NaCl, 0.02% NaN3 (TBS) 
buffer at a flow rate of 0.5 mL/minute.  Absorbance detection completed at 280 nm. 
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Figure 5.18 Size exclusion chromatograms overlaying self-assembled VKOR Nanodisc 
preparations prepared with MSP1D1 to VKOR ratios of 20:1 (red) and 10:1 (green). 
SEC separations performed on a Tosoh TSKgel BioAssist G3SWXL (7.8 mm x 300 
mm; 5 m particles; 250 Å) column equilibrated with 50 mM Tris-HCl pH 7.0, 0.15 
M NaCl, 0.02% NaN3 (TBS) buffer at a flow rate of 0.5 mL/minute.  Absorbance 
detection completed at 280 nm. 
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Figure 5.19 Characterization of fractionated VKOR Nanodisc preparation by SEC and 
catalytic activity.  Fractions collected from SEC chromatographic separation and 
concentrated.  Samples are labeled as follows: pre-SEC reconstitution mixture (P), 
and corresponding SEC fractions B2/3, B7, B8, and B9.  Percent activity calculated 
using the pre-SEC reconstitution mixture as the 100% control.  Results confirm 
fractions B2/3contains VKOR but in an aggregated form. 
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Figure 5.20 Comparison of percent catalytic activity for (A) GGCX and (B) VKOR when 
purified target membrane protein is spiked with low concentrations of purified 
membrane scaffold protein (MSP1D1) or empty Nanodiscs. 
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Figure 5.21 Atomic force microscopy (AFM) as a nanotool in membrane protein biology.  
(A)Cartoon of membrane protein unfolding experimentation.  A functionalized 
cantilever approaches the surface of a substrate and adheres through antibody-antigen 
recognition.  As the cantilever retracts from the substrate surface, force fluctuations 
will indicate structural potential energy barriers during protein unfolding.  (B) 
Experimental force-distance curve of membrane protein unfolding experimentation 
with GGCX Nanodiscs. 
 
 
 
 
 
 
 
 
CHAPTER 6: Nanodisc Applications to Hydrogen Deuterium Exchange 
Mass Spectrometry 
________________________________________________________ 
6.1 Introduction 
The dynamic nature of proteins is essential to understanding the wide range of structural 
features and functional entities that control critical biological processes.  Protein folding has 
been predicted to proceed through multiple parallel pathways being described as a protein-
energy landscape (or folding funnel) where protein folding is represented by trajectories from 
reactants to products on a potential energy surface.1, 2  Due to the extensive degrees of 
freedom possessed by a long-chain polypeptide, entropy plays a much more significant role 
in protein-folding compared to small molecule chemical reactions.3  As the initially 
unstructured protein begins to adopt a more well-defined three-dimensional structure, 
conformational entropy is lost while enthalpy is compensated by making favorable 
hydrophobic and hydrophilic interactions.  Eventually reaching a global free energy 
minimum, the protein adopts its native conformation.   
Since the majority of protein-protein and protein-ligand binding interactions are not 
merely static, there is a great deal of interest in the dynamic events that occur in proteins that 
facilitate substrate binding events.  Knowledge of local fluctuations and the energetics behind 
structural reorganization provides enhanced knowledge into understanding potential 
mechanisms by which proteins bind physiological ligands.  To address such questions, mass 
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spectrometry has emerged as a powerful analytical tool to investigate the nature of protein 
conformations and the dynamical properties that govern protein function.   
6.1.1 Hydrogen Exchange Fundamentals 
The hydrogen exchange approach was conceived by Kaj Linderstrøm-Lang in the 
early 1950s when it was realized that amide hydrogens in the backbone of polypeptide chains 
participate in continual exchange with solvent protons.4-7  Together with John Schellman, 
Lang connected the hydrogen exchange rate with protein dynamics and energetics, providing 
a novel methodology to study protein folding pathways.8  Traditionally, hydrogen exchange 
methodology has been used in conjunction with nuclear magnetic resonance (NMR) 
spectroscopy9.  Applications of hydrogen exchange, however, were revolutionized upon the 
development of electrospray ionization providing single amino acid resolution with low 
sample consumption and unparalleled limits of detection.   
In general, hydrogen deuterium exchange (HDX) is an experimental technique that 
detects the presence or absence of hydrogen bonding between amide hydrogens in peptide 
bonds and the surrounding solvent.10, 11  Although in principle, hydrogen exchange may be 
used to study any type of hydrogen bonding, some hydrogens in proteins such as those 
bonded to carbon almost never exchange, whereas side-chain hydrogens exchange too 
rapidly for sufficient characterization.  Under physiological conditions (pH 7.0) and D2O 
solvent conditions, the acid-base catalyzed hydrogen exchange mechanism will exchange 
backbone amide protons with deuterons within 1-10 seconds.12  Because proteins are 
dynamic structures in solution, the protein will fold and un-folding as a result of natural 
protein fluctuations or in response to environmental stimuli.   
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Hydrogen exchange can be considered a function of two intertwined properties, 
solvent exposure and hydrogen bonding.  Protein domains which experience slow exchange 
or low levels of deuterium incorporation are indicative of protection from solvent or 
involvement in hydrogen bonding such as -helix formation, whereas fast exchange indicates 
solvent exposure or no hydrogen bonding (Figure 6.1).  Changes to solvent exposure and 
hydrogen bonding can be determined over the entire length of the protein by measuring the 
amount and rate of deuterium incorporation at amide backbone hydrogens.   
The HDX reaction is governed by both an acid- and base-catalyzed reaction.  The 
general mechanism for isotope exchange in folded proteins at physiological pH (base-
catalyzed) requires abstraction of the amide proton by base (OD-) followed by reprotonation 
or deuteration of the amide nitrogen with a proton or deuteron from the solvent.13  Hydrogens 
that exchange slowly do so most readily following structural changes that free these 
hydrogens from intramolecular hydrogen bonding and provide access to the aqueous solvent 
and OD-.  From a kinetics standpoint, the HDX mechanism can be explained according to an 
EX1 or EX2 exchange.12  If the protein refolding rate constant (k-1) is small compared to the 
intrinsic proton exchange rate (k2), then the observed exchange reaction follows pseudo-first 
order kinetics, with protein unfolding being the rate limiting step.  Under these conditions, 
any unfolding event will result in complete amide exchange within the designated region and 
is defined by EX1 kinetics.14  If, the protein refolding rate (k-1) is much larger compared to 
the intrinsic proton exchange (k2), then the overall exchange will follow a second-order 
reaction mechanism, or EX2 kinetics.  EX2 kinetics may be envisioned as involving many 
rapid and random protein fluctuations as a result of natural protein dynamics, whereas EX1 
kinetics are described as a cooperative unfolding event involving several residues all of 
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which exchange before refolding occurs.  While most proteins undergo EX2 exchange under 
physiological conditions, only a few proteins undergo characteristic EX1 kinetics naturally..  
The appearance of EX1 kinetics in mass spectra can be diagnosed by the appearance of two 
distinct mass envelopes.  In the event of mixed kinetics involving both EX1 and EX2 
exchange, such bimodal populations are not as distinct and thus may be characterized by an 
increase in isotopic peak width indicative of multiple protein populations.15   
In addition to the location of deuterium exchange, the method by which deuterium is 
incorporated into the sample system allows one to probe different aspects of protein 
dynamics.  The primary method for introducing deuterium into a protein sample is by 
dilution.  Dilutions of 10-fold or greater will yield deuterium concentrations greater than 95% 
forcing the labeling reaction in one direction.12  With this labeling method, however, the 
original protein sample is also diluted necessitating subsequent sample concentration.  Once 
deuterium is incorporated, there are two methods for labeling experiments: continuous 
labeling and pulse labeling.16  In continuous labeling experiments, the protein is exposed to 
D2O for a set period of time.  As protein populations change in response to natural protein 
motions or some altering force (i.e. the addition of denaturant, changes in pH, or ligand 
binding), folding/unfolding transitions may be detected by the incorporation of deuterium.  In 
pulse labeling experiments, the protein sample is exposed to deuterium for a brief period of 
time when the population of molecules is undergoing a conformational change.  Such 
conformational changes can be induced by another protein molecule or by the addition of a 
perturbing agent such as a chemical denaturant.  Only those molecules that are unfolded 
when the sample is pulsed will undergo isotopic exchange while the remainder of the protein 
population remains unlabeled.  Although not as common in hydrogen exchange reactions, 
337 
pulsed labeling has been used to identify protein folding mechanisms17 as well as to probe 
kinetic intermediates in a folding reaction.18, 19 
6.1.2 Hydrogen Exchange by Mass Spectrometry 
Hydrogen exchange mass spectrometry (HX MS) is a valuable technique that 
provides the opportunity for the analysis of protein structure and conformational changes that 
occur in solution.  In comparison to other techniques including nuclear magnetic resonance 
spectroscopy (NMR), infrared spectroscopy (IR), fluorescence, and circular dichoism (CD), 
HX MS provides a high resolution alternative for the investigation of dynamic protein 
fluctuations in solution with the advantage of low sample consumption and site specific 
peptide identification12, 20, 21.  Following the introduction of electrospray ionization (ESI) and 
matrix-assisted laser desorption ionization (MALDI) in the late 1980s, it was not until 1991 
until the first protein HX MS work was reported.22   
The general scheme for the analysis of proteins by HX MS involves protein dilution 
with D2O buffer in either a continuous or pulsed labeled experimental design.  To quench the 
exchange reaction, the sample mixture is lowered to a pH of 2.5 and temperature of 0oC.  
Sample separation can be completed using liquid chromatography (LC) coupled to 
electrospray mass spectrometry (ESI-MS) or analysis by MALDI MS of intact or digested 
samples.  If digestion is desired to provide site specific evaluation of deuteration, the acid 
protease, pepsin, can be introduced prior to sample analysis providing efficient digestions 
into small peptide sequences under low pH and low temperature quench conditions.  As long 
as the quench conditions are maintained and the samples are analyzed rapidly, relative 
deuterium uptake levels are a reflection of the solution conformation at the labeling pH. 
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The ability to measure the exchange of backbone amide hydrogens provides a 
fundamental advantage for peptide evaluation.  With the exception of proline, every amino 
acid has the ability to exchange a single amide proton, providing a mass signature in which 
protein dynamics can be evaluated.  After labeling the reaction mixture in a deuterium excess 
environment, sample digestion followed by mass analysis will provide a detailed description 
of the ability of a peptide candidate to uptake deuterium.  The relative deuterium 
incorporation for a single peptide can be plotted by correlating the mass shift of a peptide’s 
isotopic distribution compared to the time period in which the sample was labeled.  The 
maximum number of exchangeable deuterium atoms is determined by the number of amino 
acids in the target peptide with the exceptions of the N-terminal amino acid and any proline 
residues in the peptide sequence.  Deuterium uptake curves may be compiled for every 
peptide identified, providing valuable information regarding protein dynamics and structural 
features that change within the solution state of a protein. 
To maximize the amount of retained label, the deuterium back-exchange to hydrogen 
must be controlled.  To minimize back-exchange, sample analysis must be rapid and 
completed at pH 2.5 and 0oC.  Under these quenching conditions, the half-life for exchange 
in unfolded polypeptides is approximately one hour.23  The majority of back-exchange occurs 
during sample handling and subsequent chromatographic separations in protiated solvents.  
When properly controlled, the back-exchange in most systems is limited to less than 10%.  A 
back-exchange correction, is only necessary when it is desired to know the exact number of 
deuterium atoms in a given peptide or protein fragment.12  In most cases, the actual number 
of deuterium exchanged is not as important as where the exchange occurred.  Thus, for 
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comparing differential experimental systems, a relative level of deuterium incorporated is 
sufficient so long as back-exchange is restricted within controllable limits.   
One of the major challenges in HX MS is the ability to exactly define the location of 
deuterium incorporation.  Several strategies have been employed to increase the spatial 
resolution of sample analysis and localize deuterium uptake to individual amino acids.  The 
simplest method involves modifying digestion conditions to allow for overlapping peptides 
to be generated.  Digestion patterns can be changed by altering digestion time, varying 
enzyme concentration, or by the addition of a chemical denaturant.  Coupling differentiating 
digestion conditions with MSMS peptide fragmentation, allows for the successful 
identification of peptide sequences.  With improvements in HX MS technology, comes the 
desire to analyze large and more complex proteins and protein systems.  The advent of ultra 
performance liquid chromatography (UPLC) prompted significant improvements in HX MS 
technology by providing superior peptide separations involving smaller particles, faster 
chromatographic analysis, and improved MS response.24  In addition, mass spectrometers 
themselves have continued to become more sensitive.  Despite these advancements, 
automation of the labeling reaction and data processing greatly limits the throughput of 
sample analysis.  Alongside with developments in technology, HX MS will continue to 
advance, providing functional information regarding protein structure and conformation. 
6.1.3 Hydrogen Exchange of Membrane Proteins 
One such complex system for hydrogen exchange investigation is the evaluation of 
membrane proteins.  Historically, most methods for the investigation of membrane proteins 
by hydrogen deuterium exchange are limited to Fourier transform infrared spectroscopy (FT-
IR)25-30 and solution31-34 or solid-state NMR.35  Although these techniques have provided 
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useful insight into basic structural dynamics of membrane proteins, they exhibit various 
limitations.  FT-IR spectroscopy provides only a global assessment of protein dynamics 
preventing investigation of peptide based site-specific topological changes.  In contrast, 
NMR techniques can determine exchange rates of specific amide hydrogens, however, 
experimentation is limited by protein size and requires large sample consumption with 
limited sensitivity.  Mass spectrometry overcomes many of the limitations found in NMR or 
IR spectroscopy; however, studies investigating membrane proteins by HX MS resort to 
sample preparation techniques involving lipid vesicles or detergent micelles.33, 36-40  Both 
detergent micelles and liposomes are limited in mimicking native membrane environments in 
either bilayer construction or size reproducibility.  In addition, many of these approaches are 
based on a MS-only method limiting the range of protein complexity without liquid 
chromatographic separations.   
 
6.2 Chapter Scope 
Membrane proteins play a role in numerous biological processes including signal 
transduction, transport, and a variety of enzymatic and metabolic pathways.  Integral 
membrane proteins alone account for up to 30% of the human proteome.41  Despite their 
abundance, membrane proteins are very difficult to study.  In particular, structural studies of 
Gamma-Glutamyl Carboxylase (GGCX) have been severely limited by sample complexities 
involving protein aggregation oligomerization, or precipitation in solution.  Chapter 5 
introduced the formation of phospholipid bilayer Nanodiscs as a novel membrane 
environment to study the biochemical characterization of GGCX.  Nanodiscs offer a 
controllable, stable, and monodisperse model membrane with a native-like lipid bilayer, 
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allowing integral membrane proteins to be isolated in a controlled water-soluble 
environment.  In Chapter 6, we present the coupling of Nanodisc technology with HX MS as 
a novel strategy for investigating fundamental structural and functional features of GGCX in 
a near-native lipid environment.  The chapter will begin with an initial focus on sample 
preparation, experimental design using conventional HPLC followed by advancements to 
sample preparation promoting enhanced chromatographic efficiency and peptide 
identification using a Waters® customized UPLC HX MS system.  In the final workflow, 
Nanodisc HX MS will be validated in a biological evaluation of propeptide substrate binding 
to GGCX.  Coupling Nanodisc technology with hydrogen-deuterium mass spectrometry not 
only provides a powerful approach for investigating the structure and function GGCX in a 
native environment, but also opens the door for significant advancements in HX MS 
technology for a variety of potential complex membrane protein systems.  
 
6.3 Experimental 
6.3.1 Materials 
Reagents used for Gamma-Glutamyl Carboxylase purification and evaluation are as 
follows: 1,2-dioleoyl-sn-glycero-3-phosphocholine [DOPC] (Avanti Polar Lipids, Alabaster, 
AL), 2-(N-morpholino)ethanesulfonic acid [MES] (Sigma-Aldrich, St. Louis, MO), 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate hydrate [CHAPS] (Sigma-Aldrich), 
3-(N-morpholino)-propanesulfonic acid [MOPS] (Sigma-Aldrich), calcium chloride 
dihydrate [CaCl2.2H2O] (Fisher Scientific, Fair Lawn, NJ), ethylenediamine-tetraacetic acid 
[EDTA] (Mallinckrodt Chemicals, Raleigh, NC), glycerol (Fisher Scientific), and sodium 
chloride [NaCl] (Fisher Scientific).  Protease inhibitors including aprotinin, leupeptin, 
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pepstatin, and phenylmethyl sulfonyl fluoride were purchased from Roche Applied Science 
(Indianapolis, IN).  Anti-HPC4 monoclonal antibody coupled Sepharose resin was obtained 
from Dr. Charles T. Esmon (Cardiovascular Biology Research Program, Oklahoma Medical 
Research Foundation, Oklahoma City, OK).42  The consensus propeptide [pCon] 
(AVFLSREQANQVLQRRRR) was synthesized and purified by Synthetic Biomolecules 
(San Diego, CA).  Additional reagents used in membrane scaffold protein purification and 
Nanodisc formation include: imidizole, sodium azide, sodium deoxycholate, 
tris(hydroxymethyl)aminomethane hydrochloride [Tris-HCl], and triton X-100 purchased 
from Sigma-Adrich.  Ni-NTA Agarose resin (QIAGEN, Valencia, CA) was purchased for 
MSP1D1 affinity purification.   
Additional reagents obtained for hydrogen exchange reactions, digestions, and analysis 
by liquid chromatography and mass spectrometry (LC-MS) include: optima grade acetonitrile 
(Fisher Scientific), sodium cholate (Sigma Aldrich), deuterium oxide > 99% (Cambridge 
Isotope Laboratories, Andover, MA), LC-MS grade formic acid (Sigma-Aldrich), pepsin 
(P6887) from porcine gastric mucosa (Sigma-Aldrich), trifluoroacetic acid [TFA] (Sigma-
Aldrich), and optima grade water (Fisher Scientific).  To aid in phospholipid removal, 
samples were treated with zirconium oxide coated silica resin (Supelco Hybrid SPE 
Precipitation Cartridge, Sigma Aldrich).   
6.3.2 Purification of Recombinant Wild-type Gamma-Glutamyl Carboxylase  
Wild-type human Gamma-Glutamyl Carboxylase (GGCX) with a carboxyl terminus 
12-amino acid epitope tag (EDQVDPRLIDGK) was isolated from Sf9 cells as previously 
described.43  Solubilized GGCX microsomes were purified using a calcium dependent HPC4 
antibody resin and eluted in 25 mM MOPS pH 7.5, 0.1 M NaCl, 15% glycerol, 0.5% 
343 
CHAPS, 0.2% DOPC, and 10 mM EDTA, stabilized by a protease inhibitor cocktail.  
Purified protein was stored at -80oC.  Protein concentration and purity was determined by 
enzymatic activity assay measurements and SDS-PAGE.  A detailed protocol describing 
Gamma-Glutamyl Carboxylase protein purification is described in Appendix A1. 
6.3.3 Membrane Scaffold Protein (MSP1D1) Expression and Purification 
MSP1D1 expression and purification was carried out as previously described.44  In 
short, the MSP1D1 plasmid with a polyhistidine tag (Addgene plasmid 20061) was expressed 
in E.coli BL21 Codon Plus (DE3) cells.  For purification, the protein was isolated by Ni-
NTA Agarose (QIAGEN, Valencia, CA) affinity purification and purity was confirmed by 
polyacrylamide gel electrophoresis.  Fractions containing MSP1D1 were pooled and dialyzed 
against standard buffer (20 mM Tris/HCl pH 7.4, 0.1 M NaCl, 0.5 mM EDTA, and 0.01% 
NaN3).  Purified protein was lyophilized and stored at -20oC.  Reconstitution was facilitated 
by dissolving the lyophilized protein in sterile water by end-over-end rotation at 4oC 
overnight.  Protein concentration was determined by absorbance at 280 nm using calculated 
extinction coefficients (280nm = 21,000 M-1cm-1 for MSP1D1).  A detailed protocol 
describing MSP1D1 protein expression and purification is described in Appendix A3. 
6.3.4 Self-assembly of Nanodiscs 
Phospholipid stock solutions were prepared in chloroform and the concentration 
determined by phosphate analysis.45, 46  A deoxycholate solubilized DOPC mixture (2:1) was 
added to purified GGCX target protein under precisely tuned conditions to promote self-
assembly.  The mixture was incubated for one hour at 4oC.  Purified MSP1D1 stock in 
standard buffer was then added to the reconstituted mixture in excess and incubated for an 
additional hour at 4oC.  Void sample volume was supplemented with 50 mM Tris-HCl pH 
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7.4, 0.15 M NaCl, and 0.02% NaN3 (TBS) buffer.  After incubation, detergent was removed 
during a 2 hour gentle rotation with damp SM-2 BioBeadsTM (BioRad, Hercules, CA) and 
samples were stored for up to one month at 4oC.  The protocol for DOPC empty Nanodisc 
preparations were similarly prepared but in the absence of target membrane protein. 
The disk preparations were purified by size exclusion chromatography by monitoring 
the absorbance at 280 nm on a Tosoh TSKgel BioAssist G3SWXL 7.8 mm  300 mm (5 m 
particles, 250 Å) column with 50 mM Tris-HCl pH 7.0, 0.15 M NaCl, 0.02% NaN3 (TBS) 
mobile phase at 0.5 mL/minute.  Fractions containing purified Nanodiscs were isolated and 
concentrated by Millipore (Bedford, MA) Microcon YM-30 centrifugal filters.  The protocol 
for sample analysis was consistent in preparation of empty Nanodiscs.  For GGCX Nanodisc 
preparations in the presence of consensus propeptide, the reaction mixture was first incubated 
with a ten fold excess of propeptide for 45 minutes at 4oC prior to the addition of solubilized 
phospholipid.  Consensus propeptide incorporation into GGCX embedded Nanodiscs was 
confirmed by measuring the carboxylation of the small pentapeptide Gla domain FLEEL 
(Bachem, Philadelphia, PA) in the absence of additional Factor IX propeptide. 
6.3.5 Conventional HPLC – Hydrogen Exchange Reaction and Analysis by Mass 
Spectrometry 
Samples of GGCX embedded Nanodiscs and empty Nanodiscs were analyzed by a 
continuous labeling hydrogen deuterium exchange where individual samples were prepared 
for each time point point in a labeling reaction.  For Nanodisc digestion, 60 pmol of purified 
GGCX incorporated Nanodiscs (120 pmol MSP1D1; 7.2 nmol DOPC) were diluted ten fold 
in 99% deuterium oxide buffer (50 mM Tris/HCl, 0.15 M NaCl, 0.02% NaN3, D2O, pD 6.6) 
at room temperature.  At selected times ranging from 10 seconds to 4 hours, after the 
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introduction of D2O, the sample was quenched to pH 2.5 by the addition of formic acid and 
placed on ice.  To retain the deuterium that exchanged into the protein, the sample was 
maintained under quench conditions (pH 2.5; 0oC) for all sample handling prior to analysis 
by mass spectrometry.47  For sample digestion, porcine pepsin immobilized Poros 20AL resin 
(Applied Biosystems, Carlsbad, CA)48, 49 was added to the sample during incubation on ice 
for five minutes.  The sample was spun filtered (0.45 m cellulose acetate filter, pre-chilled) 
at 4oC for one minute and the filtrate was immediately injected for mass analysis.  Empty 
Nanodisc sample preparations were performed in a similar manner. 
Samples were injected and desalted on a Poros 20R2 (2 mm  20 mm) trap column 
with a three times (v/v) wash with 0.05% TFA in water.  A Waters® Xbridge VanGuard pre-
column packed with 3.5 m C18 particles (2.1 mm  5 mm) was used to facilitate lipid 
trapping prior to analytical separation.  The HPLC separation was carried out on a Waters® 
Xbridge 3.5 m C18 column (1.0 mm  100 mm).  To minimize deuterium loss, the injector, 
trap, column, and tubing was immersed in an ice bath.  The peptides were eluted in the 
following elution profile: 10-50% ACN over 15 minutes followed by a five minute ramp to 
85% ACN in mobile phase containing 0.05% TFA and a flow rate of 50 L/minute.  Mass 
analysis was carried out with a Waters® LCT PremierTM equipped with a standard ESI 
source.  Myoglobin was infused at the end of each run for mass calibration.  Mass spectral 
measurements were taken at a capillary voltage of 3.2 kV, cone voltage of 35 V, source 
temperature of 80oC, desolvation temperature of 175oC, and desolvation gas at 600 L/hr.  
Each one second scan spanned m/z 200-2000 with an interscan delay time of 0.01 seconds.  
Spectra were processed with MassLynx software. 
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6.3.6 UPLC – Hydrogen Exchange Reaction and Analysis by Mass Spectrometry 
Modifications were made to hydrogen exchange sample reactions to aid in Nanodisc 
disassembly and lipid removal while improving peptide separations using a customized 
Waters® nanoACQUITYTM UPLC system.24  Purified GGCX embedded Nanodiscs (50 
pmol GGCX, 100 pmol MSP1D1; 6 nmol DOPC) were diluted ten fold in 99% deuterium 
oxide buffer (50 mM Tris/HCl, 0.15 M NaCl, 0.02% NaN3, D2O, pD 6.6) at room 
temperature for a continuous labeling reaction from 10 seconds to 4 hours.  For continuous 
labeling, individual samples were prepared for each time point point in a labeling reaction 
and analyzed separately.  After labeling, the sample was quenched to pH 2.5 and the 
temperature lowered to 0oC.  To prevent deuterium back-exchange, quench conditions were 
maintained for all subsequent sample handling procedures prior to mass analysis.  Upon 
quenching, Nanodiscs were immediately disassembled with the addition of a 25:1 ratio of 
sodium cholate to DOPC phospholipid.  Digestion was completed for five minutes on ice 
with porcine pepsin immobilized Poros 20AL resin.  In the last minute of digestion, three 
milligrams of zirconium oxide coated silica resin was added to the digestion mixture to 
remove interferences from DOPC phospholipid contaminants.  The sample was spun filtered 
at 4oC for one minute and immediately injected for mass ananalysis.  Empty Nanodiscs and 
propeptide incorporated GGCX Nanodiscs were prepared in a similar manner 
Chromatographic analysis was completed on a custom Waters® nanoAcquityTM 
UPLC system.  After offline digestion, peptic peptides were trapped on a Waters® Xbridge 
VanGuard column packed with 1.7 m C18 particles (2.1 mm  5 mm) and desalted with 
0.1% formic acid in water for 5 minutes at 100 L/minute.  The trap was placed in-line of a 
second pre-column (Waters® Xbridge VanGuard; 1.7 m C18 particles, 2.1 mm x 5 mm) 
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directly connected to the analytical column (Waters® Xbridge; 1.7 m C18 particles, 1.0 mm 
 100 mm).  The guard column between the trap and the analytical column was used as a 
precaution to trap any residual lipid that was not removed by the ZrO2 resin.  The peptides 
were eluted with an 8-40% gradient of acetonitrile in 0.05% formic acid (pH 2.5) over six 
minutes at a flow rate of 40 L/minute.  In later experiments, to improve peptide 
identification, gradient conditions were extended to a twelve minute gradient over 8-40% 
acetonitrile in 0.05% formic acid (pH 2.5) at a flow rate of 40 L/minute. 
Mass spectral analysis was carried out on a Waters® QTof PremierTM equipped with 
a standard ESI source and [Glu1]-fibrinopeptide B (200 fmol/mL) mass lock calibration.  The 
mass spectral measurements were taken at a capillary voltage of 3.5 kV, cone voltage of 40 
V, source temperature of 80oC, desolvation temperature of 175oC, and desolvation gas at 600 
L/hr.  Each 0.5 second scan spanned m/z 200-2000 with an interscan delay time of 0.05 
seconds.  Spectra were collected in positive ESI and V mode and processed with MassLynx 
software.  Undeuterated sample controls for both GGCX embedded Nanodiscs and empty 
Nanodiscs were run in triplicate analysis using Waters® MSE technology.  Peptic peptide 
identification was determined with ProteinLynx Global Server 2.4 (RC7) processing software 
and relative deuterium uptake curves were generated using HX-Express software50 for 
peptides identified in two out of three replicate injections.  Protein structure and 
identification of disordered regions within a protein sequence was provided by PONDR® 
software.  Access to PONDR® was provided by Molecular Kinetics, Indianapolis, IN. 
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6.4 Results and Discussion 
6.4.1 HX MS of Empty and GGCX Embedded Nanodiscs – Conventional HPLC 
GGCX embedded Nanodiscs were prepared at a mole ratio of 1:60 MSP1D1 to 
DOPC with deoxycholate solubilization at 4oC.  To ensure incorporation of a single GGCX 
molecule per Nanodisc, a twenty fold excess of MSP1D1 membrane scaffold protein was 
added to the reconstitution mixture.  Following the removal of detergent with polystyrene 
adsorbent beads (BioRad BiobeadsTM), purified GGCX Nanodiscs were isolated by size-
exclusion and concentrated for HX MS analysis.  Approximate reaction component 
concentrations for isolated GGCX embedded Nanodiscs are as follows: 2.0 M GGCX, 4.0 
M MSP1D1, and 2.40 mM DOPC where stoichiometric ratios are determined by SDS-
PAGE and phosphate analysis (data not shown).  Comparatively, a 1:67 mole ratio of 
MSP1D1 to DOPC was implemented for empty Nanodisc formation.   
GGCX embedded Nanodiscs were initially evaluated using an off-line conventional 
high performance liquid chromatography (HPLC) system coupled to a Waters® LCT 
PremierTM XE mass spectrometer.  A flow chart outlining the Nanodisc hydrogen exchange 
reaction and corresponding HPLC-MS system is illustrated in Figure 6.2.  GGCX Nanodiscs 
are prepared according to standard HX protocol where samples are diluted ten-fold with Tris 
Buffered Saline (TBS) in D2O for a continuous labeling time course (0, 10 or 30 seconds, 5 
minutes, 30 minutes, 2 hours, and 4 hours) at room temperature.  At defined time intervals, 
the exchange reaction is quenched by lowing the pH to 2.5 and the temperature to 0oC.  
Digestion is facilitated using pepsin immobilized Poros resin for five minutes on ice prior to 
analysis by LC-ESI-MS.  During preparation, sample handling must be minimized and 
reaction conditions completed efficiently under quench conditions to prevent deuterium 
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back-exchange.  A conventional HPLC system was modified for HX by cooling mobile 
phase components in addition to the injector and column hardware assembly in an ice bath.  
Since protonated solvents are used during chromatographic analysis, fast gradients (10-50% 
acetonitrile in 15 minutes) must be completed.  To remove trace side chain deuterons and 
concentrate sample peptides, sample desalting was completed on a Poros 20R2 trap column.   
Upon Nanodisc digestion, the release of phospholipid components severely reduces 
the analytical column lifetime and reproducibility.  If no additional measures were taken to 
modify the sample system, a representative chromatogram of an empty Nanodisc digestion is 
shown in Figure 6.3.  In this example, MSP1D1 peptides are shown to elute by 40% organic 
content followed by undigested MSP1D1 protein at 50% acetonitrile and a large interference 
from DOPC at 98% organic.  Although the presence of DOPC does not result in ion 
suppression of the MPS1D1 peptides, the column lifetime and retention time reproducibility 
is drastically limited.  To trap phospholipid interferences and protect the analytical separation 
column, a guard column (Waters® Xbridge VanGuard; 3.5 m C18 particles; 2.1 mm x 5 
mm) was positioned in front of the separation column (Waters® Xbridge; 3.5 m C18 
particles; 1.0 mm x 100 mm).  Preliminary experiments with the VanGuard column as a lipid 
reservoir showed that the guard column offered considerable entrapment of lipids at 85% 
acetonitrile, but the lifetime of the guard column was limited to only a few injections (data 
not shown).  Attempts to extract the lipid with organic solvents (i.e. ether, chloroform, etc) 
showed little efficacy in selectively removing phospholipids from our experimental setup.  
Sample chromatograms comparing an empty Nanodisc and GGCX Nanodisc pepsin 
digestion after online phospholipid trapping is represented in Figure 6.4 A and B 
respectively.   
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Undeuterated GGCX embedded Nanodiscs and empty Nanodiscs were analyzed 
using the conventional HPLC system with offline fraction collection and mass analysis using 
a Waters® QTof Premier with MSE capabilities.  Peptides identified in two out of three 
replicate sample injections were searched in time course chromatograms to monitor the level 
of deuterium incorporation over time.  Figure 6.5 illustrates a representative data analysis 
scheme for peptide identification and evaluation of deuterium incorporation.  GGCX 
embedded Nanodisc time course chromatograms are aligned in Figure 6.5 (A) where an 
undeuterated empty Nanodisc chromatogram is shown in blue and the undeuterated GGCX 
Nanodisc control in red.  Peak profiles and chromatographic efficiencies are well maintained 
throughout the time course indicative of efficient phospholipid trapping.  To identify GGCX 
peptides, undeuterated empty and GGCX Nanodisc chromatograms were compared at 
defined time intervals.  Representative raw mass spectra (Figure 6.5, B and C) identify 
unique GGCX peptides (red) and MSP1D1 peptides (black) over a fifty Dalton mass window 
for a selected chromatographic peak.  For uptake curve generation, the centroided mass of the 
peptide isotopic envelope is extracted for every target peptide at each labeled time point 
interval (Figure 6.5, D).  Using HX-Express software, the relative deuterium incorporation is 
calculated based upon the shift in centroided mass of a peptide envelope as a function of time 
and corresponding uptake curves are generated for each unique peptide identified.50  
Representative uptake curves for GGCX and MSP1D1 are illustrated in Figure 6.5 E and F 
respectively where the maximum number of deuterium atoms a single peptide can uptake is 
plotted as the y-axis maximum.   
In the interpretation of deuterium uptake curves, one must consider both the shape of 
the curve in addition to the number of deuterium that the peptide is capable of exchanging.  
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Peptides illustrating uptake curves similar to the GGCX peptide at an m/z of 532.97 (+3) 
(Figure 6.5, E), experience a rapid initial uptake in deuterium with little change over time, 
indicative of a solvent exposed domain with little involvement in secondary structure.  
Contrastingly, if just the opposite scenario was observed where very low levels of deuterium 
incorporation are seen for a peptide over a time course labeling reaction, then one can predict 
the peptide to be shielded fom solvent exposure or involved in hydrogen bonding.  Figure 6.5 
(F) in comparison, respresents a very dynamic peptide that experiences a large deviation in 
deuterium incorporation over a time course exchange.  The dynamic range of deuterium 
incorporation can be explaind by protein local fluctuations that will influence the total 
deuterium incorporated by a peptide over time.  Although the exact structural features 
facilitating deuterium exchange can not be extracted from uptake curves, relative changes in 
deuterium uptake can be compared when the protein system is perturbed to identify areas 
involved in local large- or small-scale structural fluctuations.  Time resolved deuterium 
incorporation is completed in duplicate to confirm uptake curve generation and compared 
between overlapping peptides to validate peptide identification. 
6.4.1.1 Structural Evaluation of GGCX 
Identification and uptake curve generation for GGCX peptides in a conventional 
HPLC HX MS system are indicated in red on the predicted topology diagram (Figure 6.6) 
corresponding to a 41% protein sequence coverage.  GGCX characteristic uptake curves are 
generated in panels A-D correlating to a predicted transmembrane domain (A), a highly 
conserved domain (B), a solvent exposed region (C), and a predicted substrate binding 
domain (D) where overlaid plots are indicative of reproducibility between replicate time 
course sample preparations.  A comprehensive listing of all peptide uptake curves generated 
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for GGCX Nanodisc digestions and evaluation by conventional HPLC HX MS is reported in 
Appendix A4.  Evaluation of uptake curve generation in relation to predicted GGCX 
topology may further aid to better understand native-state protein structure.   
One of the fundamental questions posed by GGCX is evaluation of protein three-
dimensional structure.  Although efforts have been made towards GGCX protein 
crystallization,51 no defined structural model has been reported to date.  In combination with 
biochemical and hydrophobic modeling, GGCX is predicted to be characterized by five 
transmembrane domains.52  To correlate hydrogen exchange and protein structure, a 
PONDR® (Predictor of Naturally Disordered Regions) plot may be generated for GGCX 
(Figure 6.7, A).  PONDR® functions from primary sequence data alone importing attributes 
such as the fractional composition or hydropathy of a particular amino acid into a neural 
network that has been trained for a specific set of ordered and disordered sequences.  The 
generated plot can then be used to predict protein regions that behave as disordered 
sequences (score > 0.5), or regions which lack a fixed tertiary structure, versus ordered 
domains (score < 0.5).  In conjunction with protein disorder, PONDER® also predicts 
exchangeable proton sites within GGCX.  Comparison between peptide deuterium uptake 
curves and PONDR® predictions are shown to correlate well with one another for peptides 
that have been identified by high or low levels of deuterium incorporation.  In addition to 
predicting solvent exposed regions of a protein, PONDR® plots can be used to explain 
digestion patterns for a protein of interest where the absence of peptide recovery in highly 
ordered domains may result from the inaccessibility of pepsin to target digestion sites.   
To our knowledge, this study represents the first successful application of HX MS 
analysis on a native membrane protein incorporated into phospholipids bilayer Nanodiscs.  
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Using the integral membrane protein GGCX as a target, initial experimentation has validated 
the methodology for investigating hydrogen exchange reactions to probe protein three-
dimensional structure.  To improve upon this system and attempt to enhance peptide 
recovery, several sample preparation modifications will be evaluated.   
6.4.1.2 Protein Dynamics of MSP1D1 
In addition to evaluation of GGCX, two copies of the membrane scaffold protein 
MSP1D1 are present in each Nanodisc entity and can be evaluated for dynamic protein 
fluctuations indicative of Nanodisc formation.  Figure 6.8 evaluates a hydrogen exchange 
time course for the free MSP1D1 protein in solution.  Modeled after Apolipoprotein A1 
(PDB 2A01), structural determinations by X-ray crystallography of MSP1D1 indicate that 
the protein is very -helical in nature.53  Characteristic uptake curves identified in MSP1D1, 
however, denote the presence of very dynamic or solvent exposed exchange patterns with 
total peptide recovery corresponding to 82% recovery.  In contrast to crystal structure 
determination, solution phase investigation of lipid-free MSP1D1 indicates several peptide 
domains which behave more closely to that of a random coil in comparison to a structured -
helix.  Similar structural inferences correlating well to uptake curve generation is provided by 
Oda et al.54  Comparing the PONDR® plots between the transmembrane protein GGCX (A) 
and the MSP1D1 (B) protein sequence in Figure 6.7, it is concluded that the scaffold protein 
is characterized by a much more disordered predicted protein structure (48.3%) compared to 
GGCX (24.2 %), thus enabling more efficient pepsin digestions. 
Similarly, the MSP1D1 protein can be evaluated after formation of Nanodiscs in both 
empty discs as well as GGCX embedded discs and compared to the lipid-free form of the 
protein (Figure 6.9).  The ribbon diagram of MSP1D1 highlights the peptides identified in a 
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hydrogen exchange reaction using conventional HPLC HX MS.  In correspondence to the 
lipid-free MSP1D1, a percent sequence coverage for the Nanodisc assembled scaffold protein 
is reported at 83%.  Nanodisc self-assembly is characterized by target membrane protein 
incorporation into a discoidal phospholipid bilayer encircled by the amphipathic membrane 
scaffold protein.  Even in the presence of phospholipid, pepsin can easily access the 
membrane scaffold protein at the edge of the Nanodisc structure providing high peptide 
recovery confirmed by several overlapping peptides.  Three representative uptake curves are 
reported in Figure 6.9 comparing membrane scaffold peptides in GGCX occupied Nanodiscs, 
empty Nanodiscs, and lipid-free MSP1D1.  As expected, almost no deviation is seen in 
MSP1D1 peptide uptake curves whether the Nanodisc is embedded with a target membrane 
protein or phospholipids alone.  Contrastingly, however, for some regions within the protein 
structure significant variations in deuterium incorporation are observed for Nanodisc 
MSP1D1 compared to free scaffold protein.  Continued evaluation of membrane scaffold 
protein dynamics in regards to peptide deuterium incorporation can be applied to future 
applications designed to model the mechanism behind Nanodisc self-assembly.  A summary 
of compiled MSP1D1 peptide uptake curves are reported in Appendix A4. 
As noted in Figure 6.3, a large contribution from undigested MSP1D1 remains after 
pepsin digestion thus providing a means to evaluate the deuterium incorporation of the intact 
protein (Figure 6.10).  Protein envelopes (A) are deconvoluted by MaxEnt1 processing (B) to 
determine the relative deuterium incorporation of the undigested protein over time.  In 
correlation to a shift in the deconvoluted molecular mass, a very dynamic uptake curve is 
generated for the intact MSP1D1 (C) protein.  Considering the MSP1D1 protein has 211 
residues with 8 prolines, the maximum number of deuterium atoms capable of exchanging 
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are 202.  After a four hour labeling reaction with deuterium, a mass shift of 168 Daltons was 
reported leaving 34 potential amino acids unexchanged.  In correlation with pepsin digestion 
data for empty Nanodiscs, undigested MSP1D1 is capable of incorporating deuterium into 
83% of its protein sequence.   
Using conventional HPLC, Nanodiscs can be evaluated by HX MS.  Modifications to 
instrumental design include the addition of a guard column prior to analytical separation to 
provide protection of chromatographic hardware from phospholipid contamination.  Peptide 
evaluation can be completed for each unique peptide in both GGCX and the amphipathic 
membrane scaffold protein, MSP1D1, where deuterium uptake can be monitored for a 
continuous labeling reaction from 10 seconds to 4 hours.  In combination with protein 
modeling, evaluation of deuterium uptake curves can be applied to further understand protein 
structure in combination with functional dynamics. 
6.4.2 Improvements in Sample Preparation for Nanodisc HX MS 
Revisiting Figure 6.3, it may be noted that in addition to membrane scaffold peptide 
separation, large contributions from undigested MSP1D1 and DOPC remain evident without 
modifications to sample or instrumental settings.  The presence of undigested MSP1D1 
indicates that the Nanodisc structure is not efficiently disassembled upon pepsin digestion 
under quench conditions.  This is further confirmed by size-exclusion chromatography 
(Figure 6.11).  Under pH 2.5 quench conditions, an empty Nanodisc sample preparation was 
evaluated by size-exclusion chromatography.  In comparison to a self-assembled empty 
Nanodisc at physiological pH, the quenched Nanodisc sample experiences a very broad 
distribution of population states indicative of a partially denatured entity.  To facilitate 
Nanodisc disassembly, cholate incorporation is proposed.   
356 
Previous studies have concluded the incorporation of cholate molecules into 
Nanodiscs cause the MSP1D1 scaffold protein to fluctuate at the circular edge of the lipid 
bilayer,55 resulting in Nanodisc disassembly at high concentrations.  In combination with 
formic acid quench conditions, a 25:1 cholate to DOPC concentration ratio was added to the 
Nanodisc sample prior to pepsin digestion.  Figure 6.12 demonstrates an overall increase in 
MSP1D1 peptide intensity upon disassembly of empty Nanodiscs with cholate using a 
conventional HPLC system.  The increase in MSP1D1 peptide intensity is coupled to a 
decrease in the amount of undigested protein further supporting evidence of Nanodisc 
disassembly.   
To improve column lifetimes, an alternative means of lipid removal was investigated 
using resin derived from Supelco HybridSPETM Precipitation cartridges. Here the zirconium 
oxide acts as a lewis acid that will interact strongly with the phosphate group inherent in all 
phospholipids.56-58  Furthermore, the presence of formic acid from the quench buffer 
subsequently acts to neutralize silanol groups improving analyte recovery by preventing 
nonspecific interactions.  Phospholipid removal by zirconium oxide resin was evaluated by 
phosphate analysis (Figure 6.13, A) and by peptide recovery in mass spectrometric analysis 
(Figure 6.13, B).  The time in which the sample is incubated with the zirconium oxide 
cartridge depends on the concentration of phospholipid present in the sample.  If Nanodisc 
samples were quickly passed through the zirconium oxide cartridge (15 seconds) almost no 
phospholipid was removed from the sample.  In contrast, if the sample was allowed to 
incubate with the zirconium oxide resin for three minutes, virtually complete phospholipid 
removal is achieved (Figure 6.13, A).  In addition to ZrO2 efficiency in phospholipid 
removal, evaluation of nonspecific peptide adsorption to the silica modified resin was 
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observed by monitoring peptide intensity of several sample sequences.  A characteristic 
MSP1D1 peptide is shown as an example in Figure 6.13 (B) at an m/z of 479.2 (CS+2).  
Using the lipid-free MSP1D1 as a control, after a one minute incubation period with the 
zirconium oxide cartridge (thirty milligrams of resin), significant peptide loss results from 
sample adsorption.  If three milligrams of zirconium oxide resin is extracted from the sample 
cartridge and allowed to incubate with Nanodiscs for one minute, substantial improvements 
in peptide recovery are noted.  Finally, incorporating both phospholipid removal with cholate 
disassembly provides an optimized system for Nanodisc peptide recovery.   
6.4.3 HX MS of GGCX Nanodiscs – UPLC 
Improvements to sample preparation including cholate disassembly and zirconium 
oxide phospholipid removal were incorporated into the experimental flow chart for Nanodisc 
HX MS evaluation (Figure 6.14).  Immediately after quenching the deuterium labeled 
sample, a 25:1 ratio of cholate to phospholipid is added to the quenched exchange reaction to 
disassemble the Nanodisc and promote more efficient pepsin digestion.  To facilitate 
phospholipid removal, three milligrams of zirconium oxide resin is added to the sample 
reaction mixture in the last minute of digestion.   
The lipid-free peptide digest is then analyzed using a customized Waters® UPLC HX 
MS system.24  In this system, Waters® nanoACQUITYTM UPLC binary and auxillary solvent 
manager pumps (BSM and ASM respectively) are interfaced with a custom-built temperature 
regulated module.  The temperature controlled chamber houses the injection and trapping 
valves with the injection port exposed on the top of the cooled chamber housing.  The system 
is designed with four Peltier cooling elements, liquid heat exchangers to dissipate heat from 
the Peltiers, and rigid insulation throughout the inner chamber.  A resistance temperature 
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detector is used for feedback control within 0.2oC of the set temperature.  Although not 
utilized for this study, a secondary chamber is designed for online pepsin digestion.  
Validation of the customized UPLC HX MS system has been reported in several studies24, 59, 
60 providing significant advantages in peptide separation and identification with enhanced 
chromatographic reproducibility.   
The UPLC HX MS system was utilized in peptide separations and mass analysis of 
Nanodisc digested continuous labeled time course reactions.  Peptide trapping and desalting 
was completed on a Waters® Xbridge VanGuard column packed with 1. 7 m C18 particles 
(2.1 mm x 5 mm) followed by a second guard column to trap any residual phospholipids 
remaining after zirconium oxide removal.  Analytical separations were completed on a 
Waters® Xbridge 1.7 m C18 column (1.0 mm x 100 mm) and analyzed by a Waters® QTof 
PremierTM with MSE capabilities.  Figure 6.15 compares the chromatographic efficiency of a 
conventional HPLC HX MS empty Nanodisc digestion (A) to a corresponding UPLC HX 
MS separation (B) where peptide elution is evaluated over a constant organic concentration 
range.  In conventional HPLC HX MS chromatograms, the large abundance of membrane 
scaffold peptides present in a 2:1 molar ratio over the target membrane protein hindered the 
mass analysis of low intensity GGCX peptides.  Using the customized UPLC HX MS 
system, however, enhanced GGCX peptide mass analysis was achieved by improving peak 
discrimination by interfering peptides.  Furthermore, UPLC chromatographic separations and 
peptide identification can be evaluated with and without Nanodisc disassembly using cholate 
(Figure 6.16, A and B).  Incorporation of cholate prior to Nanodisc digestion results in over a 
four-fold increase in the number of peptides detected providing significant improvements in 
peptide characterization and validation. 
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A UPLC HX MS time course for GGCX embedded Nanodiscs was evaluated (Figure 
6.17) demonstrating good sample-to-sample reproducibility and excellent correlation 
between replicate sample injections (Figure 6.18).  A triplicate analysis of undeuterated 
GGCX and empty Nanodisc digestions were individually evaluated using MSE technology.  
Peptides identified in two out of three replicate injections were searched in duplicate sample 
time course data sets and processed for deuterium incorporation as a function of time.  
Modeled after Figure 6.6, the topology diagram of GGCX for a UPLC HX MS sample 
analysis reported a combined peptide sequence coverage of 45% (Figure 6.19).  A 
comparison between conventional HPLC and UPLC HX MS analysis of GGCX peptides is 
observed for each targeted GGCX domain.  For respective deuterium uptake plots, the 
average deuterium incorporation is calculated for two replicate sample time course data sets 
and compared between conventional HX MS and UPLC HX MS methodologies.  Despite 
slight variations in deuterium incorporation for each peptide, uptake curves correlate within 
experimental error for the two HX MS systems.   
Although topology diagrams compare closely between the conventional HPLC and 
UPLC HX MS sample systems, minor deviations may be attributed to variations in digestion 
patterns upon incorporation of cholate into the digestion mixture.  As cholate facilitates 
Nanodisc disassembly, pepsin is provided with greater access to digestion sites on GGCX.  
Despite the large increase in detected peptides upon cholate disassembly and improvements 
to chromatographic efficiency by UPLC separation, very minor changes in peptide recovery 
were noted in topology mapping.  Thus, the majority of identified GGCX peptides upon 
cholate digestion resulted from overlapping peptide sequences. 
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The Nanodisc HX MS methodology designed in this chapter provides a novel 
approach for evaluating membrane protein dynamics in a nanoscale membrane environment.  
In contrast to soluble proteins, several sample modification protocols were designed to limit 
sample contamination by phospholipid and improve upon sample digestion and peptide 
recovery. The superior chromatography attainable by UPLC coupled with efficient cholate 
induced disassembly and ZrO2 facilitated phospholipids removal, provides an optimized 
system for complex Nanodisc digestions under short gradient conditions (8-40% in 6 
minutes) and 0oC required for minimizing undesirable deuterium back-exchange during 
sample analysis.61 
6.4.4 Biological Validation – HX MS of Propeptide Embedded GGCX Nanodiscs 
Protein systems present a very complex molecular interworking in which structural 
features and dynamic conformations contribute significantly to the functional responsibilities 
of the protein.  Nanodisc technology enables isolation of single molecule protein complexes 
in a discoidal phospholipid bilayer, providing a controlled system in which to probe protein 
dynamics using hydrogen exchange mass spectrometry.  The combination of these two 
powerful techniques provides a novel platform for investigating the uncharted territory of 
membrane proteins in a native environment.   
Using the target integral membrane protein, GGCX as a model system, methodology 
has been developed for UPLC HX MS investigation of membrane protein embedded 
Nanodisc systems.  To validate the Nanodisc UPLC HX MS system, we investigated 
biologically relevant questions involving conformational protein fluctuations upon substrate 
binding to GGCX.  As previously mentioned, the propeptide domain of vitamin K-dependent 
(VKD) proteins is an eighteen amino acid highly conserved peptide sequences that is thought 
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to bind GGCX between residues 495 and 513.62, 63  Through a processive mechanism, the 
propeptide is believed to bind tightly to GGCX and anchor the VKD protein in place, while 
selected glutamic acid residues in the Gla domain are carboxylated to gamma-carboxy 
glutamic acids in the presence of cofactors: vitamin K hydroquinone, carbon dioxide, and 
oxygen.64, 65  Propeptide incorporation into GGCX Nanodiscs is evaluated by the UPLC HX 
MS method to identify site-specific domains which experience dynamic fluctuations upon 
substrate binding and aid in better understanding conformational changes of GGCX as a 
three dimensional system.   
Following the flow chart in Figure 6.14, consensus propeptide (pCon) incorporated 
GGCX Nanodiscs are labeled with deuterium for a continuous time course experiment.  At 
selected time intervals, Nanodisc samples are quenched (pH 2.5 and 0oC) and immediately 
disassembled by the addition of cholate followed by pepsin digestion on ice.  Zirconium 
oxide resin is added to the digest sample to remove excess phospholipid released from the 
Nanodisc structure.  Peptide analysis was completed on a customized Waters® UPLC HX 
MS system under extended gradient conditions of 8-40% acetonitrile in twelve minutes.  
Propeptide incorporated GGCX Nanodiscs, GGCX Nanodiscs, and propeptide substrate 
alone were each investigated in a continuous labeling HX time course evaluation (10 
seconds, 1 minute, 5 minutes, 30 minutes, and 4 hours).  Chromatographic comparison 
between GGCX Nanodiscs and propeptide incorporated GGCX Nanodiscs is provided in 
Figure 6.20 illustrating the level of sample complexity involved in digestion of substrate 
incorporated GGCX Nanodiscs.   
GGCX and pCon peptides are identified in replicate MSE sample digestions and 
searched in duplicate time course evaluations for uptake curve generation.  Deuterium 
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incorporation into each pepsin fragment was analyzed for sample systems with and without 
incorporation of substrate additives.  In studying characteristic propeptide pepsin fragments 
(Figure 6.21) with or without the presence of GGCX Nanodiscs, uptake curve generation 
indicates propeptide protection upon binding the GGCX target membrane protein.  The 
propeptide remained protected from deuterium incorporation even after four hours of 
labeling, indicative of solvent protection and/or hydrogen bonding with GGCX. 
Limited exchange into functionally important regions of GGCX upon propeptide 
incorporation provides greater insight into the behavior of the protein in solution.  The 
topology diagram in Figure 6.22 summarizes GGCX peptides characterized in duplicate time 
course evaluation and identified in both Nanodisc digestions with and without the 
incorporation of pCon.  The combined peptide percent sequence coverage is reported as 49% 
with several overlapping peptide sequences providing further confirmation of deuterium 
uptake.  Among the peptides identified, four noteworthy GGCX domains are evaluated 
(Figure 6.22, A-D).  The collection of all remaining identified GGCX peptide uptake curves 
are referenced in Appendix A4.   
For the evaluation of GGCX uptake curves in the presence of propeptide, one must 
consider not only the positive or negative inflection in deuterium uptake upon substrate 
binding, but also the magnitude difference in deuterium incorporation between the two data 
sets.  In these studies, the cumulative error of measuring deuterium uptake is approximately ± 
0.5 Daltons.  Thus, any change in deuterium incorporation greater than ± 0.5 Daltons was 
considered significant for the purposes of comparing the two data sets.  Consistent with 
structural predictions, the representative transmembrane domain peptide (375-382) 
experiences very similar deuterium incorporation with and without the presence of the 
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consensus propeptide (A).  Although the addition of propeptide to the sample system is 
observed by a reduction in deuterium incorporation, the deuterium uptake difference is at the 
threshold limit of  0.5 Daltons used for classification of a significant change. 
Likewise, the solvent exposed peptide between residues 643-659 exhibits very little 
deviation in deuterium incorporation after the initial binding of propeptide (C).  In the ten 
second and one minute time points, propeptide binding induces a drastic conformational 
change in GGCX which is then seen to relax for most peptides such as 643-659 to a similar 
conformation observed in the unbound form.  In contrast to the transmembrane (375-382) 
and solvent exposed peptides (643-659) investigated, other domains exhibit much more 
drastic changes in deuterium uptake as shown in both the highly conserved GGCX domain 
(B) and the proposed propeptide binding domain (D).  Regions within the predicted 
propeptide binding domain, such as residues 491-507, are characterized by a very dynamic 
change in deuterium uptake supporting the notion of propeptide binding to GGCX in this 
region or propeptide induced hydrogen bonding altering protein conformation.  The most 
significant change in deuterium incorporation is experienced within the first ten seconds of 
labeling followed by gradual relaxation.  Although the 491-507 peptide appears very 
protected from deuterium exchange, this region is somewhat flexible as revealed by the 
ability to incorporate deuterium over time.   
In addition to the proposed propeptide binding domain of GGCX, another region of 
GGCX illustrating very pronounced changes in deuterium uptake is for the peptide 395-401.  
The highly conserved domain of GGCX between residues 394 and 404 are particularly of 
interest as this is the region of GGCX is thought to participate in the catalytic carboxylation 
of vitamin K-dependent proteins.66, 67  In the unbound form of GGCX, the peptide 395-401 
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appears only capable of incorporating half of the available exchange sites in the peptide 
sequence.  With this observation it can be concluded that the peptide may reside in a slightly 
solvent protected environment or be involved in secondary structural elements limiting 
exposure for deuterium exchange.  Upon incorporation of propeptide, the 395-401 peptide is 
observed as being even more protected from deuterium exchange with a gradual progression 
towards unbound conformation.  If we assume that the propeptide substrate binds GGCX in 
the 495-513 domain and that the 394-404 conserved region is involved in catalytic 
carboxylation, then changes in deuterium incorporation for the 395-401 peptide provide a 
very strong argument that propeptide binding influences structural reorganization promoting 
protein stability and conformational accessibility for VKD carboxylation.  The allosteric 
relationship between the propeptide and Gla domain for substrate carboxylation is further 
supported in the literature.64, 68, 69 
Furthermore, a connection may be deduced between propeptide binding and GGCX 
stability.  As mentioned in Chapter 5, incorporation of propeptide substrate into GGCX 
embedded Nanodiscs is shown to protect the GGCX bound complex from protein 
aggregation and enzymatic inactivity.  This conclusion can also be supported by the 
deuterium uptake curve for the GGCX peptide 395-401 where a reduction in deuterium 
exchange is evident of conformational reorganization protecting the active site from 
inactivation.  GGCX Nanodiscs HX MS with incorporated propeptide thus provides an 
excellent experimental system in which to investigate structural fluctuations experienced by 
GGCX upon substrate binding.  Large deviations in deuterium incorporation for both the 
491-507 and 395-401 peptides provide a nice correlation with biochemical data supporting 
the involvement of these protein domains in propeptide binding and catatlytic carboxylation.   
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To normalize the changes in deuterium incorporation, topology diagrams were plotted 
at each labeled time point interval expressing the difference in deuterium uptake for a given 
peptide sequence divided by the maximum number of potential deuterium exchange sites 
(Figure 6.23).  For pCon incorporated GGCX samples, a decrease in deuterium uptake is 
indicative of solvent protection or hydrogen bonding and is correlated with a positive 
normalized change in uptake.  Likewise, a negative percent deviation is expressed as an 
increase in deuterium uptake as a result of conformational loosening of protein structure or 
subtle exposure to solvent upon propeptide incorporation.  Normalized percent changes in 
deuterium incorporation for each GGCX peptide identified are color mapped onto topology 
diagrams where red represents a change in deuterium incorporation greater than 35%, orange 
34.9-25%, yellow 24.9-15%, green, 14.9-5%, and blue <4.9%.  For peptides that experience a 
decrease in deuterium uptake upon propeptide binding that is below the experimental 
threshold of 0.5 Daltons, the peptide is colored in blue and is represented as having no 
significant change.  Contrastingly, if the propeptide incorporated sample experiences an 
increase in deuterium incorporation  within the error threshold of 0.5 Daltons, the peptide is 
colored in purple.   
The topology diagrams in Figure 6.23 are compiled to provide a detailed story of 
substrate binding to GGCX highlighting the dynamic progression of conformational change 
as a function of time.  In large, changes in deuterium incorporation were mostly observed as 
a decrease in deuterium levels with the exception of minor deviations where deuterium levels 
were increased upon propeptide binding (purple).  Thus, the topology diagrams can be 
evaluated by considering green, yellow, orange, and red peptides as experiencing increasing 
solvent protection or hydrogen bonding  with increasing color intensity, blue as peptides that 
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experience  no or very little change in deuterium uptake upon propeptide binding, and purple 
residues that shown an increase in deuterium incorporation when propeptide is incorporated 
into GGCX Nanodiscs.  Percent deviations are define by a maximum of 40% change at the 
10 second time point for the 491-507 GGCX peptide and a minimum of -6.3% change for the 
305-321 GGCX peptide at the 5 minute time point interval.  Respective deuterium uptake 
plots for these peptides as well as a compiled listing of all peptides identified between the 
two samples sets can be referenced in Appendix A4. 
As mentioned in the previous section, very pronounced changes in the 394-404 and 
495-513 GGCX domains support the belief that propeptide binding induces structural 
reorganization in GGCX providing access of vitamin K-dependent proteins to the catalytic 
binding domain.66, 67, 68, 71  Treating these domains as “hot spots” in the GGCX protein 
structure, we can notice an instantaneous conformational change upon deuterium 
incorporation in propeptide incorporated samples at the ten second time interval.  
Neighboring peptide domains surrounding the 491-507 “hot” peptide are shown to 
experience moderate changes (yellow/orange) in deuterium incorporation providing a loose 
association of three-dimensional structure.  This is further supported by the notion that both 
the propeptide and catalytic active site domains must be in close proximity for VKD 
carboxylation as governed by the short peptide linker between the end of the propeptide 
domain and the first glutamic acid residue in the Gla domain.   
Once the propeptide is anchored to the binding site domain in GGCX, we begin to 
notice gradual conformational influences affecting the highly conserved 394-404 region at 
the five minute labeling time point while other domains within GGCX begin to relax to an 
unbound conformation.  For most peptides, this relaxation continues for the remainder of the 
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time course, however, for peptides overlapping the 495-513 domain, deuterium uptake 
remains strongly impacted by propeptide binding.  In addition to these functional GGCX 
domains, there are other peptide regions exhibiting interesting behavior that must be further 
explained.  Unlike most other peptides which experience an initial burst in deuterium when 
bound with propeptide, the peptide 299-304 present in the fourth transmembrane domain, 
does not experience significant deviations until the thirty minute time interval.  Referencing 
the deuterium uptake curve in Appendix A4-Figure A4.5, this peptide behaves very closely 
to what we would expect for a peptide residing in a transmembrane domain with very low 
levels of deuterium incorporation throughout the entire labeling reaction.  Upon propeptide 
labeling, however, deuterium incorporation is further obstructed.  Although we do not yet 
have a good explanation for this occurrence, reproducibility of this sighting in future 
experimentations will support if such variations are real.   
For all peptides except for 76-96 and 305-321, propeptide binding decreases the level 
of deuterium incorporated into GGCX peptides.  Although these peptides exhibit evidence of 
protein relaxation upon substrate binding, the deviation in deuterium uptake compared to the 
unbound GGCX control is very small and only temporarily induced.  Both peptides are 
shown to neighbor a transmembrane domain and it is particularly interesting that the 305-321 
peptide neighbors the fourth transmembrane domain at the point in time where the 299-304 
peptide is shown to begin exhibiting dynamic behavior.  Although no direct conclusions can 
be draw from this observance, the study of deuterium exchange upon propeptide binding 
begins to initiate a more educated storyline uniting structural influences of GGCX with 
functional roles involving carboxylation.   
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Knowldege of conformational changes influencing substrate binding is important in 
understanding protein function.  Our results using Nanodisc UPLC HX MS reports the first 
application indicating site-specific conformational changes of propeptide bound GGCX in 
solution.  As with many membrane proteins including GGCX, structural relationships upon 
substrate binding are extremely difficult to obtain in the absence of crystal structure 
determination.  Nanodisc UPLC HX MS thus provides a powerful methodology enabling 
investigation of protein conformations and dynamic structural fluctuations in an isolated 
membrane environment.   
6.4.5 Improvements to Nanodisc HX MS Methodology – Future Experimentation 
Significant advancements have been made in method determination and validation of 
Nanodisc HX MS with the target membrane protein GGCX.  To further improve this 
methodology, however, additional efforts must be focused to improve peptide recovery to 
provide a comprehensive representation of dynamic protein fluctuations in solution.  In 
addition to the hydrophobic nature of the GGCX integral membrane protein embedded into a 
discoidal phospholipid bilayer, post-translational modifications including N-linked 
glycosylations may also limit peptide recovery.  Mass spectrometry results have shown that 
N-linked glycosylations occur at positions N459, N550, N605, and N627 in GGCX.72  
Furthermore, the potential glycosylation site at N570 is present only if all five natural 
glycosylation sites are simultaneously mutated.  Removal or mutation of the oligosaccharides 
in wild-type GGCX did not affect either the carboxylation or epoxidation activity, suggesting 
that N-linked glycosylation is not required for the enzymatic function of GGCX. In contrast, 
however, strong evidence indicates the necessity for N-linked glycosylations for protein 
folding and stability.  Thus removal of the oligosaccharides by glycosidase chemical 
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cleavage will distort the three-dimensional conformation of GGCX and likely alter deuterium 
uptake plot characterization.  With such structural limitations inhibiting efficient sample 
digestion, alternative sample treatment must be investigated.   
One proposed mechanism is to reduce peptide contribution from the membrane 
scaffold protein.  In Nanodisc formation the MSP1D1 protein encircles the phospholipid 
bilayer and is present in a 2:1 ratio with the target GGCX providing direct access for 
proteolytic digestion in combination with high signal intensity for peptide identification.  The 
abundance of MSP1D1 peptides, however, further complicates data analysis resulting in 
peptide co-elution and sequence mis-assignment under short gradient conditions.  To reduce 
scaffold protein contributions, the MSP1D1 protein can be biotinylated where the degree of 
biotinylation is optimized to promote Nanodisc formation.  After continuous labeling, GGCX 
Nanodiscs are quenched and digested with pepsin in the presence of nitro-avidin promoting 
selective MSP1D1 peptide removal.  Modifying the binding-site tyrosine residue in avidin by 
nitration, reduces the pKa of the phenol group promoting binding of biotin under low pH 
conditions with a very high association constant (>109 M-1).73  The modified avidin, thus 
provides a reversible interaction with biotinylated macromolecules dependent on pH.  Early 
stage investigations of MSP1D1 peptide removal is being evaluated using the nitro-avidin 
approach and will be further characterized in future experimentation.  In addition to sample 
handling strategies, another method for improving peptide recovery is to alter the digestion 
enzyme for proteolytic digestion.  In the last few years, there has been a rise in the use of 
aspergillopepsin, also known as Factor XIII, as an alternative to porcine pepsin.74-76  As 
indicated from in-gel digestions of GGCX with pepsin (data not shown), peptide recovery is 
limited by inefficient digestions to 50% sequence coverage.  Thus, modifying digestion 
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patterns using an alternative acid catalyzed protease may provide improvements to peptide 
identification. 
In conjunction with HX MS advancements for soluble protein investigation, 
improvements for membrane protein analysis include the development of a high throughput 
standard platform for membrane protein interrogation.  Current method development flow 
schemes involve an off-line sample preparation followed by peptide separation and mass 
analysis.  Creating an online approach to sample handling will greatly improve sample 
reproducibility through automation while reducing human error and sample contamination. 
6.4.6 Conclusions 
The incorporation of HX MS with Nanodisc technology presents the first application of 
hydrogen deuterium exchange for a membrane protein incorporated into a phospholipid 
bilayer that closely mimics a native environment.  For membrane proteins, structural 
determination is a widely sought goal.  Nanodisc technology provides a uniform technique in 
which membrane proteins are assembled into a controlled and reproducible environment that 
can be optimized for a transmembrane protein of interest.  Previous studies involving 
membrane proteins have been severely limited in knowledge regarding structural and 
functional roles due to sample complexities.  Despite these challenges, membrane proteins 
provide some of the most rewarding information regarding protein transport and cell 
signaling.  Using Nanodiscs as the means and hydrogen-deuterium mass spectrometry as the 
tool, we can begin to answer questions regarding membrane protein structure and functional 
dynamics 
Investigating the target transmembrane protein GGCX, HX MS methodology was 
modified to optimize peptide recovery through Nanodisc disassembly by the addition of 
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cholate, phospholipid removal via zirconium oxide precipitation, and enhanced 
chromatographic efficiency using UPLC technology.  Peptide recovery for GGCX was 
reported at a maximum of 49% sequence coverage for a twelve minute gradient from 8-40% 
acetonitrile.  Future developments in Nanodisc HX MS are aimed to improve target 
membrane peptide recovery.  In addition to improvements in method development, 
alternative membrane protein systems, such as bacteriorhodopsin, will be investigated 
demonstrating the versatility of the Nanodisc HX MS approach as well as comparison of 
deuterium uptake with known crystal structures.   
Topology mapping of transmembrane proteins using Nanodisc HX MS provides a novel 
methodology for the advancement of membrane biology.  From a biochemical perspective, 
GGCX Nanodisc HX MS was investigated upon incorporation of propeptide substrate.  
Conformational changes observed in deuterium uptake upon substrate binding correlated 
nicely with experimental evidence of functionally important GGCX domains.  For many 
membrane proteins that lack crystal structures, Nanodisc HX MS provides a means to 
investigate protein dynamics upon substrate induced binding.  Identification of protein 
conformational changes under differing experimental conditions provides further knowledge 
regarding protein folding pathways in addition to functional responsibilities.   Great strides in 
Nanodisc HX MS methodology have had a profound impact on the study of membrane 
protein dynamics in a controlled native environment while providing a systematic approach 
for addressing critical questions regarding membrane protein function.  Future 
experimentation aimed to improve sample throughput will not only provide a universal 
methodology for membrane protein investigation, but will reveal a wealth of information in 
the mostly uncharted territory of membrane protein dynamics. 
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6.6 Figures 
D2O
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Figure 6.1 Schematic diagram illustrating hydrogen deuterium exchange of proteins. Labile 
back-bone amide hydrogens () become deuterated (red)when the protein is placed in 
a D2O solution.  The rate of deuterium incorporation is dependent on solvent 
accessibility, hydrogen bonding, pH, and temperature.  NHs that are not hydrogen 
bonded and reside in solvent exposed regions become deuterated rapidly, whereas 
amide protons involved in secondary structural elements (i.e. -helices) or protected 
from solvent exposure are less likely to exchange.  Structures created from PDB 
P05B (Horse Heart Myoglobin) using PyMol software. 
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Figure 6.2 Conventional HPLC Nanodisc HX MS workflow.  GGCX embedded Nanodiscs 
are purified by size-exclusion chromatography (SEC) and diluted ten-fold in 
deuterated buffer for a continuous labeling time course reaction.  At set time 
intervals, the sample reaction is quenched at pH 2.5 and 0oC and immediately 
digested with pepsin for five minutes on ice.  Injected samples are quickly trapped 
and desalted on a Poros 20R2 column followed by phospholipid extraction on an 
Xbridge VanGuard column packed with 3.5 m C18 particles.  Reverse phase 
separations are conducted on an Xbridge 3.5 m C18 column (1.0 mm x 100 mm) 
followed by mass analysis on a Waters® LCT PremierTM XE.  To limit sample back-
exchange mobile phase components, sample injector, and column hardware are 
cooled in an ice bath. 
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Figure 6.3 Conventional HPLC chromatographic separation of empty Nanodisc pepsin 
digestion without lipid trapping.  Peptides were separated on a Waters® Xbridge 3.5 
m C18 column (1.0 mm x 100 mm) over a 15 minute gradient from 10-50% 
acetonitrile followed by a five minute ramp to 98%.  MSP1D1 peptides were shown 
to elute by 40% organic content, followed by undigested MSP1D1 at 50% 
acetonitrile, and DOPC phospholipid at 95% organic.  Mass analysis was completed 
on a Waters® LCT PremierTM XE. 
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Figure 6.4 Conventional HPLC chromatographic separation of Nanodisc pepsin digestions 
comparing empty Nanodiscs (blue) and GGCX embedded Nanodiscs (red) with lipid 
trapping.  Peptides were separated on a Waters® Xbridge 3.5 m C18 column (1.0 
mm x 100 mm) over a 15 minute gradient from 10-50% acetonitrile.  Mass analysis 
was completed on a Waters® LCT PremierTM XE. 
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Figure 6.5 Evaluation of Nanodisc HX MS data quality and generation of deuterium uptake 
curves.  (A) Chromatographic time course exchange reaction of GGCX Nanodisc 
peptic digests and corresponding empty Nanodisc (blue) and GGCX Nanodisc (red) 
undeuterated controls.  The bar at ~11 minutes corresponds to the scan combined to 
generate panel B.  (B) Spectra for the m/z range 500-500 Daltons where MSP1D1 
peptides are highlighted in black and GGCX specific peptides distinguished in red.  
(C) Magnification of the m/z range 532-545 Daltons illustrating typical mass spectral 
quality for deuterium uptake curve generation.  The bar over the 30 minute GGCX 
peptide time point corresponds to the isotopic peptide envelope identified in panel D.  
(D) At each time point interval, the centroided mass of a peptide isotopic peak 
envelope is determined using HX Express software.  The change in peptide mass by 
deuterium incorporation is plotted as a function of label time for each unique peptide 
identified where the y-axis is represented by the maximum number of potential 
deuterium atoms a single peptide can uptake (panel E and F for GGCX and MSP1D1 
peptides respectively). 
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Figure 6.6 Deuterium incorporation of GGCX from embedded Nanodisc pepsin digestions 
and analysis by conventional HPLC HX MS.  Predicted two-dimensional membrane 
topology of GGCX is labeled with identified peptic peptides shown in red and 
characterized by a combined sequence coverage of 41%.  Deuterium incorporation in 
peptic peptides depicted in four representative regions of GGCX (A-D).  Overlaying 
uptake curves are indicative of sample reproducibility for a replicate time course 
evaluation. 
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Figure 6.7 PONDR® plots predicting naturally distorted regions in GGCX (A) and 
MSP1D1(B).  Functioning from primary sequence alone, PONDR® predicts 
unstructured protein domains based upon a model systems.  In conjunction with 
protein disorder, PONDER® can also be used to predict exchangeable proton sites 
correlating with HX uptake curves in addition to understanding digestion patterns for 
target proteins.  Access to PONDR® was provided by Molecular Kinetics 
(Inianapolis, IN). 
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Figure 6.8 Deuterium incorporation of lipid-free MSP1D1 pepsin digestion and analysis by 
conventional HPLC HX MS.  Ribbon diagram of membrane scaffold protein modeled 
after human Apolipoprotein A1(PDB 2A01).  Deuterium incorporation in peptic 
peptides depicted in five representative regions of MSP1D1.  (Figure adapted from 
Christopher Morgan). 
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Figure 6.9 Deuterium incorporation of MSP1D1 from embedded Nanodisc pepsin digestion 
and analysis by conventional HPLC HX MS.  Ribbon diagram of membrane scaffold 
protein modeled after human Apolipoprotein A1.  Identified peptic peptides shown in 
green with a combined sequence coverage of 83%.  Deuterium incorporation in peptic 
peptides depicted in three representative regions of MSP1D1.  Overlaying uptake 
curves are indicative of changes in deuterium uptake for selected peptides when 
incorporated into GGCX occupied Nanodiscs, empty Nanodiscs, or lipid-free 
MSP1D1. 
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Figure 6.10 Evaluation of deuterium uptake for undigested MSP1D1 in conventional HPLC 
HX MS analysis.  (A) Chromatographic time course exchange reaction for undigested 
MSP1D1 in empty Nanodiscs where the undeuterated control is identified in blue.  
(B) Maximum entropy processing (MaxEnt1) of protein envelopes provides a 
deconvoluted protein mass indicative of deuterium incorporation at selected time 
intervals.  (C) Corresponding deuterium uptake plot for undigested MSP1D1 
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Figure 6.11 Size exclusion chromatograms overlaying self-assembled empty Nanodiscs 
(blue) and empty Nanodiscs prepared under quench conditions (pH 2.5; red).  SEC 
separations were performed on a standard protein calibrated Tosoh TSKgel BioAssist 
G3SWXL (7.8 mm x 300 mm; 5 m particles, 250 Å) column equilibrated with 50 
mM Tris-HCl pH 7.0, 0.15 M NaCl, 0.02% NaN3 (TBS) buffer at a flow rate of 0.5 
mL/minute.  Absorbance detection was monitored at 280 nm. 
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Figure 6.12 Evaluation of empty Nanodisc cholate disassembly by conventional HPLC HX 
MS.  HPLC separation of 44 pmol empty Nanodiscs (88 pmol MSP1D1; 5.9 nmol 
DOPC) with (red) and without (blue) addition of 150 nmol sodium cholate. 
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Figure 6.13 Evaluation of zirconium oxide selected phospholipid removal in empty 
Nanodiscs.  (A) Phosphate analysis of empty Nanodisc (ND) samples before (blue) 
and after (red) sample treatment with zirconium oxide (ZrO2) precipitation cartridges 
(Supelco HybridSPETM; 30 mg resin) for indicated time intervals.  (B) Evaluation of 
nonspecific peptide adsorption upon treatment with zirconium oxide resin.  Bar graph 
and corresponding mass spectra for the selected MSP1D1 peptide at m/z 479.2 
(CS+2) is a representative example of several peptide investigated.  Recovered signal 
intensity is evaluated according to the lipid-free MSP1D1 control (blue), for 1 minute 
sample treatment with ZrO2 precipitation cartridges (red) and three milligrams of 
ZrO2 extracted resin (green) with and without cholate disassembly. 
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Figure 6.14 UPLC Nanodisc HX MS workflow.  GGCX embedded Nanodiscs are purified by 
size-exclusion chromatography (SEC) and diluted ten-fold in deuterated buffer for a 
continuous labeling time course reaction.  At set time intervals, the sample reaction is 
quenched at pH 2.5 and 0oC and immediately disassembled by the addition of cholate 
to the reaction mixture followed by pepsin digestion for five minutes on ice.  In the 
last minute of digestion ZrO2 resin was added to the digestion mixture to selectively 
remove phospholipid.  Injected samples are quickly trapped, desalted, extracted on a 
sequential pair of Xbridge VanGuard columns packed with 1.7 m C18 particles.  
Reverse phase separations are conducted on an Xbridge 1.7 m C18 column (1.0 mm 
x 100 mm) followed by mass analysis on a Waters® QTof PremierTM.  To optimize 
chromatographic performance while minimizing sample back-exchange, sample 
separations were completed using a customized Waters® UPLC HX system. 
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Figure 6.15 Chromatographic separations of empty Nanodisc pepsin digestions comparing 
conventional HPLC (A) and UPLC (B) HX systems.  For conventional HPLC 
analysis, peptide separations were completed on a Waters® Xbridge 3.5 m C18 
column (1.0 mm x 100 mm) over a 15 minute gradient from 10-50% acetonitrile.  
Contrastingly, UPLC analysis was completed on a customized HX MS system 
equipped with a Waters® Xbridge 1.7 m C18 column (1.0 mm x 100 mm) enabling 
peptide separation of cholate disassembled empty Nanodiscs over a 6 minute gradient 
from 8-40% acetonitrile.  Peptide elution profiles were compared over the acetonitrile 
concentration range of 12.5-28.5%. 
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Figure 6.16 Evaluation of empty Nanodisc cholate disassembly by UPLC HX MS.  (A) 
UPLC separation of 50 pmol GGCX Nanodiscs (100 pmol MSP1D1; 6 nmol DOPC) 
with (black) and without (green) addition of 150 nmol sodium cholate.  (B) Average 
number of peptides identified in corresponding UPLC experiments with and without 
cholate addition. 
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Figure 6.17  UPLC HX MS chromatographic time course exchange reaction of GGCX 
Nanodisc peptic digests and corresponding empty Nanodisc (blue) and GGCX 
Nanodisc (red) undeuterated controls.  UPLC analysis was completed on a 
customized HX MS system equipped with a Waters® Xbridge 1.7 m C18 column 
(1.0 mm x 100 mm) enabling peptide separation of cholate disassembled empty 
Nanodiscs over a 6 minute gradient from 8-40% acetonitrile.  Mass analysis was 
completed on a Waters® QTof PremierTM. 
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Figure 6.18 Evaluation of experimental reproducibility of duplicate UPLC HX MS empty 
Nanodisc peptide digestion preparations.  UPLC analysis was completed on a 
customized HX MS system equipped with a Waters® Xbridge 1.7 m C18 column 
(1.0 mm x 100 mm) enabling peptide separation of cholate disassembled empty 
Nanodiscs over a 6 minute gradient from 8-40% acetonitrile.  Mass analysis was 
completed on a Waters® QTof PremierTM. 
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Figure 6.19 Deuterium incorporation of GGCX from embedded Nanodisc pepsin digestion 
and analysis by UPLC HX MS.  Predicted two-dimensional membrane topology of 
GGCX is labeled with identified peptic peptides shown in red and characterized by a 
combined sequence coverage of 45%.  Deuterium incorporation in peptic peptides 
depicted in four representative regions of GGCX (A-D).  Overlaying uptake curves 
are indicative of sample reproducibility for a replicate time course evaluation 
comparing conventional HPLC HX MS and UPLC HX MS peptide deuterium 
incorporation. 
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Figure 6.20 UPLC chromatographic separations of GGCX Nanodisc pepsin digestions with 
(green) and without (red) incorporated consensus propeptide.  UPLC analysis was 
completed on a customized HX MS system equipped with a Waters® Xbridge 1.7 m 
C18 column (1.0 mm x 100 mm) enabling peptide separation of cholate disassembled 
empty Nanodiscs over a 12 minute gradient from 8-40% acetonitrile.  Mass analysis 
was completed on a Waters® QTof PremierTM mass spectrometer. 
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Figure 6.21 UPLC HX MS chromatographic time course exchange reactions after pepsin 
digestion for consensus propeptide (pCon) with (green) and without (orange) 
incorporation into GGCX Nanodiscs.  The change in peptide mass by deuterium 
incorporation is plotted as a function of label time for the pCon peptide and compared 
for sample systems with and without GGCX binding.  UPLC analysis was completed 
on a customized HX MS system equipped with a Waters® Xbridge 1.7 m C18 
column (1.0 mm x 100 mm) enabling peptide separation of cholate disassembled 
empty Nanodiscs over a 12 minute gradient from 8-40% acetonitrile.  Mass analysis 
was completed on a Waters® QTof PremierTM mass spectrometer. 
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Figure 6.22 UPLC HX MS deuterium incorporation of GGCX from embedded Nanodisc 
pepsin digestions with and without the presence of incorporated consensus propeptide 
(pCon).  Predicted two-dimensional membrane topology of GGCX is labeled with 
identified peptic peptides shown in red and characterized by a combined sequence 
coverage of 49%.  Deuterium incorporation in peptic peptides depicted in four 
representative regions of GGCX (A-D) and compared for samples with (green) and 
without (red) propeptide incorporation. 
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Figure 6.23 Summary of peptide normalized percent deuterium change for GGCX Nanodisc 
samples prepared with and without the incorporation of consensus propeptide (pCon).  
A positive percent change is represented by lower levels of deuterium incorporation 
for a given peptide in the presence of pCon and is indicative of solvent protection or 
hydrogen bonding.  A negative percent change or an increase in deuterium 
incorporation, represents conformational reorganization upon propeptide binding 
resulting in localized solvent exposure.  Changes in deuterium uptake for GGCX 
Nanodisc peptides are monitored over a continuous labeling time course and analyzed 
by a UPLC HX MS system at defined time intervals. 
 
 
 
 
 
 
 
 
Appendix A1 – Purification of Recombinant Wild-Type Gamma-Glutamyl 
Carboxylase (GGCX) 
________________________________________________________ 
 Appendix A1 will focus on a detailed protocol for purification of Gamma-Glutamyl 
Carboxylase (GGCX) from Spodoptera frugiperda (Sf9) insect cells.  The protocol is 
reported is for a 5 liter sample cell preparation decanted of cell media and frozen at -80oC.  
GGCX, expressed with a C-terminal epitope tag (EDQVDPRLIDGK), is purified using a 
calcium dependent HPC4 antibody resin for affinity chromatography.  Throughout the 
purification protocol, sample aliquots are saved to determine GGCX activity and protein 
purity.  The protocol for GGCX purification is modified from Wu et al.1 
 
A1.1  Materials 
Reagents used in Gamma-Glutamyl Carboxylase protein purification are as follows: 1,2-
dioleoyl-sn-glycero-3-phosphocholine [DOPC] (Avanti Polar Lipids, Alabaster, AL), 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate [CHAPS] (Sigma-Aldrich, St. 
Louis, MO), 3-(N-morpholino)-propanesulfonic acid [MOPS] (Sigma-Aldrich), benzamidine 
hydrochloride (Sigma-Aldrich), calcium chloride dihydrate (Fisher Scientific, Fair Lawn, NJ) 
[CaCl2.2H2O], dithiothreitol [DTT] (Roche Applied Sciences, Indianapolis, IN), 
ethylenediamine-tetraacetic acid [EDTA] (Mallinckrodt Chemicals, Raleigh, NC), glycerol 
(Fisher Scientific), immunoglobulin G [IgG] (Sigma-Aldrich), sodium azide [NaN3] (Sigma-
Aldrich), 14C labeled sodium bicarbonate [NaH14CO3] specific activity 55 mCi/mmol (MP 
401 
Biomedicals, Solon, OH), sodium chloride [NaCl] (Fisher Scientific) and Vitamin K1(25) from 
Hospira Incorporated (Lake Forst, IL) stabilized with phytonadione injectable emulsion.  
Protease inhibitors including aprotinin, leupeptin, pepstatin, and phenylmethyl sulfonyl 
fluoride were purchased from Roche Applied Science.  Anti-HPC4 monoclonal antibody 
coupled Sepharose resin was obtained from Dr. Charles T. Esmon (Cardiovascular Biology 
Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK).2  The 
pentapeptide Gla domain FLEEL (Phe-Leu-Glu-Glu-Leu) was purchased from Bachem 
(Philadelphia, PA) and the factor IX propeptide [pFIX] (TVFLDHENANKILNRPKR) was 
synthesized and purified by Chiron Mimotopes (Calyton, Victoria, Australia). 
Stock preparations and concentrations of reagents are as follows: 5% DOPC-CHAPS 
(Dissolve 2 grams of lyophilized DOPC phospholipid with 20 mL of 10% CHAPS overnight 
at room temperature.  Add 20 mL of deonizied water when dissolved), 10% CHAPS, 1 M 
MOPS pH 7.5, 1 M benzamidine hydrochloride, 1 M CaCl2.2H2O, 1M DTT, 0.5 M EDTA 
pH 8.0, 1.47 mg/mL IgG, 20% NaN3, 18.4 mM NaH14CO3, 4 M NaCl, 10 mg/mL aprotinin 
in deonized water, 1.0 mg/mL leupeptin in deonizied water, 2.0 mg/mL pepstatin in 
methanol, and 25 mg/mL PMFS in isopropanol.  Aprotinin, leupeptin, and pepstatin stock 
solutions are stored at -80oC for one month while the PMFS stock solution has a lifetime of 
one month at room temperature.  For preparation of vitamin K hydroquinone, a 5.55 mM 
vitamin K1(25) stock is prepared in Buffer K containing 25 mM Tris pH 8.5, 0.5 M NaCl, and 
0.2 M DTT and allowed to incubate overnight at 37oC.  Since KH2 is very unstable and light-
sensitive, stock solutions must be protected from light and air exposure.  When reduced, the 
yellow complex vitamin K1(25) is converted to the colorless vitamin KH2 and can be stored at 
-80oC for up to six months.  The HPC4 affinity resin (5 mg antibody/mL resin) is stored at 
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4oC in stocking buffer containing 20 mM MOPS pH 7.5, 2 M NaCl, 5 mM EDTA pH 8.0, 
0.02% NaN3, and 1 mM benzamidine hydrochloride.  Solutions of FLEEL and pFIX GGCX 
substrates for activity assay determination are prepared as a 30 mM stock in 20 mM MOPS 
pH 7.5 and 100 M stock in deionized water respectively. 
 
A1.2  GGCX Purification Protocol – Microsome Preparation and Solubilization 
 Cell pellets are gradually thawed in an ice bath and combined with chilled Buffer A 
(25 mM MOPS pH 7.5, 0.15 M NaCl, 15% glycerol, 2.0 g/mL aprotinin, 0.5 g/mL 
leupeptin, 1.0 g/mL pepstatin, and 100 g/mL PMFS) to a final volume of 400 mL.  Due to 
the limited half-life of protease inhibitors, the cocktail is added to Buffer A immediately 
prior to use.  The cell suspension is lysed by short-pulse sonication on ice using a large probe 
sonicator (Heat Systems Sonicator ® Ultrasonic Processor XL).  The sonicator was 
programmed to pulse for 1.5 seconds (ON) with an 18.5 second rest period (OFF) for a total 
ON time of 6 minutes and 45 seconds at setting 6.  During lysis, the cell suspension is stirred 
continuously and ice is replenished as needed.   
After sonication, the cell lysate is split between two-250 mL pre-chilled low speed 
centrifuge tubes.  The tubes are mass balanced and centrifuged at 4100xg (6500 rpm; ravg = 
8.7 cm; FIBERLite® F14-6x250y rotor, Piramoon Technology Inc.) on a Sorvall® RC-5B 
Refrigerated Superspeed Centrifuge (Dupont Instruments) for 15 minutes at 4oC to pellet the 
cell components.  During centrifugation, both a tight and loose pellet are formed.  To prevent 
protein contamination, the centrifugation supernant is carefully removed, leaving all pellet 
remnants behind, and placed into pre-chilled ultracentrifuge tubes.  Ultracentrifugation of the 
remaining cell lysate will separate the soluble cell components from that of the cell 
403 
microsome.  Ultracentrifugation tubes are mass balanced and centrifuged at 119,000xg 
(40,000 rpm; ravg = 6.66 cm; Sorvall T647.5 rotor) on an OptimaTM L-60 Preparative 
Ultracentrifuge (Beckman Coulter) for 90 minutes at 4oC.  The supernant from 
ultracentrifugation is removed, and the pellet is homogenized to a uniform consistency.  The 
microsome pellet is washed with Buffer A and re-centrifuged at 119,000xg (40,000 rpm; ravg 
= 6.66 cm; Sorvall T647.5 rotor) for 90 minutes at 4oC to remove any soluble protein 
contaminants.  After the second period of ultracentrifugation, the wash buffer is decanted and 
the microsome pellet is removed and homogenized.  During homogenization, samples must 
be kept on ice to maintain GGCX activity.  Homogenized microsome is suspended in a 
minimal volume of Buffer A to maintain sample consistency and stored at -80oC until total 
protein content is determined.   
To determine the total protein content of the homogenized microsome, a Bio-Rad® 
Bradford protein assay was completed.  The Bradford assay is a dye-binding assay in which a 
differential color change of a dye occurs in response to various concentrations of protein.  An 
IgG protein standard was prepared for standard calibration and serial dilutions of 
homogenized microsome were tested for concentration determination at 595 nm.  Total 
protein concentration was calculated from a standard protein calibration regression equation. 
The homogenized microsome is thawed in an ice bath and diluted with Buffer A to a total 
protein concentration of 10 mg/mL.  For solubilization, Buffer B (25 mM MOPS pH 7.5, 
0.15 M NaCl, 15% glycerol, 0.8% CHAPS, 0.2% DOPC-CHAPS, 2.0 g/mL aprotinin, 0.5 
g/mL leupeptin, 1.0 g/mL pepstatin, and 100 g/ml PMFS) was mixed in a 1:1 (v/v) with 
the diluted homogenized microsome.  The solubilized mixture is stirred in the cold room 
(4oC) for 90 minutes.  After mixing, the solubilized microsome is centrifuged at 119,000xg 
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(40,000 rpm; ravg = 6.66 cm; Sorvall T647.5 rotor) for 90 minutes at 4oC to remove any 
insoluble microsome contaminants. 
 
A1.3 GGCX Purification Protocol – Affinity Purification 
A HPC4 epitope tag (EDQVDPRLIDGK) is introduced at the C-terminal end of GGCX 
and is mimicked after a protein C binding protein where the epitope tag binds the antibody 
resin through a calcium dependent interaction.  For protein elution, EDTA is used to complex 
the calcium and release purified GGCX.  HPC4 resin is initially activated with 50 mM 
MOPS pH 7.5, 0.15 M NaCl, and 2 mM CaCl2.  Depending on the volume of solubilized 
microsome (typically 1100 mL for a 5 L cell preparation), approximately 60-65 mL of 
activated resin is needed for purification.  HPC4 resin is loaded into a BioRad gravity flow 
column (3.5 cm diameter).  Once settled, activation buffer is slowly introduced and washed 
through the resin for ten column bed volumes at a flow rate of 35 mL/hour.  Resin must be 
kept at hydrated 4oC or in the cold room at all times. 
After activating the HPC4 resin, solubilized microsome is added in equal volumes to 
aliquoted resin in 175 mL conical bottles for binding. For a 63 mL bed volume, 
approximiately 9 mL of HPC4 resin is aliquoted per container.  To maximize protein binding 
and minimize detergent bubble formation, the size and shape of the container must be 
optimized to limit dead volume while providing adequate surface area.  Calcium chloride (2 
mM) is added to each container to initiate protein affinity binding.  The solubilized 
microsome containing HPC4 activated resin is rotated end-over-end at 4oC for at least 36 
hours (no more than 48 hours) to promote binding.   
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After binding, the HPC4 resin is allowed to settle and the flow through, or sample filtrate 
not bound to the resin, is collected.  The resin is combined between all containers and added 
in a continuous slurry to the column.  The containers are washed with remaining flow 
through to minimize sample loss and added to the top of the column bed.  After the initial 30 
mL of resin is allowed to settle in the column, the remaining bed volume is compacted with 
pressured flow.  Once compressed, ten column bed volumes of chilled wash buffer are passed 
at a flow rate of 35 mL/hour at 4oC.  Wash buffer is prepared as follows: 25 mM MOPS pH 
7.5, 0.15 M NaCl, 15% glycerol, 0.3% CHAPS, 0.2% DOPC-CHAPS, 2 mM CaCl2.2H2O, 
2.0 g/mL aprotinin, 0.5 g/mL leupeptin, 1.0 g/mL pepstatin, and 100 g/ml PMFS.  To 
prevent disruption of the column bed and limit the carryover of flow through, wash buffer is 
slowly introduced in four additions allowing each addition to fall to the surface of the column 
head before the next addition was made.  Aliquots are collected throughout washing to 
monitor sample loss.   
For GGCX protein elution, wash buffer is allowed to fall to the top of the column bed and 
elution buffer is gradually introduced in 1 mL aliquots to prevent protein dilution over a large 
number of fractions.  Elution buffer is prepared with 25 mM MOPS pH 7.5, 0.15 M NaCl, 
15% glycerol, 0.3% CHAPS, 0.2% DOPC-CHAPS, 10 mM EDTA pH 8.0, 2.0 g/mL 
aprotinin, 0.5 g/mL leupeptin, 1.0 g/mL pepstatin, and 100 g/ml PMFS.  Immediately 
upon addition of elution buffer, fractions are collected (8 mL/fraction) at a flow rate of 30 
mL/hour at 4oC.  After 1.5 column volumes have passed, the flow rate and fraction volume is 
increased to 35 mL/hour and 10 mL/fraction respectively.  Once three column bed volumes 
have passed, evidence of GGCX remnants should be removed from the column.  The elution 
fractions and remaining flow through are frozen with liquid nitrogen and stored at -80oC.  To 
406 
minimize sample activity loss, elution fractions are limited to five freeze-thaw cycles per 
fraction. 
Elution fractions and sample aliquots throughout the purification protocol are tested for 
activity using a radioactivity assay which measures the incorporation of 14CO2 as the 
pentapeptide substrate FLEEL is carboxylated in the presence of factor XI propeptide, KH2, 
CO2, and O2.  A reagent mixture was prepared containing 25 mM MOPS pH 7.5, 0.5 M 
NaCl, 0.16% DOPC-CHAPS, 1.2 mM FLEEL, and 2.4 M pFIX and allowed to incubate 
with GGCX for 30 minutes on ice.  An excess of KH2 (5 L; 5.55 mM stock; -80oC) and 
NaH14CO3 (5 L; 18.4 mM stock; -80oC) in a 1:1 (v/v) ratio is added to the reaction mixture 
for a final volume of 125 L.  The carboxylation assay was allowed to proceed for 30 
minutes at 20oC.  For samples prior to microsome solubilization, 0.32% CHAPS instead of 
0.16% DOPC-CHAPS is added to the reagent mixture.  The carboxylated product (100 L) is 
then precipitated with 800 L of 5% trichloracetic acid.  The samples are boiled to remove 
excess 14CO2 and radioactivity is determined by scintiallation counting (Beckman 
LS5000TD).  The GGCX active concentration for each fraction is determined using a 
specific activity of 1.93e9 cpm per hour per mg.1   
To determine GGCX protein purity and examine sample losses in the flow through 
and wash buffer, SDS-PAGE was evaluated.  For gel analysis of GGCX, NU-PAGE Bis-Tris 
gels were purchased from Invitrogen (Carlsbad, CA) along with the Mark 12 unstained 
protein ladder, and SYPRO® Ruby protein gel stain.  SDS-PAGE buffers were prepared 
according to protocol derived from Invitrogen including a 4X SDS-PAGE loading buffer and 
a 20X MES running buffer. 
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SYPRO® Ruby protein stain requires that the gel first be fixed in a solution of 50% 
methanol and 7% acetic acid for 30 minutes prior to overnight staining with a non-covalent 
fluorescent protein stain.  After staining, the gel was washed for 30 minutes with a solution 
containing 10% methanol and 7% acetic acid and imaged using a 300 nm blue light UV 
transilluminator (Alpha Innotech AlphaImagerTM 2200) with interference wavelength 
filtering.  Figure A1.1 illustrates a typically correlation of GGCX protein active 
concentration and purity where fractions E8 and E9 represent the most concentrated protein 
fractions eluting at approximately one column bed volume.   
After confirming complete GGCX removal from the HPC4 affinity column, resin is 
washed with ten column bed volumes of stocking buffer (20 mM MOPS pH 7.5, 2 M NaCl, 5 
mM EDTA pH 8.0, 0.02% NaN3, and 1 mM benzamidine hydrochloride) and stored at 4oC. 
 
A1.4 GGCX Purification Protocol – SP Sepharose Concentration 
If the objective of protein purification is to maximize GGCX concentration, SP 
Sepharose provides a means to concentrate HPC4 affinity elution fractions using ion 
exchange chromatography.  SP-Sepharose Fast Flow (GE Healthcare, Piscataway, NJ) is a 
sulfopropyl strong cation exchanger which binds purified GGCX in low salt conditions and 
elutes concentrated protein under high salt conditions.  Purified GGCX elution fractions can 
be combined and diluted 1:1 with Buffer D (25 mM MOPS pH 7.5, 15% glycerol, 0.03% 
CHAPS, 0.2% DOPC-CHAPS, 2.0 g/mL aprotinin, 0.5 g/mL leupeptin, 1.0 g/mL 
pepstatin, and 100 g/ml PMFS) to a final concentration of 25 mM MOPS pH 7.5, 0.075 M 
NaCl, 15% glycerol, 0.3% CHAPS, 0.2% DOPC-CHAPS, 5 mM EDTA pH 8.0, 2.0 g/mL 
aprotinin, 0.5 g/mL leupeptin, 1.0 g/mL pepstatin, and 100 g/ml PMFS.  SP Sepharose 
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resin (stored in ethanol) is washed with ten column bed volumes of deionized water followed 
by ten column volumes of 25 mM MOPS pH 7.5 to equilibrate the column.  As a general 
rule, approximately 1 mL of sepharose resin is used to bind 20 mL of diluted GGCX purified 
protein fractions.  Binding is induced between the purified GGCX and SP sepharose resin 
after overnight end-over-end rotation at 4oC.   
SP sepharose resin bound with GGCX is packed into a gravity flow column and washed 
with ten column bed volumes of wash buffer (25 mM MOPS pH 7.5, 0.075 M NaCl, 15% 
glycerol, 0.3% CHAPS, 0.2% DOPC-CHAPS, 2.0 g/mL aprotinin, 0.5 g/mL leupeptin, 1.0 
g/mL pepstatin, and 100 g/ml PMFS) at 25 mL/hour at 4oC.  Elution buffer is then slowly 
introduced onto the head of the column in small aliquots to prevent sample dilution.  Elution 
buffer consists of 25 mM MOPS pH 7.5, 0.5 M NaCl, 15% glycerol, 0.3% CHAPS, 0.2% 
DOPC-CHAPS, 2.0 g/mL aprotinin, 0.5 g/mL leupeptin, 1.0 g/mL pepstatin, and 100 
g/ml PMFS.  Elution fractions are collected for five column volumes at 1 mL per fraction (2 
mL SP sepharose resin) with a flow rate of 25 mL/hour.  Protein purity and activity were 
evaluated by radiolabeleled 14CO2 incorporation and SDS-PAGE respectively.  Concentrated 
GGCX purified protein fractions were stored at -80oC.   
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Figure A1.1 Gamma-Glutamyl Carboxylase (GGCX) HPC4 affinity purification.  SDS-
PAGE gel confirming GGCX purity with overlay of active GGCX concentration for 
each fraction. Activity measured by incorporation of radiolabeled 14C upon 
carboxylation of the small pentapeptide substrate FLEEL in the presence of Factor IX 
propeptide, and vitamin K hydroquinone.  Lane notation labeled as follows: SM = 
Solubilized Microsome; E6-E13 = GGCX Elution Fractions; FT = Flow Through; W 
= Wash Buffer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix A2 – Purification of Recombinant Wild-type Vitamin K Epoxide 
Reductase (VKOR) 
________________________________________________________ 
 
 Appendix A2 will focus on a detailed protocol for purification of Vitamin K Epoxide 
Reductase (VKOR) from Spodoptera frugiperda (Sf9) insect cells.  The protocol is reported 
is for a 2.5 liter sample cell preparation decanted of cell media and frozen at -80oC.  VKOR, 
expressed with a C-terminal epitope tag (EDQVDPRLIDGK), is purified using a calcium 
dependent HPC4 antibody resin for affinity chromatography.  Throughout the purification 
protocol, sample aliquots are saved to determine VKOR activity lost and protein purity.  The 
protocol for VKOR purification is modified from Chu et al.1 
 
A2.1 Materials 
Reagents used in Vitamin K Epoxide Reductase protein purification are as follows: 1,2-
diheptanoyl-sn-glycero-3-phosphocholine [DHPC] (Avanti Polar Lipids, Alabaster, AL), 1,2-
dioleoyl-sn-glycero-3-phosphocholine [DOPC] (Avanti Polar Lipids), HPLC grade 
acetonitrile, adenosine 5’-triphosphate disodium salt solution [ATP] (Sigma Aldrich, St. 
Louis, MO), benzamidine hydrochloride (Sigma-Aldrich), calcium chloride dihydrate (Fisher 
Scientific, Fair Lawn, NJ) [CaCl2.2H2O], dithiothreitol [DTT] (Roche Applied Sciences, 
Indianapolis, IN), ethylenediamine-tetraacetic acid [EDTA] (Mallinckrodt Chemicals, 
Raleigh, NC), glycerol (Fisher Scientific), immunoglobulin G [IgG] (Sigma-Aldrich), HPLC 
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grade isopropanol (Fisher Scientific), magnesium chloride [MgCl2] (Sigma-Aldrich), silver 
nitrate [AgNO3] (Sigma Aldrich), sodium azide [NaN3] (Sigma-Aldrich) sodium chloride 
[NaCl] (Fisher Scientific), sodium deoxycholate (Sigma-Aldrich), N-
tris(hydroxymethyl)methyl-3-aminopropanesulfonic Acid [TAPS] (Sigma-Aldrich), and 
tris(hydroxypropyl)phosphine [THP] (Calbiochem, San Diego, CA).  For activity assay 
determination, Vitamin K1(25) from Hospira Incorporated (Lake Forest, IL) stabilized with 
phytonadione injectable emulsion and Vitamin K epoxide [KO] provided by Paul Dowd 
(University of Pittsburg, Pittsburg, PA) were obtained.  Protease inhibitors including 
aprotinin, leupeptin, and pepstatin were purchased from Roche Applied Science.  Aprotinin, 
leupeptin, and pepstatin stock solutions are stored at -80oC for one month.  Anti-HPC4 
monoclonal antibody coupled Sepharose resin was provided by Dr. Charles T. Esmon 
(Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, 
Oklahoma City, OK).2   
Stock preparations and concentrations of reagents are as follows: 200mM DHPC, 5% 
DOPC-Deoxycholate (Dissolve 2 grams of lyophilized DOPC phospholipid with 20 mL of 
10% deoxycholate overnight at room temperature.  Add 20 mL of deionized water when 
dissolved), 200 mM ATP, 1 M benzamidine hydrochloride, 1 M CaCl2.2H2O, 0.5 M EDTA 
pH 8.0, 1.47 mg/mL IgG, 1M MgCl2, 20% NaN3, 4 M NaCl, 10% sodium deoxycholate, 1 M 
TAPS pH 8.6, and 500 mM THP.  Protease inhibitors are prepared as 10 mg/mL aprotinin in 
deionized water, 1.0 mg/mL leupeptin in deionized water, and 2.0 mg/mL pepstatin in 
methanol.  Assay determination requires the following substrate stock solutions: 30 mg/mL 
freshly prepared DTT, 0.5 M AgNO3, 1.5 M vitamin K1(25) in hexanes, and 1 mM vitamin K 
epoxide in isopropanol. 
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A2.2 VKOR Purification Protocol – Microsome Preparation and Solubilization 
 Cell pellets are gradually thawed in an ice bath and combined with chilled Buffer A 
(25 mM TAPS pH 8.6, 0.15 M NaCl, 20% glycerol, 2.0 g/mL aprotinin, 0.5 g/mL 
leupeptin, and 0.7 g/mL pepstatin) to a final volume of 250 mL.  Due to the limited half-life 
of protease inhibitors, the cocktail is added to Buffer A immediately prior to use.  The cell 
suspension is lysed by short-pulse sonication on ice using a large probe sonicator (Heat 
Systems Sonicator ® Ultrasonic Processor XL).  The sonicator was programmed to pulse for 
1.5 seconds (ON) with an 18.5 second rest period (OFF) for a total ON time of 3 minutes and 
30 seconds at setting 6.  During lysis, the cell suspension is stirred continuously and ice is 
replenished as needed.   
After lysis, the cell lysate is split between two-250 mL pre-chilled low speed 
centrifuge tubes.  The tubes are mass balanced and centrifuged at 4100xg (6500 rpm; ravg = 
8.7 cm; FIBERLite® F14-6x250y rotor, Piramoon Technology Inc.) on a Sorvall® RC-5B 
Refrigerated Superspeed Centrifuge (Dupont Instruments) for 15 minutes at 4oC to pellet the 
cell components.  During centrifugation, both a tight a loose pellet are formed.  To prevent 
protein contamination, the centrifugation supernant is carefully removed, leaving all pellet 
remnants behind, and placed into pre-chilled ultracentrifuge tubes.  Ultracentrifugation of the 
remaining cell lysate will separate the soluble cell components from that of the cell 
microsome.  Ultracentrifugation tubes are mass balanced and centrifuged at 119,000xg 
(40,000 rpm; ravg = 6.66 cm; Sorvall T647.5 rotor) on an OptimaTM L-60 Preparative 
Ultracentrifuge (Beckman Coulter) for 90 minutes at 4oC.  The supernant from 
ultracentrifugation is removed, and the pellet is homogenized to a uniform consistency.  The 
microsome pellet is washed with Buffer A and re-centrifuged at 119,000xg (40,000 rpm; ravg 
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= 6.66 cm; Sorvall T647.5 rotor) for 90 minutes at 4oC to remove any soluble protein 
contaminants.  After the second period of ultracentrifugation, the wash buffer is decanted and 
the microsome pellet is removed and homogenized.  During homogenization, samples must 
be kept on ice to maintain VKOR activity.  Homogenized microsome is suspended in a 
minimal volume of Buffer A to maintain sample consistency and stored at -80oC until total 
protein content is determined.   
To determine the total protein content of the homogenized microsome, a Bio-Rad 
Bradford protein assay was completed.  The Bradford assay is a dye-binding assay in which a 
differential color change of a dye occurs in response to various concentrations of protein.  An 
IgG protein standard was prepared for standard calibration and serial dilutions of 
homogenized microsome were tested for concentration determination at 595 nm.  Total 
protein concentration was calculated from a standard protein calibration regression equation. 
The homogenized microsome is thawed in an ice bath and solubilized with Buffer A 
supplemented with 40 mM DHPC and 4 mM THP to a total protein concentration of 10 
mg/mL.  The solubilized mixture is stirred in the cold room (4oC) for 60 minutes.  After 
mixing, the solubilized microsome is centrifuged at 119,000xg (40,000 rpm; ravg = 6.66 cm; 
Sorvall T647.5 rotor) for 90 minutes at 4oC to remove any insoluble microsome 
contaminants.  The pellet from ultracentrifugation was discarded and the supernant was 
diluted to a final concentration of 8 mM DHPC with Buffer A. 
 
A2.3 VKOR Purification Protocol – Reconstitution and Affinity Purification 
A HPC4 epitope tag (EDQVDPRLIDGK) is introduced at the C-terminal end of VKOR 
and is mimicked after a protein C binding protein where the epitope tag binds the antibody 
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resin through a calcium dependent interaction.  For protein elution, EDTA is used to complex 
the calcium and release purified VKOR.  HPC4 resin is loaded into a BioRad gravity flow 
column (3.5 cm diameter).  Once settled, activation buffer (25 mM TAPS pH 8.6, 0.15 M 
NaCl, and 2 mM CaCl2) is slowly introduced and washed through the resin for ten column 
bed volumes at a flow rate of 35 mL/hour.  Resin must be kept at hydrated 4oC or in the cold 
room at all times. 
After activating the HPC4 resin, solubilized microsome is added in equal volumes to 
aliquoted resin in 50 mL scintillation tubes for binding. To maximize protein binding and 
minimize detergent bubble formation, the size and shape of the container must be optimized 
to limit dead volume while providing adequate surface area.  Calcium chloride (2 mM) is 
added to each container to initiate protein affinity binding.  The solubilized microsome 
containing HPC4 activated resin is rotated end-over-end at 4oC overnight (minimum 14 
hours) to promote binding.   
After binding, the HPC4 resin is allowed to settle and the flow through, or sample filtrate 
not bound to the resin, is collected.  The resin is combined between all containers and added 
in a continuous slurry to the column.  The containers are washed with remaining flow 
through to minimize sample loss and added to the top of the column bed.  After the resin is 
allowed to settle for ~30 minutes, the bed is compacted with pressured flow.  Once settled, 
ten column bed volumes of chilled wash buffer is passed at a flow rate of 35 mL/hour at 4oC.  
Wash buffer is prepared as follows: 25 mM TAPS pH 8.6, 0.15 M NaCl, 20% glycerol, 10 
mM DHPC, 10 mM MgCl2, 10 mM ATP, 2 mM CaCl2.2H2O, 4 mM THP, 2.0 g/mL 
aprotinin, 0.5 g/mL leupeptin, and 7 g/mL pepstatin.  For VKOR solubilization, the mild 
DHPC detergent was proven most effective while preserving 3D protein structure and 
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enzymatic activity.3  In addition, MgCl2 and ATP was incorporated into the wash buffer to 
remove the 70 kDa heat-shock protein which is commonly associated with denatured protein 
in the endoplasmic reticulum.4  To prevent disruption of the column bed and limit the 
carryover of flow through, wash buffer is slowly introduced in four additions allowing each 
addition to fall to the surface of the column head before the next addition was made.  
Aliquots are collected throughout washing to monitor sample loss.  To optimize protein 
solubilization and activity, the VKOR bound resin is then washed with ten column bed 
volumes with reconstitution buffer (25 mM TAPS pH 8.6, 0.15 M NaCl, 20% glycerol, 0.4% 
DOPC-Deoxycholate, 2 mM CaCl2.2H2O, 4 mM THP, 2.0 g/mL aprotinin, 0.5 g/mL 
leupeptin, and 7 g/mL pepstatin). 
For VKOR protein elution, wash buffer is allowed to fall to the top of the column bed and 
elution buffer is gradually introduced in 1 mL aliquots to prevent protein dilution over a large 
number of fractions.  Elution buffer is prepared with 25 mM TAPS pH 8.6, 0.15 M NaCl, 
20% glycerol, 0.4% DOPC-Deoxycholate, 10 mM EDTA pH 8.0, 2.0 g/mL aprotinin, 0.5 
g/mL leupeptin, and 0.7 g/mL pepstatin.  Immediately upon addition of elution buffer, 
fractions are collected at a flow rate of 30 mL/hour at 4oC.  After 1.5 column volumes have 
passed, the flow rate and fraction volume is increased slightly.  Once three column volumes 
have passed, evidence of VKOR remnants should be removed from the column.  The elution 
fractions and remaining flow through are stored at 4oC.   
After confirming complete VKOR removal from the HPC4 affinity column, resin is 
washed with ten column bed volumes of stocking buffer (20 mM TAPS pH 8.6, 2 M NaCl, 5 
mM EDTA pH 8.0, 0.02% NaN3, and 1 mM benzamidine hydrochloride) and stored at 4oC. 
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A2.4 VKOR Purification Protocol – Recovery of Activity 
Addition of any detergent to VKOR resulted in decreased VKOR activity compared with 
the microsome alone.1  Previous topology experiments predict that the active site of VKOR 
(residues 132-135) is located within a transmembrane domain, and that an intact membrane is 
needed for VKOR activity.5  To mimic a membrane environment and regain protein activity, 
purified VKOR was dialyzed against buffer containing the reducing agent 
tris(hydroxypropyl)phosphine (THP) in the absence of DOPC phospholipid or deoxycholate 
detergent.  After dialysis, deoxycholate is removed and DOPC remains as a liposomal 
membrane structure promoting active VKOR conformation.  Dialysis is completed at 4oC for 
72 hours with three buffer changes in 25 mM TAPS pH 8.6, 0.15 M NaCl, 20% glycerol, 2.0 
g/mL aprotinin, 0.5 g/mL leupeptin, and 0.7 g/mL pepstatin (10 kDa MWCO SnakeSkin 
Dialysis Tubing, Pierce).  After dialysis, 4 mM THP was added to the dialyzed sample and 
incubated overnight at 4oC during end-over-end rotation.  The reconstituted protein was 
stored at 4oC. 
Elution fractions after dialysis and sample aliquots throughout the purification protocol 
are tested for activity using a HPLC assay which measures the production of vitamin K.  
Twenty microliters of purified protein is added to 180 L of buffer containing 25 mM TAPS 
pH 8.6, 0.15 M NaCl, and 30% glycerol.  To measure the activity of the initial cell pellet or 
lysate, samples are sonicated at 4oC in four-10 second intervals using a small probe sonicator 
(1 second ON, 10 seconds OFF).  Eight microliters of 1 mM vitamin K epoxide in 
isopropanol is added as substrate and 5 L of 30mg/mL freshly prepared DTT is added to 
initiate the reaction.  The reaction mixture is incubated in the dark at 30oC for 30 minutes.  
The reaction is quenched by adding 500 L 0.5 M AgNO3: isopropanol (5:9) followed by the 
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addition of 500 L of 1.5 M K1(25) in hexane as an internal standard.  The mixture is 
vortexed for one minute followed by brief centrifugation (13000 rpm for 2-3 minutes) to 
separate the aqueous and organic phases and precipitate a pellet.  Four hundred microliters of 
the upper organic phase is dried with a gentle stream of nitrogen.  To the dried samples, 400 
L of the HPLC mobile phase (91.8% acetonitrile, 6.4% isopropanol, 1.8% water) is added 
to dissolve the dried sample.   
VKOR activity samples are analyzed by HPLC on a Vydax 5 M C18 column (4.6 mm x 
250 mm, Catalog Number 218TP54) at a flow rate of 2 mL/minute under isocratic conditions 
(100 L injection volume).  The production of vitamin K1(20) is detected by UV absorbance at 
248 nm.  Nanomoles of vitamin K1(20) produced is calculated from experimental peak area 
fitting to a standard regression calibration for increasing concentrations of vitamin K1(20).  To 
correct for variations in experimental response factors, a normalization constant is applied 
using the K1(25) internal standard. 
To determine VKOR protein purity and concentration, SDS-PAGE was evaluated.  
For gel analysis of GGCX, NU-PAGE Bis-Tris Gels were purchased from Invitrogen 
(Carlsbad, CA) along with the Mark 12 unstained protein ladder, and SYPRO® Ruby protein 
gel stain.  SDS-PAGE buffers were prepared according to protocol derived from Invitrogen 
including a 4X SDS-PAGE loading buffer and a 20X MES running buffer.  For concentration 
estimation, the intensity of VKOR purified fractions are calibrated with BSA protein 
standards by SDS-PAGE. 
SYPRO® Ruby protein stain requires that the gel first be fixed in a solution of 50% 
methanol and 7% acetic acid for 30 minutes prior to overnight staining with a non-covalent 
fluorescent protein stain.  After staining, the gel was washed for 30 minutes with a solution 
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containing 10% methanol and 7% acetic acid and imaged using a 300 nm blue light UV 
transilluminator (Alpha Innotech AlphaImagerTM 2200) with interference wavelength 
filtering.  Figure A2.1 illustrates a typically correlation of VKOR protein concentration and 
purity where fractions E6-E7 represent the most concentrated protein fractions eluting at 
approximately one column bed volume.   
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Figure A2.1 Vitamin K Epoxide Reductase (VKOR) HPC4 affinity purification.  SDS-PAGE 
gel confirming GGCX purity with overlay of calibrated VKOR concentration for each 
fraction.  Approximate gel concentration calculated from BSA calibration standards.  
Lane notation labeled as follows: SM = Solubilized Microsome; E5-E10 = GGCX 
Elution Fractions; FT = Flow Through. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix A3 – Expression and Purification of Membrane Scaffold Protein 
MSP1D1 
________________________________________________________ 
 Appendix A3 will focus on a detailed protocol for expression and purification of 
membrane scaffold protein (MSP1D1) from Escherichia coli (E. coli) BL21 Codon Plus 
(DE3) cells.  The MSP1D1 plasmid was modified with an N-terminal polyhistidine tag 
provided by AddGene (plasmid 20061) enabling isolation by Ni-NTA Agarose affinity 
purification.  Throughout the purification protocol, sample aliquots are saved to determine 
MSP1D1 sample loss and protein purity.  The protocol for MSP1D1 purification was 
modified from Denisov et al.1 
 
A3.1 Materials 
Reagents used in membrane scaffold protein (MSP1D1) expression and purification are 
as follows: Chloramphenicol Acetyltransferase from Escherichia coli (Sigma-Aldrich, St. 
Louis, MO), 95% ethanol (Fisher Scientific, Fair Lawn, NJ), ethylenediamine-tetraacetic acid 
[EDTA] (Mallinckrodt Chemicals, Raleigh, NC), glycerol (Fisher Scientific), imidazole 
(Sigma-Aldrich), isopropyl β-D-1-thiogalactopyranoside [IPTG] (Sigma-Aldrich), 
kanamycin 6′-acetyltransferase from Escherichia coli (Sigma-Aldrich), potassium chloride 
[KCl] (Sigma-Aldrich), potassium phosphate dibasic [K2HPO4] (Sigma-Aldrich), potassium 
phosphate monobasic [KH2PO4] (Sigma-Aldrich), sodium azide [NaN3] (Sigma-Aldrich), 
sodium chloride [NaCl] (Fisher Scientific), sodium phosphate dibasic [Na2HPO4] (Sigma-
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Aldrich), sodium cholate (Sigma-Aldrich), 10N sodium hydroxide [NaOH] (Fisher-
Scientific), tris(hydroxymethyl)aminomethane hydrochloride [Tris-HCl] (Sigma Aldrich), 
and Triton X-100 (Sigma-Aldrich).  Phenylmethyl sulfonyl fluoride (PMSF) protease 
inhibitor was purchased from Roche Applied Science (Indianapolis, IN).  For cell culture, 
BactoTM Tryptone (pancreas digest of casein) and BactoTM Yeast Extract (Becton Dickinson, 
Franklin Lakes, NJ) were used to prepare Luria broth (LB).  Ni-NTA Agarose resin was 
purchased from QIAGEN (Valencia, CA) for affinity purification.   
Stock preparations and concentrations of reagents are as follows: 34 mg/mL 
chloramphenicol, 30% ethanol, 0.5 M EDTA pH 8.0, 500 mM imidazole, 1 M IPTG, 50 
mg/mL kanamycin, 1 M K2HPO4 pH 7.4, 20% NaN3, 4 M NaCl, 250 mM sodium cholate, 
500 mM NaOH, 1 M Tris-HCl pH 7.4, 10% Triton X-100, and 25 mg/mL PMSF in 
isopropanol.  Phosphate buffered saline [PBS] is prepared as follows: 0.137 M NaCl, 2.7 mM 
KCl, 10 mM Na2HPO4, and 2 mM KH2PO4 at pH 7.4.  For cell culture, Luria broth (LB) is 
prepared and autoclaved prior to use (500 mL): 5.0 grams of tryptone, 2.5 grams of yeast 
extract, 5.0 grams of NaCl, and 50 g/mL kanamycin.  The Ni-NTA Agarose resin (5 mg Ni-
NTA/mL resin) is stored at 4oC in storage buffer containing 30% ethanol. 
 
A3.2 MSP1D1 Expression – E. coli BL21 Codon Plus (DE3)  
The MSP1D1gene cloned in a pET28a plasmid was provided in a DH5 bacterial stab 
from AddGene (plasmid 20061; MTA M1-8301).  The construct was designed with a 
polyhistidine N-terminal tag followed by spacer sequence and TEV protease site.  The 
MSP1D1 vector construct, DNA, and protein sequences are represented in Figure A3.1.   
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To recover the plasmid from the stab culture, kanamycin resistant LB agar plates were 
prepared (1L) as follows: 10 grams tryptone, 5.0 grams yeast extract, 10 grams NaCl, 15 
grams agar.  Agar media was autoclaved followed by addition of kanamycin antibiotic (50 
g/mL), and poured into plates for storage at 4oC.  Using a sterilized inoculation loop, the 
bacterial plasmid was plated onto kanamycin resistant agar plates and allowed to incubate 
overnight at 37oC.  A single bacterial colony was isolated from the agar plate and inoculated 
in 5 mL LB for overnight (16 hours) growth at 37oC.  From the inoculated culture, a long 
term stock was prepared in 50% glycerol for storage at -80oC (300 L bacterial culture added 
to 700 L autoclaved 70% glycerol).   
As a low copy number plasmid, the MSP1D1 overnight culture was amplified (2 mL 
bacterial culture in 200 mL LB media and 50 g/mL kanamycin overnight at 37oC) to 
provide adequate plasmid for sequencing.  The cells were then harvested by centrifugation at 
6225xg (8000 rpm; ravg = 8.7 cm; FIBERLite® F14-6x250y rotor, Piramoon Technology 
Inc.) on a Sorvall® RC-3 Refrigerated Centrifuge (Dupont Instruments) for 10 minutes at 
4oC.  Harvested cells were treated with a Midi QIAGEN Plasmid Purification kit.   
QIAGEN plasmid purification protocols are based on a modified alkaline lysis procedure.  
Cells are lysed with NaOH and sodium dodecyl sulfate (SDS) where SDS solubilizes the 
phospholipid and protein components of the cell membrane promoting cell lysis and NaOH 
denatures the chromosomal and plasmid DNA.  The presence of RNASE A ensures that 
liberated cellular RNA is digested during lysis.  After lysis, plasmid DNA is bound to a 
QIAGEN anion-exchange resin under appropriate low salt and pH conditions.  RNA, 
proteins, dyes, and low molecular weight impurities are removed by a medium salt wash.  
Plasmid DNA is eluted in a high-salt buffer and then concentrated and desalted by 
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isopropanol precipitation.  DNA is collected using a QIAGEN precipitator.  The plasmid 
concentration yield is determined by absorbance at 260 nm where 1 OD is equal to 50 ng/L 
for double stranded DNA.  The sample was then submitted for sequencing (700 ng plasmid 
and 10 pmol T7 reverse 3’ primer in 20 L total volume).   
After plasmid DNA extraction from the bacterial stab, MSP1D1 DNA must be 
transformed into E.coli.  A BL-21 (DE3) competent cell line (200 L) was added to 10 L of 
extracted plasmid and plated on kanamycin antibiotic resistant agar for overnight incubation 
at 37oC.  To improve plasmid uptake by competent host strain, the competent cell line was 
first heat shocked (30 minutes ice, 2.5 minutes at 42oC, 30 minutes ice).  Single colonies are 
represented by successful bacterial growth upon plasmid incorporation into host DNA.  After 
inoculation of a single colony, amplification is continued until OD600nm reaches 0.7-0.8.  
Absorbance measurements at 600 nm are indicative of cell density growth.  Long-term stock 
of MSP1D1 transfection into E.coli BL-21 (DE3) cells is prepared in 50% glycerol and 
stored at -80oC.   
For initial preparations, a small test culture is prepared prior to large scale MSP1D1 
expression.  When cell density is in middle of log phase (OD 0.7-0.8), MSP1D1 production 
in E.coli host is induced by addition of 1 mM IPTG.  After induction, culture is incubated at 
37oC for one hour.  The temperature is then lowered to 28oC and incubation is continued for 
2.5-3 hours.  The cell density is monitored until OD600nm reaches 3.0 (dilute induced cell 
culture to maintain accurate absorbance less than 1.0).  MSP1D1 production is monitored 
before and after IPTG induction by SDS-PAGE as shown in Figure A3.2.  The protocol for 
sample preparation is as follows: centrifuge culture at 12,000 rpm for 1 minute, dissolve 
pellet in 75 Ldeionized water and 25 L 4X SDS loading buffer, boil for 5 minutes, and 
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centrifuge 12,000 rpm for 3 minutes prior to loading (10 L) onto SDS-PAGE gel.  For 
comparison pre- and post-induction samples should be corrected to have the same cell 
density. 
Upon confirmation of MSP1D1 sequence and induction in E.coli BL-21 (DE3) cells, the 
transfected culture was amplified (5 mL culture in 500 mL LB media supplemented with 25  
g/mL kanamycin and 34 g/mL chloramphenicol) overnight at 37oC.  Chloramphenicol is 
added to the LB media to improve copy yield for BL-21 Codon Plus DE3 E.coli cell growth.  
A sterile Bio-Flow Fermenter II (New Brunswick, NJ) containing 5 L sterilized media (1.0% 
tryptone, 2.0% yeast extract, 0.5% NaCl, 0.5% (v/v) glycerol, and 100 mM K2HPO4 pH 7.4) 
supplemented with 25 g/mL kanamycin, 34 g/mL chloramphenicol, and 600 L antifoam 
was inoculated with 500 mL starting culture and incubated at 37oC at 500 rpm and aeration at 
3 L/minute.  Induction with 1 mM IPTG was performed when OD600nm reached optical 
density of 6.0 (2-3 hours).  One hour after induction the temperature was lowered to 28oC 
and MSP1D1 expression was continued for an additional 2.5-3 hours.  Cells were then 
harvested by centrifugation at 875xg (3000 rpm, ravg = 8.7 cm; FIBERLite® F14-6x250y 
rotor, Piramoon Technology Inc.) on a Sorvall® RC-3 Refrigerated Centrifuge (Dupont 
Instruments) for 30 minutes at 4oC.  Cell media was decanted and pellet was resuspended in 
chilled phosphate buffered saline (PBS) supplemented with 1 mM PMSF.  Resuspended cells 
are flash frozen with liquid nitrogen and stored at -80oC.   
 
A3.3 MSP1D1 Cell Lysis  
Cell pellet from 2L MSP1D1 expression in BL-21 Codon Plus (DE3) E. coli cells are 
gradually thawed in an ice bath and combined with 1% Triton X-100, 1 mM PMSF, and 
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chilled phosphate buffer (20 mM pH 7.4) to a final volume of 170 mL.  The cell suspension 
is lysed by short-pulse sonication on ice using a large probe sonicator (Heat Systems 
Sonicator ® Ultrasonic Processor XL).  The sonicator was programmed to pulse for 1.5 
seconds (ON) with an 18.5 second rest period (OFF) for a total ON time of 2 minutes and 42 
seconds at setting 6.  During lysis, the cell suspension is stirred continuously and ice is 
replenished as needed.  If lysate consistency remains viscous during sonication, DNAse is 
added to degrade cell components.  Cell lysate is then ultracentrifuged at 30,000xg (20,100 
rpm, Sorvall T647.5 rotor) on an OptimaTM L-60 Preparative Ultracentrifuge (Beckman 
Coulter) for 36 minutes at 4oC.  The centrifugation pellet is discarded and the supernant is 
saved for purification. 
 
A3.4 MSP1D1 Purification – Ni-NTA Agarose Affinity Purification 
Ni-NTA Agarose (QIAGEN) is used for MSP1D1 affinity purification.  Agarose resin is 
modified with nickel using nitrilotriacetic acid (NTA), a tetradentate chelating agent.  NTA 
occupies four of the six ligand binding sites in the coordination sphere of the nickel ion 
leaving two sites free to interact with the polyhistidine tag.  Buffer selection for washing and 
elution were optimized to limit non-specific binding of protein contaminants.  For a 2L cell 
culture preparation, 5 mL of Ni-NTA Agrose resin is recommended.  Ni-NTA resin (stored in 
30% ethanol) is activated with 40 mM Tris-HCL, 0.3 M NaCl, 1% Triton X-100 pH 8.0 for 
ten column bed volumes.  Resin is then incubated with cleared cell lysate for at 4oC in a 175 
mL conical tube for a 2 hour end-over-end rotation.  After binding, resin is spun down at 
1000 rpm for 5 minutes at 4oC and flow through is decanted.  MSP1D1 bound Ni-NTA 
Agarose resin is loaded into a wide diameter gravity flow column.  The resin is allowed to 
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settle in the column and compacted with pressured flow.  A limited volume of flow through 
was allowed to pass through the column bed to prevent column clogging.  The column was 
washed with five bed volumes sequentially with each of the following wash buffers: Buffer 1 
= 40 mM Tris-HCl, 0.3 M NaCl, 1% Triton X-100 pH 8.0; Buffer 2 = 40 mM Tris-HCl, 0.3 
M NaCl, 50 mM cholate pH 8.0; Buffer 3 = 40 mM Tris-HCl, 0.3 M NaCl pH 8.0; Buffer 4 = 
40 mM Tris-HCl, 0.3 M NaCl, 50 mM imidazole pH 8.0 where Tris-HCl buffer pH was 
calibrated at 25oC.  To prevent disruption of the column bed and limit the carryover between 
wash buffers, buffer is slowly introduced in four additions allowing each addition to fall to 
the surface of the column head before the next addition was made.  An aliquot of each wash 
buffer was assessed for sample loss by SDS-PAGE.   
MSP1D1 was eluted with 40 mM Tris-HCl, 0.3 M NaCl, 300 mM imidazole, and 1 mM 
PMSF at pH 8.0.  One milliliter fractions were collected and checked for purity by SDS-
PAGE (Figure A3.2).  Fractions containing highly concentrated MSP1D1 were pooled and 
dialyzed with three buffer changes against standard buffer (10 mM Tris-HCl, 0.1 M NaCl, 
and 1 mM EDTA pH 7.4) using 10kDa MWCO (Pierce SnakeSkin) dialysis tubing at 4oC for 
the removal of imidazole.  The protein was filtered with a 0.22 m filter and 0.01% NaN3 
was added as a preservative.  MSP1D1 concentration was determined by absorbance at 280 
nm using calculated extinction coefficients (280nm = 21000 M-1cm-1).  MSP1D1 lyophilized 
protein is stable long-term at -20oC or in standard buffer at 4oC for one month 
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A3.6 Figures 
 
 
Nco I
0
pMSP1D1 – 20061
5940 base pairs
640
Hind III
MSP1D1:
Protein:
GHHHHHHHDYDIPTTENLYFQGSTFSKLREQLGPVTQEFWDNLEKETEGLRQEM
SKDLEEVKAKVQPYLDDFQKKWQEEMELYRQKVEPLRAELQEGARQKLHELQE
KLSPLGEEMRDRARAHVDALRTHLAPYSDELRQRLAARLEALKENGGARLAEY
HAKATEHLSTLSEKAKPALEDLRQGLLPVLESFKVSFLSALEEYTKKLNTQ
DNA:
ACCATGGGTCATCATCATCATCATCATCACGATTATGATATTCCTACTACTGA
GAATTTGTATTTTCAGGGTTCTACCTTCAGTAAACTTCGCGAACAACTGGGCC
CCGTGACGCAGGAATTCTGGGACAACCTGGAAAAAGAAACCGAGGGACTGC
GTCAGGAAATGTCCAAAGATTTAGAAGAGGTGAAGGCCAAGGTTCAGCCATA
TCTCGATGACTTTCAGAAAAAATGGCAGGAAGAGATGGAATTATATCGTCAA
AAGGTGGAACCGCTGCGTGCGGAACTGCAAGAGGGGGCACGCCAAAAACTC
CATGAGCTCCAAGAGAAGCTCAGCCCATTAGGCGAAGAAATGCGCGATCGCG
CCCGTGCACATGTTGATGCACTCCGGACTCATTTGGCGCCGTATTCGGATGAA
CTTCGCCAGCGTTTGGCCGCACGTCTCGAGGCGCTGAAAGAAAACGGGGGTG
CCCGCTTGGCTGAGTACCACGCGAAAGCgACAGAACACCTGAGCACCTTGAG
CGAAAAAGCGAAACCGGCGCTGGAAGATCTACGCCAGGGCTTATTGCCTGTT
CTTGAGAGCTTTAAAGTCAGTTTTCTGTCAGCTCTGGAAGAATATACTAAAAA
GCTGAATACCCAGTAAGCTT
 
 
Figure A3.1 Membrane Scaffold Protein (MSP1D1) expression vector and corresponding 
protein and DNA sequence provided by Sligar laboratory at the University of Illinois 
Urbana-Champagne.1 
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Figure A3.2 Membrane Scaffold Protein (MSP1D1) expression in E.coli BL-21 Codon Plus 
(DE3) cells and purification by Ni-NTA Agarose.  Lanes –IPTG and + IPTG illustrate 
confirmation of MSP1D1 selective induction.  Lanes I, II, III compare protein purity 
where lane I is purified MSP1D1 provided by Sligar laboratory (MSP1D1 
P209080530), lane II is purified MSP1D1 pre-dialysis, and lane III is purified 
MSP1D1 post-dialysis. 
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Appendix A4 – Nanodisc Hydrogen Deuterium Exchange  
________________________________________________________ 
 
 Appendix A4 will report Nanodisc hydrogen deuterium exchange (HX) uptake curves 
for Gamma-Glutamyl Carboxylase (GGCX) and the membrane scaffold protein MSP1D1 
referenced in Chapter 6.  HX uptake curves are acquired using a conventional HPLC or 
customized Waters® nanoACQUITYTM UPLC system coupled to mass spectrometry. 
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A4.1  Tables 
 
 
 
 
 
 
 
 
 
 
 
Residues Proposed Region
1-60 Cytoplasm
61-81 Transmembrane (TM1)
82-113 Lumen
114-134 Transmembrane (TM2)
135-136 Cytoplasm
137-157 Transmembrane (TM3)
158-292 Lumen
293-313 Transmembrane (TM4)
314-361 Cytoplasm
362-382 Transmembrane (TM5)
383-758 Lumen
 
 
Table A4.1 Topological prediction for Gamma-Glutamyl Carboxylase (GGCX). 
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A4.2  Figures 
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Figure A4.1 Relative deuterium incorporation curves for MSP1D1 in GGCX embedded 
Nanodiscs for analysis by conventional HPLC HX MS.  The y-axis maximum for 
each plot indicates the theoretical maximum number of deuterium that the associated 
peptide is capable of exchange.  No correction has been made for back-exchange.  A 
duplicate time course was completed and representative uptake curves are plotted for 
each peptide 
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Figure A4.2 
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Figure A4.2 Relative deuterium incorporation curves for MSP1D1 in GGCX embedded 
Nanodiscs, empty Nanodiscs, or lipid-free samples for analysis by conventional 
HPLC HX MS.  The y-axis maximum for each plot indicates the theoretical 
maximum number of deuterium that the associated peptide is capable of exchange.  
No correction has been made for back-exchange. 
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Figure A4.3 Relative deuterium incorporation curves for GGCX in embedded Nanodiscs for 
analysis by UPLC HX MS.  The y-axis maximum for each plot indicates the 
theoretical maximum number of deuterium that the associated peptide is capable of 
exchange.  No correction has been made for back-exchange.  A duplicate time course 
was completed and representative uptake curves are plotted for each peptide. 
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Figure A4.4 Comparison of relative deuterium incorporation curves for GGCX in embedded 
Nanodiscs for analysis by conventional HPLC or UPLC HX MS methods.  For 
peptides that replicate between conventional HPLC and UPLC methods, duplicate 
uptake curves for each method are averaged and represented in gray scale.  Those 
peptides that are unique to either the conventional HPLC or UPLC methods are 
reported as replicate data sets and enclosed in representative colored boxes.  No 
correction has been made for back-exchange.  . 
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Figure A4.5 Relative deuterium incorporation curves for GGCX in embedded Nanodiscs 
with and without incorporated consensus propeptide for analysis by UPLC HX MS.  
No correction has been made for back-exchange.  Only peptides replicating in both 
data sets are plotted. 
